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In the search for high affinity therapeutics, medicinal chemists are turning their attention to free ligand 
conformations as it is well known that if a large conformational reorganisation is required upon binding, 
then a weaker binding affinity will be observed. This has been highlighted as an important strategy in 
the inhibition of protein–protein interactions (PPIs), due to the large, flat and featureless binding sites 
they present. This thesis discusses the design, synthesis and conformational analysis of a novel class of 
conformationally controlled α-helix mimetics, aimed at targeting aberrant PPIs. Their ability to target 
the p53-Mdm2 PPI with reasonable affinity is demonstrated.   
Molecular Mechanics (MM) conformational search calculations were used to design a conformationally 
controlled scaffold that mimicked the i, i + 3/4 and i + 7 positions of the α-helix. Following the design 
of a general scaffold, appropriate side chains were added to mimic those of p53, and protein-ligand 
molecular docking calculations were performed to assess the binding of the designed ligand to Mdm2. 
Molecular docking was also used to design a library of p53 mimetics with binding affinities comparable 
to that of Nutlin-2, a highly successful p53-Mdm2 inhibitor.  
With promising p53 mimetics designed using computation, their synthesis was explored using 
lithiation–borylation. Using lithiation–borylation a diverse set of side chains can be incorporated onto 
the scaffold by the insertion of the correct benzoate ester into the synthetic sequence. Thus, broad 
libraries of α-helix mimetics bearing different side chains can be synthesised using the same iterative 
methodology.  
To confirm that the designed p53 mimetics exhibit the conformational bias that was predicted by MM 
calculations, a hybrid quantum mechanics (QM) and NMR spectroscopy approach was used to explore 
the conformation of one of the p53 mimetics. Experimentally measured scalar coupling constants, 
interproton distances derived from 1D-NOESY spectroscopy and both 1H and 13C chemical shifts were 
compared to the Boltzmann averaged values, calculated using DFT calculations. An excellent 
correlation was observed between the two data sets, confirming the predicted conformational bias.  
Finally, the binding of the p53 mimetics to Mdm2 was explored using 1H-15N HSQC spectroscopy. The 
chemical shift perturbations (CSPs) that were observed upon binding of the ligands were mapped to 
amino acids located primarily in, or on the periphery of, the p53 binding pocket on Mdm2. The CSPs 
were tracked with increasing concentrations of ligand to obtain dissociation constants (Kd). Two 
different p53 mimetics were tested and binding affinities as low as 8.8 µM were obtained. Additionally, 
the binding of two control molecules was assessed using 1H-15N HSQC spectroscopy, to confirm the 
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Chapter 1: Introduction 
1.1 Understanding and Controlling Molecular Conformation 
The structure of a molecule, both its configuration and its conformation, are central to how the molecule 
behaves and the properties its exhibits. A different 2-dimensional or 3-dimensional arrangement of the 
same set of atoms will result in a unique molecule with distinct properties and thus correctly identifying 
a molecules 2D- and 3D- structure is crucial in molecular design.[1] Understanding how atoms are 
connected to form the 2D-structure is now relatively straightforward, owing to improvements in a 
number of analytical techniques, although none are as important as the developments in nuclear 
magnetic resonance (NMR) spectroscopy.[2] Examining a molecules 3D-structure or conformation, i.e. 
how the atoms arrange themselves in space once they are connected, is a much bigger challenge. The 
classic methodology used to confirm a molecules conformation or 3D-structure is X-ray crystallography. 
However, this technique requires a solid crystal of the molecule to be grown, which is not always a 
possibility. Additionally, only information regarding the solid-state conformation is provided, which 
can be affected by factors including crystal packing. Exploring the conformation of a molecule in 
solution is a much more challenging problem as conformational dynamics now come into play. 
Fortunately, NMR spectroscopy exists and can provide a plethora of information regarding molecular 
conformation in solution that one would want to ask, especially when coupled with computation.[3]  
Section 1.1 will discuss the importance of molecular conformation, with a focus on the design of potent 
therapeutics, and discuss some of the methods that are available when trying to control molecular 
conformation. A short discussion of relevant examples from the literature demonstrating how molecular 
preorganisation can improve binding affinity is also present. The chapter will later go on to discuss how 
conformationally controlled molecules can be synthesised and analysed, before discussing the 
importance of conformational control in the inhibition of protein–protein interactions (PPIs).  
1.1.1 The Importance of Molecular Conformation in Drug Discovery 
In the drug discovery industry, structure-based drug design (SBDD) has fast become a mainstay in 
modern drug design and has led to the design of multiple successful small molecule drugs.[4–6] During 
this process, a small molecule is designed to fit complementary to its targeted binding pocket. Typically, 
x-ray crystal structures or NMR-derived three-dimensional structures of the receptor are used to design 
a ligand that fits into the binding pocket. If a structure of the receptor is not experimentally available, it 
is possible to computationally derive a model of the receptor.[7] Despite the success that has been 
achieved with SBDD, the process often overlooks two important points. The first being the 
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is.[8] Often the bound conformation of the ligand is not a low energy conformation in solution and thus 
the molecule must undergo a conformational rearrangement to fit into the binding pocket.[9] The second 
is that it assumes the receptor is rigid and that the ligand will dock by an ‘induced fit’ mechanism. 
However, this is not true, and a receptor can present many different conformations of the binding pocket 
to the ligand, one of which will be selected by the ligand that maximises binding affinity.[10] This PhD 
project is concerned with the former of these two issues and will explore methods to understand and 
control molecular conformation in solution. 
Very often in SBDD the conformation of the free ligand in solution is not given adequate consideration 
during the drug design process. This is likely due to the lack of high throughput experimentation 
available that can accurately estimate the conformation of a flexible molecule in solution. Currently, 
the most accurate experimental method for analysing molecular conformation in solution is advanced 
NMR spectroscopy, such as NOESY spectroscopy, which is not particularly amenable to high-
throughput experimentation.[11] This is unfortunate as it is known that if the conformation of the ligand 
free in solution does not reflect that of the bound ligand conformation a conformational reorganisation 
of the ligand is required for binding (Figure 1).[12]  
 
Figure 1. The conformational reorganisation required if the bound ligand conformation is not a low energy conformation in 
solution. 
This conformational reorganisation reduces the overall binding affinity of the ligand to the receptor, 
due to both enthalpic and entropic factors.[6] Although it is experimentally not possible to measure the 
value of ΔGreorganization
[13], a number of theoretical studies have been performed and values typically exist 
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ligands that can adopt multiple conformations, of which the bound conformation is not present as a low 
energy conformer, are not ideal drug candidates and will demonstrate lower binding affinities.  
A more attractive approach is to design drug candidates rationally and intelligently, that display a 
conformational preorganisation of the free ligand in solution towards the bound conformation.[16–18] 
This prevents a conformational reorganisation from being required, lowering the entropic penalties of 
binding and thus increasing the binding affinity. A conformationally preorganised molecule also 
displays much faster on-rate kinetics (kon) for protein-ligand binding, which also increases the binding 
affinity.[19] Since a conformationally preorganised molecule in solution effectively presents an increased 
concentration of the bioactive conformation towards the protein and no reorganisation is required prior 
to binding, an increase in the rate of kon is observed.  
It is clear that conformational preorganisation improves binding affinity and an understanding of free 
ligand conformation in solution can be used to rationally design ligands with higher binding affinities. 
If this analysis is completed during SBDD, it will significantly reduce the number of candidates having 
to be synthesised and tested, as a greater likelihood of finding a high affinity ligand will be achieved.[6] 
So, the question remains why this isn’t standard practice in SBDD? As mentioned earlier it is very 
challenging to obtain experimental information regarding the free ligand conformation in solution, and 
typically advanced NMR spectroscopy and computational chemistry must be employed. Despite this, a 
number of examples in the literature exist from both industry and academia where an understanding of 
free ligand conformation in solution has been used to design conformationally preorganised molecules. 
A discussion of a small number of examples will be given in section 1.1.3, following a discussion of 
how molecular conformation can be controlled.  
1.1.2 How is Molecular Conformation Controlled? 
Before we can discuss how to control molecular conformation, an understanding of what 
conformational isomerism is will be helpful. Conformational isomers of a molecule arise from the free 
rotation around single bonds in the molecule to generate a new 3D- arrangement of the atoms, known 
as a conformer. The energies of the different conformers possible for a molecule differ based on various 
stereo- and electronic- factors.[20] The low energy conformers, or local minima on the energy surface, 
are referred to as conformational isomers of the molecule. The high energy conformations however, or 
local maxima, are referred to as transition states. The interconversion between conformations is 
dependent on the rotational energy barrier.[21] Controlling molecular conformation is typically 
concerned with making this rotational energy barrier higher for certain bond rotations, favouring certain 
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This concept of local minima and maxima existing on an energy surface can be demonstrated simply 
by looking at butane. The central C-C bond of butane can freely rotate giving rise to six different 
conformations with different energies, primarily differing due to steric interactions.[22] There are three 
local minima of butane (1a, 1c, 1e), all of which avoid sterically incumbering eclipsing interactions. 
These conformations are known as the staggered conformations. The global minimum, known as the 
antiperiplanar conformation (1a), has a dihedral angle of 180° between the methyl groups, placing the 
methyl groups anti to one another. The two other staggered conformations (1c and 1e) place the methyl 
groups in a gauche conformation, with a dihedral angle of 60°. The steric interactions between methyl 
groups in a gauche interaction increases the energy of the conformer by ~3.3 kJ mol-1, calculated using 
ab initio Density Functional Theory (DFT) methods.[23] The three local maxima of butane (1b, 1d, 1f), 
all exhibit an eclipsed conformation. The global maximum (1d) features an eclipsed interaction between 
the methyl groups, increasing the energy of the conformer by 17-25 kJ mol-1, due to both torsional strain 
and Me-Me steric interactions. The two other local maxima (1b and 1f) feature a Me-H eclipsing 
interaction, raising the energy from the global minima by ~14.2 kJ mol-1.[24,25] This conformational 
behaviour can be represented by a potential energy surface diagram (Figure 2).   
 
Figure 2. The potential energy diagram for butane. The Newman projections of the different conformations are shown 
below. 
Unbranched alkyl chains feature complex conformational behaviour and have a huge number of low 
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present, typically the conformer will dihedral backbone dihedral angles of 180°, the propensity for the 
molecule to adopt this conformation reduces as the number of rotatable bonds increases because the 
enthalpic gain in reducing the number of unfavourable interactions is outweighed by the entropic cost 
of preorganisation.[27] However, it is possible to favour certain conformations over others by increasing 
the barrier to single bond rotation often through the introduction of steric strain. A discussion of some 
of the examples available for controlling conformation is included.  
One method that has proven successful involves constraining acyclic linear chains into rings. For 
example, hexane has twelve unique conformations, which can freely interconvert at room 
temperature.[28,29] However, constraining hexane into a cyclic ring, and forming cyclohexane, reduces 
the number of rotatable bonds and as a result only six conformations of cyclohexane are possible, of 
which the two chair conformations are considerably lower in energy. A second example of introducing 
rings to control molecular conformation was described by Clark Still. He demonstrated that it was 
possible to control the conformation of the polyethylene glycol chain 2, which has over 1000 
conformations within 13 kJ mol-1 of the global minimum, by annealing six membered rings along the 
chain (3). This reduces the number of conformations that can exist within 13 kJ mol-1 of the global 
minimum to 25 (Figure 3).[1,30]  
 
Figure 3. The effect of ring annellation on the conformational landscape of open chains. 
The introduction of rings is a common strategy in the drug discovery industry, with many small 
molecule drugs containing multiple aromatic or aliphatic ring systems. It has also become increasingly 
common to constrain the conformation of flexible drugs with larger ring systems, through 
macrocyclization.[31,32] Although controlling molecular conformation through the introduction of rings 
has had considerable success, especially in the pharmaceutical industry, it is not without its limitations. 
Some of which include the addition of considerable molecular weight to the molecule and the fact that 
the introduction of rings is not always synthetically straightforward. A second strategy, that does not 
actively prevent the rotation of C-C bonds, but simply increases the barrier to rotation is the introduction 
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A destabilising interaction that can control conformation or direct the outcome of stereoselective 
reactions is known as allylic strain, or A1,3 strain.[33] The concept of allylic strain was first proposed by 
Johnson and Malhotra in 1965 when they noticed that certain conformations of cyclohexene were 
disfavoured over others due to unfavourable steric interactions for certain geometries of the double 
bond.[34] For example, consider the rotation around the single bond of an allylic system such as 4. The 
global energy minimum for structures such as this, would be the one that places the two hydrogen atoms 
eclipsed to one another (4a), with a H-C-C=C dihedral angle between 0 ± 30°.[35] If two methyl groups 
are eclipsed however (4b), then A1,3 strain is introduced forcing this conformation up in energy by 
~17 kJ mol-1, determined by ab initio DFT calculations (MP2-631G(d)//3-21G).[36] Although rotation 
of the vinylic bond is possible, it is unlikely at room temperature due to the high barrier of rotation 
enforced by A1,3 strain. Thus, molecules such as 4 will typically populate a single conformation 
corresponding to 4a (Figure 4).[33] The major factor governing the magnitude of allylic strain is the size 
of the substituents at the 1 and 3 positions, with large bulky substituents introducing greater allylic 
strain.[37] 
 
Figure 4. Conformational bias imposed by allylic strain. 
A second destabilising interaction that can be introduced to a molecule to control conformation is the 
syn-pentane interaction.[38] Pentane, like butane, can adopt a number of conformations resulting from 
rotation of single bonds, and these conformations differ in energy (Figure 5). The lowest energy 
conformation of pentane is where the two dihedral angles are both antiperiplanar, eliminating any 
unfavourable interactions (aa 5b). Rotation of one of the dihedral angles by 60° results in conformer 
5c, which contains an antiperiplanar dihedral angle followed by a gauche+ dihedral angle (ag+). The 
unfavourable gauche interaction increases the energy of conformer 5c by ~3.3 kJ mol-1, calculated using 
ab initio DFT calculations (MP4SDQ/6-31G(d)).[39] The rotation of the second dihedral angle by 60° 
gives a conformer featuring a gauche+ dihedral angle followed by a second gauche+ dihedral angle (g+g+ 
5d). Two unfavourable gauche+ interactions are now present, increasing the energy of this conformation 
by ~5.9 kJ mol-1 from the global minimum. A final rotation of the first dihedral angle by 60° gives the 
global maximum, with a gauche+ dihedral angle followed by a gauche– dihedral angle (g+g– 5a). The 
two methyl groups are now eclipsed to one another and the hydrogen atoms on the carbon are in very 
close proximity resulting in a steric clash. This interaction is known as the syn-pentane interaction and 
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Figure 5. The different conformations of pentane and their relative energies 
For pentane, the conformational control is poor with only one conformation being strongly disfavoured, 
however through the careful design of the substituent pattern on the hydrocarbon chain multiple syn-
pentane interactions can be introduced to destabilise all but one conformer.[26] Controlling molecular 
conformation by exploiting the syn-pentane interaction was pioneered by Reinhard Hoffmann. He 
showed that the simple alkyl chain 6, which would have numerous low energy conformations, can be 
controlled by the addition of methyl groups (7 or 8), inducing syn-pentane interactions (Figure 6).[33] 
The two molecules 7 and 8 have only two conformations that avoid a destabilising syn-pentane 
interaction. For molecule 7, conformer 7a is more energetically favourable, giving rise to a 
conformational bias towards an all-trans chain whereas for molecule 8, conformer 8a is more 
favourable leading to a bending of the main chain. This suggests that molecules of the type 7 and 8 have 
specific folding patterns due to the avoidance of syn-pentane interactions and that by changing the 
relationship of the methyl groups relative to each other it is possible to switch the shape of the backbone. 
This phenomenon has been observed previously in polymers of polypropylene.[41] Syndiotactic 
polypropylene, which features a repeating unit similar to 7 exists as an all-trans chain, or a linear chain. 
Isotactic polypropylene, which features a repeating unit similar to 8 exists as a helical chain with a 
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Figure 6. The conformational preference of 7 and 8 
Hoffmann also demonstrated that it is possible to reduce the number of conformations further from two 
to one by the introduction of another methyl group, to give polymethylated hydrocarbon chains. For 
example, on examination of 2,3,4,5-tetramethylhexane (9), only one conformation that is devoid of syn-
pentane interactions is possible (9a) (Figure 7).[1] The rotation of any C-C bond in the molecule will 
create a syn-pentane rendering 9 monoconformational. 
 
Figure 7. The conformational preference of 2,3,4,5-tetramethylhexane 9 
In 2014, Aggarwal et. al. demonstrated the utility of the syn-pentane interaction in controlling molecular 
conformation.[27] Inspired by the pioneering work of Hoffmann, Aggarwal et. al. synthesised molecules 
containing ten contiguous methyl groups on a hydrocarbon backbone. The molecules were synthesised 
by iterative lithiation–borylation[42], which will be discussed in section 1.2. Three different 
diastereomers were synthesised with differing relationships between the methyl groups. In an analogous 
fashion to molecules 7 and 8, the molecules should take on defined conformations depending on the 
relationship of the methyl groups due to the avoidance of syn-pentane interactions.  
The diastereomer that has all-syn relationships between the methyl groups (10) should adopt a helical 
conformation, while the diastereomer that has alternating anti-syn relationships between the methyl 
groups (11) should adopt a linear conformation (Figure 8). If any other conformation of these molecules 
were to be adopted, at least one syn-pentane interaction would be present, effectively reducing the 




 UOB Open 
diastereomer was predicted to have no conformational bias as no conformation of this molecule can 
avoid syn-pentane interactions. X-ray crystallography and NMR spectroscopy coupled with 
computation confirmed the suspected conformational bias for the three diastereomers, work which will 
be discussed in section 1.3.3. This work demonstrates how effective the incorporation of multiple syn-
pentane interactions into a molecule can be at controlling molecular conformation. 
 
Figure 8. The conformational bias of 10 and 11. (a) The structures of diastereomers 10 and 11. (b) The diamond lattice 
analysis of the two diastereomers. Using the diamond lattice, it is clear that the rotation of any C-C bond would result in a 
conformer that has at least one syn-pentane interaction. (c) A 3D representation of 10 and 11 
1.1.3 Specific Examples of Molecular Preorganisation in Drug Discovery 
Although controlling molecular conformation is not straightforward, and the analysis of free ligand 
conformations in solution is challenging, several examples exist in the drug discovery process where 
preorganised molecules which demonstrate improved binding affinities. A few of these examples will 
be discussed. For example, in 2017 a team of scientists from AstraZeneca reported the rational design 
of a high affinity Mcl-1 specific inhibitor.[43] Mcl-1 is a member of the Bcl-2 family of proteins and is 
involved in a number of protein–protein interactions (PPIs) that regulate apoptosis.[44] An initial affinity-




 UOB Open 
IC50 of 2 µM. Crystallisation of a derivative of 12 bound to Mcl-1 revealed that the bound conformation 
placed two sterically hindering groups in very close proximity, suggesting that the bound conformation 
is unlikely to be a low energy conformation of the free ligand in solution. They proposed that the free 
ligand conformation could be preorganised to adopt the bound conformation through macrocyclization. 
This resulted in compound 13 which demonstrated a much higher affinity to Mcl-1 with an IC50 of <3 
nM. Indeed, the bound conformation of 13 matches with the free ligand conformation of 13, predicted 
by NMR (Figure 9).[43] 
 
Figure 9. The 2D-structure and free and bound conformations of both 12 and 13. The free ligand conformations of 12 are 
shown in grey, with the bioactive conformation superimposed in green (left). The free ligand conformation of 13 matches 
with the bound conformation of 13 (right). The figure was reproduced from reference[45] PDB ID: 5KU9 and 5MEV 
Typically, a full analysis of scalar coupling constants, chemical shifts and interproton distances derived 
from NOESY is required to assess the conformational landscape of a flexible molecule in solution. 
However, the team of scientists at AstraZeneca demonstrated that the 1D 1H-NMR spectrum could be 
used to indicate if the free ligand conformation adopted the bound conformation.[19] For the candidates 
discussed previously (12 vs 13), if the bioactive conformation was adopted then a large upfield shift of 
one of the aromatic residues is observed, caused by shielding from the dichlorosubstituted aromatic ring. 
The proton shown in blue on 13 (Figure 10), described as the reporter proton, shifts from 7.1 to 6.4 
ppm after macrocyclization suggesting that the proton has been shielded by ring current effects from 
the dichlorosubstituted aromatic ring.[43] This would result in a conformation resembling that of the 
bioactive conformation. Additionally, upon rigidification from macrocyclization, each methylene pair 
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Figure 10. The 1D-1H NMR spectrum of 12 (top) and 13 (bottom). The reporter proton is highlighted and the upfield shift 
from 7.1 ppm to 6.4 ppm is shown. The three methylene pairs indicative of macrocyclization, X, Y and Z, are also noted. 
The figure was reproduced from reference[45] 
This methodology reported by AstraZeneca is incredibly powerful as the acquisition of 1D 1H NMR 
spectra is very fast and the measurement of 1H chemical shifts is straightforward. Using the 1H NMR 
conformational signatures to indicate if the desired conformation is adopted, will enable the rapid 
screening of potential drug candidates. This information can be used to guide medicinal chemistry 
decisions, hopefully reducing the number of candidates that have to be synthesised.  
Using a reporter proton and observing changes in the 1D-1H NMR spectrum upon macrocyclization, 
AstraZeneca have been able to identify a number of preorganised macrocyclic drugs, all of which show 
an improved binding affinity compared to their flexible counterparts.[10,46] Macrocyclization is a well-
known strategy in ligand rigidification and as a result the prevalence of macrocycles in small molecule 
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small molecules. It has also found use in the conformational control of peptides. Peptide therapeutics, 
despite their typically higher selectivity and specificity over small molecules, often demonstrate poor 
conformational control and proteolytic digestion.[49,50] Maintaining the secondary structure of short 
peptide sequences is challenging and typically they display significant conformational flexibility in 
water. This limits their biological activity and thus strategies that control the conformation of peptides 
are of high importance.  
One strategy that has proven successful in the control of peptide conformation involves the introduction 
of a covalent staple across between 4 to 7 residues of the peptide sequence, forming a macrocycle across 
the peptide.[51] Typically, olefinic side chains are added to judicious residues in the peptide sequence 
and the macrocycle is formed by ring closing metathesis (RCM).[52,53] Such peptides are known as 
stapled peptides and they are very efficient at stabilising the secondary structure of a peptide, essentially 
locking it in a certain conformation, whilst also helping to improve the pharmacokinetic properties by 
introduction of certain groups onto the macrocycle (Figure 11).[54] A huge number of stapled peptides 
have been reported in the literature, almost all of which show improved binding affinity to their desired 
target that the unstapled version.[51]   
 
Figure 11. A schematic to show the impact on peptide structure upon introducing a staple.  
In 2016, Keating et. al. demonstrated that by increasing the helicity of Mcl-1 inhibitor peptides through 
both stapling and the introduction of residues known to promote helicity results in an increased binding 
affinity attributed to slower off-rate kinetics.[55] The introduction of a hydrocarbon staple (M1d) across 
the original peptide sequence (MS1) increases the % helicity by 3-fold, determined by CD spectroscopy. 
The % helicity was increased further by introducing non-natural amino acid residues with helix inducing 
side chains (M2d and M3d). A positive linear correlation between % helicity and binding affinity was 
observed (Figure 12a and Figure 12b). Additionally, a positive linear correlation between % helicity 
and peptide half-life was also observed, suggesting that the peptides with a higher % helicity were also 
more stable to protease digestion (Figure 12a and Figure 12b). This work clearly demonstrates the 
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Figure 12. The results obtained from Keating et. al. clearly demonstrate that a high % of helicity is required for potent 
binding. a) The results from the CD spectroscopy which show an increase in helicity from the unstapled peptide MS1 to the 
stapled peptides M1d – M2d. b) The IC50 obtained for the four different peptides showing an increase in potency as the 
helicity is increased. c) The increase in half-life as the helicity is increased in clearly demonstrated on exposure of the 
peptides to chymotrypsin. This figure was reproduced from reference[55] 
In the previous example, the peptide sequences were very long, with >20 amino acids in the sequence. 
However, much shorter peptide sequences are also common therapeutics, with a molecular weight and 
behaviour more closely aligned to a traditional small molecule. The hepatitis C virus (HCV) protease 
enzyme has been a long sought-after target of the pharmaceutical industry and nearly all strategies in 
the literature are derived from a hexapeptide sequence (DDIVPC, 14).[56] However, since it is well 
known that peptidic therapeutics display complex conformational behaviour, a group of scientists at 
Boehringer Ingelheim, led by Stephen Kawai, used the structure of DDIVPC to design a 
conformationally controlled derivative.[57]  
The team of scientists at Boehringer Ingelheim first confirmed by NMR spectroscopy that the free 
conformation of DDIVPC did not reflect that of the bound conformation. Following this, a number of 
modifications were made to the structure of DDIVPC, employing classical SBDD methods, including 
truncation of the N-terminus to yield a tri-peptide moiety, introduction of a t-butyl group and 
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significantly improved binding affinity compared to DDIVPC. A crystal structure of a urea analogue of 
15 bound to the active site of the HCV protease enzyme was obtained (PDB: 4K8B), confirming that 
15 bound in a very similar fashion as DDIVPC. ROESY NMR spectroscopy was used to obtained 
quantitative interproton distances of 15 in solution, which suggested that the free conformation of 15 in 
solution correlated very well with that of the bound.  
 
Figure 13. The structure and binding affinities of DDIVPC (14) and 15. 
The improvement in the binding affinity observed from DDIVPC to 15 supports the theory that by 
conformationally restraining the free conformation towards the bound conformation it is possible to 
increase binding affinity, However, the group at Boehringer Ingelheim used NMR spectroscopy, 
specifically 3JNH-Hα coupling constants, to confirm that this is indeed true for this example. They 
synthesised three derivatives of 15, with decreasing steric bulk on the side chain of first amino acid. 
They found that as they decreased the steric bulk from t-butyl>methyl>proton, the value of 3JNH-Hα also 
decreased from 8.3>7.6>5.6 Hz (Table 1). For structure 15, the t-butyl group enforces a trans 
conformation of the peptide bond, resulting in a large coupling constant. For structure 17, the hydrogen 
is not capable at controlling conformation and allows free rotation around the peptide bond, resulting 
in a smaller coupling constant. The positive effect of the conformational control exerted by the t-butyl 
group, and also the methyl group to a lesser extent, is observed as an improvement in the binding affinity. 
Thus, this work serves to further confirm the importance of exploiting conformational control in the 
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Table 1. The effect on the binding affinity upon reducing the steric bulk on the side chain of first amino acid. The decrease 
in binding affinity is caused by a reduction in the number of conformers adopting the required trans-conformation, evident 
from the decrease in the 3JNH-Hα coupling constant 
Inhibitor Ki (µM) 3JNH-Hα (Hz) % trans-conformer 
 
0.02 8.3 87 
 
0.31 7.6 80 
 
3.0 5.6 41 
The previous two examples discussed the conformational control of peptide therapeutics, however, 
peptides suffer significantly from proteolytic digestion and poor membrane permeation and are thus 
often considered undesirable. In an attempt to overcome this, peptoids were developed.[58] The term 
peptoid was coined to describe synthetic oligomers based on repeating units of oligo(N-substituted 
glycine) (oligo-NSG, 19).[59–61] Peptoids typically display enhanced proteolytic stability and membrane 
permeability than peptides, however they still suffer from poor conformational control. Attempts at 
controlling the conformation of peptoids was previously limited to the introduction of bulky and 
hydrophoboic N-substituents[62,63] however, this severely limits the water solubility and restricts the 
choice of the N-substituent. Kodadek et. al.[64] and Sando et. al.[65] have addressed this issue through 
the introduction of a methyl group on the backbone α-carbon of oligo-NSG, synthesising what is known 




 UOB Open 
 
Figure 14. The structures of a peptide, an oligo-NSA and an oligo-NSG 
The methyl group introduced causes conformational control primarily through the avoidance of pseudo-
1,3-allylic strain. Two mechanisms by which pseudo-1,3-allylic strain is avoided are operational. The 
first being between the methyl group and the carbonyl oxygen of the preceding residue and the second 
between the methyl group and the N-substituent of the next residue. These two mechanisms restrict the 
rotation around the dihedral angles φ and ψ respectively. Additionally, the rotation around a third 
dihedral angle, ω, is restricted to ~180° to avoid a steric clash between the methyl groups that would 
exist if the value of ω was ~0°. This forces dihedral angle ω, which exists between the peptide bond, 
into a trans conformation (Figure 15). These mechanisms result in oligo-NSA having an extended 
linear conformation in water. It was also found that the nature of the N-substituent did not affect the 
extended conformation of oligo-NSA and the N-substituents were well-dispersed in space.[65] 
 
Figure 15. A diagram showing the definition of the three important dihedral angles ω, φ and ψ and the pseudo-1,3-allylic 
strain and restricted rotation around ω controlling the conformation of oligo-NSA. 
Sando and co-workers demonstrated that oligo-NSA has superior biological activity to oligo-NSG, due 
to its conformational control, through the design of an inhibitor of the p53-Mdm2 PPI. The p53-Mdm2 
PPI is perhaps the most well-known PPI in the scientific literature and is involved with cellular 
pathways regulating apoptosis to DNA repair.[66] More about this PPI will be discussed in section 1.5. 
Sando et. al. synthesised a p53 mimetic based on both oligo-NSG and oligo NSA and reported a binding 
affinity to Mdm2 of >300 µM and 1.1 µM respectively.[65] This clearly demonstrates that by 
conformationally preorganising a molecule, even one as large as a peptoid, much higher binding 
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Many of the examples that have been discussed in this section have involved the design of an inhibitor 
of a PPI. PPIs are very challenging targets in drug discovery, for reasons which will be discussed in 
section 1.4, however conformational rigidity of potential small molecule inhibitors has been highlighted 
as a key parameter to consider in their design, highlighted recently in a review by Lawson et. al.[67] This 
PhD project aims to further demonstrate that conformational control of a small molecule PPI inhibitor 
can improve the binding affinity to these notoriously hard to drug targets.  
1.2 The Iterative Homologation of Boronic Esters  
Synthesising conformationally controlled molecules is not a straightforward process. Often the 
introduction of new stereocentres are required, and enantioselective synthesis is challenging. For 
example, controlling molecular conformation through the avoidance of destabilising syn-pentane 
interactions requires contiguously substituted methyl groups to be placed enantiospecifically onto a 
hydrocarbon backbone. The next section will discuss a synthetic methodology that enables the synthesis 
of contiguously methyl substituted hydrocarbons. 
Organoboranes and boronic esters are one of the most synthetically versatile groups and can be 
transformed into a wide range of functional groups, often with complete stereospecificity.[68] Their 
impressive reactivity is due to the vacant boron-centred p-orbital which is able to accept a nucleophilic 
electron pair to form boronate complexes. Organoboranes are very electrophilic, owing to this vacant 
p-orbital, and can react with a wide range of nucleophiles however, they typically display very poor 
stability and are prone to oxidation. Boronic esters circumvent many of these stability issues due to π-
donation from the lone pair of an oxygen atom of the ester group into the vacant p-orbital of boron.[69] 
This π-donation does reduce the electrophilic character of boronic esters, compared to organoboranes, 
however their improved stability renders them the preferred functional group in organoboron chemistry.  
One of the most attractive features of organoboranes and boronic esters is that they can be homologated 
cleanly and with high stereochemical fidelity, provided there is a leaving group on the nucleophilic 
carbon and that a substituent on boron can arrange itself antiperiplanar to the leaving group.[42] If this is 
the case, the boronate complex 23 can undergo a stereospecific 1,2-metallate rearrangement to yield a 
homologated species 24, with inversion of stereochemistry (Scheme 1). During this process, a boron 
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Scheme 1. The reaction of an organoboron species with a nucleophile to form a boronate complex which can undergo a 
stereospecific 1,2-metallate rearrangement 
The homologation of boronic esters was first reported in 1980 by Matteson in which a chiral boronic 
ester reacts with (dichloromethyl)lithium to give a homologated boronic ester (Scheme 2).[71,72] In this 
approach, a chiral auxiliary is attached to the diol group of the boronic ester and thus the chirality of 
the product is determined by the substrate. This approach is known as the substrate-controlled 
homologation of boronic esters. 
 
Scheme 2. The substrate-controlled homo logation of boronic esters proposed by Matteson. 
The first step of the substrate-controlled homologation of a boronic ester involves the reaction of an 
enantiopure boronic ester 25 with (dichloromethyl)lithium to yield a (dichloromethyl)borate complex 
26. The subsequent addition of zinc chloride causes the borate complex to undergo a rearrangement via 
the favoured transition state 27a to give an α-chloroboronic ester (28) in high diastereomeric purity, 
typically >99:1 dr. The zinc chloride is thought to promote this rearrangement by interaction with the 
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chloride stabilises the preferred TS (27a) through interaction of a chloride from the zinc chloride with 
the C-H bond of the borate complex. The newly formed α-chloroboronic ester 28 can react with a 
Grignard or organolithium reagent to give a borate complex 29. The borate complex 29 then undergoes 
a stereospecific 1,2-metallate rearrangement to yield a homologated boronic ester, 30.[73]  
Although Matteson’s substrate-controlled homologation methodology is able to homologate a boronic 
ester with exceptional stereocontrol, the stereochemistry of the product is governed by the 
stereochemistry of the chiral auxiliary attached to the boronic ester.[42] In order to access a different 
stereoisomer a sometimes challenging manipulation is required to invert the stereochemistry of the diol 
on the boronic ester. This can add up to three steps to the sequence, making this an unattractive approach 
for the iterative homologation of a boronic ester. A more attractive approach would be for the 
stereochemical outcome to be dictated by the stereochemistry of the reagent. This would enable access 
to different stereoisomers by simply switching the enantiomer of the reagent used. This approach is 
known as the reagent-controlled homologation of boronic esters.  
The reagent-controlled homologation of boronic esters involves the formation of a chiral boronate 
complex, using a suitable chiral reagent, that can then undergo a stereospecific 1,2-metallate 
rearrangement to yield a homologated chiral boronic ester that can then be used in subsequent 
homologations. In order to achieve this, a reagent that can act as a chiral carbanion that also possesses 
a leaving group at the same carbon as the carbanion, is required.[74] Additionally, the chiral carbenoid 
needs to display excellent chemical and configurational stability.[75]  
One class of compounds that meets these requirements are Hoppe’s lithiated carbamates. Hoppe has 
shown that chiral lithiated carbamates (32), generated from the chiral ligand-assisted deprotonation of 
a carbamate (31), can be trapped with B(OiPr)3 to yield an α-carbamoyl alkylboronate, which can be 
converted to the corresponding boronic ester through the addition of pinacol borane (33) (Scheme 
3).[76,77] Hoppe showed that both enantiomers of the chiral diamine sparteine could be used to generate 
both enantiomers of the chiral carbanion upon deprotonation with s-BuLi. The corresponding chiral 
carbenoid was chemically and configurationally stable at -78 °C. Addition of a Grignard reagent to the 
newly formed boronic ester gave a boronate complex (34) that, upon warming the flask to room 
temperature, underwent a 1,2-metallate rearrangement to yield a homologated boronic ester (35) after 
expulsion of the carbamate moiety as a leaving group. The carbamate group (OCb) also acts as a 
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Scheme 3. Hoppe's alkylation of boronic esters using lithiated carbamates 
Following on from this seminal work by Hoppe et. al., the groups of both Aggarwal[75] and Kocienski[79] 
have shown that a pinacol boronic ester (or borane) can be added directly to the lithiated carbamate 
(Scheme 4). The methodology developed by both groups has now been coined lithiation–borylation.  
 
Scheme 4. The direct reaction of a pinacol boronic ester with enantioenriched lithiated carbamates developed by both 
Kocienski and Aggarwal.  
Whilst exploring the scope of this reaction, Aggarwal et. al. found that certain boronic esters were slow 
to migrate and Lewis acids were required to promote the 1,2-metallate rearrangement. Because of this, 
alternative leaving groups that could enhance the rate of the 1,2-metallate rearrangement were 
considered. Beak has previously reported that 1,4,6-triisopropylbenzoates (TIB) can be deprotonated 
by s-BuLi and TMEDA at the α position, suggesting that TIB esters would be suitable in lithiation–
borylation.[80,81] Aggarwal et. al. have reported that using the hindered TIB esters in lithiation–
borylation enables the 1,2-metallate rearrangement of slow migrating groups.[82]  
The mechanism of lithiation–borylation involves three distinct steps: lithiation, electrophilic trapping 
or borylation, and the 1,2-metallate rearrangement (Scheme 5). The first step involves the formation of 
a chemically and configurationally stable chiral carbenoid (41a/b) through the α-lithiation of either a 
carbamate (39) or a benzoate (40). The chiral carbenoids can be accessed using the chiral ligand-assisted 
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deprotonation of enantioenriched secondary carbamates or benzoates can be used. Finally, the chiral 
carbenoids can be accessed from the stereospecific tin-lithium exchange of enantioenriched stannanes. 
Following this, an electrophilic organoboron species (42) traps the newly formed chiral carbenoid to 
form a chiral boronate species (43a/b). Again, this species is chemically and configurationally stable at 
-78 °C. Typically this process occurs with retention of configuration however, invertive pathways have 
been observed when using benzylic carbamates and boranes. The final stage is a stereospecific 1,2-
metallate rearrangement of a group from boron to its attached carbon, resulting in expulsion of a leaving 
group. This forms a new carbon-carbon bond and yields the homologated boronic ester (44a/b). This 
process only occurs upon warming the flask to room temperature.  
 
Scheme 5. The mechanism of lithiation–borylation 
Aggarwal et. al. have gone on to show that this process can be performed iteratively, with the 
homologated boronic ester being used as the starting boronic ester in a subsequent homologation. Using 
Hoppe’s lithiated carbamates, they demonstrated that three iterative homologations of a boronic ester 
could be performed in good yield and good d.r. Further homologations were less successful with a 
mixture of starting boronic ester (under homologated product), desired product and the over 
homologated product being formed (Scheme 6). They proposed that the 1,2-metallate rearrangement of 
the boronate complex was too slow, allowing it to reverse back to the starting boronic ester and the 
lithiated carbamate.[83] This would allow for 48 to react with any homologated product 49 that had 
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Scheme 6. The three iterative homologations performed by the Aggarwal group using lithiation–borylation 
To overcome this problem, Aggarwal et. al. explored the use of triisopropylbenzoates in the iterative 
homologation of boronic esters, as they have been shown to aid the rearrangement of slow migrating 
groups. They demonstrated that, provided a chiral carbenoid could be accessed in >99.9:0.1 e.r., the 
iterative homologation of boronic esters could be performed to generate molecules with up to ten 
contiguous methyl substituents with total stereocontrol.[27] If the chiral carbenoid cannot be accessed in 
high enantiomeric ratios and if each homologation does not occur with yields in excess of 95% then the 
resulting product distribution after nine iterative homologations would be extremely complicated.  
In order to meet these requirements, Aggarwal et. al. used the stereospecific tin-lithium exchange of 
enantioenriched stannanes for generation of the chiral carbenoid (Scheme 7). The enantioenriched 
stannanes (53) can be generated from the lithiation of ethyl triisopropylbenzoate (51) in the presence of 
s-BuLi and (±)-sparteine followed by electrophilic trapping with trimethyltin chloride to yield the α-
stannyl benzoate (53) in good enantiopurity. The resulting stannane can be recrystalised in methanol to 
provide the high enantiopurity required. Using this methodology, both enantiomers of the stannane were 
able to be synthesised as bench stable crystalline solids, ready for use in the iterative process.  
 




 UOB Open 
Using the enantioenriched stannanes as the chiral carbenoid precursor, nine iterative homologations 
could be performed with essentially one diastereomer formed. This resulted in the preparation of 
hydrocarbons bearing ten contiguously substituted methyl groups with complete stereocontrol and no 
column chromatography required until the end. Three diastereomers were synthesised (54, 55, 56) by 
changing the enantiomer of the stannane used in the sequence (Scheme 8). This process has been 
likened to a molecular assembly line of molecules with tailored shapes. By synthesising molecules of 
this type, the Aggarwal group were able to confirm the syn-pentane control that is expected for these 
molecules, as discussed in section 1.1.2. The conformational bias that was expected of the three 
diastereomers was confirmed using a combined NMR spectroscopy and computational approach.[27] 
This strategy for examining molecular conformation will be discussed in the next section.  
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1.3 The Analysis of Molecular Conformation using a hybrid NMR 
Spectroscopy and Molecular Mechanical/Quantum Mechanical 
Computational Approach  
Investigating the conformational landscape of a molecule in solution is not a trivial challenge, especially 
for molecules with a large number of rotatable bonds such as molecules 54, 55 and 56. NMR 
spectroscopy is arguably the most useful analytical tool for exploring conformation in solution as it 
provides information about the conformational ensemble of species that are present in solution. For a 
rigid molecule, with only a few conformers contributing to the conformational landscape at room 
temperature, NMR spectroscopy alone can be used to estimate conformer populations. However, for a 
flexible molecule with complex conformational dynamics contributing to the NMR spectra observed, 
NMR spectroscopy alone cannot accurately estimate conformer populations. Coupling NMR 
spectroscopy with molecular mechanics (MM) and quantum mechanics (QM) calculations can 
overcome this problem and provide insights into the molecular conformation in solution for highly 
flexible molecules.  
This hybrid NMR spectroscopy and computational approach has been routinely used throughout the 
literature to study the conformation of a molecule in solution and in the assignment of relative 
stereochemistry.[84–86] During this process, the experimentally derived chemical shifts, scalar coupling 
constants and interproton distances are compared to those calculated by density functional theory 
calculations (DFT). The mean absolute deviation (MAD) obtained between calculated and experimental 
data can be compared to the MAD typically observed in the literature to assess whether the computation 
has correctly estimated the conformational landscape of the molecule in solution.[3] To use this method 
to assign relative stereochemistry, it is possible to calculate the NMR parameters of the possible 
diastereomers and compare to the experimental NMR data. The correct diastereomer should provide the 
lowest MAD between experimental data and calculated data.  
This section will discuss the hybrid NMR and QM workflow used in the analysis of solution 
conformation. Select examples from the literature that have employed the hybrid QM and NMR 
spectroscopy approach to solving 3D molecular structure or relative stereochemistry will also be 
discussed.  
1.3.1 Extracting 2D- and 3D- Molecular Information using NMR Spectroscopy 
NMR spectroscopy provides a plethora of information regarding chemical structure and conformation. 
It is well known that the 1H and 13C chemical shift provides information regarding the chemical 
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question. This can help to build up a 2D-structure of the molecule however, much more information 
can be extracted using NMR spectroscopy that can also help deduce a molecules 3D-structure.  
The first parameter that will be discussed are vicinal scalar coupling constants, or 3J coupling constants, 
which have a strong dependence on the dihedral angle between the coupling nuclei. This was first 
reported by Martin Karplus in 1963.[87,88] The relationship between 3J and dihedral angle, described by 
the Karplus equation, and summarised in the Karplus curve is routinely used in the elucidation of 3D 
molecular structure and has proved reliable for a wide range of molecules. However, care must be taken 
if a molecule exhibits atypical bond lengths or bond angles, caused by ring strain for example, or 
contains electronegative substituents in the coupling pathway.[89–91] The equation was first developed to 
describe the relationship of 3-bond 1H-1H vicinal coupling constants (3JHH) to dihedral angle, however 
it has since been shown that a similar relationship is observed between 3-bond 1H-13C vicinal coupling 
constants (3JHC) and dihedral angle.[92]  
The relationship between 3JHH and 3JCH with dihedral angle be clearly seen from the Karplus curve 
shown in Figure 16. Using the Karplus relationship, a dihedral angle of 180°, corresponding to an anti-
relationship between X and H, will result in a large coupling constant (3JHH = 8 – 14 Hz, 3JCH = 6 – 8 
Hz ), due to optimal orbital overlap between the vicinal sp3 orbitals. However, a dihedral angle of 60°, 
corresponding to a gauche relationship between X and H, will result in a small coupling constant (3JHH = 
2 – 5 Hz, 3JCH = 1 – 3 Hz ). Thus, the magnitude of the coupling constant can be used to deduce the 
dihedral angle between the vicinal nuclei, helping to elucidate a 3D structure of a molecule.[93]  
 
Figure 16. The relationship between dihedral angle and vicinal scalar coupling constants. 
The experimental measurement of 3JHH is typically a straightforward process, with couplings measured 
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a number of 2D-methods exist which can aid in the extraction of nJHH values. For example, 2D J-
resolved methods, such as the 2D-J PSYCHE, which decouple spectra in the direct dimension (F2) and 
projects the multiplets to a second dimension (F1), from which the multiplet structure can be extracted.
[94] 
However, the acquisition of 2D J-resolved spectra is not trivial and is often plagued by poor lineshapes 
resulting from a 45° titling of the final 2D spectra.[95] Thus, it is very advantageous to have well resolved 
signals in the 1D 1H spectrum, from which the values of 3JHH can be measured.  
It is also possible to simulate complex or overlapped multiplets using spin simulation software such as 
SpinSimulation from MestreNova. Using spin simulation, the simulated multiplet arising from 
estimated coupling constants is compared to the experimental coupling constant. If deviations between 
the two multiplets are observed then the simulated multiplet is re-simulated using altered coupling 
constants and the process is repeated until no deviations are observed between the two multiplets. This 
method prevents the acquisition of additional spectra, however for severely overlapped or broad peaks 
it is usually still insufficient for measuring 3JHH values. 
Although 3JHH values provide valuable conformational information, they provide no information about 
quaternary centres within the molecule. This is where the measurement of 3JCH values can complement 
the measurement of 3JHH and provide further conformational information. In addition to providing 
information regarding quaternary centres, there are typically many more 3JCH values in a molecule than 
3JHH. Furthermore, 3JCH values can pass through heteroatoms and provide information connecting 
different spin systems. Despite the wealth information than 3JCH values can provide, they are not 
routinely used in conformational analysis due to the challenges associated with their measurement, 
primarily caused by the low natural abundance of 13C.[96–98] Large values of nJCH (typically, 1JCH) can be 
directly measured from the 1D 1H spectrum because they appear as 13C satellites. However, the intensity 
of these peaks is very weak and often overlapped with other 1H resonances in the spectrum. Values of 
nJCH can also be obtained from 1D coupled 13C spectra, however the spectra often comprise of complex 
overlapped multiplets caused by large values of 1JCH. Additionally, the spectra take a considerable 
amount of time to acquire due to direct 13C-detection.[99] Nevertheless, a number of 2D- methods exist 
that have enabled to accurate measurement of nJCH values.
[98] In 2017 Dickson et. al. reviewed the 
popular 2D-methods, focussing on the accuracy and practicality of the various methods, and reported 
that for a global nJCH analysis of a molecule the IPAP-HSQMBC (Inphase-Antiphased hetereonuclear 
single quantum multiple bond correlation) was the best choice.[99] This is primarily due to the ease of 
extraction of coupling constants from the data and the reduced experimental time required to measure 
the nJCH values (~3-6 minutes per nJCH, whilst other methods commonly require at least three times this). 
In a IPAP-HSQMBC experiment two separate HSQMBC spectra are recorded, one with the nJCH scalar 
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separate experiments or interleaved. The sum and the difference of the IP and AP FID’s are performed 
prior to the Fourier transformation of each. The sum and difference spectra are then overlaid and the 
nJCH scalar couplings can be extracted from the offset between multiplets in the F2 dimension between 
the two spectra (Figure 17).[100,101] The IPAP-HSQMBC experiment makes it simpler to extract 
couplings as it does not rely on the lineshape analysis of complex F2 multiplets. However, it is reliant 
on the sum and difference spectra exhibiting the same multiplet shape, which is not always the case. 
Additionally, the value of nJCH measured from the different peaks of an overlaid multiplet is not always 
consistent. This can be addressed by calculating the nJCH value as an average of the splitting’s.
[99]  
 
Figure 17. The IPAP-HSQMBC analysis of a multiplet. The sum (red) and the difference (blue) of the IP and AP HSQMBC 
spectra are overlaid and the coupling is measured from the offset between the multiplets.  
Another experimental NMR technique that provides useful 3D-information of a molecule is NOESY 
(Nuclear Overhauser Effect SpectroscopY). In a NOESY experiment, spin active nuclei that are close 
in space (typically <5 Å) can transfer spin polarization between dipolar coupled nuclei, giving rise to 
an NOE correlation. The strength of the NOE correlation has a 1/r6 dependence on the internuclear 
distance and thus NOESY can be used to provide information on the spatial arrangement of nuclei.[102] 
Typically, the nuclei concerned are protons, however heteronuclear NOE between, for example 1H and 
19F, has also been reported.[103] This methodology has historically been performed in a qualitative 
(NOE/no NOE) or semi-quantitative (weak/medium/strong) manner only, due to a lack of accuracy 
associated with a quantitative NOE analysis largely caused by additional cross-relaxation pathways 
contributing to the observed NOE.[104] However, improvements in NOE experimental methods and data 
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The NOE experiment can be used to obtain quantitative information regarding interproton distances 
due to the relationship between NOE intensity, cross relaxation rate and mixing time (Equation 1). The 
observed NOE intensity between two spins I and S (ηIS) at a given mixing time (τm), is proportional to 
the cross-relaxation rate between I and S (𝜎𝐼𝑆).  
𝜂𝐼𝑆 =  𝜎𝐼𝑆𝜏𝑚 
Equation 1 
The cross-relaxation rate between I and S is, in turn, inversely proportional to the internuclear distance 
between I and S (rIS-6) to the sixth power, when in the fast tumbling regime (Equation 2). In the fast 
tumbling regime, NOEs are independent of rotational correlation time (τc) and Larmor frequency and 
are dominated by the double quantum (ω2) cross relaxation pathway and are thus positive NOE 
correlations. Therefore, assuming that the parameters which define k remain constant, the NOE intensity 
between spins I and S (ηIS) is proportional to the internuclear distance between the two nuclei (rIS). This 
however, assumes that the initial rate approximation is true and that NOE build up is linear with mixing 
time. If this is the case, it is therefore true that the ratio of NOE intensities for a pair of NOE signals is 
proportional to the ratio of their internuclear distances. Thus, using a well-defined rigid reference 
distance (rref) that is not affected by conformational dynamics, the distance between other nuclei in the 
molecule (such as I and S) can be determined by comparing the relative NOE intensities of the peak of 
interest (ηIS) to that of the reference distance (ηref) (Equation 3). A common reference distance is that 
between geminal protons of a methylene group (~1.78 Å). 
𝜎𝐼𝑆 = 𝑘𝑟𝐼𝑆









2 −  𝜏𝑐) 
Equation 2 









However, NOE intensities do not build up linearly with mixing time, and deviations away from the 
initial rate approximation typically occur at short mixing times (~250 ms). A linear build up between 
NOE intensity and mixing time is usually only true at short mixing times when the NOE intensity is 
weak and the quantitative analysis of cross-relaxation rates is less accurate due to higher signal to 
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In 1986, Macura et. al. reported the quantitative analysis of 2D-NOESY spectra by internal calibration 
of the cross-peak NOE intensities against the diagonal peak intensities.[106] This approach effectively 
extends the length of mixing times that have a linear correlation with NOE intensity, enabling the 
measurement of cross-relaxation rates to be performed at longer mixing times which benefit from 
increased signal intensity. The effects of external relaxation are in effect cancelled out in this approach.  
This approach was extended by Krishnamurthy to selective 1D-NOE experiments and the method was 
coined PANIC (Peak Amplitude Normalization for Improved Cross Relaxation).[107] The PANIC 
method corrects for different forms of relaxation by standardization of the irradiated peak which allows 
for NOE intensities obtained in separate inversion experiments to be directly compared. This effectively 
eliminates any perturbations to the irradiated peak or cross-peaks that proportionately affect all spins in 
an NOE experiment. The PANIC method successfully eliminates any nonlinear NOE buildup, which is 
typically observed at moderate mixing times, and thus the ratio of NOE intensities for a pair of NOE 
signals is proportional to the ratio of their internuclear distances and importantly this ratio is 
independent of mixing time. Therefore, by using the PANIC method, longer mixing times can be used 
which increases the signal-to noise and significantly improves the accuracy of the analysis.[108]  
Butts et. al. have since demonstrated that this method can be used to extract experimental interproton 
distances from both rigid[104] and flexible[109] molecules, with deviations as low as 3% when compared 
to either QM calculated structures or x-ray crystal structures. They have also demonstrated that this 
method can be used to identify conformers with populations as low as 2%.[102] NOE is much more 
sensitive to high energy conformations, and traditional NMR methods to explore conformation such as 
scalar couplings would not have been able to identify conformers with populations this low.  
For example, in 2011, Butts et. al. used quantitative 1D-NOESY to identify a high energy conformation 
of strychnine (57), previously unidentified using standard conformational analysis. Their initial 
quantitative analysis of strychnine using NOESY gave a MAD of 3.5% and a standard deviation (SD) 
of 2.7% when the experimental NOE distances were compared to those from DFT calculation and X-
ray crystallography.[104] Although the overall correlation was good, an unusually large deviation of 14.9% 
was observed for the H11b-H23b distance. The experimentally derived interproton distance (3.49 Å) was 
shorter than the distance observed in the DFT calculations (4.10 Å), suggesting that a high energy 
conformer with a shorter H11b-H23b exists. If this were true, this conformation would have a 
disproportionally large effect of the NOE intensity because of the strong rIS-6 relationship between 
distance and NOE intensity. Further computational calculations revealed a second conformer with a 
population of 2.5% at room temperature with a H11b-H23b distance of 2.11 Å (Figure 18). Accounting 
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Figure 18. The structure of strychnine 57 and the two conformers found by DFT calculations. The clear conformational 
change of the seven membered ring is shown giving rise to the shorter H11b-H23b distance. 
NMR spectroscopy is an incredibly valuable method for studying molecular structure and conformation 
in solution as demonstrated in this section, although the methods described are not an exhaustive list of 
methods available to evaluate molecular conformation/configuration. However, NMR is not without its 
limitations and the elucidation of conformation for highly flexible molecules by NMR spectroscopy 
alone is extremely challenging, due to a large number of conformers interconverting on the NMR 
timescale. Fortunately, the analysis of molecular conformation by NMR spectroscopy can be supported 
by molecular mechanics (MM) and quantum mechanics (QM) calculations, enabling the elucidation of 
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1.3.2 Aiding Structure Elucidation using Molecular Mechanical and Quantum 
Mechanical Calculations  
For flexible molecules, using NMR to elucidate 3D molecular conformation is challenging because a 
large number of conformers contribute to the observed NMR parameters (δ, J and interproton distances) 
making it extremely difficult to estimate the populations of all contributing conformers. For cases such 
as this, it is possible to use MM and QM calculations to calculate conformer populations, geometries 
and Boltzmann averaged NMR parameters. These can be directly compared with the experimental NMR 
parameters and the quality of the fit can be assessed, helping to elucidate conformer populations and 
ultimately 3D molecular structure.  
The first, and arguably most important, stage of this process involves the exploration of conformational 
space to identify the global and local minima on the potential energy surface. If the conformational 
space is inadequately sampled, then a poor correlation between experimental and calculated NMR will 
be observed. For molecules with a small number of rotatable bonds, exploring conformational landscape 
is relatively straightforward. However, as the number of conformational degrees of freedom increases 
so does the number of conformers, exponentially.[111]  
Different computational methods are available for exploring conformational space, with vastly differing 
levels of computational intensiveness and accuracy. Very sophisticated ab initio QM methods exist and 
can provide highly accurate conformer geometries and energies.[112] However, these are very time 
demanding calculations. [113] Alternative methods, employ MM and include molecular dynamics (MD) 
simulations or Monte Carlo (MC) sampling.[114] MM methods treat the molecule as a ‘ball and spring’ 
and calculates the strain energy of a molecule as a sum of independent terms, described by Equation 
4.[115] By simplifying a molecule to just atoms and bonds, and not including nuclei and electrons, the 
computational time required to calculate conformer energies is greatly reduced. These terms are 
parameterised by a force field. Examples include MMFF[116], MMFFs, MM2[117], MM3[118], 
OPLS_2001.[119] The choice of force field is largely down to the molecule in question.  
𝐸𝑡𝑜𝑡𝑎𝑙 =  𝐸𝑠𝑡𝑟𝑒𝑡𝑐ℎ + 𝐸𝑏𝑒𝑛𝑑 + 𝐸𝑡𝑜𝑟𝑠𝑖𝑜𝑛 + 𝐸𝑐𝑜𝑢𝑙𝑜𝑚𝑏𝑖𝑐 + 𝐸𝑉𝑎𝑛 𝐷𝑒𝑟 𝑊𝑎𝑎𝑙𝑠   
Equation 4 
MM conformational search methods fall into one of two categories, stochastic or systematic. Systematic 
methods involve incrementing either cartesian xyz coordinates or torsional angles by a predetermined 
amount. Although these methods are exhaustive, the exponential increase in the conformational space 
that is searched with increasing number of rotatable bonds, limits their application to rigid molecules. 
Stochastic methods, such as MC conformational searching, however are much faster and a more 
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preceding conformer randomly by a small change. The different conformational search methods are 
compared in Table 2. 
Table 2. A comparison of conformational search methods, highlighting their advantages and disadvantages 
 Quantum Mechanics (QM) Molecular Mechanics (MM) 
Advantages - Higher Accuracy 
- Better at identifying low 
energy conformers as it is more 
likely to correctly identify local 
and global minima  
-MD provides information about a system in 
time (dynamic information) 
-MC methods are considerably less time 
demanding 
-MC methods are very effective at crossing 
high energy barriers due to the stochastic 
nature of the search 
-MD is very effective if solvation is required 
as explicit solvent models are routinely 
employed 
Disadvantages  - Time Demanding 
- Unsuitable for high-throughput 
analysis 
-No dynamic information 
-Lower accuracy of conformer energies and 
geometries 
-MD methods remain time demanding for long 
timescale simulations  
-MD methods can poorly sample 
conformational space if large energy barriers 
to torsional rotation are present 
The Monte Carlo Multiple Minimum (MCMM) is a stochastic method routinely used in the 
conformational search of flexible molecules.[120] During an MCMM conformational search, the starting 
conformer is distorted randomly based on either cartesian xyz coordinates or torsional angles. The 
distorted conformer is then minimized, and the resulting conformation is compared to those previously 
generated. The structure is either retained as a new conformation or it is eliminated if it is either 
redundant to a previously found conformation or if it is too high in energy. The process is repeated until 
the number of steps, defined by the user, has been reached (Figure 19). Since the MCMM method 
makes random changes to the structure the conformational space is usually well sampled, provided that 
enough iterations are defined by the user. To ensure that the calculation finds all the possible 
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Figure 19. The general workflow followed in a stochastic conformational search such as MCMM. 
The energies of the conformers estimated using MM methods (Equation 4) are low in accuracy due to 
the approximation that molecules can be treated as a ‘ball and spring’. Furthermore, using MCMM 
methods, the zero-point energy correction, entropy and solvation are not typically taken into 
consideration hence reducing the accuracy further. This can be addressed with the use of QM methods 
such as Density Functional Theory (DFT). Using DFT calculations it is possible to calculate optimised 
conformer geometries, the Gibbs free energies of the conformers and the NMR parameters including 
magnetic shielding tensors, which can be converted to chemical shift, and scalar coupling constants.  
QM methods, such as DFT, differ from MM methods by approximating the Schrödinger equation and 
treating the molecules as collections of nuclei and electrons. In DFT, the ground state energy of a system 
is approximated as a sum of the kinetic energy, the electronnuclear interaction energy, the Coulomb 
energy and the exchange-correlation energy. These terms all depend on electron density and thus the 
ground state energy can be summarised as a function of electron density.[121,122] The exact form of the 
exchange-correlation energy is unknown[123]; however, it can be approximated using one of the many 
functionals developed to address this such as B3LYP[124] and mPW1PW91[125].  
The electron density of the atomic orbitals is described by basis sets, which describe both the core and 
valence molecular orbitals. Functions can be added to the basis sets to describe the polarisation and 
diffusivity of the basis sets.[126,127] The most popular choice of basis sets are typically split-valence basis 
sets, with two or more functions describing the valence orbitals. An example of split-valence basis sets 
are the Pople basis sets, which use primitive Gaussian functions to describe the electron density of the 
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N represents the number of gaussian functions describing the core orbits and I, J and K are the gaussian 
functions describing the valence orbitals. With three functions describing the valence orbital, it is known 
as a triple-ζ basis set, however double- ζ basis sets with only two functions describing the valence 
orbitals also ssexist.[129] Examples of some Pople basis sets are: 3-21G, 6-31G and 6-311G. The addition 
of polarisation functions, which describe distortions to the symmetry of polarisation of electron density 
around the nucleus upon the approach of other nuclei, are denoted as either an asterisk or as a letter 
denoting the polarisation function added.[130] For example, the addition of polarisation functions to 6-
311G results in the following notation: 6-311G** or 6-311G(d,p).  
DFT can be used to calculate optimised geometries of structures along with the Gibbs free energy of 
the resulting coordinates. This information can be used to calculate the Boltzmann populations of a set 
of conformers which can be used to Boltzmann average interproton distances across the set of 
conformers. DFT can also be used to calculate NMR parameters, including magnetic shielding tensors 
(MST) and scalar coupling constants.[131,132] The Gauge Independent Atomic Orbital (GIAO) method 
has been widely used to calculate magnetic shielding tensors.[133,134] The GIAO method, which uses 
basis functions that have an explicit field dependence, calculates the isotropic component of the 
magnetic shielding tensors. These can then be converted to a chemical shift by calibrating the isotropic 
shielding tensors to those calculated for tetramethylsilane (TMS) at the same level of theory.[135] DFT 
can also be used to calculate scalar coupling by parameterisation of the four terms that contribute to 
spin-spin couplings including, the Fermi Contact (FC), the diamagnetic spin-orbit (DSO), the 
paramagnetic spin-orbit (PSO) and the spin-dipole (SD). The scalar coupling constants and chemical 
shifts calculated for each conformer are averaged using their calculated Boltzmann population, to obtain 
Boltzmann averaged NMR parameters which can be directly compared to the experimental NMR 
parameters.  
1.3.3 The Application of the Hybrid NMR Spectroscopy and Computational 
Approach to Solving 3D Molecular Structure  
As mentioned previously, the hybrid QM and NMR spectroscopy method has been used throughout the 
scientific literature to examine 3D molecular structure through the comparison of one or more 
experimental NMR parameter (J,  or interproton distance) to those calculated using DFT calculations.  
One of the earliest examples of using the hybrid NMR spectroscopy and computational approach was 
reported in 2012 by Butts and Bifulco et. al. in the elucidation of the stereochemistry of the natural 
product Conicasterol F.[108] The work marked the first occurrence of measuring multiple NMR 
parameters, including chemical shifts and quantitative interproton distances, and comparing to those 
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pioneered by Bifulco, involved the comparison of only one NMR parameter and was restricted to using 
1H or 13C chemical shifts or scalar coupling constants.[86,110,136,137] The workflow proposed by Butts and 
Bifulco et. al. is shown in Figure 20. This workflow, although often tweaked on a case by case basis, 
has formed the general protocol adopted in the hybrid QM and NMR spectroscopy approach towards 
structural elucidation of natural products.  
 
Figure 20. The general workflow employed by Butts and Bifulco et. al. in the hybrid QM and NMR spectroscopy approach 
to solve the relative stereochemistry of Conicasterol F.[108] 
The hybrid QM and NMR spectroscopy approach was used to solve the ambiguity over the relative 
stereochemistry of the epoxy ring. The calculated 13C chemical shifts and interproton distances, derived 
from 1D-ROE, for two diastereomers of Conicasterol F were compared to those obtained 
experimentally. DFT calculations, using the mPW1PW91 functional and 6-31G(d) basis set, were used 
to calculate δc and interproton distances. Calculated δc and interproton distances for each conformation 
were Boltzmann averaged against their calculated Boltzmann populations.  
They first examined the comparison of interproton distances and found that diastereomer 59, as opposed 
to 58, clearly gave a better fit between the experimental data of the natural product and calculated data, 
suggesting that this is the correct diastereomer of Conicasterol F (Table 3). To support their hypothesis, 
calculated δc were compared to the experimental δc and a much lower MAD was also observed for 
diastereomer 59. Confirming that the correct diastereomer of Conicasterol F is 59, supported by two 
separate analyses. Comparing multiple NMR parameters is especially useful in cases when the 
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Table 3. The MAD and SD obtained in the comparison of experimental interproton distances and 13C chemical shifts to the 
calculated data for two diastereomers of Conicasterol F.[108] 
 
The first example discussed involved the application of the hybrid NMR spectroscopy and 
computational approach to solve the relative stereochemistry of a rigid steroid, with conformational 
search calculations identifying a single conformation of the steroid ring system.[108] Performing this 
analysis on very rigid systems such as this is relatively straightforward process. However, it has been 
shown by Aggarwal et. al that this methodology can be applied to highly flexible open chain compounds 
with similar levels of accuracy. The conformation of the molecules synthesised by Aggarwal et. al. 54, 
55 and 56, discussed in section 1.2, were explored by the hybrid QM and NMR spectroscopy approach, 
presenting one of the first examples of this method being applied to a molecule with such a large number 
of rotatable bonds.[27] The terminal boronic ester was first oxidised to the corresponding phenol before 
the conformational analysis.  
Two of the three molecules synthesised (10 and 11) by Aggarwal et. al. should display a conformational 
bias in solution, due to the avoidance of destabilising syn pentane interactions. X-ray crystallography 
was initially used to confirm the expected conformational bias of the molecules however, the 
conformation of a molecule in the solid state can be influenced by crystal packing and thus the hybrid 
QM and NMR spectroscopy approach was used to examine the conformational bias in solution. NMR 
spectroscopy was used to measure quantitative interproton distances, using the PANIC method, as 
described previously. In addition, H-H scalar coupling constants were either measured directly from the 
multiplets in the 1D-1H spectrum or from spectrum simulation using SpinSimulation in MestreNova. 
Finally, H-C scalar couplings were measured using EXSIDE. The experimental NMR parameters 
measured were then compared to those calculated using DFT calculations (mPW1PW91/6-311 G(d,p)). 
The mPW1PW91, a Generalised Gradient Approximation (GGA) functional that improves the 
approximation of total energy by considering the gradient of the electron density, has been shown by 
Bifulco et.al. to be the best functional to use when calculating chemical shifts using the GIAO 
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predicted J couplings. The scalar coupling constants and interproton distances were Boltzmann 
averaged against their calculated conformer energies to provided Boltzmann averaged NMR parameters 
that could be compared to the experimental NMR data.  
The DFT calculations predicted that for the alternating syn-anti diastereomer 11 >95% of conformers 
were predicted to be linear. Similarly, for the all-syn diastereomer 10 >74% of conformers were 
predicted to be helical (Table 4). For the all-anti diastereomer (56) a MM conformational search 
revealed no conformational bias, and thus no further computational or NMR work was performed. For 
both 10 and 11 an excellent correlation between the experimental and calculated NMR parameters were 
observed with a 1 Hz MAD in the comparison of scalar coupling constants and a 5% error in the 
comparison of interproton distances. Although these deviations are marginally larger than those 
observed previously on very rigid structures, they are in line with those obtained for flexible molecules. 
The excellent correlation observed between experimental and calculated NMR parameters, confirms 
that the conformational bias predicted computationally is present in solution. 
Table 4. The MADs obtained between experimental and computational NMR datasets for the two diastereomers 10 and 11.  
 
The previous two examples involved the comparison of multiple NMR parameters. However, it is 
possible to use only one NMR parameter in the hybrid QM and NMR spectroscopy approach. 
Commonly, 1H or 13C chemical shifts are used as these are experimentally very simple to measure. 
Additionally, by removing the calculation of scalar couplings from the NMR calculations, the 
computational time required is greatly reduced. This allows for a comparison between experimental and 
calculated data to be obtained much faster although often with less discrimination.  
The comparison of experimental and calculated chemical shifts has pioneered by the research group of 
Dean Tantillo, who have reported the use of this methodology on a structurally and flexibly diverse 
range of molecules.[139] Recently, they have shown that this methodology can be performed on cyclic 
peptides of up to 6 residues (Figure 21, 60).[140] Analysing the structure and conformation of cyclic 
peptides is particularly challenging due to the unusual chemical environments that are often observed, 
caused by shielding or deshielding from ring current effects. This results in chemical shifts that are 
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calculations using MCMM search methods, followed by QM calculations to predict cyclic peptide 1H 
and 13C chemical shifts. When compared to the experimental 1H and 13C chemical shifts, good MADs 
of 2.3-3.1 ppm for 13C and 0.27-0.3 ppm for 1H were obtained. However, Tantillo et. al. have since 
shown that the MAD can be significantly improved to <2 ppm for 13C and <0.2 ppm for 1H when using 
MD to explore conformational space.[141] They showed that using high temperature MD simulations, 
allowing for cis-trans rotamerisation of the amide bonds to occur, captured more subtle conformational 
motion than MM resulting in a better description of the conformational landscape.  
 
Figure 21. An example of a cyclic peptide studied by Tantillo et. al. This figure was reproduced from reference [141] 
The previous examples have employed the use of statistical analyses to compare experimental and 
calculated data, namely MAD and SD. It is also possible to use probability-based methods to quantify 
the quality of fit between the two datasets. One example that has been widely adopted is DP4, reported 
by Goodman et. al. in 2010.[135] Probability based methods usually offer a greater discrimination 
between diastereomers than statistical analyses.[142] DP4 involves the calculation of 1H and 13C chemical 
shifts by QM calculations followed by an empirical scaling of the predicted chemical shifts to remove 
any systematic errors. An error between the experimental shifts and the calculated scaled shifts is 
obtained (δcalc – δexp) for each shift. Assuming that each error follows a normal or t distribution, then the 
probability of encountering each error in a correct structure is calculated. The probabilities for each 
signal are multiplied to give the absolute probability that the structure is correct. DP4 has been shown 
to provide high levels of discrimination between diastereomers in the stereochemical assignment of 
many natural products however, it only considered the comparison of chemical shifts and there are 
many situations where chemical shifts alone are not capable at confidently assigning stereochemistry, 
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1.4 The Inhibition of Protein–Protein Interactions  
As discussed previously, conformationally preorganising a drug candidate towards the bound 
conformation is particularly important in the inhibition of protein–protein interactions (PPIs). This 
section will discuss what PPIs are, why they are such important therapeutic targets, the challenges 
associated with inhibiting PPIs and the breakthrough strategy that turned PPIs into ‘druggable’ targets.  
1.4.1 What are Protein–Protein Interactions? 
Proteins are responsible for the structure, function and regulation of our bodies tissues and organs and 
are integral in almost all cellular processes, from catalysing cellular reactions to transmitting the 
information needed for DNA replication. However, proteins rarely act alone and many of these 
functions are dependent on proteins forming specific interactions with other proteins, forming what is 
known as protein–protein interactions (PPIs).[143] PPIs are specific, they are not a chance or accidental 
interaction with another protein.[144] The complex network of interacting proteins is known as the 
interactome and the human interactome is estimated to include >650,000 distinct pair-wise interactions, 
estimated using a statistical analysis of the wealth protein interaction data available in the literature.[145] 
Mapping this interactome and understanding how the hundreds of thousands of interactions regulate 
cellular function is by no means a simple challenge.  
Since PPIs play such a crucial role in the regulation of so many cellular functions, they also possess the 
ability to cause numerous diseases if they become aberrant. Indeed, a number of diseases including 
cancer, Alzheimer’s and HIV, can be attributed to misregulated PPIs.[146] Despite this therapeutic need, 
very few strategies to target these misregulated PPIs currently exist. This is due to the nature of the 
binding interface that typically exists between PPIs, which is not one that can be considered to be easily 
‘druggable’.[147] Typically, the design of a competitive inhibitor of protein function will involve the 
design of a small molecule that fits into a well-defined pocket on the protein of interest. In addition to 
high shape complementarity between the ligand and protein, often dominant interactions such as 
hydrogen bonding, salt-bridges or covalent interactions exist. This is seen in the ‘lock-and-key’ 
mechanism for the inhibition of enzyme-substrate complexes with a small molecule and has been hugely 
successful in the pharmaceutical industry.  
The binding interface between proteins in a PPI however does not involve one protein binding to a well-
defined small pocket on another protein. Instead, it involves very large binding interfaces of >1000 Å2 
between the two proteins (Figure 22).[148] Additionally, the binding interface is shallow, featureless and 
non-contiguous.[149] The binding between proteins in a PPI is also typically dominated by the 
hydrophobic effect and very few specific interactions, such as hydrogen bonds, exist between the two 
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there are often no specific interactions between the two interacting proteins. It is for these reasons that 
PPIs were originally considered to be ‘undruggable’ targets because it was extremely challenging to 
design a small molecule that could cover the large surface areas and complement the poorly defined 
binding interface across a relatively flat surface.[145]  
 
Figure 22. The inhibition of a) an enzyme-substrate interaction and b) a protein–protein interaction 
1.4.2 How can Protein–Protein Interactions be Disrupted? 
Perhaps the obvious choice in the inhibition of PPIs would be the use of peptide based therapeutics. 
Peptides offer a logical strategy to protein inhibition since the natural protein sequence can be mimicked 
by the peptide.[151] This would offer the advantages of greater selectivity and specificity over a small 
molecule. Additional benefits of peptide based therapeutics include their ease of synthesis and better 
pharmacokinetic properties and less off target side effects.[152] However, peptide based therapeutics 
exhibit poor membrane permeability and rapid proteolytic digestion. Additionally, they often show poor 
conformational stability which decreases affinity to the target as discussed previously.[50,153] Although 
strategies have been developed to address these issues, such as peptide stapling, peptides remain the 
less favoured choice when compared to small molecules. However, small molecules are also not well 
suited for the inhibition of PPIs, due to the nature of the binding interface. That was, until the realisation 
that the binding affinity between PPIs is typically dominated by a few key residues.  
In 1995, Wells and Clackson reported that although PPIs take place over a large interface, the 
interactions that drive formation of the PPI are focussed on a few key amino acids, termed hot-spot 
residues (Figure 23).[154] Using alanine mutagenesis studies, whereby each residue is sequentially 
mutated to alanine and the effect on the affinity to its protein partner is computationally investigated, it 
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hot-spot residues constitute less than half of the binding interface of a PPI and are located at the central 
region of the binding interface.[156] Additionally, the hot-spot groups are often found in tightly packed 
clusters and interact cooperatively.[157] The hot-spot approach to PPI inhibition proposed by Wells and 
Clackson was ground-breaking for the development of small molecule PPI inhibitors and it suggests 
that a small molecule that simply mimics these hot-spot as opposed to the entire binding interface, will 
be sufficient for competitive inhibition. Indeed, the hot-spot approach kickstarted the development of 
small molecule inhibitors of PPIs and now a number of therapeutic molecules are present at various 
stages in the drug discovery pipeline.[158,159]  
 
Figure 23. The hot-spot approach to PPI inhibition proposed by Wells and Clackson. The three hot-spot groups are 
represented as blue circles. They bind to a groove or pocket on a second protein.[160]  
1.5 The p53-Mdm2 Protein–Protein Interaction 
Across all 650,000 PPIs that exist in the interactome, the p53-Mdm2 PPI has captured scientist’s 
attention and become one of the most studied in the scientific literature. This next section will discuss 
the p53-Mdm2 pathway, the mechanisms by which this PPI becomes aberrant and the current 
therapeutic pathways aimed at treating this PPI.  
1.5.1 The p53-Mdm2 Pathway  
p53, a tumour suppressor protein, is responsible for protecting cells from malignant transformation 
giving it the rightly deserved nickname the ‘guardian of the genome’.[161,162] p53 is a powerful 
transcription factor that regulates the cellular pathways responsible for, although not limited to, DNA 
repair, cell cycle arrest, apoptosis, angiogenesis and senescence.[163],[164]  
Human p53 contains 393 amino acids and consists of different structural and functional domains. It is 
biologically active as a homotetramer. The first 42 amino acids at the N terminus form the 
transactivation domain, responsible for transcriptional activation through the interaction with various 
transcription factors.[163] Following this is a proline rich region from 61-94, which plays a role in a 
regulatory functions including p53-mediated apoptosis.[165,166] The core of p53, residues 94-292, is 
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DNA.[167] Residues 324-355 make up the C-terminal tetramerization domain, responsible for 
oligomerization of p53.[168,169] Finally, a regulatory domain from residues 363-393 is present at the C-
terminus. Residues in this region undergo posttranslational modifications including phosphorylation, 
methylation and ubiquitination, promoting structural changes to the central region of p53, controlling 
the sequence specific binding of p53 to DNA.[170],[171]   
The N-terminal transactivation domain is also the location of binding of Mdm2, p53’s negative 
regulator.[172] Mdm2 is an oncogene whose primary responsibility is to modulate p53’s tumour 
suppressor activity through an autoregulatory feedback loop. Mdm2 has been shown to make extensive 
contacts with several hydrophobic residues, namely F19, L22, W23 and L26, on p53. Two of these 
amino acids, L22 and W23, are also key to the interaction of p53 with transcription factors.[173,174] Thus, 
when bound to Mdm2, p53 loses its transcriptional activation activity.  
The regulation of the Mdm2-p53 autoregulatory feedback loop is critical in protecting cells from 
damage. The role of the p53-Mdm2 autoregulatory loop is to maintain low cellular concentration of p53 
in healthy cells and to increase p53 concentration on response to cellular damage.[175] Mdm2 regulates 
the activity of p53 through different mechanisms. As mentioned previously, Mdm2 blocks the 
transactivation domain of p53, preventing p53-mediated transcription.[176] Mdm2 also promotes p53 
degradation through ubiquitination as it is an E3 ligase protein. Finally, Mdm2 binding induces the 
nuclear export of p53. If p53 is not present in the nucleus it can no longer bind to DNA. Through these 
three mechanisms, the levels of cellular p53 are tightly controlled by Mdm2 and p53 is present at low 
concentrations in healthy cells.[177,178] The autoregulatory negative feedback loop is completed as Mdm2 
is itself a product of p53-mediated transcription (Figure 24).[179]  
In response to cellular stress however, this feedback loop is disrupted allowing p53 to accumulate and 
bind to DNA. Several pathways resulting in the activation of p53 through disruption of the p53-Mdm2 
feedback loop exist. For example, following DNA damage, specific residues in the N-terminal 
transactivation domain are phosphorylated (S15, T18 and S20) disrupting the interaction between p53 
and Mdm2.[180] When p53 is unregulated by Mdm2 it can enter the nucleus, bind to DNA and promote 
the transcription of genes responsible for protecting the cell. Additionally, p53 can now promote the 
transcription of Mdm2, increasing cellular concentrations of Mdm2.[181] This causes a subsequent 
decrease in the concentration of p53 back to the baseline levels. This autoregulatory feedback loop is 
critical for the survival of cells however, numerous mechanisms exist that prevent the correct 
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Figure 24. The autoregulatory feedback loop of p53 and Mdm2. 
1.5.2 Disruption of the p53-Mdm2 PPI through Mutation of p53 
The correct functioning of the p53-Mdm2 autoregulatory feedback loop is critical for the survival of 
healthy cells, and interruptions to this loop directly contribute to tumour growth. In fact p53 is the most 
frequently inactivated protein in human cancers with over 50% of diagnoses linked to misregulation of 
the autoregulatory loop between p53 and Mdm2.[183] Due to this, restoration of the p53-Mdm2 feedback 
loop is the key aim of many cancer treatments and it is capable of halting tumour growth.  
The most frequent interruption to this loop is due to the mutation of p53, which causes the loss of p53 
activity.[184] 95% of the p53 mutations that have been reported are point mutations located in the centre 
of the sequence-specific DNA binding domain and influence either the conformation of p53 or the 
residues responsible for making contacts with DNA.[185],[186] Despite mutations in p53 being responsible 
for approximately half of all new cancer diagnoses, there are very few drugs in the pipeline designed to 
restore the function of mutated p53.   
A strategy that has showed signs of promise is the design of a small molecule that can bind to either a 
transient or long-lived pocket on mutated p53 for long enough to restore the conformation of p53 to its 
native conformation allowing it to bind to DNA.[187] PRIMA-1 (61), or the more potent methylated 
version, PRIMA-1MET (62) (or APR-246) developed by Aprea AB, is currently the most successful small 
molecule drug capable of restoring mutated p53 function. PRIMA-1MET is now in stage II clinical trials 
for women exhibiting ovarian cancer, which is very commonly caused by p53 mutations.[188] The exact 
mechanism of PRIMA-1MET is not yet fully understood however it was discovered that PRIMA-1 and 
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reacts covalently with thiol residues on mutated p53 and restores the conformation of mutated p53 to 
wild-type p53 (Figure 25).[190]  
 
Figure 25. A schematic of the suggested mechanism of PRIMA-1MET towards p53 reactivation. 
The proposed mechanism of action of PRIMA-1MET was confirmed by extensive computer simulations, 
performed by Amaro et. al. Using all atom explicit solvent molecular dynamics simulations, they were 
able to examine how p53 mutations destabilise the conformation of p53 and prevent it from binding to 
DNA.[191] The simulations confirmed that in mutant p53 a small pocket transiently forms in the core of 
the protein (Figure 26). This cleft is large enough to capture a small molecule, supporting the theory 
that a small molecule can be used to bind to mutated p53. Present within the cleft are three cysteine 
residues, all of which are possible targets for alkylation with MQ. The simulations performed by Amaro 
et. al. confirmed that MQ alkylates Cys124 and restores the conformation of mutant p53 to wild-type 
p53. The irreversible alkylation of a cysteine residue by MQ is a significant disadvantage of the 
molecule, since once it is bound to the transient cleft it remains there and increases the risk of toxic side 
effects. Additionally, cysteine residues are located on numerous other proteins, not just p53, although 
it has been proposed that the shape complementarity between the transient cleft of mutated p53 and MQ 
promotes alkylation of this site over other cysteine residues. A more desirable strategy is a small 
molecule that can temporarily lodge into the cleft and remain there for long enough to restore p53 
function, and then eventually fall off, reducing the risk of side effects. Amaro et. al. screened a library 
of over 1 million compounds against mutated p53 in the hope that a small molecule that met these 
requirements could be identified. Several hundred compounds were found to bind to the cleft transiently 
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Figure 26. Visualisation of the DNA binding domain of p53. a) The crystal structure of wild-type p53 shows that Cys124 is 
obstructed. b) MD simulations of mutated p53 reveal a transiently open pocket that exposes Cys124. This pocket can be 















 UOB Open 
1.5.3 Disruption of the p53-Mdm2 PPI through Overexpression of Mdm2 
The mutation of p53 is not the only mechanism by which the misregulation of this PPI can result in 
malignancy. It has also been found that in ~30% of human cancers that Mdm2 is overexpressed and as 
a result of the autoregulatory feedback loop, levels of cellular p53 are decreased.[192] This prevents 
activation of the p53 pathway upon cellular stress, allowing malignant cells to go unchecked.  
The therapeutic targeting of the p53-Mdm2 pathway has primarily focussed on solving the issue of 
Mdm2 overexpression through the design of small molecules that can inhibit the p53-Mdm2 PPI by 
competitive inhibition of Mdm2 and reactivation of the p53 pathway (Figure 27).[193] As discussed 
previously, targeting a PPI with a small molecule is challenging due to the large interfacial areas and 
featureless binding sites. However, the hot-spot approach described by Wells provides a strategy for 
drugging PPIs with a small molecule. p53 binds to a hydrophobic pocket on Mdm2 with the binding 
affinity being dominated by a Phenylalanine residue (Phe19), a Tryptophan residue (Trp23) and a 
Leucine residue (Leu26).[194] The three residues are located on one face of an α-helical region of p53. 
This poses the possibility of inhibition of this PPI with a small molecule. If a small molecule that binds 
competitively to Mdm2 can be developed, it is possible that it could be used in the treatment of cancers 
caused by the overexpression of Mdm2 and reactivate p53, thereby protecting the cell. The next section 
will discuss the significant developments that have been made in the search of small molecule p53-
Mdm2 inhibitors.  
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1.5.4 Small Molecule Inhibitors of the p53-Mdm2 PPI 
The search for small molecules that can disrupt the p53-Mdm2 PPI has not been straightforward, and 
currently there are no commercially available p53-Mdm2 inhibitors available despite over two decades 
of intense interest from both academia and industry. The first successful attempt at drugging the p53-
Mdm2 PPI was made by a team at Hoffman-La Roche, led by Lyubomir Vassilev.[195] Vassilev et. al. 
identified a family of potent and selective small molecule inhibitors of Mdm2, known as the Nutlins 
(64, 65 and 66).[195] The Nutlins are a family of tetra-substituted imidazolines that bind competitively 
to Mdm2 in the p53 binding pocket (Figure 28). They have been shown capable of reactivating the p53 
pathway in cells overexpressing Mdm2. Nutlin-3 (66) is the most potent member and is able to disrupt 
the p53-Mdm2 PPI with an IC50 of 90 nM.  
 
Figure 28. The Nutlins are a potent family of Mdm2 inhibitors. The structures of a) Nutlin-1, b) Nutlin-2 and c) Nutlin-3 are 
shown.  
The binding of the Nutlins to Mdm2 was confirmed using x-ray crystallography, and a crystal structure 
of nutlin-2 bound to Mdm2 was obtained (PDB ID = 1RV1) (Figure 29). The crystal structure revealed 
that Nutlin-2 binds in a similar fashion to p53, placing three hydrophobic groups into the same position 
typically occupied by the three hot-spot groups of p53. A 4-bromo-phenyl group occupies the Trp23 
pocket, a second 4-bromo-phenyl group is located in the Leu26 pocket and the ethyl ether side chain is 
directed toward the Phe19 pocket. The hydrogen bond between the indole NH of the Trp23 residue of 
p53 and the backbone carbonyl of Leu54 on Mdm2 is not maintained however, the excellent binding 
affinity observed suggests that this interaction is not essential for competitive inhibition. It is interesting 
to note that a non-aromatic group of Nutlin-2 has occupied the phenylalanine pocket, whilst an aromatic 
group of Nutlin-2 has occupied the leucine pocket. It has been suggested that this is to allow for a π-π 
stacking interaction between one of the 4-bromo-phenyl groups and a histidine residue on Mdm2 
(His96). The crystal structure also revealed that two molecules of Nutlin-2 are initially associated with 
the surface of Mdm2. It has been proposed that before Nutlin-2 occupies the p53 binding pocket of 
Mdm2, it first makes contact with a second site and then tumbles into the binding pocket. It has been 
suggested that the competitive binding of the Nutlins to Mdm2 is due to the presence of the chlorine 
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indole is present. This void is perfectly occupied by a chlorine atom and is a contributing factor to the 
competitive binding of the Nutlins. The Nutlins feature a conformationally rigid imidazoline core, 
which orients the binding groups towards the correct pockets. Due to the rigidity of the Nutlins it is 
likely that the bound conformation reflects the conformation of the free ligand in solution, and no major 
conformational reorganisation is required.  
 
Figure 29. a) The two binding sites of Nutlin-2 (65) to the p53 binding site of Mdm2. b) The overlay of p53 with Nutlin-2 
bound to Mdm2. It is clear that the rigid conformation of Nutlin orients three hydrophobic groups into the three pockets of 
Mdm2 in an analogous fashion to p53. c) The proposed π-π interaction between His96 (shown in grey) of Mdm2 and a 4-
bromophenyl group of Nutlin-2.PDB ID: 1RV1 
The Nutlins showed an impressive ability to selectively bind to the p53 pocket of Mdm2 and reactivate 
the p53 pathway through inhibition of the interaction between Mdm2 and p53.[196] However, the Nutlins 
showed less than favourable pharmacokinetics and were metabolically unstable. Roche therefore 
optimised the structure of the Nutlins to improve their binding affinity, cellular potency, 
pharmacokinetics and chemical stability.[197] The resulting structure, RG7112 (67), retained the 
imidazoline core with four groups projecting from this central region. RG7112 was the first small 
molecule inhibitor of Mdm2 to enter clinical trials. The structure of both Nutlin-3a and RG7112 are 
shown in Figure 30. The key difference is the addition of two methyl groups to the imidazoline ring to 
prevent oxidation of the ring. The isopropyl ether group of Nutlin-3a was replaced with an ethyl ether 
group as this was assumed to retain good binding with Mdm2 while reducing molecular weight. In 
Nutlin-3a the methoxy group is prone to metabolic digestion and has been replaced with a tert-butyl 
group to improve metabolic stability. The addition of the sulfonyl group was aimed at improving the 
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to that of Nutlin-2. The crystal structure suggests that the π-π interaction between a 4-chlorophenyl 
group on RG7112 and His96 is better aligned than observed in the crystal structure of Nutlin-2 and 
Mdm2. RG7112 gave an improved IC50 of 11 nM and has been shown to activate wild-type p53 both in 
vitro and in vivo, causing the inhibition of cell growth in cancer cell lines.[198]  
 
Figure 30. The structural revisions of Nutlin-3a (66) to result in RG7112 (67). The crystal structure of 67 bound to Mdm2 
(PDB: 4IPF) shows that it binds in a similar fashion to the Nutlins. The π-π interaction between the 4-chlorophenyl group 
and His96 (grey) is better aligned than observed for the Nutlins. 
The Nutlin scaffold has inspired many similar small molecule Mdm2 inhibitors that feature a rigid core 
with four groups projecting from it. One class of structures with many similarities to the Nutlins is the 
spiro-oxaindoles, first reported by Ding et. al.[199] The most potent of the family, MI-219 (68), 
demonstrates good pharmacokinetics and has an IC50 of 45 nM. Although the spiro-oxaindoles display 
good pharmacokinetics and potency, their conformation is not optimal. As discussed previously, it is 
thought that an aromatic group is preferred in the Leu26 pocket due to a π-π stacking interaction with 
His96. However, for MI-219 the neopentyl group is occupying the Leu26 pocket. The group at Roche, 
responsible for many of the previous successes in Mdm2 inhibition, revised the scaffold to switch the 
orientation of binding and place an aromatic group in the Leu26 pocket (Figure 31).[200] The scaffold 
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Figure 31. The structure of Nutlin-3a (66), RG7338 (69) and MI-219 (68). The binding pockets that the groups are located 
in are highlighted. 
The group at Roche examined the conformation of the spiro-oxaindole MI-219 and realised that by 
changing the relationship of the groups on the pyrrolidine ring they could change the orientation of 
binding of the molecule to place an aromatic group in the Leu26 pocket. For MI-219 the oxindole group 
and the 3-chlorophenyl group are cis to each other whilst the neopentyl group and the oxindole are trans 
to each other. This results in a conformation of MI-219 that places the neopentyl group in the Leu26 
pocket. Roche realised that by introducing a trans relationship between the two phenyl groups and 
maintain the trans relationship between the 3-chloro-2-phenyl group and the neopentyl group will result 
in the former being oriented towards the Leu26 pocket.[201] RG7388 is now in clinical trials and shows 
superior potency and selectivity to both 68 and 66. RG7388 binds to Mdm2 with an impressive IC50 of 
6 nM and shows potent tumour inhibition in cancer cell lines containing wild-type p53, moderate 
clearance (t1/2 = 1.6 h) and good metabolic stability.  
It is also possible to switch the orientation of binding of the spiro-oxaindoles by changing the 
stereochemistry of the quaternary centre. The optimisation of MI-219 to incorporate this change, along 
with a different halogen substitution pattern on both phenyl groups and a conformationally constrained 
cyclohexanol group gave compound MI-77301 (70) (Figure 32).[202] MI-77301, has a very impressive 
Ki of 0.88 nM and has been shown to activate wild-type p53 in cancer cell lines at concentrations as 
low as 30 nM in vitro. MI-77301 is the most potent Mdm2 inhibitor reported to date and has also entered 
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Figure 32. The structure of both MI-219 (68) and MI-77301 (69). The binding pockets that the groups occupy are 
highlighted. 
The majority of small molecule inhibitors of the p53-Mdm2 PPI are based on the original Nutlin 
scaffold however, there are a number of other structures that bear little to no similarity to the Nutlin 
scaffold. Following the Nutlins, and the scaffolds that they have inspired, the next most well-known 
small molecule inhibitor of the p53-Mdm2 PPI are the terphenyls, designed by Hamilton et. al.[202] Their 
importance in the scientific literature is not necessarily due to their inhibitory activity against Mdm2, 
but rather that they represented one of the first classes of small molecule α-helix mimetics. The 
importance of small molecule α-helix mimetics and the progress in the field will be discussed in section 
1.6, including the conception and development of the terphenyls.  
A comprehensive library of terphenyl scaffolds bearing different substituents at the ortho position of 
the three phenyl rings were prepared by Hamilton et. al. and their ability to inhibit the p53-Mdm2 PPI 
was explored using fluorescence polarisation assays and 1H-15N HSQC spectroscopy.[203] The modular 
synthesis of the terphenyls which sees phenyl groups connected by simple Suzuki cross coupling 
reactions, allows a broad range and combination of ortho-substituents to be screened, helping to identify 
hot-spot mimetic groups that provide high affinity to Mdm2. A selection of the terphenyls synthesised 
by Hamilton et. al. are shown in Table 5. The results obtained confirmed the importance of the ortho 
side chains in establishing good affinity with Mdm2 as removal of one or more side chains resulted in 
a loss of affinity. Additionally, a comparison between 72 and 73 reveals that the 2’,6’-dimethyl 
substituted terphenyl shows improved affinity over its monomethyl substituted counterpart, likely due 
to the increased conformational rigidity of the terphenyl backbone imposed by the sterically hindering 
methyl group preventing rotation around the aryl-aryl bonds. Finally, the results obtained suggest that 
the naphthyl group is a suitable mimetic of the indole group of tryptophan with strong binding affinities 
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Table 5. A selection of the terphenyl scaffolds designed by Hamilton et. al. towards the inhibition of p53-Mdm2.[203] 
Structure  R1 R2 R3 R4 Ki ± S.D. (µM) 
 
71 H H H H >1000 
72 Bn Me Me H 12.6 ± 2.1 
73 Bn Me Me Me 3.83 ± 0.7 
74 iBu CH2(2-Naph) iBu H 0.182 ± 0.02 
75 iBu CH2(2-Naph) H H 82.0 ± 8.6 
76 iBu Bn iBu H 3.5 ± 1.0  
77 Bn Bn iBu H 0.978 ± 0.171 
78 Bn Me Bn Me 2.17 ± 0.14 
79 iBu Me iBu Me 2.97 ± 0.15 
1.6 Small Molecule α-Helix Mimetics 
The α-helix is the most common secondary structure found within proteins, defined by a tight right-
handed helical coil consisting of 3.6 residues per turn resulting in a pitch of 5.4 Å.[204] The side chains 
of the amino acids point outwards away from the helix in a staggered arrangement, minimising steric 
interference. The prevalence and regularity of α-helices in protein structure has made them interesting 
targets in the design of protein mimetics. The field of α-helix mimetics is especially important in the 
inhibition of PPIs, with over 62% of all PPIs featuring an α-helix at the binding surface.[205,206]  
The primary aim in the design of α-helix mimetics is to design a scaffold that projects side chains at 
analogous distances and angular relationships to the side chains of residues in an α-helix. The scaffold 
needs to be conformationally controlled to ensure that it remains in the correct conformation for α-
helical mimicry. Early examples of α-helix mimetics were focussed on the design of short 
conformationally restricted peptide sequences, with strategies such as hydrocarbon stapling, disulfide 
bridges, cross linking between residue side chains and hydrogen bonding routinely used in an attempt 
to control the conformation of unstructured peptides.[207] However, as discussed previously, peptide 
sequences have some major drawback, namely their metabolic instability and thus, attention was turned 
to identify small molecule α-helix mimetics. This section will discuss some of the success that has been 
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1.6.1 Single Faced Small Molecule α-Helix Mimetics 
The α-helix contains multiple binding interfaces, all of which can potentially form contacts with other 
proteins when engaged in a PPI. However, it has been found that the hot-spot residues are located on 
one recognition face of the α-helix for over 60% of all PPIs that feature an α-helix at the binding 
interface.[205] The three positions of the α-helix that were found by Arora et. al. to contribute most 
significantly to binding were the i, i + 4 and i + 7 positions (Figure 33). Arora et. al. used alanine 
scanning mutagenesis, which involves the sequential mutation of one amino acid in the sequence to 
alanine and the effect on binding affinity to its protein partner is monitored.[208] Any amino acid that 
when mutated to alanine results in a drop of binding affinity by more than 8.4 kJ mol-1 is deduced to be 
a hot-spot residue. Arora et. al. performed this analysis on 480 strongly interacting interfaces found 
within the PDB, enabling the identification of the most favourable hots-spot positions.[205]  
 
Figure 33. The α-helix and the frequency of positions occurring as a hot-spot residue. Figure reproduced from reference[205] 
The investigation also revealed that hydrophobic residues were the most common residues found at 
binding interfaces with 34% of hot-spot residues being hydrophobic in nature. This was closely 
followed by residues with aromatic side chains, with 27% of hot-spots being aromatic. Polar or charged 
residues were also common, with 13% of amino acids with negatively charges side chains and 20% 
with positively charged side chains.[205] The finding reported by Arora et. al. supports the theory that 
PPIs are typically hydrophobic in nature.  
The prevalence of PPIs that exist over one binding interface of an α-helix has led to the discovery of 
several small molecule α-helix mimetics that can mimic the i, i + 3/4 and i + 7 positions of the α-helix. 
The earliest example was reported by Hamilton et. al. in 2001, who designed terphenyl derivatives as 
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molecule α-helix mimetics and many of the scaffolds that we see today bear resemblance to the original 
terphenyl scaffolds.  
The terphenyl scaffold 80, consists of three consecutive ortho-substituted phenyl groups. The three 
phenyl groups arrange themselves in a staggered conformation to reduce steric interactions between the 
ortho-substituents.[210] Although free rotation is still possible around the aryl-aryl bonds and other low 
energy conformations will be present in solution, it is believed that the staggered conformation is 
favoured due to the reduced steric clash between the ortho-substituents. Indeed, X-ray crystallography 
of a terphenyl derivative revealed a staggered conformation with dihedral angles of 59.1° and 120.7°.[209] 
The ortho-substituents project from the terphenyl core with similar angular relationships and distances 
to those of the i, i + 3/4 and i + 7 β-carbons in an α-helix (Figure 34).[211]  
 
Figure 34. The terphenyl scaffold reported by Hamilton et. al. Overlaying the terphenyl scaffold with the α-helix, clearly 
shows excellent mimicry of the ortho-substituents with the i, i + 3/4 and i + 7 positions of the α-helix.  
One of the major advantages of the terphenyl derivatives is that they can be synthesised in a modular 
fashion using sequential Negishi or Suzuki cross coupling reactions.[212] The reactions are high yielding 
and allow for the facile synthesis of libraries of terphenyls featuring different ortho-substituents by the 
simple substitution of the required coupling partner into the synthetic sequence. The terphenyl scaffold 
has been appended with suitable groups to inhibit a number of PPIs including the p53-Mdm2 PPI[203], 
the Bcl-xL-Bak PPI[213] and the interaction between CaM and smMLCK.[209] Although the terphenyl 
scaffold shows promise, they demonstrate very poor aqueous solubility and the low barrier of rotation 
between the aryl-aryl group renders them conformationally too flexible. Therefore, the original 
terphenyl scaffold has been subsequently modified, by Hamilton et. al. and many others.  
The first modification to the terphenyl scaffold was introduced by Hamilton et. al. in an attempt to 
improve their solubility. By replacing the ortho-substituted phenyl groups with ortho-substituted 




 UOB Open 
terpyridine derivatives 81 are expected to take on the same staggered conformation as the terphenyl 
derivatives, with the ortho-substituents mimicking the i, i + 3/4 and i + 7 positions of an α-helix. The 
biological activity of the terpyridines has however, not been explored by Hamilton et. al.  
Hamilton et. al. are responsible for several classes of small molecule α-helix mimetics that can mimic 
one face of the α-helix. Including the terphenyls and the terpyridines, Hamilton et. al. have also reported 
the terephthalamides 82[215], the tris-benzamides 83[216], the diphenylindane 84[217], the 5-6-5 imidazole-
phenyl-thiazoles 85[218], the biphenyl 4,4’-dicarboxamides 86[219], the enaminones 87[220] and the 
benzoylurea oligomers 88[221]. All of these scaffolds project side chains that mimic the i, i + 3/4, i + 7 
and in some situations the i + 11 positions of an α-helix (Figure 35). Heteroatoms are routinely 
incorporated to improve the aqueous solubility compared to the terphenyl scaffold. Additionally, 
hydrogen-bonding networks are often employed to ensure that the conformation that mimics the α-helix 
is the favoured conformation.232,233 
 
Figure 35. A collected of single faced α-helix mimetics designed and synthesised by Hamilton et. al.  
Hamilton et. al. are not the only research group to explore the development of single faced small 
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mimetic, based on a triazine–piperazine–triazine scaffold.[224] The scaffold contains three functional 
side chains that match the distances and angular relationships between the i, i + 3/4 and i + 7 positions 
of the α-helix. Whilst the scaffold still bears a resemblance to those reported by Hamilton et. al., a 
covalent bridge was introduced to reduce rotation around the central axis of the scaffold. The covalent 
bridge restricts the conformational freedom of the scaffold, addressing one of the major limitations of 
the terphenyls and other scaffolds reported by Hamilton et. al. A PEG bridge was introduced across the 
scaffold and the binding of the bridged analogue (90) and its parent compound (89)[225] to Mcl-1 was 
tested using a competitive fluorescent polarisation (FP) assay. Lim and co-workers were able to 
demonstrate that the covalently bridged analogous bind with a greater affinity and specificity to Mcl-1 
than the non-bridged derivative (Figure 36). Lim et. al. propose that the increase in binding affinity is 
due to the entropic benefit of conformational restriction.[224]  
 
Figure 36. The triazine–piperazine–triazine scaffold reported by Lim et. al. The improvement in the binding affinity to 
Mcl1 following the incorporation of a PEG bridge is shown.  
Many of the α-helical scaffolds that have been reported in the literature were inspired by the original 
terphenyl scaffold reported by Hamilton et. al. However, one example which was not inspired by the 
terphenyls is the polycyclic ether skeleton, reported by Hirama and co-workers.[226] Hirama et. al. took 
inspiration from the topological similarity between trans-fused polycyclic ether marine toxins and α-
helices to design a ladder-like polycyclic ether scaffold as a new class of α-helix mimetics. Hirama et. 
al. noticed that the distance between two equatorial hydroxy groups on a 6/6/6/6/6 trans-fused 
pentacyclic ether scaffold (91) (4.8 Å) closely matches the distance between the side chains of the i and 
the i + 4 residues (~5 Å) (Figure 37). These hydroxy groups can be easily functionalised to incorporate 
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conformational rigidity that the scaffold will present due to the fused ring systems. Furthermore, the 
scaffold will likely display improved aqueous solubility than the terphenyls due to the introduction of 
oxygen atoms into the scaffold.  
 
Figure 37. The polycyclic ether skeleton, reported by Hirama and co-workers. The distance between two equatorial hydroxy 
side chains, such as those highlighted, closely matches the distance between the i and i + 4 residues of the α-helix. 
1.6.2 Multi-Facial Small Molecule α-Helix Mimetics 
With over 60% of PPIs that feature an α-helix at the binding occurring over one face of the helix it is 
understandable that much of the focus on small molecule α-helix mimetics has been on developing 
scaffolds that can mimic the i, i + 3/4, i + 7 positions of the α-helix. However, roughly ~30% of PPIs 
utilize two faces of the α-helix for complexation while ~10% exist across all three faces of the α-helix 
(Figure 38). Therefore, there has also been a recent interest in the design of multi-facial small molecule 
α-helix mimetics. Historically, the design of multi-faced α-helix mimetics was limited to stabilised 
peptide helices as it is challenging to design a small molecule with two or more distinct binding faces.  
 
Figure 38. A pie-chart to show the percentage of PPIs that have hot-spot groups located on one, two and three recognition 
faces. Reference reproduced from reference[205] 
Once again, Hamilton et. al. have pioneered the field of multi-faced α-helix mimicry, with some of the 
scaffolds that were originally designed to mimic one face of the α-helix derivatised to mimic multiple 
faces. For example, the tris-benzamide scaffold (83) reported by Hamilton et. al. in 2003[216] was 
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proposed that intramolecular hydrogen bonding is responsible for the constrained conformation which 
places the side chains in the correct spatial orientation to mimic the desired positions. The synthesis of 
a bis-benzamide derivative was performed, and an x-ray crystal structure of a fully methylated 
derivative (R1-4 = Me) confirmed the intramolecular hydrogen bonding. Superposition of the x-ray 
structure and a representative α-helix yielded an RMSD of 0.43 Å, confirming excellent mimicry of the 
i, i + 2, i + 4 and i + 6 positions of an α-helix. Hamilton et. al. have also synthesised a hexa-substituted 
tris-benzamide (93), capable of mimicking the i, i + 2, i + 4, i + 6, i + 8 and i + 10 positions of an α-
helix. This impressive result is possible due to the modular and scalable synthesis designed by Hamilton 
et.al., which is amenable to extension, with much higher oligoamides able to be synthesised in theory.  
 
Figure 39. The evolution of the original tris-benzamide scaffold that can mimic one face of the α-helix, to the oligoamides 
that can mimic multiple faces of the α-helix. This figure was partly reproduced from reference [227]  
A second scaffold originally reported by Hamilton et. al. as a single faced α-helix mimetic and since 
functionalised to mimic multiple faces of the α-helix is the benzoylurea scaffold (87). The original 
benzoylurea scaffold reported by Hamilton et. al.[221], features a conformationally controlled scaffold, 
held in a staggered conformation by intramolecular hydrogen bonding between the urea NH groups and 
the carbonyl oxygen atoms. Hamilton et. al. demonstrated that a benzoylurea scaffold could be used to 
design a mimetic of the i, i + 1, i + 4, i + 6 and i + 8 positions of an α-helix (94) (Figure 40).[228] The 
benzoylurea scaffold was synthesised in a modular fashion using dihydroxylated aromatics, which can 
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chains. An x-ray crystal structure of a representative benzoylurea confirmed the presence of 
intramolecular hydrogen bonding, responsible for holding the scaffold in the correct spatial orientation 
for α-helix mimicry. Superposition of the x-ray crystal structure with a model α-helix revealed excellent 
overlap of the substituents with the i, i + 1, i + 4, i + 6 and i + 8 residue side chains (RMSD = 1.25 Å).      
 
Figure 40. Modifying the original benzoylurea scaffold reported by Hamilton et. al. to mimic multiple faces of the α-helix.  
Not all multi-faced α-helix mimetics were derived from single-faced α-helix mimetics. Instead Fletcher 
and co-workers drew inspiration from 1,2-diphenylacetylenes, common scaffolds used in the mimicry 
of β-turns and β-sheets.[229] Seminal work by Kemp et. al. demonstrated that 2,2’-functionalised 
diphenylacetylenes could mimic the β-turn by uni-directional β-sheet formation, held together by 
intramolecular hydrogen bonding.[230] The Fletcher group however, explored whether a similar 
diphenylacetylene scaffold could be used to induce α-helix mimicry (Figure 41). Four R groups are 
present which are intended to mimic the i, i + 2, i + 5 and i + 7 residues of an α-helix. Intramolecular 
hydrogen bonding was proposed to be key in maintaining the structural integrity required for α-helix 
mimicry. Substitution of the R groups with Me groups and superposition of a conformer of 95, generated 
from an MD simulation, with an idealised polyalanine α-helix revealed an RMSD of 0.52 Å. This 
suggests that 95 mimics the i, i + 2, i + 5 and i + 7 residues of an α-helix to a high degree.  
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A number of small molecule α-helix mimetic scaffolds have been reported in the literature, many of 
which were either invented by or inspired by the seminal work of Hamilton et. al. The majority of the 
scaffolds that current exist are only able to mimic one face of the α-helix, however, a transition towards 
multifaced α-helix mimetics, with more flexibility over the positions that can be mimicked, is present 
in the literature. Despite the progress that has been made in the field, a number of limitations are still 
yet to be overcome. The first is that often the synthesis of these scaffolds involves lengthy and low 
yielding routes. A second limitation of many of the scaffolds is the poor conformational control that 
they exhibit. Finally, the scaffolds that have been reported all mimic a set of residues very specific to 
that scaffold and little in the way of flexibility, in terms of the positions mimicked, is offered. A more 
desirable strategy would be to have one conformationally controlled scaffold, with multiple faces that 
can mimic any position desired by the incorporation of the appropriate side chain at the appropriate 
place on the scaffold. Such a scaffold could be described as a ‘universal’ α-helix mimetic.  
1.7 Summary 
The conformational preorganisation of therapeutics leads to higher binding affinities due to both 
entropic and enthalpic factors. This is especially important when targeting PPIs, which typically present 
featureless and large binding sites poorly amenable to the design of specific small molecule inhibitors. 
However, the consideration of free ligand conformation is often overlooked in SBDD. This is likely 
due to the challenges associated with measuring free ligand conformations of flexible molecules in 
solution. It requires a knowledge of the stereo and electronic factors that govern molecular conformation 
and the stereospecific synthetic methodologies available to synthesise conformationally controlled 
molecules. Finally, an understanding of the methods available to measure conformational behaviour in 
solution, including computational methods and NMR spectroscopy, is required. The multidisciplinary 
nature of this endeavour is perhaps the reason why it is often overlooked. This thesis presents the design, 
synthesis and conformational analysis of a new class of conformationally controlled α-helix mimetics 
using a combination of computational chemistry, organic synthesis and NMR spectroscopy. The 
multidisciplinary strategy is used to design a conformationally controlled mimetic of p53, and its 









Chapter 2: Project Outline 
The design of small molecule α-helix mimetics has been driven by the seminal work from Hamilton et. 
al., who have reported the terphenyls as structural mimetics of the i, i + 3/4 and i + 7 residues of the α-
helix.[209] Many of the scaffolds that have since been reported bear a resemblance to the original 
terphenyl scaffold. This thesis presents an entirely new class of small molecule α-helix mimetics devoid 
of strong similarity to the terphenyl scaffold. This thesis shows that conformationally controlled 
hydrocarbons, controlled through the avoidance of destabilising syn-pentane interactions, show promise 
as structural mimetics of the i, i + 3/4 and i + 7 residues of the α-helix.  
In chapter 1, the design, synthesis and conformational analysis of molecules with tailored shapes using 
the iterative lithiation–borylation of boronic esters was discussed.[27] It was shown that an alternating 
syn-anti relationship between the methyl groups (11) yielded a linear conformational bias whereas an 
all-syn relationship (10) yielded a helical conformational bias, controlled by the avoidance of 
destabilising syn-pentane interactions. An investigation into the conformation of both 10 and 11 in 
solution using NMR spectroscopy and computation, revealed that both the linear (11) and the helical 
(10) scaffold present distinct faces from which methyl groups project. Furthermore, the distances 
between the methyl groups on one face of either 11 or 10 closely match the distances typically observed 
between the side chains of residues located at the i, i + 3/4 and i + 7 positions of the α-helix (5-7 Å) 
(Figure 42).  
 
Figure 42. The distances between methyl groups on one face of both the linear and the helical scaffold are shown and 




The access to a conformationally controlled scaffolds that can project methyl groups at analogous 
distances and angular relationships to those observed in the α-helix prompted the exploration of these 
scaffolds as a new class of small molecule α-helix mimetics. This forms the work of this thesis. Our 
focus in this PhD project has been on the alternating syn-anti diastereomer 11, since the distances are a 
closer match to those typically observed in the α-helix. Additionally, significantly fewer homologations 
would be required to mimic the i, i + 3/4 and i + 7 residues for a linear scaffold compared to a helical 
scaffold. It is also challenging to have full control over the pitch of the helix for the all-syn diastereomer 
10. Superposition of the linear scaffold 11 with a representative polyalanine α-helix, clearly shows that 
the methyl groups found at the 1st, 5th and 9th position of the hydrocarbon scaffold closely match the 
methyl side chains of the i, i + 3/4 and i + 7 residues of the polyalanine α-helix (RMSD = 0.85 Å) 
(Figure 43). Therefore, the alternating syn-anti diastereomer 11 can be proposed to be suitable 
structural mimetic of the i, i + 3/4 and i + 7 residues of an α-helix.  
 
Figure 43. The superposition of the linear scaffold with a model polyalanine α -helix. The 1st, 5th and 9th positions of the 
linear scaffold 11 closely match the i, i + 3/4 and i + 7 residues of an α-helix.  
Small molecule α-helix mimetics are an important class of targets in the inhibition of protein–protein 
interactions (PPIs). The hot-spot groups that dominate the binding between proteins engaged in a PPI 
are more often than not located on one face of an α-helical domain of one of the interacting proteins, 
and thus the methyl groups can potentially mimic these hot-spot groups. However, alanine is not 
typically found to be a hot-spot group as it cannot make extensive hydrophobic interactions with the 
binding partner. Therefore, groups other than methyl would need to be installed onto the scaffold to 
mimic a wider range of amino acids.  
Fortunately, the iterative homologation of boronic esters, used to synthesise 11, is easily amenable to 
the substitution of different groups on the scaffold in place of the methyl group. The linear scaffold 11 
is synthesised using an assembly line process whereby an enantioenriched stannane undergoes a 
stereospecific tin-lithium exchange to yield a chiral carbenoid that can react with an electrophilic 
boronic ester to form a chiral boronate complex. Upon warming the boronate complex undergoes a 
stereospecific 1,2-metallate rearrangement to yield a homologated boronic ester that can be subjected 




stannane used in the synthesis of 11 resulted in methyl groups being incorporated alone the backbone. 
However, it is possible to incorporate different groups along the backbone using the same methodology 
by simply changing the side chains of the chiral carbenoid used in the sequence (Figure 44).   
The enantioenriched stannanes used in the synthesis of 11 are generated from the stereospecific 
lithiation of ethyl triisopropylbenzoate (TIB) in the presence of s-BuLi and (±)-sparteine to form the 
chiral carbenoid. This is followed by electrophilic trapping with trimethyltin chloride to yield the α-
stannyl benzoate in good enantiopurity.[27] The resulting stannane can be recrystalised in methanol to 
provide the stannane in >99.9:0.1 e.r. To change the group incorporated onto the scaffold all one must 
do is use a different benzoate ester in place of ethyl-TIB. If the resulting stannane is not a crystalline 
solid, and can thus not be recrystallised to high enantiopurities, then it is also possible to use the chiral 
ligand-assisted asymmetric deprotonation of the primary benzoate to generate the chiral carbenoid.[42] 
Benzoates can be synthesised by a simple Mitsunobu reaction of the corresponding alcohol, and thus a 
broad range of benzoates can be synthesised.[231]  
 





Therefore, using the iterative homologation of boronic esters it should be possible to synthesise 
conformationally controlled hydrocarbons bearing side chains at the 1st, 5th and 9th positions that mimic 
the side chains of the i, i + 3/4 and i + 7 residues of an α-helix. By the simple substitution of the benzoate 
ester, at judicious positions within the lithiation–borylation sequence, it is possible to install a hugely 
diverse set of side chains using one, high yielding and iterative methodology.  
This thesis will first explore the effect on the conformational bias of the scaffold upon the introduction 
of extended side chains at the 1st, 5th and 9th position of the scaffold using computational methods 
including MM conformational searching. It is important to confirm that extending the methyl group by 
an additional methylene unit, does not disrupt the conformational bias by introducing additional syn-
pentane interactions that disfavour the linear conformation. Once a suitable scaffold has been identified, 
the inhibition of the p53-Mdm2 PPI will be explored. p53 binds to a hydrophobic pocket on Mdm2, 
with the binding dominated by a Leu residue at i, a Trp residue at i + 4 and a Phe residue at i + 7. This 
thesis will explore the design of a scaffold bearing appropriate groups to mimic the side chain of the 
Leu, Trp and Phe residues of p53 using MM conformational search calculations, such as scaffold 96. 
The binding of designed p53 mimetics to Mdm2 will also be explored using protein-ligand docking 
calculations (Figure 45). 
Following the design of potential p53 mimetics, the synthesis of the molecules will be performed by 
lithiation–borylation. Additionally, strategies to improve the aqueous solubility of the scaffold will be 
explored to allow for experimental validation of binding of the designed p53 mimetics to Mdm2.  
Upon completion of the synthesis, a hybrid NMR spectroscopy and QM calculations workflow will be 
performed to examine the conformation of the designed p53 mimetic in solution. During this procedure, 
experimentally derived interproton distances, obtained from NOESY experiments, scalar coupling 
constants and chemical shifts are compared to Boltzmann averaged values calculated using QM 
calculations. The quality of the correlation between the two datasets will provide information regarding 
the population of conformers in solution.  
Finally, the binding of the p53 mimetic to Mdm2 will be explored by 1H-15N HSQC spectroscopy. 15N-
labelled Mdm2 will be expressed and purified and the binding of the designed p53 mimetics will be 
confirmed by the presence of chemical shift perturbations (CSPs) in the 1H-15N HSQC spectra. The 
CSPs can be used to locate the binding of the ligand to Mdm2, confirming whether the ligand binds to 
the p53 pocket on Mdm2. Additionally, the CSPs can be tracked with increasing ligand concentration 




If this project is successful and demonstrates that conformationally controlled hydrocarbons can act as 
structural mimetics of p53 and bind to Mdm2, we hope that it will inspire the design of other α-helix 
mimetics, bearing different side chains to disrupt other therapeutically important PPIs. 
 
Figure 45. A summary of the proposed inhibition of the p53-Mdm2 PPI using conformationally controlled hydrocarbons a) 
The p53-Mdm2 PPI. The Mdm2 binding domain of p53 is shown in blue and Mdm2 is shown in purple. b) A zoom in of the 
p53-Mdm2 interaction, with the three hot-spot groups labelled. c) The overlay of the original linear scaffold 11 and p53. The 
1st, 5th and 9th positions of the linear scaffold overlay well with the i, i + 4 and i + 7 residues of p53 as expected. d) A 
proposed p53 mimetic. The linear scaffold has been functionalised with suitable hot-spot groups. e) The proposed binding of 
a designed p53 mimetic, 96 to Mdm2. The binding of the designed p53 mimetic is similar to the binding of p53, however it 










Chapter 3: The Computational Design of an α-Helix Mimetic of p53 
The principal aim of this project is to design a conformationally controlled scaffold that can mimic the 
key distances and angular relationships observed between residues located over one face of the α-helix. 
As discussed previously, many of the α-helix mimetics that have been previously reported suffer from 
poor conformational control, and a significant conformational reorganisation is required for binding, 
reducing the binding affinity. This conformational reorganisation can be avoided by the rational design 
of conformationally biased scaffolds, through the introduction of conformationally controlling groups 
onto the scaffold. This can include the introduction of syn-pentane interactions, capable of destabilising 
unwanted conformations and favouring the desired conformation, provided they are correctly 
introduced onto the scaffold.  
Designing an alkane-based scaffold that is conformationally biased due to the avoidance of syn-pentane 
interactions can in theory be done using a simple diamond lattice analysis. This process involves 
manually drawing the alkyl chain onto a diamond lattice, and then redrawing conformers with certain 
bonds rotated to explore the potential gauche and syn-pentane interactions (Figure 46). Although this 
is a useful tool for quickly identifying conformations containing syn-pentane or gauche interactions, it 
does not provide quantitative information regarding the populations of various conformations in 
solution. It is also a very laborious task, requiring many manual drawings of conformers, and 
conformations can be easily missed in molecule with a large number of rotatable bonds.  
 
Figure 46. The diamond lattice analysis of 3 conformers of pentane. The first conformer shown features a syn-pentane 
interaction however using the diamond lattice it is clear that rotation of this final dihedral by 60° leads to a conformer with 
no syn-pentane interaction present. This process can be repeated. The diamond lattice can help to identify those conformers 
with no syn-pentane interactions.  
An alternative approach is to use computational methods such as molecular mechanics (MM) 
conformational searching. This chapter will discuss the design of an α-helix mimetic of p53 using both 
the diamond lattice and MM conformational searching. Additionally, this chapter will explore the 





3.1 Using the Diamond Lattice to Investigate Molecular Conformation 
As discussed in chapter 2, the alternating syn-anti diastereomer (11) of the contiguously methyl 
substituted scaffolds designed and synthesised by Aggarwal et. al. favours a linear conformation in 
solution.[27] The methyl groups at the 1st, 5th and 9th positions can mimic the residues at the i, i + 3/4 and 
i + 7 position of an α-helix and therefore the linear scaffold could act as a suitable α-helix mimetic. The 
conformation of the molecule is controlled by the avoidance of destabilising syn-pentane interactions 
between the methyl groups. Drawing the linear conformation of a syn-anti diastereomer of a poly-
methylated hydrocarbon (97) onto a simple 2D-diamond lattice it can clearly be seen that no syn-pentane 
interactions exist and thus this conformation is favoured (Figure 47). If the molecule were to adopt any 
conformation other than linear, at least one syn-pentane interaction would be incurred, reducing the 
population of these conformers to <0.5% at room temperature.  
 
Figure 47. The diamond lattice analysis of a linear scaffold 97. The conformational bias of the molecule is such that it 
avoids all syn-pentane interactions (red arrows). 
Using the linear scaffold 97 as a starting point, the diamond lattice analysis was used to explore the 
effect on the conformation upon adding hot-spot groups at the 1st, 5th and 9th positions of the scaffold. 
If the chain length of a methyl group is increased by one carbon, resulting in structure 98, it can clearly 
be seen using the diamond lattice, that there is no position for the additional carbon that avoids a syn-
pentane interaction (Figure 48b). However, if an adjacent methyl group is removed from the scaffold 
then a linear conformation can exist with no syn-pentane interactions (Figure 48c). Additionally, if a 
third carbon is added to the side chain, such as structure 99, there is only one position on the diamond 
lattice for this atom that avoids a syn-pentane interaction. Thus, by removing one adjacent methyl group 





Figure 48. The diamond lattice design of an α-helix mimetic. a) The conformation of the linear scaffold b) Increasing the 
length of a methyl group by one carbon results in a syn-pentane interaction c) Removing an adjacent methyl group prevents 
a syn-pentane interaction.  
Based on the diamond lattice analysis, a suitable scaffold that can mimic the i, i + 3/4 and i + 7 positions 
of the α-helix is shown in Figure 49. Methyl groups have been removed at adjacent positions to each 
mimetic side chain. The linear conformation of this molecule is predicted by the diamond lattice 
analysis to avoid any syn-pentane interactions, resulting in a linear conformational bias. In order to 
confirm this conformational bias and calculate the population of conformers adopting a linear 
conformation, MM conformational searching needs to be employed.   
 
Figure 49. A proposed linear scaffold capable of mimicking the i, i + 3/4 and i + 7 positions of the α-helix.  
3.2 Molecular Mechanics Conformational Searching to Explore the 
Conformational Space of a Designed p53 Mimetic  
To investigate whether the conformational bias of the molecule is as predicted by the diamond lattice 
analysis, and to calculate the potential energies and corresponding conformer populations, a MM 
conformational search was performed. The conformational search was performed using MacroModel, 
a software package available from Schrödinger.[232] As discussed in section 1.3.2 of chapter 1, a 
conformational search locates a number of low energy conformers of a molecule and estimates their 




A Monte Carlo Multiple Minimum (MCMM) conformational search was used in this study. The 
MCMM conformational search method is a stochastic search method whereby conformers are generated 
by randomly rotating either the cartesian coordinated or the torsional bonds by differing amounts.[233] 
The distorted structure is minimised and compared to the structures generated in previous 
conformational search steps. The minimised conformer is either stored as a new structure or eliminated 
on the groups of its energy or redundancy with previous conformers found. The MCMM method was 
chosen based on its ability to explore both close and distance areas of the potential energy surface. This 
is very important when studying the conformational landscape of flexible molecules with a large 
number of rotatable bonds. The conformers generated from the MCMM conformational search were 
minimised using the Truncated Newton Conjugate Gradient (TNCG) minimisation method. The TNCG 
method uses the gradient of the energy function to identify convergence. The TNCG method is very 
efficient at diverting the direction of the minimisation away from nonconvex regions towards low 
gradient structures, reducing the number of imaginary frequencies found.[234,235] The energy of the 
conformers was estimated using the Merck Molecular Force Field (MMFFs) force field, which was 
developed to accurately treat non-bonding interactions.[236] Due to the potential for syn-pentane 
interactions, a non-bonding interaction, within the molecule contributing to their energy, the MMFFs 
force field was chosen. A full description of the MM conformational search parameters used in this 
study is provided in the supporting information.  
An MCMM conformational search was performed on a representative structure (100) with propyl side 
chains representing the hot-spot groups. By simplifying the hot-spot groups to propyl side chains the 
computational time taken for the calculation is reduced but information about the conformational bias 
of the backbone is still obtained. The results of the conformational search are summarised as a bubble 
plot whereby each dihedral angle along the backbone of the molecule is represented by a bubble whose 
size is related to the population of the conformer corresponding to that dihedral angle (Figure 50). For 
a linear conformation, the dihedral angles along the backbone of the molecule should all be anti or 
~180°. It is clear from the graph in Figure 50 that this is not the case and structure 100 does not 
preferentially adopt a linear conformation. Instead, alternating dihedral angles of gauche-anti-anti-
gauche-gauche-anti-anti etc are observed, resulting in a kinked conformation. This was unexpected as 
the linear conformation contains no syn-pentane interactions, however, the lowest energy conformer 
found by MM also has no syn-pentane interactions.  
If 100 was controlled by the avoidance of syn-pentane interactions alone, a roughly equal weighting of 
the kinked conformer and the linear conformer would be expected, since they both contain no syn-
pentane interactions so one should not be favoured over the other. Additionally, the two conformers 
contain the same number of gauche interactions. This effect can be explained by a deviation of the 




angles from the ideal values, reduces the energy penalty of any destabilising interactions such as syn-
pentane or gauche interactions. This makes it impossible to discriminate between conformers with the 
same number of destabilising interactions using a diamond lattice analysis.    
 
Figure 50. The bubble plot of representative structure 100. The plot clearly shows that a linear conformation is not favoured. 
This problem can be addressed by investigating what would happen to the conformational landscape if 
the adjacent methyl groups are not removed. It may then be possible to find ways of destabilising the 
preferred conformation and favouring the linear conformation. Interestingly, it was found that a linear 
conformation was preferred for the fully-methylated structure 101, despite incurring multiple syn-
pentane interactions. The bubble plot in Figure 51 clearly shows a bias towards a linear conformation, 
with dihedral angles of ~180° along the backbone. Totalling the contributions from all conformers 





Figure 51. The bubble plot from a MM conformer search of 101. Dihedral angles of ~180° are favoured, resulting in a linear 
conformational bias. 
The linear bias that is observed for 101 is unexpected because of the syn-pentane interactions present. 
However, a closer inspection of the linear conformation of 101 reveals that, although two syn-pentane 
interactions are present, the dihedral angles within the molecule have distorted away from their ideal 
values. This offsets one of the syn-pentane interactions by ~40° (Figure 52). This will reduce the energy 
penalty of the syn-pentane interaction considerably making the linear conformation more favourable. 
Importantly, the other conformers that are populated contain two or more syn-pentane interactions, 
which do not exhibit such a considerable offset between the groups involved. This will raise the energy 
of the other conformations, resulting in the linear conformational bias observed.  
 
Figure 52. The two syn-pentane interactions present in the linear conformation of 101. The one highlighted on the right is 




Although structure 101 demonstrates the conformational bias desired, synthetically it is very demanding 
with ten lithiation–borylation reactions to be performed. The length of the mimetic can be shortened by 
incorporating one of the propyl side chains directly onto the aromatic ring as shown in structure 102 
(Figure 53). By doing this, the increased conformational control of planarity of the aromatic ring over 
an sp3-hybridised methine centre is also exploited. A MM conformational search of 102 revealed that a 
linear conformation is preferred with over 94% of the conformer population adopting a linear 
conformation. The increased bias towards a linear conformation, for structure 102 compared to structure 
101, could be attributed to the fact that the linear conformation of 102 only contains one syn-pentane 
interaction whilst other conformations have two or more. Additionally, shortening the chain reduces the 
entropic penalty incurred on conformational organisation.  
 
Figure 53. The bubble plot of structure 102 reveals a linear conformation is preferred with over 94% of the conformer 
population adopting a linear conformation. 
To confirm whether the designed scaffold mimics the key distances and angular relationships to those 
observed in p53, the lowest energy conformation of structure 102 was overlaid with the Mdm2 binding 
domain of p53. This revealed that the propyl side chains closely align with the side chains of the hot-
spot groups of p53. Using the pair fitting function in PyMol, and fitting the three carbon atoms on the 




of 0.60 Å. An RMSD of <1 Å is considered to be a strong match between two structures and confirms 
that our designed scaffold closely matches the i, i + 4 and i + 7 positions of p53.  
 
Figure 54. An overlay of the designed scaffold 102 with p53. The atoms used in the pair fitting are highlighted by orange 
circles. 
With a suitable scaffold designed, the effect on the conformational bias upon the addition of suitable 
hot-spot groups was explored. A total of three hot-spot groups exist on p53; a leucine residue at i, a 
tryptophan residue at i + 4 and a phenylalanine residue at i + 7. The designed p53 mimetic 96 is shown 
in Figure 55. An isopropyl group has been incorporated to mimic the leucine side chain, a naphthyl 
group is in place to mimic the indole ring of the tryptophan side chain and a benzyl group is present to 
mimic the phenylalanine side chain. Although the indole NH of tryptophan in p53 is engaged in a 
hydrogen bond with Leu54 of Mdm2[179], it has been reported by Hamilton et. al. that a naphthyl group 
is a suitable mimetic of the indole of tryptophan.[203] Using a naphthyl group in place of an indole group 
avoids the need for NH protection and deprotection during the synthetic procedure, making it 
synthetically more attractive. The scaffold was further simplified by shortening the length of the 
scaffold through the removal of the terminal methylene group since adjacent methylene group.     
The hot-spot groups are large and contain aromatic groups that could interact via π-π stacking. To ensure 
that these groups do not perturb the desired conformational bias of the scaffold, a MM conformational 
search of structure 96 was performed (Figure 55). The MM conformer search of structure 96 reveals a 






Figure 55. The bubble plot of the designed p53 mimetic 96. The linear conformational bias is retained upon addition of the 
hot-spot groups with over 74% of the conformer population adopting a linear conformation. 
The conformational control of the molecule only extends along the chain of the hot-spot groups by one 
carbon atom, meaning that the position of the side chains is flexible. For example, an overlay of the 
three lowest energy conformers, which have a combined population of ~64%, reveals a linear backbone 
with differing positions of the hot-spot groups (Figure 56). This side chain flexibility is advantageous 
for binding to Mdm2, as it will allow the hot-spot groups to adopt the position needed to maximise the 
binding affinity between the designed mimetic and Mdm2, with little increase in the free energy of the 
mimetic. Additionally, the conformational mobility of the side chains will improve the mobility of the 





Figure 56. The three lowest energy conformers of the designed mimetic 96 showing the side chain flexibility. 
We have now successfully designed a p53 mimetic (96) which places the hot-spot groups at key 
distances and angular relationships to mimic those of p53. Although a mimetic of p53 has been designed, 
the basic scaffold designed is capable of mimicking the i, i + 3/4 and i + 7 positions of an α-helix, and 
simple substitution of the hot-spot groups, using lithiation–borylation, provides access to a universal 
single faced α-helix mimetic.  
3.3 Exploring Binding of the Designed p53 Mimetic 96 to Mdm2 using 
Molecular Docking  
Following the successful design of a conformationally controlled p53 mimetic (96) the binding of the 
designed mimetic to Mdm2 was explored using molecular docking. Molecular docking, also known as 
protein-ligand docking, predicts how strongly a molecule binds to a receptor, typically a protein. In 
addition, it predicts the preferred pose of the ligand in the binding site of the receptor. Protein-ligand 
docking is routinely used in the drug discovery process, most typically it is used to screen large virtual 
libraries of typical drug molecules against a receptor. Once suitable candidates have been identified 
from the virtual screening, the structure is revised and functional groups altered to maximise the binding 
interaction between the ligand and the protein, predicted by protein-ligand docking. This process is 
known as structure-based drug design (SBDD).[238]  
A number of challenges exist in the accurate prediction of protein-ligand docking and as a result a large 
number of docking programs are available that all aim to address these challenges in differing ways. 
There are two key challenges in molecular docking that docking programs routinely address and aim to 
improve. The first is the generation of ligand poses i.e. correctly predicting the possible conformations 
of the ligand, and the energy of that conformation, along with the fit between this pose and the binding 
site. It is not uncommon for small molecules to contain many conformational degrees of freedom and 
accurately incorporating this ligand flexibility into the calculation is not straightforward.[239] Ideally, a 
simulation would account for both the bound and the unbound conformation of the ligand and account 




molecular docking simulations are currently unable to do this. As well as limitations in ligand flexibility, 
molecular docking simulations do not typically consider receptor flexibility. However, it is known that 
proteins are conformationally labile and can select different conformations to maximise affinity with a 
small molecule.[10]  
The second important parameter is the scoring function used, which predicts the energy of the 
interaction and ultimately which pose of the ligand is preferred. The aim of the scoring function is to 
provide accurate predictions of ligand binding in reasonable computational time.[240] Advancements in 
computing power has made this aim more realistic however, limitations within the scoring functions of 
many molecular docking programs exist including correctly accounting for entropy, solvation and 
receptor flexibility.[241] Despite the limitations associated with molecular docking, molecular docking 
programs are able to predict binding affinities with errors of roughly 8.5-13 kJ mol-1 provided the 
receptor protein does not exist in multiple conformations.[242] 
Several molecular docking programs exist, such as Glide, GOLD and FlexAID. However one of the 
most successful and well cited docking software programs is AutoDock.[243] AutoDock is a preferred 
choice for many drug discoverers as it enables ample sampling of the conformational space of both the 
ligand and receptor. This is achieved by allowing selected side chains of the receptor to be flexible and 
not fixing the bond length or angles within the receptor, two common limitations of other docking 
software.[242]  
AutoDock Vina, a development of the initial software with improved speed and accuracy, was chosen 
for performing the ligand-protein docking calculations. An additional benefit of AutoDock Vina is the 
scoring function used. Most scoring functions will be based on only one of the classes of scoring 
functions, of which the most typical are force field, empirical or knowledge-based. Vina however uses 
a hybrid of both the empirical and knowledge-based classes. Empirical based scoring functions 
combines the contributions of various types of interactions between two partners while knowledge-
based scoring functions reproduce the rules and principles statistically derived from experimentally 
determined structures. The scoring function from AutoDock Vina uses empirical information from 
conformational preferences of receptor-ligand preferences and experimental binding affinities[244] The 
scoring function of AutoDock Vina is shown in Equation 5.  




Where 𝑓𝑡𝑖𝑡𝑗  is a symmetric set of functions and 𝑟𝑖𝑗 is the interatomic distance between atoms i and j. 




function aims to find the global and local minima of c and rank them. AutoDock Vina was found to 
perform best for ligands with 8 or more rotational bonds.[245,246] Many groups have compared the 
performance of the most popular molecular docking programs (such as AutoDock Vina, GOLD, Glide 
and LeDock) and they have all found AutoDock Vina to perform well and more often than not delivers 
the most accurate binding affinities, attributed to the superior scoring function.[246–248]  
To perform a docking simulation in AutoDock Vina the receptor and the ligand are prepared using 
AutoDock Tools, a graphical user interface for coordinate preparation, docking and analysis.[242] The 
lowest energy conformation of the designed p53 mimetic 96, found from the MM conformational search, 
was chosen as the starting coordinates for the ligand and the receptor coordinates were taken from a 
crystal structure. The choice of crystal structure, from which the receptor coordinates are taken, is an 
important parameter to consider. A crystal structure of Mdm2 and the Mdm2 binding domain of p53 
exists (PDB: 1YCR), however a number of crystal structures of Mdm2 with small molecule or peptide 
therapeutics also exist (PDB: 4HFZ, 1RV1, 4ERF). Examination of these crystal structures reveals that 
the conformation of the binding site on Mdm2 changes slightly depending on the ligand/peptide bound 
to it. For instance, when p53 is bound to Mdm2, a much more open binding cleft was observed compared 
to small molecule inhibitors of Mdm2. This is not unexpected, as it has been reported that the p53 
binding site of Mdm2 is moderately conformationally labile.[249–252] Although AutoDock Vina allows 
for receptor side chain flexibility, it is not adequate enough to sample the conformational flexibility of 
the p53 binding site of Mdm2. Thus, it is important to use an appropriate crystal structure, with a p53 
binding site conformation similar to that expected with the designed ligand. Since a mimetic of p53 is 
being designed, the crystal structure of p53 and Mdm2 (PDB: 1YCR) was chosen for the molecular 
docking.[194] The full parameters used in the molecular docking calculations using AutoDock Vina are 
provided in the supporting information. 
Before the docking of our designed ligand to Mdm2 was explored, the docking of a known Mdm2 
inhibitor, Nutlin-2, was explored.[195] This was performed to enable a comparison between the binding 
of our ligand to Mdm2 with that of a successful inhibitor. Although a crystal structure of Nutlin-2 and 
Mdm2 exists (PDB: 1RV1), the coordinates of Mdm2 used were still taken from its crystal structure 
with p53. A MM conformational search of Nutlin-2 was performed, and the lowest energy conformation 
found was used in the docking calculation. It is important to use the receptor from a different crystal 
structure to avoid biasing the results from re-docking.  
Re-docking, when the ligand is docked into the receptor from the crystal structure it was extracted from, 
typically gives elevated binding affinities since the conformation of the binding site perfectly 
accommodates the ligand. Cross-docking however, when the ligand is docked into a receptor from a 
different crystal structure, avoids this problem.[253] Since a crystal structure of our designed ligand 96 




and in order to compare our ligand with Nutlin-2, Nutlin-2 needs to be cross-docked with the same 
receptor as that chosen for our ligand i.e. from 1YCR.  
The molecular docking calculation of Nutlin-2 with Mdm2 gave a predicted binding affinity of 
– 41.4 kJ mol-1. The most favourable binding pose of Nutlin-2 found by AutoDock Vina closely 
reproduces the bound conformation of Nutlin-2 observed in the crystal structure (1RV1) (Figure 57). 
This confirms that the binding affinity of Nutlin-2 to Mdm2, predicted by AutoDock Vina, is reliable 
and can be used to compare the performance of our ligand too. The three binding groups of Nutlin-2 
have been placed into the three hydrophobic binding pockets of Mdm2 and make extensive nonspecific 
van der Waals contacts with Mdm2. Slight conformational differences of these binding groups are 
however observed when compared to the bound conformation of Nutlin-2 in the crystal structure. In 
particular the 4-chlorophenyl group found in the Leu26 pocket. This could be caused by cross-docking 
Nutlin-2 with a different receptor. The crystal structure of Nutlin-2 with Mdm2 revealed that the 4-
chlorophenyl group in the Leu26 pocket orients itself to engage in a π-π interaction with the His96 
residue of Mdm2.[196] This π-π interaction will contribute to the overall conformation of the Mdm2 
binding site which, as you can see clearly in Figure 57, is different to the conformation of the binding 
site that Nutlin-2 was docked into. By docking Nutlin-2 into Mdm2 with a different conformation of 
the binding site, this π-π interaction is lost and as a result the conformation of the 4-chlorophenyl group 
changes.  
 
Figure 57. a) The crystal structure of Nutlin-2 and Mdm2 (PDB ID:1RV1) b) The binding pose of Nutlin-2 with Mdm2 
found by AutoDock Vina. 
The binding of our designed mimetic 96 to Mdm2 using AutoDock Vina was next explored. As 
mentioned, Mdm2 was taken from the crystal structure with p53 (1YCR) and the lowest energy 
conformation of 96 found from the MM conformational search was used in the calculation. The top 
binding pose of 96 found by AutoDock Vina places the hot-spot groups into the p53 binding pockets of 




binding groups of p53. However, the ligand is now binding in the opposite direction to what was 
expected by the design process i.e. the Leu mimetic is in the Phe19 pocket and vice versa. As discussed 
in the introduction, many small molecule inhibitors of the p53-Mdm2 PPI have been designed to place 
an aromatic group in the Leu26 pocket as it has been suggested that this improves the binding affinity 
due to π-π interactions with the His96 residue.[200] On examination of the binding of ligand 96 to Mdm2, 
predicted by AutoDock Vina, it is clear that a π-π interaction with His96 is unlikely to be occurring as 
it is not in the correct orientation to engage in this interaction, and so is not the reason as to why the 96 
is binding in the opposite direction. It is also possible that the direction of the ligand is simply due to 
the fact that AutoDock Vina cannot differentiate between the size and the hydrophobic interactions 
made between the receptor and the Phenyl group vs the isopropyl group. 
The predicted binding affinity between our designed mimetic 96 and Mdm2 is -36.8 kJ mol-1. Although 
this is not as strong as Nutlin-2, it is a competitive binding affinity. The binding affinities obtained from 
AutoDock Vina typically range from -8.5 kJ mol-1 to -63 kJ mol-1. Typically, a weakly binding inhibitor 
will have a binding affinity of <25 kJ mol-1, a moderately binding inhibitor will have a binding affinity 
between 25-33 kJ mol-1 and a strongly binding inhibitor will have a binding affinity between 33-54 
kJ mol-1, while binding affinities >54 kJ mol-1 are only observed when reproducing a crystal structure 
(i.e. cross-docking).[242,254] Thus, with the binding affinity observed, 96 is expected to be a strongly 
binding inhibitor and capable of binding to Mdm2. The designed mimetic 96 is predicted to be a 
promising ligand for the inhibition of the p53-Mdm2 PPI and thus will be synthesised and analysed to 
confirm binding to Mdm2.  
 
Figure 58. The predicted binding pose of 96 with Mdm2. It can clearly be seen that 96 is binding in the opposite direction as 




3.4 The Computational Design of a Library of p53 Mimetics  
During SBDD, binding groups on the molecule will be altered in an attempt to increase the binding 
affinity between a ligand and its receptor through improved induced fit or by increasing the likelihood 
of interactions such as the hydrogen bond. The altered structures can then be tested computationally, 
using tools such as molecular docking, to investigate whether the redesigned molecule is a better 
candidate. This process was followed and a small library of compounds, differing in the hot-spot groups 
attached to the hydrocarbon backbone, was designed in an attempt to increase the binding affinity. The 
designed library of structures can be easily synthesised using lithiation–borylation by simply by 
substituting the appropriate benzoate ester into the sequence at judicious points.  
Our first re-design was inspired by the work of Furet et. al. who have demonstrated that the correct 
placement of a chlorine atom on the group binding to the Trp23 pocket can significantly improve the 
binding affinity.[255] A chlorine atom is able to occupy a deep void in the Trp23 pocket and make 
additional van der Waals contacts with residues located deeper in the binding pocket, including Phe86 
and Ile99.[256,257] It is for this reason that an overwhelming majority of both small molecule and peptide 
inhibitors of the p53-Mdm2 PPI contain a chlorine atom at a judicious position. Examining the binding 
of mimetic 96 to Mdm2, shown in Figure 58, it is clear that a large void below the naphthyl group in 
the Trp23 pocket is unoccupied. The effect of placing a chlorine atom at the 5- or 6-position of the 
naphthyl group (103 and 104) was explored. Using AutoDock Vina, the lowest energy conformer of 
both 103 and 104, found from MM conformational search calculations, was docked into Mdm2. 
However, the hot-spot group was now too large to fit in the binding pocket and the void was not filled 
by the chlorine atom (Figure 59). As a result, the binding affinity was not improved.  
 




This problem can be overcome by removing the chloro-substituted naphthyl group and replacing it with 
a para-chloro substituted phenyl group. To obtain the best induced fit, the chain length needs to be 
extended by one methylene unit. A conformational search of structure 105 revealed that a linear 
conformation was still preferred despite the additional chain length which increases the possibility of a 
syn-pentane interaction between the side chain and the backbone. The lowest energy conformation was 
subjected to molecular docking and a predicted binding affinity of -38.9 kJ mol- 1 was observed (Figure 
60). Examination of the binding pocket confirms that the chlorine atom has filled the void of the Trp23 
pocket, and the increased binding affinity can be attributed to additional van der Waals contacts with 
Mdm2. It is worthwhile to note that the molecule has bound to Mdm2 in the opposite direction as 105, 
with the phenyl group now in the Phe19 pocket and the isopropyl group now in the Leu26 pocket, as 
originally intended.  
 
Figure 60. The predicted binding pose of candidate 105 as predicted by AutoDock Vina. 
Examining the binding pocket when mimetic 105 is bound reveals that the Trp23 pocket still has space 
available. Vassilev has previously reported that the addition of fluorine atoms to the hydrophobic 
binding groups can improve the affinity of a class of pyrrolidine based Mdm2 inhibitors.[200] The 




The fluorine atoms were added to the position on the ring deemed the most suitable for accommodation 
of the fluorine atom within the binding pocket. The resulting structure 106 bound to Mdm2 in the 
expected pose, with the binding groups located in the three binding pockets, in a similar manner to that 
observed with 105 (Figure 61). However, an increased binding affinity of -41 kJ mol-1 was obtained, 
attributed to increased van der Waals interactions from the two additional fluorine atoms with Mdm2.  
 
Figure 61. The predicted binding pose of candidate 106 as predicted by AutoDock Vina. 
Although the majority of interactions between p53 and Mdm2 are hydrophobic, they are supplemented 
by a hydrogen bond between the indole NH of Trp23 on p53 and Leu54 on Mdm2. Many groups have 
reported that mimicking this hydrogen bond in a small molecule Mdm2 inhibitor is not important for 
strong inhibition of the p53-Mdm2 PPI however, AutoDock Vina was used to investigate the binding 
of an indole substituted mimetic (107) (Figure 62). Additionally, a chloro-substituted indole was 
investigated. As expected, the chloro-substituted indole (108) gave a stronger predicted binding affinity 




However, in general the two indole substituted derivatives bind to Mdm2 with a lower affinity compared 
to the naphthyl- or phenyl- derivatives. On examination of the binding site with 107 and 108, it is clear 
that the indole derivatives do not occupy the Mdm2 binding site to as great an extent as the other 
structures investigated. A further caveat of the indole derivatives is that their synthesis will be more 
challenging owing to the NH of the indole which will require protection if it is to survive the lithiation–
borylation sequence.  
 
Figure 62. The predicted binding poses of indole derivatives 107 and 108 as predicted by AutoDock Vina. 
A final structure (110) investigated is shown in Figure 63. An oxygen atom has replaced a CH2 group 
in the side chain for the Trp23 hot-spot group mimetic. Recently Bootwicha et. al. have shown that the 
assembly line synthesis of polypropionate motif through the iterative introduction of carbinol units is 
possible. Using enantioenriched lithiated α-chlorosilanes in the reagent-controlled homologation of 
boronic esters yields α-silylalkyl boronates with exceptional stereocontrol. Oxidation of the silyl group 
reveals the corresponding alcohol.[258] Using this methodology interspersed with the previously 
described methods for homologating boronic esters using benzoate esters, mimetic 109 could be 
synthesised. From this derivative, alkylation of the alcohol could reveal a number of possible mimetics. 
The binding of a possible mimetic (110) was explored by AutoDock Vina. The MM conformational 
search calculations revealed that the presence of the oxygen atom did not significantly affect the 




The lowest energy conformer of 110 was docked into Mdm2, which revealed that the incorporation of 
the oxygen atom in the side chain does not significantly diminish the binding to Mdm2 and a binding 
affinity of - 38.1 kJ mol-1 was obtained.  
 
Figure 63. The predicted binding pose of candidate 110 as predicted by AutoDock Vina. 
In addition to designing a library of structures that will bind well to Mdm2, the importance of both the 
hot-spot groups and the conformational control in obtaining high affinity candidates in the inhibition of 
PPIs needs to be confirmed. The importance of the hot-spot groups in PPI inhibition is well known and 
many groups have reported weaker binding affinities if the hot-spot groups are removed from the 
inhibitors.[203]  This will be confirmed experimentally, by synthesising the all methyl substituted 
structure 111. This candidate still exhibits excellent conformational control with over 97% of 
conformers adopting a linear conformation, calculated by a MM conformational search, however a 
weaker binding affinity due to the removal of the hot-spot groups is expected. Molecular docking of the 
lowest energy conformer of 111 revealed a weaker predicted binding affinity of -29.0 kJ mol-1. It is 
clear from Figure 64 that the Trp23 binding pocket is not occupied to any extent with mimetic 111, 





Figure 64. The predicted binding pose of control candidate 111 as predicted by AutoDock Vina. 
The importance of conformational control in PPI inhibition can be confirmed by removing the methyl 
groups from structure 96 and leaving only the hot-spot groups, resulting in structure 112. The 
conformation of the molecule will no longer be controlled by the avoidance of syn-pentane interactions 
and no conformational bias of the molecule is expected. Indeed, a MM conformational search of 
structure 112 revealed no conformational bias of the molecule with only 1.4% of conformers under 
21 kJ mol-1 adopting a linear conformation. The first conformer to adopt a linear conformation is 6.23 kJ 
mol-1 above the global energy minima found by MM. Thus, a significant conformational reorganisation 
is required to access the linear conformer, which represents the expected bound conformation.  
Previously, molecular docking was performed on the lowest energy conformer of the candidates from 
a MM conformational search, which represented the overwhelming conformational bias observed. For 
candidate 112, no conformational bias was observed and thus no clear conformation could be taken 
through to molecular docking (Figure 65). It is expected that a weaker binding affinity will be observed 
due to the conformational reorganisation that will need to take place to access the bioactive 
conformation. This energy penalty cannot be evaluated using molecular docking and instead much more 
sophisticated computational methods, such as molecular dynamics, would be needed to provide an 




112 could not be explored using molecular docking, however it will be tested experimentally to confirm 
the importance of conformational control. 
 
Figure 65. The MM conformational search results of control molecule 112 which reveals no conformational bias is observed 
for the molecule. 
Using both MM conformational searching and molecular docking using AutoDock Vina a small library 
of potential Mdm2 inhibitors has been designed. MM conformational searching has confirmed that the 
addition of hot-spot groups to the scaffold does not perturb the conformational bias, with a linear 
conformation preferred for all structures (with the exemption of structure 112, which was designed to 
display no conformational control). The estimated binding affinities for the candidates reveal strongly 
binding structures with candidate 106 displaying a binding affinity competitive with that of one of the 
most successful inhibitors of the p53-Mdm2 PPI, Nutlin-2. The synthesis of some of these structures 






Chapter 4: The Synthesis of an α-Helix Mimetic of p53 
The methods developed and molecules synthesised in Section 4.1 and 4.2 were performed by Lydia 
Dewis. The molecules synthesised in Section 4.3 and 4.4 were performed by Dr. Madhavachary 
Rudrakshula. 
In order to experimentally confirm that the designed p53 mimetics adopt the conformation expected 
and can bind to Mdm2, they need to be synthesised. As discussed in section 1.2 of chapter 1, the 
hydrocarbon scaffold is accessible using lithiation–borylation. This methodology allows hot-spot 
mimetic groups to be substituted onto the scaffold in high yields and with high diasteroselectivities. 
Using lithiation–borylation, a variety of hot-spot mimetic groups can be incorporated onto the scaffold, 
simply by the substitution of the appropriate benzoate ester into the sequence at judicious points. Thus, 
using only one synthetic methodology one can access a small molecule α-helical scaffold bearing the 
appropriate hot-spot groups to mimic the α-helix in question.  
4.1 Using Lithiation–Borylation to Synthesise α-Helix Mimetics 
The homologation of boronic esters is a powerful C–C bond forming technique that typically displays 
high yields and if required high stereoselectivities. This process proceeds through three main steps: 1) 
Enantioselective lithiation of a carbenoid precursor (113/114) to generate a chiral carbenoid (115) that 
is chemically and configurationally stable at –78 °C. 2) Borylation, during which the chiral carbenoid 
is trapped by an electrophilic boronic ester species (116) to yield a boronate complex (117). This is also 
chemically and configurationally stable at –78 °C. 3) A stereospecific 1,2-metallate rearrangement upon 
warming the boronate complex to room temperature. This forms a new C–C bond to yield a 
homologated boronic ester (118) that is ready for subsequent homologations (Scheme 9).  
 
Scheme 9. The general mechanism of lithiation–borylation. 
The proposed retrosynthesis of a phenol derivative 119 of the first designed p53 mimetic, 96, is shown 




to improve the scaffold aqueous solubility. The phenol group will be revealed from a deprotection of 
the MOM ether. This will be followed by the oxidation of the terminal boronic ester to the secondary 
alcohol which can also be further functionalised to improve solubility. More will be discussed on 
strategies to improve aqueous solubility in section 4.2. The retrosynthetic analysis of molecule 119 
reveals a total of seven homologations to be performed using the lithiation–borylation methodology. 
Different strategies to generate the chiral carbenoid will be used depending on whether a methyl group 
or a hot-spot group is attached. Previously, Aggarwal et al. have shown that tin-lithium exchange of 
enantioenriched stannanes can be used to generate the chiral lithium carbenoid, and this carbenoid can 
be used in an iterative lithiation–borylation sequence since the required stannane is crystalline and can 
be recrystallised to >99.9:0.1 e.r.[27] For the synthesis of 119, the carbenoid precursor used in the 
sequence will change from enantioenriched stannanes to primary benzoates, depending on the group 
being installed onto the growing carbon chain. Using the chiral ligand-assisted deprotonation of primary 
benzoates to generate the chiral carbenoid results in a slight decrease in the diastereoselectivity of the 
reaction and as a result, column chromatography will be performed at certain points in the synthesis. 
Additionally, the boronic ester being homologated in this synthesis will become sterically very hindered, 
which can decrease the rate of borylation, and potentially lead to under-homologated product, which is 
important to remove by purification.  
 




Prior to starting the lithiation–borylation sequence, the starting boronic ester (123) needs to be 
synthesised. The synthesis of 123 was based on two previous syntheses of similar organoboron species. 
In 2006, Spencer et. al. reported the synthesis of photoactivatable analogues of cholesterol involving a 
Suzuki carbonylative coupling with the phenylboronic acid 127 (Scheme 11).[259] The synthesis 
reported by Spencer is high yielding and involves reactions that are well reported and known to be 
widely applicable.  
 
Scheme 11. The synthesis of boronic acid 127 by Spencer et. al. in 2006.[259] 
It is interesting to note the choice of conditions for the hydrogenation. Typically, hydrogenation is 
performed using heterogeneous or homogeneous catalysis using gaseous hydrogen and a metal catalyst, 
ordinarily palladium. The diimide reduction employed by Spencer is not frequently used however, it 
does provide a metal-free alternative to catalytic hydrogenation reactions that avoids the use of gaseous 
hydrogen. The diimide reduction is also advantageous if the substrate in question contains sensitive O-
O or N-O bonds since it does not lead to reductive cleavage of these bonds, a common problem when 
using catalytic hydrogenation conditions. Diimide reductions do however typically suffer from long 
reactions times and high reaction temperatures.[260] Additionally, a large excess of the reagents that 
generate the diimide are required to compete with both the decomposition of diimide to N2 and H2 and 
the disproportionation of diimide to hydrazine and N2.
[261]   
A second reported synthesis of an organoboron species similar to the starting boronic ester 123 was 
reported in 2016 by Tuck et. al. (Scheme 12).[262] The boronic ester 130 was a required coupling partner 
in a Suzuki cross-coupling reaction to synthesise a pyrimidine-based tercyclic α-helix mimetic. The first 
step involves a Wittig reaction, similar to the one reported by Spencer, followed by a hydrogenation 
using more typical platinum catalysis conditions. The resulting aryl halide 129 was subjected to a 
Miyaura borylation to afford the final aryl boronic ester 130. 
 




Taking inspiration from the two previous syntheses described, we report the following synthesis for the 
starting boronic ester 123 (Scheme 13). The first step involves a MOM protection of the commercially 
available phenol 131. The MOM protection of phenol 131 has been described previously in the literature, 
with a yield of 76% reported.[263] Using the same conditions as described previously, a higher yield of 
96% was obtained in the synthesis of 132. This yield is reproducible on both a small (<100 mg) and 
moderate (>5g) scale. Following the MOM protection of phenol 131, the Wittig reaction was performed 
using isobutyltriphenylphosphonium bromide providing a high yield of 93% of 133, comparable to the 
yields observed in the Wittig reactions performed by Tuck and Spencer. Again, this yield is reproducible 
on both a small and moderate scale. 
After the installation of the first hot-spot group by the Wittig reaction, halogen-lithium exchange 
followed by borylation using 2-isopropoxy pinacolborane ((OiPr)Bpin) was performed on 133 to install 
the pinacol boronic ester needed to start the lithiation–borylation sequence. This two-step reaction 
yielded the boronic ester 134 in a 95% yield, and the two-step sequence could be performed on both a 
small and moderate scale with no change in yield. The final step towards the synthesis of the starting 
boronic ester 123, was a palladium catalysed hydrogenation of the alkene to the corresponding alkane. 
Using 5% palladium on charcoal (Pd/C) with a H2 balloon in ethanol proved successful, and the 
hydrogenation was completed in quantitative yield. When this reaction was performed on a small scale, 
catalyst loadings of 10% were employed. However, upon increasing the scale of the reaction to >5g, 
catalyst loadings could be reduced to 5%. 
 




The next stage of the synthesis of the designed p53 mimetic 119 involves the homologation of boronic 
ester 123. To install the methyl groups, the methodology developed by Aggarwal et. al. was employed 
during which enantioenriched stannanes are used to generate the chiral carbenoid.[260] The two 
enantiomers of the stannane required in the synthesis of 119 can be generated from the deprotonation 
of ethyl 2,4,6-triisopropylbenzoate 51 using s-BuLi in the presence of (+)-sparteine or (-)-sparteine, to 
generate the carbenoid 52. This was followed by electrophilic trapping with trimethyltinchloride to 
generate stannane 53 in a 91.0:9.0 enantiomeric ratio. Stannane 53 is a white crystalline solid and can 
be recrystallised in methanol to >99.9:0.1 e.r (Scheme 14). The stannanes are bench stable and can be 
stored until needed. Upon tin-lithium exchange of the enantioenriched stannanes with n-BuLi at –78 °C, 
the corresponding chiral carbenoid is formed which can be used to homologate the desired boronic ester. 
Using this methodology, both enantiomers of the stannane 53 can be prepared on a large scale (>10g), 
recrystallised to >99.9:0.1 e.r and simply stored under air. 
 
Scheme 14. The generation of enantioenriched stannanes and the corresponding stereospecific tin-lithium exchange to 
generate the chiral carbenoid needed for the homologation of boronic esters. 
This methodology was not performed when installing the hot-spot groups for several reasons. The first 
being that the corresponding stannane of the benzoate ester needed to install appropriate hot-spot groups 
will most likely not be a crystalline solid. The enantioenriched stannanes need to be recrystallised if 
they are to be accessed in the high enantiopurities required for lithiation–borylation. Secondly, the 
synthesis of the enantioenriched stannanes is much more effective on a large scale, principally to 
increase the percentage recovery of the sparteine used in their synthesis. Since the hot-spot groups are 
only introduced once in the sequence, synthesising large amounts is unnecessary. The hot-spot groups 
will therefore be installed using the sparteine assisted deprotonation of the corresponding benzoate ester. 
The benzoate esters, 139, can be synthesised by Mitsunobu reaction of the corresponding alcohols, 138, 





Scheme 15. The Misunobu reaction to form the TIB esters from the corresponding alcohols followed by sparteine mediated 
asymmetric deprotonation of a benzoate ester in the homologation of a boronic ester. 
An optimised protocol for the iterative homologation of boronic esters using enantioenriched stannanes 
has been established by Aggarwal et. al. Nine consecutive homologations were performed with an 
aqueous workup performed after every third homologation, with column chromatography performed 
after the final homologation only. The fact that column chromatography was not required until the final 
homologation was only possible due to the very high enantiomeric ratio that the stannanes can be 
accessed in and the impressive conversions of >95% for each homologation. Since the sparteine 
mediated asymmetric deprotonation of benzoates is also being used in the synthesis of 119, which 
typically occurs with lower enantiomeric ratios of ~95.0:5.0, each homologation cannot be performed 
iteratively.  
In total seven homologations, starting from boronic ester 123 were performed, to yield the final boronic 
ester 120 (Scheme 16). The first two homologations were performed iteratively following the exact 
procedure reported by Aggarwal et. al.[27] Following the first two iterative homologations using 
enantioenriched stannanes, the second hot-spot group was installed by sparteine-mediated 
homologation. The lithiation time for benzoate 122 can be estimated to be ~1 hr, based on an extensive 
study into the reaction times of lithiation and borylation using different benzoates, carbamates, diamines 




used to estimate a borylation time with boronic ester 122 of <3 hrs. The 1,2-metallate rearrangement 
can be monitored using 11B NMR, which revealed that full migration had occurred after 2 hrs. Complete 
conversion of boronic ester 146 to boronic ester 147 was revealed by TLC analysis. The crude reaction 
mixture was purified by column chromatography to remove any unreacted TIB ester 122, which is 
present in excess, and to remove any under-homologated product. Following column chromatography, 
boronic ester 147 was obtained in 72% yield. The 1H and 13C NMR spectra of 147 revealed one 
diastereomer with a d.r. of >95:5.  
A further three homologations were performed using enantioenriched stannanes, with borylation times 
of 3 hrs to ensure complete conversion of the lithiated carbenoid to the boronate complex. The 1,2-
migration was followed by 11B NMR, which revealed full migration was achieved for all three 
homologations after 2 hrs. Column chromatography was performed after each homologation to remove 
any under-homologated product. 1H and 13C NMR revealed one diastereomer with a d.r. of >95:5. A 
final sparteine mediated homologation of boronic ester 150 was performed using the benzoate ester 121 
to install the final hot-spot group. The lithiation of this benzoate ester has been reported previously by 
Aggarwal et. al. and full lithiation was achieved within 1 hr.[78] Following lithiation of the benzoate 
ester 121, boronic ester 150 was added to the reaction mixture and the reaction mixture was stirred at 
- 78 °C for 3 hrs. The 1,2-metallate rearrangement was again followed by 11B NMR, and after 2 hrs full 
migration had occurred. The final boronic ester 120 was accessed in 84% yield, following column 






Scheme 16. The forward synthesis of boronic ester 120 using the homologation of boronic esters. 
The aim of this project is to demonstrate that the conformationally controlled α-helix mimetics designed 
and synthesised can bind to the p53 binding domain of Mdm2. In order to confirm that the designed 
p53 mimetic binds to the correct location on Mdm2, experimental procedures to measure protein-ligand 
binding will need to be performed. However, since Mdm2 is only stable in aqueous environments, the 
designed p53 mimetics will need to be functionalised to improve their water solubility as they are 
currently very lipophilic. Fortunately, the boronic ester is one of the most useful groups for further 
functionalisation and can be easily transformed into many other functional groups. The next section 




4.2 Improving the Aqueous Solubility of the p53 Mimetic 
The current designed mimetic 120 is very lipophilic and will display poor water solubility. Poor water 
solubility is a very common issue with small molecule inhibitors of PPIs, since the binding interactions 
between the proteins engaged in a PPI are usually very hydrophobic, thus any small molecule capable 
of interrupting this interaction needs to contain a large number of hydrophobic groups. Therefore, in 
order to experimentally confirm binding of our designed mimetic to Mdm2, water solubilising groups 
need to be installed onto the scaffold. It is hoped that the addition of hydrophilic groups at either ends 
of the molecule will improve its aqueous solubility whilst maintaining its conformational preference 
and ability to bind to Mdm2. 
When it comes to choosing how to functionalise the terminal boronic ester there are a large number of 
choices. The terminal boronic ester can be oxidised to reveal the alcohol which can be further 
functionalised. Alternatively, amination can be performed to transform the boronic ester to the 
corresponding amine which again can be further functionalised. Aggarwal and co-workers have also 
shown that boronic esters can also be converted to alkyne derivatives[264] which can be reacted with 
azides bearing water solubilising groups to form the corresponding triazole in the ‘click’ reaction.   
The terphenyl scaffold synthesised by Hamilton et. al. were used as a starting point for deciding the 
best direction for functionalisation.[265] The terphenyl molecules are also very lipophilic and Hamilton 
et. al. improved water solubility by functionalising with terminal carboxylic acids located at either end 
of the terphenyl scaffold. Taking inspiration from Hamilton et. al. the addition of terminal carboxylic 
acid groups to the scaffold was explored. Terminal carboxylic acid groups can be installed by first 
revealing the phenol, from deprotection of the MOM ether, followed by oxidation of the boronic ester 
to yield the secondary alcohol (Scheme 17). The phenol and alcohol could then be simultaneously 
deprotonated with a suitable base and subsequently alkylated with appropriate groups to install terminal 
carboxylic acids on either end of the scaffold. The deprotection of the phenol and oxidation of the 
boronic ester were both high yielding with a yield of 86% obtained over the two steps, to reveal the 
bisalcohol 119.  
 




The next step involves the deprotonation of both the phenol and the secondary alcohol, followed by 
alkylation. The initial conditions employed in the alkylation are shown in Scheme 18. These conditions 
have been used routinely in the literature for the alkylation of both phenols and secondary or tertiary 
alcohols.[266,267] Unfortunately, only alkylation of the phenol was achieved (152), confirmed by NMR. 
The secondary alcohol is likely to be very sterically hindered making it a poor nucleophile, explaining 
the monoalkylation observed.  
 
Scheme 18. The attempted alkylation of the phenol and the alcohol to install two terminal carboxylic acid groups. Instead, 
alkylation of only the phenol was achieved. 
In an attempt to make monitoring the reaction by TLC and purification of the reaction mixture by silica 
chromatography simpler, the corresponding methyl ester was used in place of the carboxylic acid. 
However, upon repeating the reaction and allowing to heat at reflux for 48h only alkylation of the phenol 
was observed. A wide range of conditions can be used in the alkylation of phenols and hindered alcohols, 
such as increasing the strength of the base, the reactivity of the electrophile and the solvent. A summary 
of the alternative conditions tried are shown in Table 6. Unfortunately, all other conditions tried yielded 
only alkylation of the phenol (153). 
Initial attempts to yield the dialkylated product involved the addition of tetrabutylammoniumiodide 
(TBAI) to the reaction mixture (entry 2). If TBAI is present it should convert the alkyl bromide to an 
alkyl iodide in a Finklestein type reaction. Iodide is a better leaving group than bromide, making the 
alkyl iodide a better electrophile in the alkylation reaction compared to the alkyl bromide. However, 
the reaction with TBAI added still yielded monoalkylation of the phenol only (153). The solvent was 
changed to DMF, which has a higher boiling point than THF, and so the reaction could be performed 
at a higher temperature, however only monoalkylation of the phenol was obtained (entry 3). The use of 




was used directly in the reaction instead of using the alkyl bromide and forming the alkyl iodide in situ 
with TBAI, however the desired reaction was still unsuccessful (entry 5). 
Table 6. The conditions used in the attempted alkylation of the bisalcohol 119 
 
Entry Reagent Base Solvent Temp (°C) Additive 
1 X=Br NaH THF 66 - 
2 X=Br NaH THF 66 TBAI 
3 X=Br NaH DMF 120 TBAI 
4 X=Br KH THF 66 TBAI 
5 X=I NaH THF 66 - 
In an attempt to make the secondary alcohol less sterically hindered and increase reactivity, a Matteson 
homologation was performed on the final boronic ester 120. The Matteson homologation adds a 
methylene group to the carbon chain, and after oxidation of the resulting boronic ester, will yield a 
primary alcohol.[268] The Matteson homologation typically occurs with >95% conversion and NMR of 
the crude reaction material revealed full conversion of the starting boronic ester 120 to the homologated 
boronic ester 154. The crude reaction mixture was subjected to deprotection of the MOM group and 
oxidation of the boronic ester, using the conditions described in the section 9.3 of the supporting 





Scheme 19. The Matteson homologation followed by MOM deprotection and oxidation of the boronic ester. 
With a primary alcohol now present, the alkylation should hopefully proceed more rapidly than the 
secondary alcohol. The alkylation of 155 was performed using the conditions listed in entry 1 and entry 
2 of Table 6. However, both alkylation attempts were unsuccessful and yielded only monoalkylation 
of the phenol. With no success made in the alkylation of both the phenol and the alcohol to form a bis 
functionalised product, the possibility of forming the corresponding acyl chlorides from the alcohols 
was investigated. The acyl chloride is highly electrophilic and should react with a large range of 
nucleophiles.  
A strategy that has proved successful when attempting to improve aqueous solubility of lipophilic 
ligands is the addition of polyethylene glycol (PEG) chains. In addition to improving aqueous solubility, 
PEGylated therapeutics typically demonstrate longer circulating half-lives, lower enzymatic 
degradation, improved resistance from renal clearance, lower peak plasma concentrations and reduced 
immunogenicity, antigenicity and toxicity.[269–271] Due to the favourable properties that PEG chains can 
exert on a therapeutic molecule, the use of a PEGylated nucleophile capable of reacting with the acyl 
chloride was explored. Due to their importance in medicinal chemistry, a large catalogue of 
functionalised PEG chains are commercially available. Methoxypolyethylene glycol amine (average 
Mw = 750 gmol-1) was chosen as the nucleophile.  
Formation of the acyl chloride at both the phenol and the alcohol was first attempted with triphosgene 
and pyridine in DCM.[272,273] However, the reaction was unsuccessful and incomplete formation of the 
acyl chloride was observed by TLC. Using phosgene, as a solution in toluene, successfully yielded full 
conversion of both hydroxy groups to the corresponding acyl chlorides, which was confirmed by TLC, 
to afford compound 156 (Scheme 20). Upon completion of the reaction, the solvent was removed in 
vacuo to remove the excess phosgene, and the crude reaction mixture resuspended in DCM. Pyridine 
was added to the solution dropwise at 0 °C, followed by a solution of methoxypolyethylene glycol 
amine in DCM. The reaction was heated to 40 °C and monitored by TLC (Scheme 20). Upon 
completion of the reaction, the crude reaction mixture was filtered through a plug of silica and eluted 
using 10% MeOH in DCM. The bisPEGylated product 157, was purified by reverse phase-HPLC in 
11% yield. With a bisfunctionalised molecule in hand that should display improved water solubility the 





















4.3 The Synthesis of a Library of p53 Mimetics   
Chapter 3, demonstrated that by using molecular docking the binding affinity of the designed p53 
mimetic 96 to Mdm2 could be increased by substituting the naphthyl group for a para-chloro substituted 
phenyl group (105). The positive effect of the chlorine atom on the binding affinity has also been 
reported by many others.[196] It was also demonstrated that the introduction of fluorine atoms onto the 
scaffold (106) increased the binding affinity further. Using lithiation–borylation, the synthesis of a 
mimetic with a different group in place of the naphthyl group is accomplished simply by substituting a 
different benzoate ester in the sequence. This will allow for a library of p53 mimetics to be synthesised 
using one synthetic methodology.   
The second member of the library of p53 mimetics to be synthesised was based on 105, featuring a 
para-chloro phenyl group in place of the naphthyl group. This can be achieved by replacing the naphthyl 
benzoate ester (122) used in the synthesis of 157 with a benzoate ester featuring an appropriate side 
chain. The synthesis of the benzoate ester used in the sequence (159) is shown in Scheme 21.  
 
Scheme 21. The synthesis of the benzoate ester 159 used in the synthetic sequence of a second p53 mimetic 
A similar lithiation–borylation sequence was performed as described previously for 120. However, in 
addition to the first and second being performed iteratively, for the synthesis of 161, the fourth, fifth 
and sixth homologations were also performed iteratively. Following the introduction of the hot-spot 
groups and the methyl groups, a Matteson homologation was performed as described previously, to 
install the methylene group, affording compound 162. This was followed by the deprotection of the 
MOM group and oxidation of the boronic ester to yield the bisalcohol 163. The bisalcohol 163 was 
converted to the corresponding bisacyl chloride with phosgene, as described previously. Subsequent 
reaction with methoxypolyethylene glycol amine gave the form the bisPEGylated derivative 164 
(Scheme 22). The PEG derivative 164 was purified by reverse phase-HPLC in 9% yield and 





Scheme 22. The synthesis of a second p53 mimetic 164 using iterative lithiation–borylation. 
Following the successful synthesis of 164, we turned our attention to substituting the para-chloro 
phenyl ring with a fluorine atom, resembling the designed p53 mimetic 106. Unfortunately, the 
attempted lithiation of the benzoate ester 165 did not yield lithiation at the desired α-position and as a 




CD3OD revealed lithiation at the aromatic proton adjacent to fluorine, confirmed by full deuteration of 
this position observed by NMR. This suggests that the fluorine directs lithiation to the ortho position 
for benzoate ester 165 (Scheme 23). Strategies to overcome this, such as blocking the proton α- to 
fluorine or masking the fluorine itself and revealing it after the lithiation–borylation sequence will be 
explored in future work.  
 
Scheme 23. The unexpected lithiation of benzoate ester 165 
4.4 The Synthesis of Control Molecules  
Chapter 3 also discussed the need for two control molecules, to confirm the importance of 
conformational control and the hot-spots in obtaining higher affinity therapeutics. The two control 
molecules can also be synthesised by iterative lithiation–borylation. The first control molecule 
synthesised was 172, which featured no hot-spot groups. This molecule was synthesised in a very 
similar fashion to that reported by Aggarwal et. al. The synthesis of control molecule 172 is shown in 
Scheme 24. Although the molecules synthesised by Aggarawal et. al. were performed fully iteratively 
with no column chromatography, for the control molecule 172, column chromatography was performed 
after the second, fourth and seventh homologation to ensure no under-homologated product was carried 
through the reaction. Upon completion of the synthesis of the final boronic ester 170, the phenol was 
deprotected and the alcohol was oxidised as performed previously for the two p53 mimetics. The 
resulting bisalcohol, 171 was subjected to reaction with phosgene to form the acyl chloride, followed 
by reaction with methoxypolyethylene glycol amine to form the bisPEGylated derivative 172. The PEG 
derivative 172 was purified by reverse phase-HPLC in 15% yield, and concentrated ready for biological 





Scheme 24. The synthesis of control molecule 172 using lithiation–borylation 
The second control molecule, 179, features no methyl groups and thus should display no conformational 
control. This synthesis of the control molecule is shown in Scheme 25. The first step of the synthesis 
involves an iron-catalysed cross coupling reaction between an alkenyl acetate and the aromatic bromide 
species 173 to form the trisubstituted phenyl 174 in 48% yield. An iridium catalysed hydroboration is 
used to install the pinacol boronic ester, to give the starting boronic ester 175 in 86% yield. The boronic 
ester 175 can then undergo a lithiation–borylation sequence, as shown in Scheme 25. Matteson 
homologations are interspersed with homologations to introduce the two hot-spot groups using 
sparteine-mediated deprotonation of the corresponding benzoate esters, as described previously.  The 
final boronic ester 177 was subjected to the MOM deprotection, oxidation of the boronic ester and 
PEGylation as seen for the previous p53 mimetics the other control molecule. The PEG derivative 179 





Scheme 25. The synthesis of control molecule 179 
With the synthesis of two p53 mimetics (157 and 164) and two control molecules (172 and 179) bearing 
groups that should improve their water solubility, their binding to Mdm2 can be explored. Prior to this 
however, the conformational bias of these molecules in solution will be confirmed using a hybrid NMR 






Chapter 5: Using NMR Spectroscopy and Computation to Analyse 
the Conformation of the Designed α-Helix Mimetic of p53 
Section 3.2 of Chapter 3, discussed the use of MM to explore the conformational landscape of a suitable 
mimetic of p53. MM revealed a linear conformational bias for the designed ligand 96 with over 74% of 
conformers adopting a linear conformation. This conformational bias can be confirmed experimentally 
using a hybrid NMR spectroscopy and computational approach. This approach involves comparing 
experimental NMR parameters, including both 1H-1H and 1H-13C scalar coupling constants, interproton 
distances and chemical shifts, to those that are calculated using DFT calculations.[109] Following an 
initial stochastic MM conformational search, a redundant conformer elimination is performed which 
removes conformers that are identical in energy and whose cartesian coordinates differ by less than a 
predefined distance. The resulting conformers are taken through to QM calculations using DFT, which 
calculates the Gibbs free energies and resulting Boltzmann populations of each conformer, along with 
their GIAO-based NMR parameters. The NMR parameters are Boltzmann averaged using the calculated 
conformer populations, to provide the ensemble-averaged NMR properties of the molecule, which can 
be compared to the experimental NMR data. The workflow employed in this project for this procedure 
is shown in Figure 66.  
 




5.1 The Choice of a Representative Structure  
Although five ligands have been synthesised (119, 155, 157, 163, 164, Figure 67), their structural 
similarity and computational demand of the workflow described in Figure 66, led us to validate the 
structure of them all by analysis of the conformation of a single representative structure. The full DFT-
based conformational analysis will therefore be performed on a representative structure however, the 
conformation of the other structures will be considered from examination of their NMR spectra and 
comparison to MM conformational searching.  
 





An ideal candidate for the conformational analysis will have a well dispersed NMR spectrum with little 
or no overlap. This will aid with assignment, measuring the scalar coupling constants and obtaining 
interproton distances from selective 1D-NOE spectroscopy. The PEG derivatives 157 and 164 are not 
ideal candidates due to the signals from the PEG chains dominating the NMR spectrum. Additionally, 
the peaks are very broad due to fast T2 relaxation (relaxation in the x-y plane).  T2 relaxation, known as 
spin-spin relaxation, is related to line with by ν1/2 = 1/πT2 where ν1/2 = width at half height. Thus, fast 
relaxation in the x-y plane leads to broader peaks. The value of T2 decreases as molecular size or solvent 
viscosity decreases since it is related to the rotational correlation time, τc, which time describes the 
average time taken for the molecule to rotate through one radian. Therefore, the PEG derivatives are 
expected to have the shortest T2 and thus broadest peaks. Furthermore, it is likely that the tumbling of 
the molecules is anisotropic in solution, i.e. different rotational axes of the molecule will have different 
values of τc. This anisotropic motion also reduces T2 leading to broad peaks. 
An additional negative effect of the high molecular weight of the PEG derivatives, which have a 
molecular weight of >2000 gmol-1, is that the NOE intensity approaches zero and becomes negative as 
molecular weight increases. (Figure 68) As molecular weight increases, τc increases and molecular 
motion becomes slower than the Larmor frequency. In cases such as this, the zero quantum (ω0) cross 
relaxation pathway dominates and a negative NOE results. The measured NOEs of the PEG derivatives 
will likely not be at a maximum negative NOE, which is not ideal for the accurate quantitative analysis 
of interproton distances using NOE. Additionally, the signals of the CH backbone peaks for the PEG 
derivatives are not well dispersed.  
 




The NMR spectra of the three remaining candidates, 119, 155, and 163, were examined to identify the 
best structure for the conformational analysis. The spectral dispersity of the backbone CH protons along 
the is the most important parameter when considering the choice of a representative structure for several 
reasons. The first reason for this is that it makes it easier to measure the 3JHH coupling constants along 
the backbone which provide valuable conformational information along the backbone, due to the 
relationship between 3JHH values and dihedral angle, as described by the Karplus relationship.[87,88] 
Furthermore, a well resolved spectra is important for selective irradiation in 1D-NOE experiments used 
to determine accurate interproton distances. In selective 1D-NOE methods, a peak generally needs to 
be separated from other peaks in the spectrum by ~50 Hz to ensure selective irradiation. The NMR 
spectra of the naphthyl derivative 119 was the most dispersed spectra with each CH proton along the 
backbone giving a separated, or partially separated, resonance (Figure 69). The NMR spectra of the 
Matteson homologated naphthyl derivative 155 and the para-Cl phenyl derivative 163 revealed 
considerable overlap between the backbone CH protons and were therefore not ideal for use in the full 
DFT-based conformational analysis. Thus, our analysis will be performed on the naphthyl derivative 
119.  
 
Figure 69. The 1H NMR spectra of the naphthyl mimetic 119, with an expansion of the backbone CH region showing well 




5.2 The Calculation of Conformer Geometries, Energies and NMR 
Parameters using DFT Calculations 
Section 3.2 of Chapter 3 discussed the use of MM to explore the conformational landscape of a possible 
p53 mimetic and found that structure 96 displayed a linear conformational bias with over 74% of 
conformations adopting a linear conformation. Although MM is a useful tool in identifying the overall 
conformational bias of a molecule, it is not adequate at accurately predicting conformer energies and 
corresponding Boltzmann populations. Therefore, DFT will be used to further optimise conformer 
geometries, and calculate conformer energies and NMR parameters.  
The conformational search of 119 (Figure 70) was performed in chloroform using the MMFFs 
forcefield and MCMM searching method. A total of 17380 conformers were found within 21 kJ mol-1 
of the global minimum. The MM results revealed that for 119, 77.5% of the conformers adopted a linear 
conformation. DFT calculations cannot be performed on all 17380 conformers, as this is too demanding 
for the computational resources available. The number of conformers was first reduced by performing 
a redundant conformer elimination, during which redundant conformers are eliminated using maximum 
atom deviations. If the sum deviation in the positions of the selected atoms differs by more than 0.5 Å 
it will be retained as a unique conformer. Only atoms in the backbone and first carbon of the side chains 
were selected and as a result, rotation of the side chains past the first carbon atom will be poorly sampled. 
Although this step results in parts of the molecule being poorly described, the backbone of the molecule 
will still be well explored. The redundant conformer elimination reduced the number of conformers 
within 30 kJ mol-1 to 1115.  
 
Figure 70. The structure of ligand 119, with the dihedral angles of the backbone annotated. 
The relative potential energies obtained from MM for the 1115 conformers were used to calculate the 
Boltzmann population of each conformer. The results are summarised as a bubble plot, shown in Figure 
71).  The clear bias towards dihedral angles of 180° along the backbone is indicative of a linear 






Figure 71. The results of the MM conformational search of ligand 119, summarised as a bubble plot. Dihedral angles of 
180° along the backbone are clearly favoured.   
Because of the time demands of DFT computation (hours to days per conformer) compared to MM 
(second to minutes per conformer), a further reduction in the number of conformers was required prior 
to DFT calculations, so only conformers that comprised the top 99.9% of Boltzmann populations (241 
conformers) were selected. All 241 conformers were subjected to DFT geometry optimisation and 
frequency calculation using mPW1PW91/6-31g (d) basis set (basis set 1). All DFT calculations were 
performed in chloroform using the implicit solvent model, IEFPCM. The functional was chosen as it 
has been shown by Bifulco et al. to be the most accurate functional for computing chemical shifts and 
nJCH scalar coupling constants.[274] Although a triple ζ basis set has been shown, by Dr. Zhong at the 
University of Bristol, to provide the greatest accuracy when Boltzmann averaged NMR parameters were 
compared to calculated values, it comes at significant computational cost.[275] Therefore, a double ζ 
basis set was used for the first geometry optimisation and frequency calculation and a triple ζ basis set 
for the subsequent single point energy calculation, which will provide a more accurate estimation of the 
Gibbs free energy and also correct for the zero point energy. Additionally, polarisation wavefunctions 
(d,p) were included to allow for charge polarization in the single point calculation. Again, adding the 
polarisation functions adds significant computational cost, so the effect of adding these to the 
calculation is estimated using a single point energy calculation. Of the 241 conformers subjected to the 
first DFT calculation, 9 conformers did not converge during the geometry optimisation and were 
eliminated. Additionally, 5 conformers were found to possess an imaginary frequency and were 




in a saddle point and not a local minimum on the potential energy surface and thus is not a stable 
structure and can be removed. 
Following the first geometry optimisation and frequency calculation, the 227 converged conformers 
were subjected to a single point energy calculation using mPW1PW91/6-311g (d,p) (basis set 2). The 
Gibbs free energies of each conformer were estimated using Equation 6.  
𝐺𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡2 =  𝐸𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡2  + (𝐺𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡1 −  𝐸𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡1) 
Equation 6. The estimation of the Gibbs energy of conformer i. 
Where 𝐺𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡2  is the estimated Gibbs energy of conformer i using the 6-311g(d,p) basis set, 
𝐸𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡2 is the potential energy of conformer i calculated using the 6-311g(d,p) basis set, 𝐺𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡1 
is the calculated Gibbs energy of conformer i using the 6-31g(d) basis set and 𝐸𝑖
𝐵𝑎𝑠𝑖𝑠 𝑆𝑒𝑡1 is the potential 
energy of conformer i calculated using the 6-31g(d) basis set.  
The calculated Gibbs energies were used to recalculate the Boltzmann distribution of the conformers 
for ligand 119. A slight increase in the percentage of conformers adopting a linear conformation from 
77.5% to 80.8% was observed after going from MM to QM (Figure 72).  
 




Following the calculation of conformer energies and Boltzmann populations, the calculation of 
Boltzmann averaged calculated NMR parameters and interproton distances was performed. The 
interproton distances were extracted from the optimised geometries and were Boltzmann averaged 
against their calculated populations to provide the ensembled averaged interproton distances. These 
distances can then be compared to those derived using 1D-NOE spectroscopy to provide an indication 
towards the conformational landscape of 119 in solution. The quantitative interproton distance analysis 
by 1D-NOE is highly sensitive to conformer populations since interproton distances scale with r-6 and 
thus it is very important that the calculated Boltzmann populations are accurate and that all conformers 
subjected to DFT are included in the extraction of the calculated ensembled averaged interproton 
distances. Therefore all 227 converged conformers were used in the interproton distance analysis, 
discussed in section 5.4.  
The final stage of the DFT procedure is to calculate the NMR parameters. Magnetic shielding tensors 
and spin-spin coupling constants were calculated with the GIAO method using mPW1PW91/6-311g 
(d,p). Decontracted core orbitals were used, called with the Gaussian keyword ‘mixed’, to improve the 
description of electron density at the nucleus by mixing the core orbitals into the Fermi contact term. 
This has been shown to improve the accuracy of calculated scalar couplings.[276] The calculation of 
NMR parameters is computationally extremely intensive and as a result a reduced subset of conformers 
were subjected to the NMR calculations. Scalar coupling constants and chemical shifts are not nearly 
as sensitive to conformer populations compared to interproton distances from 1D-NOE, and thus this 
reduction in conformers is justified. The Boltzmann distribution after DFT was used to select 
conformers for the NMR calculations. The top 99% of conformers after DFT were taken through to the 
NMR calculations, corresponding to 81 conformations. The magnetic shielding tensors and scalar 
coupling constants were Boltzmann averaged against their Boltzmann populations. The magnetic 
shielding tensors were converted to a chemical shift by referencing the magnetic shielding tensors to 
those calculated for tetramethylsilane (TMS) at the same level of theory (Equation 7).[135]      
𝛿𝑐𝑎𝑙𝑐
𝑥 =  
𝜎𝑂 −  𝜎 𝑥
1 −  𝜎𝑥/106
 
Equation 7. The calculation of chemical shifts from magnetic shielding tensors. 
Where 𝛿𝑐𝑎𝑙𝑐
𝑥  is the calculated chemical shift for nucleus x (in ppm), 𝜎 𝑥  is the Boltzmann averaged 
magnetic shielding tensor for nucleus x and 𝜎𝑂 is the magnetic shielding tensor for TMS.  
The calculated Boltzmann averaged interproton distances, scalar coupling constants and chemical shifts 
can be compared to those derived experimentally by NMR spectroscopy. If the conformational 
landscape of 119 has been adequately described by DFT calculations, a good fit between experimental 




If, however, the experimental and calculated data does not correlate well, it suggests that the Boltzmann 
populations of the conformers has not been correctly estimated by DFT and the conformational 
landscape of 119 may not be what computation suggests.  
5.3 A Comparison of the Experimental 1H-1H and 1H-13C Scalar Coupling 
Constants to the Boltzmann Averaged Calculated Values 
As discussed in the introduction, both the 1H-1H and 1H-13C scalar coupling constants provide valuable 
information regarding the conformation of a molecule, primarily due to the relationship of vicinal 3JXH 
(where X = H or C) with dihedral angle, known as the Karplus relationship. The conformation of 119 
was first explored by examining the 3JHH coupling constants along the backbone of the molecule. If a 
linear conformation is favoured the HCCH dihedral angles along the backbone of the molecule should 
alternate between 180° and 60° corresponding to an alternating anti - gauche relationship along the 
backbone. Thus, alternatingly large and small values of 3JHH should be observed based on the Karplus 
relationship (Figure 73). 
 
Figure 73. The lowest energy conformer of 119, with the backbone CHs of the first two dihedral angles highlighted. The 
two Newman projections show that the dihedral angle between H1 (green) and H2 (pink) is 180° and between H2 (pink) and 
H3 (orange) is 60°. This 180° – 60° – 180° – 60° pattern of HCCH dihedral angles continues along the chain.   
Although the CH peaks corresponding to the protons along the backbone (H1-7) are well dispersed, they 
are very broad and the multiplicities of the peaks cannot easily be distinguished, making the values of 
3JHH difficult to measure experimentally. Peak broadening can be caused by a number of issues 
including instrumental problems such as poor tuning and shimming or issues with the sample itself such 
as sample inhomogeneity or paramagnetic impurities. However, it is more likely that the broad peaks 




Despite broadening of the peaks, values of 3JHH were measured directly from the 1D 1H NMR spectrum 
using SpinSimulation; software from MestreNova. During a spin simulation, the expected coupling 
constant and the exact chemical shift, typically measured from pureshift 1H spectra, are used to simulate 
the spectra. The simulated spectra are then compared to the measured spectra and the estimated coupling 
constant altered until the simulated spectrum matches the measured spectrum. Using SpinSimulation, 
it is very easy to quickly identify whether the value of 3JHH is large (> 9 Hz), small (<4 Hz) or an average 
(=7 Hz) as the rough peak shape will only match to the correct answer. For example in Figure 74 it is 
very clear that a small value of 3JHH is contributing to the multiplicity of this peak as if a large or average 
value of 3JHH is used in the simulation then the simulated spectrum does not match the experimental 
spectrum. From this, the coupling constant can be changed by very small increments (0.1 Hz) to find 
the best fit between simulation and experimental.  
 
Figure 74. The simulation of the H4-H5 peak for 119 with three different values of 3JHH. 
This process was performed for 119, and a good correlation between the simulated spectrum and the 
experimental spectrum was obtained. An example of two peaks simulated for 119 is shown in Figure 
75.  
 




The experimentally measured values of 3JHH, obtained from spin simulation, are shown in Table 7. It 
can clearly be seen that the HCCH dihedral angles along the backbone of 119 alternate between large 
and small, confirming that an anti-gauche-anti-gauche relationship exists and suggesting a linear 
conformation is preferred. This preference can be confirmed by comparing the values obtained 
experimentally to those calculated by DFT calculations. As discussed in section 1.3.2 of Chater 1, the 
Boltzmann averaged NMR parameters can be calculated using DFT calculations and can provide a more 
detailed conformational analysis. A good correlation between experimental and calculated values of 
3JHH was observed, with a mean absolute deviation (MAD) of 0.48 Hz and a standard deviation (SD) of 
0.33 Hz (Table 7). This confirms that the populations of the conformers estimated by DFT is in good 
agreement with the populations of the conformers that exist experimentally at room temperature, 
confirming the linear conformational bias. As well as considering 3-bond H-H scalar coupling, 2-bond 
and 4-bond H-H scalar couplings were also measured experimentally and compared to the values 
calculated by DFT. Comparing all experimental values of nJHH  to the Boltzmann averaged values 
calculated using DFT calculations a MAD of 0.71 Hz and SD of 0.58 Hz was obtained for nJHH.    
Table 7. The experimental 3JHH values measured for 119 using spin simulation. Only the 3JHH values along the backbone are 
shown. 
 















1 2 Anti 180 Large >8 10.3 10.7 0.4 
2 3 Gauche 60 Small <5 2.0 2.6 0.6 
3 4 Anti 180 Large >8 8.2 9.3 1.1 
4 5 Gauche 60 Small <5 2.9 3.2 0.3 
5 6 Anti 180 Large >8 9.2 9.4 0.2 
6 7 Gauche 60 Small <5 4.6 4.9 0.3 
Mean Absolute Deviation (Hz) 0.48 





The MAD and SD obtained can be compared to those reported in the literature for similar molecules, 
to confirm that validity of the analysis. For a rigid molecule a MAD of <0.5 Hz can be expected, 
however for molecules of increasing flexibility, such as the molecules 10, 11, reported by Aggarwal et. 
al.[27] a MAD of ~1 Hz is expected. Therefore, the MAD and SD obtained in the comparison of 
experimental values of nJHH to Boltzmann averaged calculated values of nJHH is aligned with those 
previously reported in the literature, confirming that the analysis is valid and that a linear 
conformational bias is likely, based on H-H scalar couplings. 
The accuracy and validity of the analysis can be increased by incorporating more NMR parameters into 
the analysis. As discussed previously, 3JCH values also demonstrate a relationship to dihedral angle and 
can thus provide useful conformational information. On examination of structure 119, it is clear that 
two HCCC dihedral angles can be used to provide information regarding the conformation of the 
backbone. The HCCC dihedral angle between a backbone CH proton and the relevant backbone carbons 
(i.e. H1C1C2C3) should always be ~60° resulting in a small 
3JCH value. Additionally, the dihedral angles 
between the backbone CH protons and the carbon of the CH3 or CH2 groups can be examined. For the 
terminal CH protons (H1 and H7) one dihedral angle can be examined, both of which should be ~60°. 
For H2 – H6 two dihedral angles can be examined, one of which should be ~180 ° and one ~60° (Figure 
76). Thus, provided they can be experimentally determined, a large number of potential 3JCH values can 
be measured to provide more information regarding the conformation of 119 in solution.  
 




The acquisition of 3JCH values experimentally by NMR spectroscopy is less straightforward than that 
for 3JHH. IPAP-HSQMBC (Inphase-Antiphased heteronuclear single quantum multiple bond correlation) 
was chosen for the analysis as it has been reported by Butts et. al. that the IPAP-HSQMBC is the best 
option if a global analysis of nJCH values is desired.[99] The IPAP-HSQMBC is a relatively time efficient 
method as it does not require the acquisition of multiple datasets. It is however challenging to measure 
couplings of <2 Hz due to the insensitivity of the experiment. The IPAP-HSQMBC proved to be very 
successful for 119, with a total of forty-seven values of nJCH measured. Of these, eleven corresponded 
to 3JCH values along the backbone that are of interest for the conformational analysis of 119 (Table 8). 
Overlap in the F2 dimension prevented the measurement of further 
3JCH values of interest.  
The dihedral angle between H7 and C13 is expected to be >5Hz for a linear conformation. However, a 
dihedral angle of 4.4 Hz was measured experimentally, with a comparable value obtained from DFT 
calculations. The dihedral angle in question is affected by the terminal hydroxy group. The effect of 
electronegative substituents on the value of 3JCH has been investigated previously by Bifulco et. al. who 
explored the effect of electronegative substituents on butane to the 3JCH values.[277] They found that the 
presence of electronegative atoms reduced the value of 3JCH from the value predicted by Karplus 
equations. For example, the value of the coupling constant between H33-Me32 in the marine natural 
product Sphinxolide, 180, was measured to be 4.4 Hz and calculated to be 4.8 Hz, despite a dihedral 
angle of ~180° between these two groups, caused by the adjacent methoxy group (Figure 77).[277]  
 
Figure 77. The effect of electronegative atoms on the 3JCH coupling constant is clear on examination of the H33-Me32 
coupling.[277] 
The experimentally measured values of 3JCH were compared to those calculated using DFT, and an 
excellent correlation was observed, with a MAD of 0.32 Hz and a SD of 0.29 Hz obtained. This will 
well within the bounds of MADs and SDs reported in the literature for molecules of similar flexibility. 




measured were also compared to those calculated using DFT. The comparison of all fourty-seven 
experimental and calculated nJCH values gave a MAD of 0.35 Hz and a SD of 0.48 Hz.  
Table 8. The 3JCH values along the backbone of the molecule capable of being measured using IPAP-HSQMBC 
 













1 9 Gauche 60 Small <3 2.5 1.7 0.7 
2 8 Gauche 60 Small <3 3.3 3.3 0.0 
3 11 Gauche 60 Small <3 3.2 2.4 0.8 
3 9 Anti 180 Large >5 6.1 6.2 0.1 
4 12 Anti 180 Large >5 5.6 5.5 0.1 
4 2 Gauche 60 Small <3 2.7 2.2 0.5 
5 7 Gauche 60 Small <3 2.2 2.4 0.2 
6 12 Gauche 60 Small <3 2.6 2.6 0.1 
6 14 Anti 180 Large >5 5.0 5.2 0.2 
7 5 Gauche 60 Small <3 2.0 1.4 0.7 
7 13 Anti 180 Large >5 4.4 4.5 0.1 
 Mean Absolute Deviation (Hz) 0.32 
 Standard Deviation (Hz) 0.41 
*mPW1PW91/6-311g(d,p) 
The impressive correlation between experimentally measured values of nJXH (X = H, C) to the 
Boltzmann averaged values, calculated by DFT, confirms that the DFT calculated Boltzmann 
populations of the conformers are accurate and agree with the conformational behaviour of 119 in 
solution, as observed by NMR spectroscopy. Figure 78 shows a comparison of all sixty-four 
experimental coupling constants to those calculated by DFT and a clear positive correlation can be seen 
from the data. The results from the analysis of experimental and calculated scalar couplings, suggest 




to conformer populations. Therefore a more discriminating technique will also be used to explore the 
conformational behaviour of 119 in solution. The next section will discuss the conformational analysis 
of 119 using 1D-NOESY.  
 











5.4 A Comparison of the Experimental Interproton Distances Obtained 
from 1D-NOE Spectroscopy to the Boltzmann Averaged Calculated Values 
Although scalar coupling constants provide valuable information regarding the conformation of a 
molecule in solution, they are not sensitive to high energy conformers i.e. those with low Boltzmann 
populations. For example, if a conformer with a population of <2% was not considered in the 
conformational analysis, any one Boltzmann-averaged scalar coupling constants would only change by 
<0.2Hz at most and so it is not likely to highlight this missing conformer. Thus, a technique that can 
detect weakly populated conformers is desirable in conformational analysis. Fortunately, such a 
technique exists. Nuclear Overhauser Effect Spectroscopy, or NOESY, provides information regarding 
the spatial arrangement of protons and can be used to measure quantitative interproton distances for 
protons <5 Å apart. NOESY is substantially more discriminating against minute conformational 
contributions than scalar couplings and can be used to identify weakly populated conformers.[278]  
The quantitative measurement of interproton distances by NOESY, can be performed using both 1D or 
2D NOESY methods. Although 2D- methods provide information on all NOE correlations within the 
molecule, selective 1D-NOE experiments were chosen for the extraction of quantitative interproton 
distances, as they are easier to process (phasing and baseline correction) and do not suffer from t1-noise. 
One limitation to a simple selective 1D-NOE experiments is that ~50 Hz separation between 1H 
resonances in the 1D proton spectrum is required for clean irradiation of the desired peak. Unfortunately, 
for 119 only three 1H are isolated enough to selectively irradiate. However, the CSSF NOESY addresses 
this and allows highly selective irradiation of overlapped 1H resonances using chemical shift selective 
filtering (Figure 79). Provided two overlapped 1H peaks have different 1H chemical shifts, and are not 
strongly coupled, one can be selectively irradiated over the other, regardless of how much their 
multiplets overlap.[279,280] A pureshift 1D-1H NMR spectrum must be first acquired since the exact 
chemical shift of the peak of interest must be known. Using CSSF-NOESY, an additional four 1H 
resonances were able to be selectively irradiated. The seven 1H resonances irradiated yielded a total of 





Figure 79. (a) The seven 1H resonances irradiated by both 1D-NOE and CSSF-NOESY. The advantage of using CSSF-
NOESY in overlapped regions of the spectra is exemplified by the unsuccessful irradiation of the peak at 2.67 ppm by 1D-
NOE (b) and the successful irradiation of the same peak using CSSF-NOESY (c). 
Section 1.3.1 of Chapter 1 discussed how NOE signal intensities (𝜂NOE) can be used to derive interproton 
distances using the PANIC method.[106] The PANIC technique determines accurate interproton distances 
by comparing the relative NOE intensities from a selective inversion experiment to a reference peak, 
typically the irradiated peak, that has been set to an arbitrary intensity (usually 1000).[107] Provided that 
the molecule is in the fast tumbling regime, the ratio of the NOE intensities of two separate nuclei pairs 
to the ratio of the corresponding interproton distances (raised to the negative sixth power). Thus, using 
a well-defined reference distance, typically one not affected by conformational dynamics, other 
interproton NOE-distances can be derived. The preferred choice of reference distance is that between 




changes in the geometries of contributing conformers. Fortunately the methylene pair H10’ and H10’’ of 
119 can be selectively irradiated and used as the reference distance (rref). The NOE for the reference 
distance is prone to the same errors as every other NOE in the molecule. To correct for this, after 
calculation of an initial set of NOE-distances for the whole molecule, the reference NOE-distance is 
subsequently adjusted to maximise the quality of fit between experimental and computed distances. 
Strictly speaking this means the entire dataset is being used as “reference distances” rather than relying 
on one, potentially erroneous, datapoint. In this instance, the best fit was found with the reference 
distance set to be 1.74 Å. A summary of the NOE-interproton distances derived from 1D-NOE and 
CSSF-NOESY is shown in Table 9.  
The integration of the irradiated 1H resonance was set to 1000 and the integration of the NOE 
correlations were measured. NOE correlations with an integral of <5 were eliminated from the analysis 
due to inaccuracy in the integration of such weak correlations. Additionally, NOE correlations arising 
from overlapping 1H resonances were not considered as the contributions of each 1H resonance to the 
NOE intensity cannot be easily deduced. For a CH→CH3 NOE correlation, the resulting integral of the 
CH3 peak was divided by three in order to average the three distances between the CH proton and the 
three equivalent CH3 protons, as described in the supporting information from Aggarwal et. al.[281] The 
NOE intensities (𝜂NOE) were converted to interproton distances (rNOE) using the H10’-10’’ pair as the 
reference NOE (𝜂ref) and distance (rref). For example, the interproton distance experimentally derived 
for the H10’’-H4 distance (rH10’’,H4) is obtained from the ratio of the 𝜂H10’’,H4 intensity to the 𝜂H10’,H10’’ 
intensity, multiplied by the reference distance (Figure 80).  
 
Figure 80. Using 1D-NOESY to experimentally measure the H4-H3 interproton distance. The reference distance chosen was 




The experimental NOE-interproton distances can be compared to the Boltzmann averaged interproton 
distances obtained from DFT. The NOE intensities are very sensitive to conformer populations and a 
poor correlation to DFT will be observed if the conformer populations are not accurate. For a rigid 
molecule a MAD of ~3% or 0.1 Å is typically observed if the calculation of conformer populations is 
accurate.[104] Although molecule 119 displays a conformational bias, it contains a large number of 
rotatable bonds making the calculation of its conformational landscape much more challenging. As 
discussed in section 5.2 >17000 conformations of 119 were found within 30 kJ mol-1 of the global 
minima. Approximately 1.5% of these conformers were taken through to DFT calculations resulting in 
an approximation of the conformational landscape of the molecule rather than an exhaustive analysis 
of the conformational landscape. This will likely result in a larger deviation between experimental and 
calculated interproton distances due to the sensitivity of NOE intensities to conformer populations. For 
flexible molecules, deviations of <5% are considered to be acceptable. Indeed, for the molecules studied 
by Aggarwal et. al., 10, 11 a deviation of ~5% for interproton distances were observed.[27]  
The experimentally derived interproton distances (Table 9, column 4) were compared to the Boltzmann 
averaged calculated values (Table 9, column 5) and a MAD of 3.7% and SD of 5.4% were obtained. 
This strong agreement between the two datasets further confirms that a linear conformational bias, as 











Table 9. The experimental NOE-interproton distances obtained from 1D-NOE and CSSF-NOESY and the Boltzmann 



















7 14’ 17.18 2.60 2.49 4.42 
 14’’ 6.77 3.04 3.04 0.02 
 4 14.04 2.69 3.11 15.66 
 13 2.37 3.62 3.59 0.63 
 12 12.67 2.74 2.77 1.40 
10’ 1 60.52 2.11 2.08 1.48 
 10’’ 182.70 1.75 1.74 0.64 
 3 19.99 2.54 2.67 5.28 
1 10’ 34.86 2.31 2.08 10.13 
 20’ 40.61 2.25 2.19 2.84 
 20’’ 21.76 2.50 2.45 2.20 
 3 11.73 2.77 2.91 5.03 
 2 5.66 3.13 3.02 3.56 
10’’ 10’ (ref) 191.53 1.74 1.74 0.15 
 4 31.63 2.35 2.41 2.53 
3 10’ 15.69 2.64 2.67 1.11 
 1 13.11 2.72 2.91 7.00 
 2 25.06 2.44 2.48 1.54 
 4 13.14 2.72 2.83 4.08 
 8 18.88 2.56 2.51 1.97 
 11 4.27 3.28 3.27 0.19 
2 16 48.81 2.19 2.27 4.10 
 3 22.77 2.48 2.48 0.07 
 8 6.96 3.02 2.93 3.18 
 11 15.60 2.64 2.68 1.46 
4 7 14.60 2.67 3.11 16.42 
 10’’ 20.57 2.52 2.41 4.56 
 3 11.13 2.80 2.83 1.24 
 13 15.17 2.66 2.75 3.49 
Mean Absolute Deviation (%) 3.67 





The %deviation between the experimental NOE-interproton distances and the Boltzmann averaged DFT 
calculated interproton distances is <5%. However, the H7-H4 distance, gives an average deviation of 
16.0% or 0.41 Å. The experimental distance measured for the H7-H4 distance is 2.68 Å, averaged across 
the two distances measured, whilst the calculated distance is longer at 3.11 Å. This large deviation can 
be clearly seen when looking at Figure 81, which shown the %deviation obtained for all interproton 
distances. 
 
Figure 81. A graph showing the %deviation between calculated and experimental interproton distance obtained for each 
atom pair investigated by 1D-NOE. 
As H4 and H7 give well isolated peaks then experimental issues in the accurate integration or assignment 
of the NOE peak is unlikely. Additionally, very similar experimentally measured values of the H7-H4 
distance are obtained when either H7 is irradiated or H4. This suggests that the population of conformers 
with a short H7-H4 distance are underestimated by DFT. As discussed previously the NOE intensity 
between two nuclear spins is strongly related to interproton distance, scaled with r-6. This implies that 
conformers with a shorter value of r4-7 will have a disproportionally large effect of the NOE intensity, 
even if those conformers are present in low quantities.[102] The distance between H7 and H4 for 
conformers adopting a linear conformer is ~4.75 Å however, the distance between H7 and H4 for the 
next most populated cluster of conformers (see the bubble plot in Figure 72) is ~2.20 Å (Figure 82). 
The results from the NOE-interproton distance analysis suggests that the combined population of the 
second most populated cluster of conformers is >10%. This would require a reduction in the combined 
population of the linear conformers. However, the change in population is likely to be very small due 





Figure 82. A representative linear conformer with the H4-H7 distance shown and a representative conformer from the second 
most populated cluster of conformers with the shorter H4-H7 distance shown.  
The other 1H resonance that presents a much large deviation between experiment and calculation is the 
H1-H10’’ interproton distance, with a deviation of 10.1%. The corresponding H10’’-H1 distance however 
presents a typical deviation of 1.5%. This suggests that experimental reasons are behind the large 
deviation observed for the H1-H10’’ interproton distance. Examination of the CSSF-NOEY spectra of H1 
reveals that H10’’ is separated from H1 by ~50 Hz. It is possible that the selective irradiation of H1 was 
not achieved.  
In summary, the interproton distances obtained from 1D-NOE and CSSF-NOESY experiments 
correlated well with those calculated by DFT. This suggests that the linear conformational bias observed 











5.5 A Comparison of the Experimental 1H and 13C Chemical Shifts to the 
Boltzmann Averaged Calculated Values 
Alongside scalar couplings and quantitative interproton distances, 1H and 13C chemical shifts can be 
used to obtain conformational information about a structure. Chemical shifts are very sensitive to their 
surrounding chemical environment, and the conformational bias of a molecule can sometimes be 
deduced from the 1D-1H or 13C spectrum. For example, as discussed in section 1.1.3 of Chapter 1 a 
team of scientists at AstraZeneca used 1H chemical shifts to confirm that the free ligand conformation 
of potential drug candidates reflected the bound conformation of the molecules. Of all of the NMR 
parameters, chemical shifts are the easiest to measure and require the least experimental time.  
The experimental chemical shifts, both 1H and 13C were measured directly from the corresponding 1D-
spectrum. The acquisition of a pure-shift 1H spectrum, which removes scalar coupling to other 1H 
resonances, was critical in obtaining accurate values of δH due to peak broadening and overlap. 
Following the experimental acquisition of both δH and δC, the DFT calculated values was performed. 
The DFT NMR GIAO calculations calculate magnetic shielding tensors (σ) which are converted to a 
chemical shift by referencing the magnetic shielding tensors to those calculated for trimethyl silane 
(TMS) at the same level of theory in the same solvent, using Equation 8.  
𝛿𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 =  
𝜎𝑇𝑀𝑆 −  𝜎𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑
1 −  𝜎𝑇𝑀𝑆  𝑥 10−6
 
Equation 8. The conversion of magnetic shielding tensors to chemical shifts by referencing to TMS. 
The calculated chemical shifts were then scaled according to Equation 9: 
𝛿𝑠𝑐𝑎𝑙𝑒𝑑 = (𝛿𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 − 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡)/𝑠𝑙𝑜𝑝𝑒 
Equation 9. The scaling of calculated chemical shifts. 
Where the intercept and the slope were obtained by plotting the calculated chemical shifts (δcalculated) 
against the experimental chemical shifts. The linear scaling has been shown to reduce systematic errors 
and is performed routinely in the comparison of experimental chemical shifts against calculated 
chemical shifts.[110,135] After scaling, the corrected calculated chemical shifts were compared to the 
experimental chemical shifts and a MAD of 0.11 ppm and SD of 0.16 ppm was observed for δH and a 
MAD of 1.14 ppm and SD of 1.46 ppm was observed for δC. The full tables of the experimental and 
computed chemical shifts are given in section 9.6.4 of Chapter 9. Again, the MAD and SD align with 
previously obtained MAD and SD deviations in the literature for flexible molecules, further confirming 
that the conformation of 119 in solution behaves as predicted computationally, suggesting a strong bias 




5.6 A summary of the Conformational Analysis of 119 
The conformation of 119 in solution has been explored extensively through a hybrid computational and 
NMR spectroscopy approach. This has involved an experimental examination of scalar coupling 
constants, chemical shifts and quantitative interproton distances using 1D-NOESY followed by a 
comparison of the experimental data to that calculated using DFT calculations. An excellent correlation 
between computational and experimental data was observed for all NMR parameters (Figure 83), and 
the MADs and SDs obtained are of comparable quality to literature reports for molecules of similar size 
and flexibility (Table 10). This confirms the computational prediction that the conformational bias of 
molecule 119 in solution is towards a linear conformation.  
Table 10. A summary of the comparison of the experimental NMR parameters to the calculated NMR parameters for 119 
NMR Parameter MAD SD 
nJHH 0.71 Hz 0.85 Hz 
nJCH 0.35 Hz 0.48 Hz 
Interproton Distances 3.7% 5.4% 
δ1H 0.11 ppm 0.16 ppm 
δ13C 1.14 ppm 1.46 ppm 
 
Figure 83. A graph to show the correlation between the experimentally derived scalar coupling constants and interproton 




5.7 An Examination of Structures 155, 157 and 163.  
This section will investigate the conformation of 155, 157 and 163 computationally by MM 
conformational searching and experimentally through a qualitative examination of their 3JHH coupling 
constants. 
A full conformational analysis of all structures is not necessary as MM conformational searching 
suggests that structures 155 and 163 also demonstrate a linear conformational bias. The additional 
methylene group (155) and the substitution of the ‘hot-spot’ group from naphthyl (119) to the para-
chloro substituted phenyl group (163) has a minimal effect on the conformational bias and the 
conformation is still controlled by syn-pentane interactions. For molecule 119, a very small change in 
the total percentage of conformers adopting a linear conformation was observed when moving from 
MM to DFT, although the populations of the individual conformers changed considerably. Therefore, 
the conformational bias of 155 and 163 as predicted by MM can be assumed to be reliable. 3JHH coupling 
constants will however, confirm that the molecule is displaying a linear conformational bias. A 
conformational search of the PEG derivative, 157, cannot be performed as simulation of the PEG chain 
in implicit solvent is not accurate and will require considerable computation time due to the number of 
rotatable bonds. However, the values of 3JHH coupling constants measured from the NMR spectra of 
157 should indicate what the conformational bias is in solution. A summary of the conformational 
search results for 119, 155 and 163 are shown in Table 11.  
Table 11. A summary of the conformational search results for compounds 119, 155 and 163. The bubble plots are provided 
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As discussed previously, the values of 3JHH provide an indication as to the conformational bias of a 
molecule due to their relationship with dihedral angle, described by the Karplus equation. For molecules, 
155, 157, and 163 SpinSimulation had to be used to extract values of 3JHH due to broadening and overlap 
of the peaks precluding the measurement of these values directly from multiplets in the 1D 1H NMR. 
This proved very successful for 119 and all values of 3JHH were obtained for the backbone HCCH 
dihedrals.  
For structure 155, many of the 1H resonances are significantly overlapped and broadened to a greater extent than structure 
119. This makes simulation of these peaks very challenging. It is clear from the spectrum in Figure 84 that the 1H 
resonances for H2, H3, H5, H6, H7 are all either too overlapped or broad to obtain reliable values of 3JHH. However, the 1H 






Table 12). These coupling constants, along with the MM conformational search, suggest that the 
additional methylene group has not affected the overall conformational bias of the molecule towards a 









Table 12. The three values of 3JHH obtained for 155. The experimental coupling constants matched the anticipated coupling 
constants for a linear conformational bias.  
 







1 2 Anti 180 Large >9 9.9 
3 4 Anti 180 Large >9 2.0 
4 5 Gauche 60 Small <5 8.7 
 
Figure 84. The experimental spectrum of 155 (red) and the simulated spectrum (blue). Only three 1H resonances were able 
to be reliably simulated, however this did yield three values of 3JHH for the backbone HCCH dihedral angles. 
For molecule 163, the peaks in the 1D-1H spectrum were also significantly broadened and overlapped. 
Again, this led to challenges in the SpinSimulation and only three of the CH backbone peaks were able 
to be accurately simulated (Figure 85). The peaks corresponding to H1, H2 and H6 were successfully 
simulated and the four coupling constants obtained match with the anticipated coupling constants for a 




computational MM conformational search suggest that changing the hot-spot group from a naphthyl to 
a para-chloro phenyl group does not affect the conformational bias and a linear conformational is 
preferred for 163.  
Table 13. The four values of 3JHH obtained for 163. The experimental coupling constants matched the anticipated coupling 
constants for a linear conformational bias. 
 







1 2 Anti 180 Large >9 10.3 
2 3 Gauche 60 Small <5 1.3 
5 6 Anti 180 Large >9 9.9 
6 7 Gauche 60 Small <5 2.6 
 
Figure 85. The three 1H resonances of 163 that were successfully simulated using spin simulation. 
The PEG derivative 157 was the most challenging to investigate with the highest degree of spectral 
overlap and peak broadening observed. In addition, only a small amount of material was obtained which, 
for a molecule with a molecular weight in excess of 2000 Da, resulted in a sample of low concentration. 
However, all of the backbone CH peaks were able to be assigned. The distribution of the 1H resonances 
is similar to that observed for its precursor 155, with the 1H resonances occurring at a similar chemical 




PEG chains, as chemical shifts are very sensitive to their surrounding chemical environment. However, 
three backbone CH peaks were able to be simulated with some success to provide an estimate for the 
couplings along the backbone (Figure 86). The four values of 3JHH along the backbone that could be 
obtained are shown in Table 14. Again, the experimental values of 3JHH match with the expected values 
for a linear conformational bias. This result suggests that the addition of the PEG chain does not disrupt 
the conformation of the 157, and a linear conformational bias is still observed. 
 Table 14. The four values of 3JHH obtained for 157. The experimental coupling constants matched the anticipated coupling 
constants for a linear conformational bias. 
 







1 2 Anti 180 Large >9 10.1 
4 5 Gauche 60 Small <5 2.4 
5 6 Anti 180 Large >9 9.7 
6 7 Gauche 60 Small <5 2.8 
 
Figure 86. The experimental spectrum of 157 (red) and the simulated spectrum (blue). Only three 1H resonances were able 
to be reliably simulated.  
In summary, all of the molecules investigated within this study show a linear conformational bias 
regardless of the groups projecting from the conformationally controlled backbone or the size and nature 









Chapter 6: Analysing the Binding of the Designed p53 Mimetic to 
Mdm2  
The binding of the designed ligands to Mdm2 needs to be examined experimentally to confirm that they 
act as α-helix mimetics and bind to a pocket on a protein that is typically occupied by an α-helix of a 
second protein. There are many biophysical methods to study protein–ligand interactions including 
fluorescence spectroscopy, mass spectrometry, isothermal titration calorimetry and ultraviolet/visible 
spectroscopy. However, one of the most powerful methods to study protein–ligand binding is NMR 
spectroscopy, as it provides information on the thermodynamic, kinetic and structural features of 
protein–ligand binding.[282] There are several NMR methods to study protein–ligand interactions, some 
of which observe changes to the protein whilst others observe changes to the ligand. For example, 
Saturation Transfer Difference (STD) detects areas of the ligand interacting with the protein through 
magnetisation transfer whilst 1H-15N HSQC spectroscopy detects perturbation of chemical shifts of the 
protein upon binding of a ligand. Protein observed methods are often preferred as it is possible to 
directly observe the fully saturated protein. An advantage of ligand observed methods is that 
isotopically enriched proteins do not need to be expressed.[283]  
6.1 The Binding of the Designed p53 Mimetics to Mdm2 using 1H-15N HSQC 
spectroscopy 
Studying protein–ligand interactions by NMR spectroscopy is a favourable choice as information 
regarding the strength and location of binding can be obtained. Of all the NMR experiments available, 
one of the most widely adopted is the 1H-15N HSQC spectroscopy.[284] The method is simple to perform, 
the data is straightforward to analyse and on a high field spectrometer a 2D-HSQC can be acquired in 
~30 minutes at protein concentrations as low as 50 μM. It is also one of the most effective methods of 
analysing weak protein–ligand or protein–protein interactions due to the high sensitivity of the 
experiment.[285] The 1H-15N HSQC is typically performed on 15N labelled proteins due to the low natural 
abundance of the magnetically active 15N nuclei (~0.4%). In a 1H-15N HSQC spectrum a correlation is 
seen between the amide proton and its attached nitrogen in the peptide bond, thus each amide in the 
protein provides a correlation in the 2D-spectrum (Figure 87).[286] Typically, especially if the protein is 
folded, each amino acid will give a unique peak and little to no overlap will be observed. The binding 




the correlations in the 2D-HSQC spectrum and these can be tracked with increasing ligand 
concentration to plot binding curves, from which the dissociation constant can be derived.[287] The most 
commonly observed NMR parameter is the chemical shift perturbation (CSP) upon ligand binding.[288]  
 
Figure 87. The 1H-15N HSQC spectra of Mdm2 with the polarization scheme for the experiment shown. 
CSP’s are caused by either changes in the chemical environment of the amino acid caused by interaction 
of the amino acids with the ligand, or by a conformational change to the protein upon binding of the 
ligand (Figure 88).[289] In the former case, CSP’s will only be observed for residues interacting with the 
ligand, and thus information regarding the location of binding can be derived from the amino acids that 
have experienced a CSP. In the latter case, an entirely different conformation of the protein could be 
selected by the ligand, resulting in an entirely different 2D-spectrum, or a small conformational change 
of a region of the protein can result, resulting in CSP’s of just these residues.[290] More often than not, a 
combination of factors are responsible for the observed CSP’s, some may be from interactions with the 





Figure 88. A schematic to demonstrate the CSP effect of addition of a ligand to a 1H-15N HSQC spectrum. On addition of a 
ligand, CSP’s will be observed for amino acids interacting with the ligand if the ligand binds. For example, in the schematic 
shown above, the green peaks correspond to those of apo-Mdm2. Upon binding of the ligand certain residues shift, giving 
rise to the purple peaks. PDB ID: 1YCR 
Using the CSP’s it is possible to identify the location of binding, provided the protein has been able to 
be confidently assigned. However, the 1H-15N HSQC experiment can also provide information 
regarding the kinetics and thermodynamics of protein–ligand binding. An examination of the CSP’s 
with increasing ligand concentration can help to elucidate the exchange kinetics of protein–ligand 
complex formation, which provides an indication regarding the strength of binding.[291]  
The reversible interaction of a ligand [L] with a protein [P] to form a complex [PL] can be characterised 
by a second order exchange process governed by the rate constants for association (kon) and dissociation 
(koff) (Equation 10).[292]  
 




If the exchange rate between free and bound ligand is slow on the chemical shift timescale, then as the 
ligand is titrated in, the chemical shift corresponding to the free protein gradually decreases while that 
of the saturated complex gradually increases at the same rate (Figure 89a). In the slow exchange regime, 
koff is slower than the difference in Hz of the chemical shift of the free protein and the saturated complex 
(koff ≪ Δδ). Slow exchange kinetics usually indicate a strongly bound ligand. If however, the exchange 
rate is fast on the chemical shift timescale, then the chemical shift of the free protein gradually shifts 
from its original position towards the chemical shift of the saturated complex (Figure 89b). In the fast 
exchange regime, koff is faster than the difference in Hz of the chemical shift of the free protein and the 
saturated complex (koff ≫ Δδ). Fast exchange kinetics usually indicate a weaker binding ligand. It is 
also possible for koff to be roughly equal to the chemical shift difference in Hz of the chemical shift of 
the free protein and the saturated complex (koff ~ Δδ). This is known as the intermediate exchange 
regime and in it, the peaks shift from that of the free to the bound whilst also broadening.[293]-[294] 
Therefore, on examination of the CSP’s following ligand binding it should be possible to identify which 
exchange regime the system is operating under and indicate the strength of the protein–ligand 
interaction.   
 
Figure 89. The dependence of the NMR peaks in a 1H-15N HSQC on the exchange rate between protein and ligand. In the 
fast exchange regime, as ligand concentration is increased, the peaks shift from the free (black) to the bound (purple). In the 
slow exchange regime, as ligand concentration is increased the free peak (black) decreases in intensity as that of the bound 




Using 1H-15N HSQC spectroscopy, it is also possible to calculate a value for the dissociation constant, 
Kd, which is equal to the ratio of the rate constant for dissociation (koff) to the rate constant of association 
(kon), at equilibrium. For systems in the fast exchange regime, the CSP can be monitored as [L] increases 
to plot a binding curve and calculate the Kd of the protein–ligand interaction (Figure 90). Although it 
is possible, it is much more challenging to measure the Kd of systems in the slow exchange regime as a 
change in peak intensity is monitored as [L] is increased and this is experimentally much more 
challenging.[283]  
 
Figure 90. A schematic of a typical binding curve showing the change in CSP as ligand concentration increases. The 
experimentally measured data points are shown as circles in dark blue and the fitted binding curve is shown as a light blue 
curve.  
The CSP’s measured at different ligand concentrations can be used in a nonlinear least-square fitting to 
calculate Kd using Equation 11. This equation assumes the fast regime is operational and that a single 
binding site is occupied.[295]  
𝛥𝛿𝑜𝑏𝑠 =  𝛥𝛿𝑚𝑎𝑥






Equation 11. Using CSP’s to estimate Kd. 
Where 𝛥𝛿𝑜𝑏𝑠 is the change in the observed shift from the shift of the apo-protein, 𝛥𝛿𝑚𝑎𝑥  is the 
maximum chemical shift change on saturation of the protein with ligand, [P]t is the total protein 
concentration and [L]t is the total ligand concentration. In practice it is very challenging to reach 𝛥𝛿𝑚𝑎𝑥 
due to solubility limitations of the ligand so 𝛥𝛿𝑚𝑎𝑥 is typically obtained as part of the fitting procedure. 
The extrapolation of the measured data to estimate 𝛥𝛿𝑚𝑎𝑥 using nonlinear least-square fitting is one of 
the major sources of error in the estimation of Kd by CSP’s.[291] To calculate the observed CSP, which 




12. In the Euclidean distance, the chemical shift of the 15N nuclei is scaled by a scaling factor, α. Scaling 
factors of 0.1[296] to 0.45[297] have been reported and are typically calculated from the ratio of the 
chemical shift range (in ppm) of 1H to that of 15N.[291] It is also possible to use a scaling factor specific 
to each amino acid as some amino acids show much greater chemical shift ranges than others.  






Equation 12. The calculation of Euclidean distance. 
6.2 The 1H-15N TROSY Spectra of Mdm2 
The binding of 157 to Mdm2 was explored using 1H-15N HSQC spectroscopy. To achieve this, 15N-
labelled Mdm2 was required. 15N-Mdm2 has been expressed numerous times in the literature, with 
varying lengths of construct used.[265,298–308] It has been noted that Mdm2 is prone to aggregation, and 
as a result specific pHs, salt concentrations and additives are required to try to stabilise the protein.[298,300] 
The full details of protein expression and purification are provided in section 9.7.1 of Chapter 9.  
A fragment of the N-terminal domain of Mdm2 (residues 27-127) was expressed in the E.coli 
BL21(DE3) strain in M9 minimal media with 15NH4Cl as the nitrogen source. A hexahistidine tag was 
added to the N-terminus of the Mdm2 construct to aid with purification using immobilised metal affinity 
chromatography (IMAC). However, all attempts to cleave the His6-tag with TEV protease were 
unsuccessful. A report by Vassilev et. al. explored the binding of a small molecule inhibitor of Mdm2 
by 1H-15N HSQC, using His6-tagged Mdm2.
[304] Therefore perform the analysis of Mdm2 and the 
binding of the designed ligands was performed using the His6-tagged Mdm2. Following a second 
purification by size exclusion chromatography (SEC) using a HiLoad 26/60 Superdex 75 prep grade 
column, MALDI mass spectroscopy was performed which confirmed that full 15N labelling had 
occurred. With a purified 15N-labelled sample of Mdm2 in hand, the binding of the designed ligands to 
Mdm2 by 1H-15N HSQC spectroscopy can be explored.  
Although the 1H-15N HSQC is a very powerful experiment for studying protein structure and protein-
ligand interactions by NMR, the TROSY derivative of the experiment typically provides much better 
resolution and sensitivity. It achieves this by selecting the slowest relaxing component of a multiplet in 
a decoupled HSQC caused by the constructive interference of two relaxation pathways, dipolar-dipolar 
coupling and chemical shift anisotropy. This reduces the T2 relaxation rate, leading to sharper lines. The 
TROSY is typically acquired with a larger number of scans than a corresponding HSQC, since 
sensitivity is lost when only one component of a multiplet is selected. A 1H-15N TROSY of Mdm2 was 




resonance micro-cryo probe. The protein was solubilised in a 10 mM NaHPO4 solution with 150 mM 
NaCl at pH 7.4. The acquired TROSY was compared to reported HSQC or TROSY spectra of Mdm2 
published in the literature[249,298,300] which confirmed that the expressed Mdm2 had folded correctly and 
that the majority of resonances were present (Figure 91).  
 
Figure 91. The acquired 1H-15N TROSY of Mdm2 (right) and the 1H-15N HSQC acquired by Holak et. al. The graph on the 
right has been reproduced from reference [300]  
Mdm2 is prone to aggregation and the previous conditions used for solvation of Mdm2 resulted in 
aggregation after 48 hrs. It was found that solubilising the protein in 20mM Tris base with 250 mM 
NaCl and 1 mM TCEP at pH 7.5 was sufficient at preventing aggregation of Mdm2. A 1H-15N TROSY 
of Mdm2 in the revised solvation conditions was acquired at a concentration of 50 μM. As well as many 
published 1H-15N HSQC spectra of Mdm2, triple resonance protein NMR experiments have been 
performed previously to fully assign Mdm2. These assignments have been published in the BMRB 
(BMRB ID: 2410[300] and 15945[306]) and were used to partially assign the TROSY spectrum of Mdm2. 
Ambiguity in the central region precluded the assignment of some peaks and since the His6-tag was not 
removed additional peaks corresponding to His6-tag are present and could not be assigned. However, 
76% of identified peaks were able to be assigned based on the previous literature assignments. The 





Figure 92. The partially assigned 1H-15N TROSY of Mdm2. The peaks that have been assigned are shown. 
With the majority of peaks assigned, the binding of ligand 157 can be explored. The p53 binding pocket 
of Mdm2 is composed of fifteen amino acids (Table 15), some or all of which would be expected to 
shift upon binding of a small molecule to the p53 pocket. However, it is very common for other peaks, 
located on the periphery of the binding pocket to shift. Examination of the sets of amino acids reported 
to shift upon binding of a small molecule to Mdm2 differs from study to study and even between 
members of the same family of inhibitors. For example, a study by McDonnell et. al. revealed that for 
12 isoindolinone inhibitors with highly conserved structures, different chemical shift changes were 
observed indicating that slight changes in ligand structure will change the binding mode and result in a 
different set of amino acids exhibiting a CSP.[306] However, there are a few residues, common across 
the majority of studies, that are reported to shift upon binding of a small molecule. The amino acids of 
the three binding pockets that p53 occupies on Mdm2 along with other amino acids that commonly 
undergo CSP’s upon binding of a small molecule are shown in Table 15.[265,298,306] All of the residues 





Table 15. The amino acids of the p53 binding pockets on Mdm2 and other important amino acids that commonly shift upon 
binding of a small molecule. 
Important Residues 
L26 Pocket W23 Pocket F19 Pocket  Others 
100 S92 Y67 M50 
T101 L54 E69 L57 
V53 G58 H73 I61 
 Y60 I74 H96 
 F91 V75 I99 
  M62 T26 
  V93 V108 
   E52 
   F55 
   L85 
   K94 
 
6.3 The Qualitative Binding of Ligand 157 to Mdm2 
This section discusses the binding of ligand 157 (Figure 93) to Mdm2 using a 1H-15N TROSY. Ligand 
157 in acetone-d6 was added to 50 μM Mdm2 to a final concentration of 70 μM, in the same solvation 
conditions as described previously. In total, 10% acetone-d6 was added to the final solution to improve 
the solubility of the ligand. A control experiment of the apo-protein with 10% acetone-d6 was performed 
to confirm that any CSP’s were due to ligand binding. The spectra of the apo-protein with 10% acetone-
d6 perfectly matched the spectra with no acetone-d6. Upon adding ligand 157 to Mdm2, significant peak 
shifts were observed for a number of residues, many of which are located either in the binding pocket 
or on the periphery (Figure 94). The CSP’s were calculated as a Euclidean distance, as described by 
Equation 12 with a value of α = 0.14, calculated from the ratio of the chemical shift range (in ppm) of 
1H to that of 15N (3.08/22.1 = 0.139). Deciding which shifts are large enough to be considered an 
indicator of the binding site is not straightforward. The standard method is to calculate the standard 
deviation, σ, of the Euclidean CSP and any residues that display a CSP >σ are considered significant.[291] 
This cut-off is also commonly increased to >2σ to increase the specificity of the analysis and generate 





Figure 93. Ligand 157 
 
Figure 94. The 1H-15N TROSY of Mdm2 (red) and Mdm2 157 (blue). The significant CSP’s are noted. 
The largest chemical shift changes are observed for residues in the Leu26 pocket, with all three residues 
(Y100, T101, V53) that define the L26 pocket shifting by >2σ. Large chemical shift changes (>2σ) are 
also observed for residues V93 and S92 which are both located in the F19 pocket. Of the remaining 
residues that induce a large chemical shift change, F86, K98, K94, T26 and E52 are located on the 
periphery of the binding pocket and commonly observed to shift upon binding of a small molecule. An 
additional 23 residues exhibited a moderate CSP (CSP > 1σ) many of which are located in the W23 and 
F19 pockets. A table summarising the measured CSP’s and their calculated Euclidean distance is shown 




which is commonly considered the lower threshold that indicates whether that the amino acid is 
involved in binding to the ligand.[293]  
The residues that exhibit CSPs have been mapped onto Mdm2, shown in Figure 95. The residues 
coloured in red are those with a CSP > 2σ, those coloured in orange are those with a CSP > 1σ and those 
coloured in yellow are those with a CSP < 1σ. It is clear from Figure 95 that most of the residues that 
shift are located in or on the periphery of the p53 binding pocket. The most perturbed regions of Mdm2 
upon binding of 157 are composed of residues F91 to Y104 and residues M50 to T63. The first set of 
residues are located on an α-helical domain and β-sheet that forms the sides of the cleft near the F19 
pocket whilst the second set of residues are located on a second α-helical domain that forms the side of 
the cleft that runs along the entire p53 binding region.     
 
Figure 95. The binding of 157 to Mdm2 deduced by 1H-15N TROSY. Residues coloured in red experience a large CSP 
(>2σ), residues coloured in orange experience a moderate CSP (>1σ) whilst those coloured in yellow experience a weak CSP 
(<1σ). PDB ID: 1YCR 
CSP’s are also observed for a few residues not in the binding pocket (Y47, V28, L33, V110, D68, S40). 
These changes could be attributed to conformational changes in Mdm2 upon binding of 157. It is well 
known that ligands can induce a conformational change in either the whole protein or in regions of its 
secondary structure to accommodate the ligand. CSP’s observed for residues outside of the binding 
pocket can be caused by this secondary effect rather than direct binding of 157 with this region of Mdm2. 
This is supported by the fact that the residues not in the p53 binding pocket that have shifted are isolated 
from one another. If ligand 157 were binding to a second site on Mdm2, one would expect to see a 
group of chemical shifts of residues located close to one another shift. Reports by Hamilton et. al. (V28, 
D68)[265] and Holak et. al. (Y47, V28)[301] report similar residues located outside of the binding pocket 




6.4 The Quantitative Binding of Ligand 157 to Mdm2 
With the binding of ligand 157 to Mdm2 confirmed, the estimation of the Kd between ligand 157 and 
Mdm2 was performed using a ligand titration by 1H-15N HSQC spectroscopy, as described previously. 
Although it would make analysis much simpler using the 1H-15N TROSY due to the enhancement in 
resolution and sensitivity, it is not possible as this requires 12 hours of spectrometer time per experiment. 
Therefore, a 1H-15N-SOFAST HMQC, a derivative of the HSQC experiment that uses short inter-scan 
delays to reduce experimental time, was performed. The SOFAST-HMQC does however come at a loss 
of sensitivity and resolution, and not all residues are well resolved. A protein concentration of 70 μM 
was used and five ligand concentrations ranging from 17.5 to 280 μM were used (Figure 96). Ligand 
concentrations >300 μM could not be explored as precipitation of the ligand was observed. Therefore, 
it is possible that δmax will not be identified and a large error in the estimation of Kd will be obtained. 
Mbinding (software released by MestreNova) was used to analyse the CSP’s and calculate the Kd. The 
measured CSP’s are used to generate a calculated binding curve from which δmax is estimated and Kd is 
calculated using Equation 11. The Kd was calculated for a total of 20 peaks, 18 of which corresponded 
to assigned peaks, and an average Kd and σ was calculated.  
 
Figure 96. The titration of ligand 157 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 17.5 μM ligand), 
orange (70 μM Mdm2 + 35 μM ligand), green (70 μM Mdm2 + 70 μM ligand), pink (70 μM Mdm2 + 140 μM ligand), dark 




Although the CSP’s seem moderate, the low concentrations of ligand required to induce these shifts 
resulted in an average Kd of 17.2 ± 4.5 μM (Table 16). The data shows that for the residues where 
CSP >2σ, the lower values of Kd were observed, confirming that these residues are interacting strongly 
with 157. An exemplar binding curve for T101 and a zoom in of this peak is shown in Figure 97.  
Table 16. The calculated value of Kd and maximum CSP for 20 different residues interacting with 157. The average Kd and 
σ Kd are also shown. 
Residue  K
d
 (μM) CSP Max (ppm) 
C77 16.9 0.09 
E95 16.0 0.03 
F86 13.2 0.06 
G42 20.3 0.02 
G83 25.0 0.03 
K94 12.3 0.06 
K98 12.9 0.05 
L107 15.2 0.04 
L37 23.4 0.07 
L82 21.5 0.04 
M62 20.9 0.03 
R29 17.1 0.05 
S40 18.2 0.03 
S92 11.6 0.06 
T101 10.5 0.07 
T47 12.1 0.05 
Y104 15.3 0.04 
E69 21.0 0.03 
unassigned1 (U1) 24.2 0.05 







The value of Kd obtained suggests a moderate affinity between ligand 157 and Mdm2. Although the 
molecular docking simulations performed by AutoDock Vina suggested that ligand 157 would bind to 
Mdm2 with only a slightly lower affinity than that of Nutlin-2, experimentally there is a large difference 
in the strength of binding (Kd = 90 nM).
[195] This is likely due to the fact that during the AutoDock 
simulations, solvation effects are not considered at all. Ligand 157 has much poorer aqueous solubility 
than the Nutlins, possibly causing the reduction in binding affinity observed experimentally. If the 
aqueous solubility of 157 is not sufficient then the concentration of 157 in solution will be lower than 
expected, resulting in a weaker binding affinity calculated. The binding affinity experimentally 
measured for 157 more closely resembles those reported for the terphenyls synthesised by Hamilton et. 
al. which ranged from 0.18-297 μM depending on the hot-spot groups attached to the terphenyl 





Figure 97. A close up of the CSP for T101 with increasing concentrations of 157. The experimentally determined CSP 
(blue) was used to calculate a binding curve (red) from which a value of Kd could be calculated using a nonlinear least-







6.5 The Binding of Ligands 164, 172 and 179 to Mdm2 
In addition to ligand 157, three other ligands (164, 172, and 179, Figure 98) were synthesised and their 
binding to Mdm2 was explored experimentally using the 1H-15N SOFAST HMQC. A titration of all 
three ligands at varying concentrations against Mdm2 was performed.  
 
Figure 98. Ligands 164, 172 and 179 
The first ligand explored was ligand 164 (Figure 98), which is expected to display a stronger binding 
affinity to Mdm2 than that of ligand 157 due to the introduction of the Cl atom that should occupy a 
deep void in the Trp23 pocket, which has been reported to be critical for competitive binding.[265] The 
binding of ligand 164 to Mdm2 is shown in Figure 99. A protein concentration of 70 μM was used and 
five ligand concentrations ranging from 17.5 to 280 μM were used. Ligand concentrations >300 μM 
could not be explored as precipitation of the ligand could be observed. A total of 20 residues, 18 of 
which have been assigned, were used in the analysis of Kd. A very similar set of residues exhibit a CSP 
upon binding of the two ligands 157 and 164, however the CSP’s observed for ligand 164, compared to 





Figure 99. The titration of ligand 164 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 17.5 μM ligand), 
orange (70 μM Mdm2 + 35 μM ligand), green (70 μM Mdm2 + 70 μM ligand), pink (70 μM Mdm2 + 140 μM ligand), dark 
blue (70 μM Mdm2 + 280 μM ligand). The 20 peaks that were considered in the calculation of Kd are highlighted. 
A comparison of the 1H-15N SOFAST HMQC spectra in Figure 96 and Figure 99 clearly shows that 
very similar peaks shift upon binding of 164 and 157. This suggests that the two ligands are binding in 
an analogous fashion to Mdm2 and interacting with similar residues. A stronger binding affinity of 8.8 
± 3.1 μM was observed for 164, confirming the importance of the correct placement of the Cl atom in 
obtaining an improved binding affinity. The calculated Kd of all 20 peaks are shown in Table 17. 
Although every effort was made to analyse the same set of peaks for 164 and 157, challenges with 
spectral overlap or resolution precluded the analysis of some peaks for 164 that were analysed for 157. 
Alternative peaks that could be confidently analysed were chosen as an alternative. Despite a few peaks 
missing, it can clearly be seen, from the comparison of Table 17 with Table 16, that many of the 







Table 17. The calculated value of Kd and maximum CSP for 20 different residues interacting with 164. The average Kd and 
σKd are also shown. 
Residue  K
d
 (μM) CSP Max (ppm) 
C77 11.8 0.09 
E69 3.3 0.05 
F86 5.4 0.13 
F91 7.3 0.06 
G83 6.9 0.05 
K64 9.7 0.06 
K94 6.9 0.11 
L107 8.0 0.08 
L37 12.4 0.05 
L82 11.1 0.04 
M62 14.5 0.08 
S40 10.6 0.07 
S92 3.7 0.13 
T47 7.4 0.10 
T49 10.0 0.06 
U1 7.2 0.07 
U2 11.7 0.07 
Y104 8.6 0.07 
Y48 6.7 0.04 







The effect of the Cl atom can be confirmed by examining residues that are located deep in the W23 
pocket, such as L85, which is located on an α-helix that forms the bottom of the binding cleft. It has 
been suggested by Hamilton et. al. that strong CSPs of the L85 residue are indicative of strong binding 
due to occupancy of the deep void in the W23 pocket.[265] Whilst the naphthyl derivative 157 does 
induce a small CSP in L85, it is notably larger with the Cl derivative 164 (Figure 100), suggesting a 
much stronger interaction between ligand 164 and L85 than ligand 157 and L85.  
 
Figure 100. The effect of ligand 157 (left) and ligand 164 (right) on the L85 residue. It can clearly be seen that the CSP 
induced by 164 for L85 is much more significant, indicating a stronger interaction between 164 and the L85 residue. Purple 




As well as L85, G83 and L82 are also present deep in the W23 pocket, both of which exhibit a more 
significant CSP upon binding of ligand 164 compared to ligand 157. The results obtained from residues 
G83, L82 and L85 confirm that ligand 164 is able to penetrate deeper into the W23 pocket than ligand 
157, as a result of the Cl atom occupying the deep void in the W23 pocket, as predicted by molecular 
docking (Figure 101). 
 
Figure 101. The binding of ligand 157 (blue) and ligand 164 (purple) as predicted by AutoDock Vina. Residues L82, G83 
and L85 are shown in green.  
In addition to the two ligands 157 and 164, which display moderate binding to Mdm2, two control 
ligands were synthesised. Ligand 172 was synthesised to confirm the importance of the hot-spot groups 
in binding to Mdm2 whilst ligand 179 was synthesised to confirm the importance of preorganising the 
free conformation of the ligand for improved binding affinities. Both ligand 172 and 179 are expected 
to bind weakly, if at all, to Mdm2. The binding of both ligands was explored using the 1H-15N SOFAST 
HMQC. 
The binding of ligand 172 revealed very few significant CSPs, with the chemical shift of many residues 
remaining unchanged on increasing concentrations of ligand 172 (Figure 102). A protein concentration 
of 70 μM was used and five ligand concentrations ranging from 35 to 350 μM were used. The lack of 





Figure 102. The titration of ligand 172 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 35 μM ligand), 
orange (70 μM Mdm2 + 70 μM ligand), green (70 μM Mdm2 + 140 μM ligand), pink (70 μM Mdm2 + 280 μM ligand), dark 
blue (70 μM Mdm2 + 350 μM). The 5 peaks that were considered in the calculation of Kd are highlighted. 
Due to the lack of CSPs, the quantitative analysis of binding of ligand 172 is much more challenging. 
Furthermore, it is more likely that δmax will not be attainable and a large error will be associated with 
the calculated value of δmax and Kd. Indeed, it is clear from the binding curve of M62, shown in Figure 
103, that δmax is not achieved and a poor binding curve is obtained. Therefore, we cannot reliably 
measure Kd for the control molecule 172. However, it is clear that 172 is binding very weakly to Mdm2, 





Figure 103. The binding curve for M62 from the binding of 172 to Mdm2. The red line is a non-linear least square fitting to 
Equation 11 
The binding of the second control ligand 179 was explored, to confirm the importance of conformational 
preorganisation. A protein concentration of 70 μM was used and six increasing concentrations of ligand 
179 were used ranging from 35 μM to 350 μM. The binding of ligand 179 to Mdm2 revealed a small 
set of residues, many of which are located in the binding pocket of Mdm2, exhibiting small CSP’s upon 
increasing concentrations of 179 (Figure 104). However, these CSP’s were much smaller in magnitude 
when compared to ligands 164 and 157 and required larger concentrations of 179 to induce these CSP’s. 
In analogy to control ligand 172, poor binding curves were obtained for control molecule 179 because 
δmax could not be experimentally attained. Therefore, a reliable value of Kd was not obtained. However, 
the lack of measurable CSPs confirms that the control molecule 179 is binding weakly to Mdm2, 
compared to the two ligand 164 and 157. This result confirms that conformationally preorganising the 





Figure 104. The titration of ligand 179 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 35 μM ligand), 
orange (70 μM Mdm2 + 70 μM ligand), green (70 μM Mdm2 + 105 μM ligand), yellow (70 μM Mdm2 + 140 μM ligand) 
pink (70 μM Mdm2 + 280 μM ligand), dark blue (70 μM Mdm2 + 350 μM). The 5 peaks that were considered in the 











6.5 A Summary of the Binding of Ligands 157, 164, 172 and 179 by NMR 
spectroscopy 
The CSP’s observed in the 1H-15N SOFAST HMQC or TROSY spectra of ligands 157, 164, 172 and 
179 confirms that the p53 mimetics 164 and 157 bind to the p53 cleft on Mdm2. This was deduced from 
the observation of CSP’s for many residues located in the p53 binding pocket whilst only a few CSP’s 
were observed for residues located far from the p53 pocket, which are likely the result of conformational 
changes upon binding of a ligand. In contrast, the control ligands 172 and 179 do not induce significant 
CSP’s and those residues that do shift upon binding of the control ligands do not shift to the same 
magnitude as seen for ligands 157 and 164. Additionally, greater concentrations of the control ligands 
are required to induce the shifts. This suggests that the control ligands 172 and 179 have a lower affinity 
to Mdm2 than ligands 157 and 164, confirming the importance of both the hot-spot groups and 
conformational preorganisation in obtaining higher affinity therapeutics.   
For the two designed p53 mimetics (ligand 157 and ligand 164) the CSP’s were tracked with increasing 
concentrations of the ligands and using Mbinding from MestreNova the binding curves were calculated 
and a value of Kd was estimated. A summary of the experimentally determined values of Kd are shown 
in Table 18.  
Table 18. A summary of the experimentally determined Kd values from 1H-15N-SOFAST HMQC spectroscopy for ligands 






Ideally, the binding of the ligands would be explored by different biophysical methods to confirm the 
results obtained from 1H-15N SOFAST HMQC spectroscopy, however the poor solubility of the ligands 
prevents the use of certain methods due to their sensitivity. Since the aqueous solubility of the ligands 
is far from ideal, alterations to the scaffold to improve the water solubility should be performed before 
a wide range of biophysical methods are tested. Alternative biophysical methods that could be used 








Chapter 7: Future Work  
7.1 Improving the Solubility of the p53 Mimetics  
Although the p53 mimetics designed and synthesised demonstrate reasonable affinity to Mdm2, the 
pharmacokinetic properties of the molecule are far from ideal, restricting their application as potential 
therapeutics. The lipophilicity of the molecules should be addressed before their biological activity is 
fully explored as currently their poor aqueous solubility will lead to large uncertainties in any binding 
constants measured experimentally. Additionally, the poor solubility will result in some analytical 
methods being unusable due to high concentrations of ligand relative to protein required. With a 
calculated LogP (calculated using ACD labs) of 8.97 the big-PEGylated p53 mimetic (157) is far from 
the ideal LogP of 5, governed by Lipinski’s rules.  
One strategy to improve the LogP is to add better solubilising groups onto the two terminal positions 
of the scaffold, in place of the PEG chains. One example that has proven successful in the design of 
water-soluble glucose receptors is the addition of multicharged water solubilising dendrimer chains. 
The dendrimer chains contain multiple anionic groups and the synthetic glucose receptors are readily 
soluble in aqueous solvents.[309,310] The impressive water solubilising properties of dendrimers has been 
exploited previously in drug design, with examples of dendritic therapeutics having been reported in 
the literature.[311,312] One promising application of dendrimers is their use in drug conjugation. It has 
been demonstrated that a dendrimer unit can be conjugated to a therapeutic molecule via a cleavable 
linker such as disulphide bridges.[313] Using this method, it is possible to ensure that the dendrimers do 
not interact with the receptor but enable hydrophobic drugs to be delivered to their site of action. A 
future endeavour of this project could be to explore the addition of multianionic dendrimer chains to 
the scaffold. A possible synthetic route is shown in Scheme 26. A very similar synthetic sequence for 
installation of the dendrimer chains to the installation of the PEG chains can be proposed with a change 
in the amine used. The amine needed can be synthesised from the reduction of 





Scheme 26. The proposed synthesis of a p53 mimetic functionalised with dendrimers, 181. 
The addition of solubilising groups at the terminal positions requires no redesign on the lithiation–
borylation sequence used to synthesise the mimetics themselves. However, adding large polar groups 
at either end of long nonpolar molecule could encourage the formation of large aggregates. Instead, it 
should be explored whether it is possible to incorporate solubility onto the backbone of the molecule 
instead, or in addition to the terminal positions. Recently Bootwitcha et. al. have reported an iterative 
assembly line process towards the synthesis of polypropionates through the introduction of carbinol 
units.[258] The polypropionate motif features alternating methyl and hydroxy groups along a 
hydrocarbon backbone. The synthesis of this motif is extremely challenging often requiring multiple 
redox processes. Bootwitcha et. al. have demonstrated that enantioenriched lithiated α-chlorosilanes, 
183, can be used in the reagent-controlled homologation of boronic ester to generate α-silylalkyl 
boronates, 186 (Scheme 27). Oxidation of the silyl group reveals the corresponding hydroxy group, 
187. The resulting boronic ester can either be subjected to further homologations with either 
enantioenriched lithiated α-chlorosilanes to install contiguous hydroxy groups or α-lithiated benzoate 





Scheme 27. The proposed mechanism of the stereocontrolled homologation of lithiated α-chloromethyl silane with a boronic 
ester.  
Using this methodology, hydroxy groups could be incorporated onto the backbone of the scaffold, in 
place of the methyl groups, such as structure 191 (Scheme 28). The hydroxy groups could be left intact 
or further functionalised to introduce either hot-spot groups or solubilising groups. A potential pitfall 
of this approach is that the syn-pentane control, previously enforced by the methyl groups, is no longer 
as dominating as the hydroxy group is considerably smaller in size than the methyl group. The effect of 
introducing hydroxy groups onto the scaffold would need to be fully investigated using MM 
conformational search calculations and QM calculations prior to synthesis.  
 
Scheme 28. A proposed synthesis of a p53 mimetic bearing hydroxy groups on the backbone, 191, using the homologation 




The final option for introducing greater solubility into the molecule is to change the hot-spot groups 
added onto the scaffold, to introduce more polar groups. For example, p53 features a tryptophan residue 
as one of the hot-spot groups. The NH of the indole of tryptophan is engaged in a hydrogen bond with 
a leucine residue on p53. Incorporation of an indole group onto the scaffold would not only improve 
solubility slightly but also potentially increase the binding affinity of the mimetic with Mdm2, although 
it has been suggested that this hydrogen bond is not necessary for competitive binding. The introduction 
of the indole group using lithiation–borylation is challenging as the NH of the indole will need to be 
protected. The choice of protecting group will need to be fully explored to ensure that lithiation on the 
indole does not occur. For example, the BOC protecting group, which is a common choice of amine 
protecting group, would likely direct lithiation onto the indole. A potential protecting group that could 
be used is the benzyl group. Future work would be to explore the installation of protected amine groups 
onto the scaffold using lithiation–borylation.  
7.2 Further Experiments to Investigate Binding of our Designed Mimetic 
to Mdm2 
Chapter 6, discussed the use of 1H-15N HSQC spectroscopy to analyse the binding of the designed 
mimetics to Mdm2. This methodology allowed us to confirm the location of binding of the mimetics 
and provided an estimate of the Kd. However, other biophysical methods should also be explored in 
future work to further explore the binding of the designed mimetics to Mdm2.[314]  
Previously, the use of protein-based NMR methods were used to analyse protein-ligand binding. 
Protein-based methods are advantageous as they can be used to directly monitor changes to protein 
conformation and structure upon ligand binding.[287] It can provide atomistic information about protein-
ligand binding, such as which amino acids are interacting with the ligand. Additionally, protein-based 
methods have been reliably used to determine dissociation constants (Kd).[283] However, they typically 
require considerable amounts of isotopically enriched protein and acquisition of 2D-NMR data can be 
very time demanding. Furthermore, protein-based methods are typically only possible for smaller 
proteins of <50 kDa.[314] An alternative to protein-based methods are ligand-based NMR methods 
whereby changes to the spectrum of the ligand are monitored upon binding to the protein. Using ligand-
based methods, the binding of a ligand to a protein can be studied using unlabelled proteins of any 
size.[282] The most popular ligand-based NMR method is saturation-transfer difference (STD) 
spectroscopy. 
During an STD experiment, the protein is irradiated at a specific radiofrequency field that selectively 
targets the protein resonances.[315] This is known as the on-resonance spectrum. The magnetisation is 
transferred from the protein to any ligands that are bound to it, by spin diffusion, which will be 




second spectrum is acquired using a radiofrequency pulse where no saturation will take place, known 
as the off-resonance spectrum. The difference between the two spectra (the on-resonance and the off-
resonance) is recorded, revealing a spectrum of the ligand featuring only resonances that were saturated 
by the protein. Protons on the ligand that interact strongly with the protein with therefore receive a 
greater amount of saturation and will have enhanced NMR signals compared to protons that do not 
interact with the protein. Therefore, STD can be used to identify the regions of the ligand strongly 
interacting with the protein. The STD method is very useful is several ligands are to be screened for 
binding to the protein, as only those ligands that interact with the protein will be observed in the 
difference spectrum (Figure 105).[287] Using the STD method, a large excess of the ligand to protein is 
typically required, which is challenging for highly lipophilic molecules. Despite this limitation, the STD 
NMR experiment would be a relatively straightforward experiment to perform in future work and may 
provide information regarding the regions of the ligand that are strongly interacting with Mdm2. This 
information could help to improve the design of stronger binding ligands.  
 
Figure 105. A schematic to demonstrate the principal of saturation transfer difference (STD) NMR experiments to monitor 
protein-ligand interactions 
Protein-ligand interactions are also routinely studied by fluorescence polarisation (FP). The significant 
advantage of FP assays is that they are amenable to high throughput screening, making them a 
favourable choice in drug discovery.[316] Additionally, it does not require isotopically labelled proteins. 
Fluorescence polarisation, also commonly referred to as fluorescence anisotropy, monitors changes in 
fluorescence which is proportional to the rotation time of a molecule, as a fluorescent ligand is either 
bound to a protein or competitively displaced (Figure 106). If the fluorophore is attached to the ligand 
itself, then a titration of ligand against protein can be performed and Kd can be measured. If however, a 
fluorophore is not present on the molecule it is possible to measure Ki through the competitive 
displacement of a known inhibitor that possess a fluorophore. As the ligand displaces the known 




bind to the protein with a similar affinity to the designed ligand so a strong idea of the Kd between the 
ligand and protein is required.  
 
Figure 106. A general schematic to show the competitive fluorescence polarisation assay. 
Since a fluorophore is not present on our designed p53 mimetics, the more suitable approach would be 
to bind a competitive inhibitor with a fluorophore to Mdm2 and displace this with the designed p53 
ligands, to obtain a value of Kd. Preliminary work using this method has been conducted by Dr. 
Madhavachary Rudrakshula however, the assay was unsuccessful and inconclusive results were 
obtained. A fluorescently labelled p53 analogue (Ac-SQETFSDLWKLLPENNVC(Flu)-NH2) was 
chosen as the competitive inhibitor however upon binding the peptide to Mdm2, a Kd of 1.86 ± 0.16 
µM was obtained. This binding affinity is lower than those predicted by NMR for the designed p53 
ligands and as a result a high concentration of the ligand would be required for competitive displacement. 
Indeed, at a concentration of 1 mM, poor and scattered competition results are obtained (Figure 107). 
This could possibly be due to precipitation of the ligand at such high concentrations resulting in a much 
lower effective concentration of ligand in solution. Future work would be to design a p53 peptide 
analogue with a lower affinity to Mdm2. This could possibly be done by alanine mutagenesis.  
 
Figure 107. a) The results of the FP assay for the p53 analogue. b) The attempt to displace the p53 analogue with ligand 157 




This project has assumed that the designed p53 mimetics bind to Mdm2 as a linear conformation, 
thereby reducing the conformational reorganizational energy that is required upon binding as the free 
ligand conformation is biased towards a linear conformation. Although H-15N HSQC spectroscopy 
confirmed that the molecules bound to the p53 binding site on Mdm2, it did not provide any detailed 
information regarding the orientation of binding and the bound conformation of the molecules. In order 
to explore the bound conformation of the designed p53 mimetics to Mdm2, X-ray crystallography needs 
to be performed. Not only will X-ray crystallography confirm whether the free conformation of the 
ligands reflects the bound conformation of the ligands, but it will also allow for visualisation of the 
protein-ligand interactions and allow for structural optimisation of the hot-spot groups to maximise the 
binding affinity.[317] However, a major limitation of X-ray crystallography is that it requires suitable 
crystals of the protein-ligand complex to be grown.  
The previous methods discussed do not allow for a direct measurement of the thermodynamic 
parameters involved with the protein-ligand binding event. One method that can allow for the 
measurement of such parameters is isothermal titration calorimetry (ITC). ITC works by measuring the 
heat either released or absorbed during a titration of the ligand into a sample of the protein. The quantity 
of the heat measured is directly proportional to the extent of binding. ITC can be used to measure the 
association constant (Ka), the enthalpy changes upon binding (ΔH), from which the Gibbs free energy 
change (ΔG) and entropy change (ΔS) can be derived. Although ITC allows for a direct measurement 
of the association constant and the thermodynamic parameters of protein-ligand binding, it typically 
requires high protein concentrations as it suffers from low sensitivity.[318] In turn this causes 
considerable challenges in the solubility limits of the titrated compound, with highly aqueous soluble 
compounds often required. This will be a major limitation in the analysis of the conformationally 
controlled hydrocarbons using ITC.  
It is also possible to use mass spectroscopy (MS) to characterise the protein-ligand complex. Using 
native-MS, whereby protein-ligand complexes are analysed in their native biological state, it is possible 
to measure the exact mass of the protein-ligand complex. This confirms that the protein-ligand complex 
is present and can be used to determine the stoichiometry of binding.[319] Due to the high sensitivity of 
MS, very small amounts of protein are required. Additionally, the protein does not need to be labelled 
unlike in NMR. Native-MS however provides no information on the location of binding, and so does 
not confirm that the ligand has bound in a specific manner to the protein. An additional caveat of native-
MS is the more challenging sample preparation which requires the sample to be desalted. The protein-
ligand complex needs to remain stable in the desalted conditions for it to be successful.[314] However, 
the relative ease of acquisition makes native-MS an attractive biophysical technique to test in future 




Although many biophysical methods are available for studying protein-ligand interactions, all of them 
rely on good aqueous solubility of the ligand and a solid understanding of the concentration of ligand 
in solution. Many of the biophysical methods described may yield inconclusive results due to ambiguity 
of the concentration of ligand in solution due to possible precipitation. Therefore, before a large range 
of biophysical methods are screened, the aqueous solubility of the ligand should be addressed first.  
7.3 The extension to a ‘universal’ α-helix mimetic  
This thesis has explored the design of a conformationally controlled hydrocarbon scaffold capable of 
mimicking the i, i + 3/4 and the i + 7 positions of the α-helix. However, as mentioned in section 1.6.2 
of Chapter 1, scaffolds that can mimic multiple faces of the α-helix are of high importance as roughly 
40% of PPIs mediated by an α-helix display hot-spot groups across two or more faces.[205] The linear 
scaffold reported in this thesis has 4 distinct binding faces and a promising avenue of future work would 
be to explore the mimicry of multiple faces of the α-helix with the conformationally controlled 
hydrocarbon scaffold (Figure 108).  
 
Figure 108. An illustration of the four distinct faces of the linear molecule 
We hypothesise that the linear scaffold can be substituted with suitable side chains, using iterative 
lithiation–borylation, to mimic a highly diverse combination of positions of the α-helix. By simply 
overlaying the linear scaffold (11) with the helix hoping to be mimicked it is possible to identify the 
positions of the linear scaffold that can mimic the required α-helical residues. Then a simple adjustment 
of the lithiation–borylation sequence to incorporate appropriate benzoates at judicious positions, will 
provide access to a conformationally controlled α-helix mimetic of your choice. If successful, we will 




adjusting the reagents used in the sequence, it is possible to mimic any position on the α-helix as 
desired.[320] Examples of combinations of residues that could potentially be mimicked by the linear 
scaffold are shown in (Figure 109). For example, the first scaffold (192) is proposed to mimic the i, i 
+ 2 and i + 5 positions of the α-helix by substituting the 2nd, 3rd and 7th positions on the linear scaffold. 
Other combinations than the three shown in Figure 109 are possible.  
 
Figure 109. An example of three different sets of residues that could be inhibited using conformationally controlled 
hydrocarbons. 1 – the mimicry of the i, i + 2 and i + 5 residues of the α-helix requires side chains at the 2nd, 3rd and 7th 
positions of the linear scaffold (192). 2 – the mimicry of the i, i + 4 and i + 6 residues of the α-helix requires side chains at 
the 1st, 5th and 8th positions of the linear scaffold (193). 3 – the mimicry of the i, i + 1, i + 4 and i + 7 residues of the α-helix 
requires side chains at the 1st, 2nd, 5th and 9th positions of the linear scaffold (195). 
The Mcl1-NoxaB PPI is a key therapeutic target due to its role in regulating apoptosis. Attempts to 
inhibit this PPI have been reported, and although some success has been met, with a candidate from 
AstraZeneca now in clinical trials[10], it remains a significant therapeutic challenge. This is because the 
PPI features a long α-helical region with hotspot groups located across multiple faces. Woolfson et. al. 
recently reported the hot-spot residues of Mcl1-NoxaB, found by computational alanine scanning 




Asp16 and Val18), known as the short motif, and three residues in an extended motif (Leu4, Leu25 and 
Asn26) were important for binding to Mcl1. Mimicry of the extended motif with a small molecule is a 
huge challenge, however mimicry of the short motif may be possible, especially considering that the 
two dominating hot-spot groups are found on the short motif.  
 
Figure 110. The hot-spot residues of Noxa-B found using computational alanine scanning by Woolfson et. al. Residues with 
a G of >4.2 kJ mol-1 are coloured in purple. This figure has been reproduced from reference[321]. 
With hot-spot groups located at the i, i + 1, i + 3, i + 5 and i + 7 positions, the Mcl1-NoxaB PPI is a 
good candidate to explore whether conformationally controlled hydrocarbons are capable of mimicking 
multiple faces of the α-helix. Overlaying the linear scaffold with NoxaB, it is possible to identify the 
positions that need to be functionalised if mimicry of the i, i + 1, i + 3, i + 5 and i + 7 positions is to be 
achieved. The 1st, 3rd, 5th, 7th and 9th position overlay well with these residues.  Extending the methyl 
groups to propyl side chains reveals a good overlap between the 1st, 3rd, 5th, 7th and 9th positions of the 
linear hydrocarbon and the i, i + 1, i + 3, i + 5 and i + 7 residues of Noxa-B (Figure 111).  
The first stage of this project would be to explore the effect on the conformational bias of the linear 
scaffold following the addition of a larger number of side chains, positioned closer together, when 
compared to the scaffolds explored in this PhD. Following this, the synthesis of the scaffold would need 
to be developed as incorporating a mimetic of an aspartic acid residue and an arginine residue is 
challenging due to the acidic/basic nature of their side chains. Finally, exploration of the conformation 
of the scaffold by NMR spectroscopy and QM calculations followed by experimentally measuring 




conformationally controlled hydrocarbons, synthesised through iterative lithiation–borylation, show 
promise as a new class of universal α-helix mimetics.  
 
Figure 111. Noxa-B has hot-spot residues at the i, i + 1, i + 3, i + 5 and i + 7 which could potentially be mimicked by side 
chains added to the 1st, 3rd, 5th, 7th and 9th positions of the linear scaffold (195). A potential mimetic of Noxa-B is shown. 













Chapter 8: Conclusions 
This thesis has demonstrated that contiguously methyl substituted hydrocarbons, conformationally 
biased due to the avoidance of destabilising syn-pentane interactions, are suitable mimetics of the α-
helix. The methyl groups positioned at the 1st, 5th and 9th position of the hydrocarbon scaffold 11 closely 
match the key distances and angular relationships observed between Cβ of i, i + 3/4 and i + 7 residues 
of an α-helix, with an RMSD of 0.85 Å (Figure 112).  
 
Figure 112. The overlay of a linear hydrocarbon scaffold (11) with a model α-helix. It can clearly be seen that the 1st, 5th and 
9th methyl groups closely match with the i, i + 3/4 and i + 7 residues.  
Small molecule α-helix mimetics are important targets in the inhibition of aberrant PPIs. The binding 
affinity between proteins engaged in a PPI is typically dominated by a few key residues, known as hot-
spot residues, so the search for inhibitors of PPIs has focussed on the mimicry of the hot-spot residues 
as opposed to the entire protein–protein interface. These hot-spot residues are most commonly found 
on one face of the α-helix, typically the i, i + 3/4 and i + 7 residues. This thesis explored whether our 
contiguously methyl substituted scaffold could be substituted with suitable hot-spot groups to mimic 
the Mdm2 binding domain of p53 and potentially disrupt the p53-Mdm2 PPI. Using lithiation–
borylation, the substitution of the methyl group for a suitable mimetic of p53 is as simple as switching 
the benzoate ester used in the sequence. Using lithiation–borylation it is possible to incorporate 
mimetics of most amino acid side chains onto the scaffold at any position by designing the correct 
sequence of benzoate esters to be used.  
It was first confirmed that the conformational bias previously observed for the fully methylated 
hydrocarbon (11) was not lost upon replacement of methyl groups for suitable p53 mimetic groups. 
MM conformational search calculations confirmed that the methyl groups could be directly substituted 
for propyl side chains (101) with no significant loss in conformational control observed with over 73% 
of conformers adopting a linear conformation. This result was initially unexpected, as the extended side 
chains have now introduced two syn-pentane interactions. However, on closer inspection of the lowest 
energy conformer found from MM calculations, it can be seen that the dihedral angles have distorted 




of ~40° between the eclipsing groups in a syn-pentane interaction the energy penalty of this interaction 
will be reduced, resulting in a linear conformational bias still being observed. With a general scaffold 
successfully designed, the design of a p53 mimetic was explored. The scaffold was initially shortened 
to reduce the number of homologations required, by incorporating the Leu26 mimetic on the starting 
aromatic group. The two remaining propyl side chains were transformed to introduce groups to mimic 
the Trp23 and Phe19 of p53 (96). A MM conformational search confirmed that these changes did not 
perturb the conformational bias, with over 74% adopting a linear conformation (Figure 113). 
 
Figure 113. A summary of the key findings from the MM conformational search calculations. The results show that adding 
longer side chains, or large aromatic hot-spot groups does not perturb the conformational bias, with a linear preference still 
observed.  
The lowest energy conformer of 96 overlays well with p53. Using the pair fitting function in PyMol, 
and fitting the corresponding carbon atoms of the three ‘hot-spot’ side chains of 96 with the Cα and Cβ 
atoms of the ‘hot-spot’ residues on p53 revealed an RMSD of 0.71 Å (Figure 114).  
 
Figure 114. An overlay of p53 (teal) and the lowest energy conformer of the designed p53 mimetic 96 (purple). 
Molecular Docking, using AutoDock Vina, confirmed that the designed p53 mimetic (96) could bind 
to Mdm2. A good binding affinity was predicted (-36.8 kJ mol-1 vs -41.4 kJ mol-1 for Nutlin-2) with the 
three hydrophobic groups in the three pockets on Mdm2 that are typically occupied by p53. The ligand 
has bound to Mdm2 in the opposite direction as originally intended, with the Leu mimetic in the Phe19 




interaction between the phenyl group on the scaffold and the His96 residue in the Leu26 pocket. 
Molecular Docking also revealed a deep void in the Trp23 pocket that is not occupied by the naphthyl 
group. This deep void has been filled previously in the literature by a chlorine atom. Molecular Docking 
confirmed that by changing the naphthyl group (96) to a para-chloro phenyl group (106) this deep void 
can be occupied by the chlorine atom and the binding affinity is increased to -38.9 kJ mol-1 (Figure 
115).  
 
Figure 115. The results of the molecular docking study performed using AutoDock Vina. It can clearly be seen that the Cl 
atom of ligand 106 fills a deep void in the Trp23 pocket of Mdm2 
Following the design of two suitable p53 mimetics their synthesis was explored using lithiation–
borylation. In order to introduce a handle for functionalisation to improve solubility, a phenol group 
was added to the scaffold. The synthesis of the p53 mimetics (157 and 164) was performed semi-
iteratively with column chromatography performed after certain homologations. The same synthetic 
methodology could be followed for the synthesis of both 157 and 164, with a change to the benzoate 
ester used in the third homologation (Scheme 29). The starting boronic ester used in the synthesis of 
both 157 and 164 could be synthesised in four steps on a multigram scale with an overall yield of 85% 
obtained. From this starting boronic ester, seven homologations were performed. When installing the 
methyl groups, the chiral carbenoids used in the synthesis were derived from the lithiation of 
enantioenriched stannanes. When the hot-spot groups were installed, the chiral carbenoids were derived 
from the chiral-ligand assisted lithiation of primary benzoate esters. For the p53 mimetic 157, only the 




seven homologations. For the p53 mimetic 164, the first, second, fourth, fifth and sixth homologations 
were performed iteratively, and an overall yield of 24% was obtained over the seven homologations.  
 
Scheme 29. The general lithiation–borylation route followed for the synthesis of the boronic ester precursors, 120 and 161, 
of the p53 mimetics 157 and 164 
In addition to the two p53 mimetics 157 and 164, two control molecules were synthesised. Control 
molecule 172 was synthesised to confirm the importance of the hot-spot groups and control molecule 
177 was synthesised to confirm the importance of conformational preorganisation. An iterative 
lithiation–borylation sequence was used to synthesise both 172 and 177, with overall yields of 38% and 
35% obtained respectively over the homologation sequence.  
To improve the aqueous solubility of the scaffolds, a Matteson homologation was first performed on 
the terminal boronic ester to introduce a methylene unit. A MOM deprotection was performed to reveal 
the phenol followed by oxidation of the boronic ester to the primary alcohol. High yields were obtained 
over the three steps with yields ranging from 72% to 89% for the p53 mimetics and the control 
molecules. To introduce water solubilising groups, the two hydroxy groups on each molecule were 
converted to the corresponding acyl chloride with phosgene and pyridine in DCM. An in-situ reaction 
with methoxypolyethylene glycol amine introduced two PEG chains, of 750 average Mw, onto the 
scaffold (Scheme 30). The yields observed over these two steps were low, with yields of <15% obtained, 
due to poor conversion of the acyl chloride to the amide-PEG derivative. The bis-PEG derivatives were 





Scheme 30. The general synthesis followed for installing water solubilising PEG chains. 
Of the structures synthesised, a representative was chosen on which the solution state conformation was 
explored (119). The representative structure was chosen as the candidate with the least spectral overlap 
to help with assignment and measurement of NMR parameters. The 1H and 13C chemical shifts were 
measured from the corresponding 1D-spectrum. Vicinal 1H-1H scalar couplings were measured 
experimentally either directly from the multiplets in the 1D-1H spectrum or using SpinSimulation from 
MestreNova. 1H-13C scalar coupling constants were measured using IPAP-HSQMBC. Finally, 
quantitative interproton distances were measured using selective 1D-NOESY and CSSF-NOESY. The 
PANIC method was applied, with the irradiated peak set to 1000 and a methylene group chosen as the 
reference distance (1.74 Å).  
The measured NMR parameters were compared to those calculated using DFT methods. A selection of 
conformers from the MM conformational search were subjected to a geometry optimisation and 
frequency calculation (mPW1PW91, 6-31g (d)), followed by a single point energy calculation 
(mPW1PW91, 6-311g (d,p)). The calculated conformer energies were used to calculate conformer 
Boltzmann populations. A final DFT calculation was performed to calculate the magnetic shielding 
tensors and the scalar coupling constants (GIAO, mPW1PW91, 6-311g (d,p)). The magnetic shielding 
tensors were converted to chemical shifts, and Boltzmann averaged using the calculated populations. 




were also Boltzmann averaged. An excellent correlation between the experimental and calculated NMR 
parameters was obtained, with low MADs and SDs obtained for all NMR parameters (Table 19). This 
confirms that the molecule exists in solution with a linear conformational bias.  
Table 19. A summary of the MAD and SD obtained when experimental NMR parameters were compared to those calculated 
using DFT, for ligand 119 
 
NMR Parameter MAD SD 
nJHH 0.71 Hz 0.58 Hz 
nJCH 0.35 Hz 0.32 Hz 
Interproton Distances 3.7 % 4.1 % 
δ1H 0.11 ppm 0.12 ppm 
δ13C 1.14 ppm 0.9 ppm 
The final stage of this PhD was to explore the binding of the designed p53 mimetics to Mdm2. This 
was performed by 1H-15N HSQC spectroscopy. This allows the location of binding to Mdm2 to be 
identified as well as the dissociation constant (Kd) to be measured. 15N-Mdm2 was expressed in 
the E.Coli BL21(DE3) strain using M9 minimal media with 15NH4Cl as the nitrogen source. Initial 
purification using IMAC followed by a subsequent purification using SEC yielded good quantities of 
15N-Mdm2. The mass was confirmed by MALDI spectroscopy, which confirmed that full 15N labelling 
had occurred. A 1H-15N TROSY was acquired and compared to those reported in the literature which 
confirmed that Mdm2 had folded into the correct tertiary structure. A partial assignment (76%) of the 
peaks was achieved by comparison to the assignments in the BMRB (2410 and 15945). Upon binding 
of the naphthyl derivative 157, significant CSPs were observed for residues located primarily in, or on 
the periphery of, the p53 binding pocket (Figure 116). CSPs that were observed for residues not in the 
p53 binding pocket were attributed to conformational changes in Mdm2 upon accommodation of a 
ligand. Similar CSPs were observed upon binding of the para-chloro phenyl derivative 164, although 





Figure 116. The 1H-15N TROSY obtained for apo-Mdm2 (red) and Mdm2+ligand 157. CSPs can be clearly observed for 
certain residues which can be mapped to residues located in the p53 binding pocket of Mdm2.  
To estimate the dissociation constant Kd, a titration of five increasing concentrations of the ligands 157 
and 164 against Mdm2 was performed. Mbinding from MestreNova was used to analyse the 1H-15N 
SOFAST-HMQC spectra. Mbinding calculates the Euclidean CSP at each concentration, plots the 
calculated binding curves and estimates the Kd. In addition to the two p53 mimetics 157 and 164, the 
binding of the two control molecules 172 and 179 was explored. A summary of the Kd values obtained 
for the two p53 mimetics 157 and 164 from 1H-15N SOFAST-HMQC spectroscopy is shown in Table 
20. It confirms that the para-chloro phenyl derivative (164) binds to Mdm2 with a higher affinity than 
the naphthyl derivative (157), as predicted by molecular docking. The two control molecules, 172 and 
179, do not induce significant CSPs and reliable values of Kd cannot be obtained. However, the lack of 
CSPs confirms that the two control molecules bind to Mdm2 with a considerably weaker affinity than 
ligands 157 and 164, confirming the importance of both the hot-spot groups and conformational 






Table 20. A summary of the dissociation constants (Kd) obtained from 1H-15N HSQC titrations for the two p53 mimetics  
 
Ligand  Kd (µM) 
157 17.18  
164 8.81  
In summary, a new class of conformationally controlled α-helix mimetics has been designed and 
synthesised. Using our modular and flexible iterative lithiation–borylation methodology, a vast range 
of groups can be incorporated onto the scaffold through the simple substitution of the benzoate ester 
used in the synthetic sequence. This thesis has shown that these scaffolds can mimic one face of the α-
helix (the i, i + 3/4 and i + 7) however, it is also believed that they can be used as multi-faced α-helix 
mimetics and this will be explored in due course. Finally, it was demonstrated that the scaffold can be 
functionalised with suitable groups to mimic the Mdm2 binding domain to p53 and bind to the p53 
binding pocket on Mdm2 with binding affinities as low as 9 µM. We hope that this work will encourage 





Chapter 9: Supporting Information 
9.1 Molecular Mechanics Conformational Searching  
9.1.1 General Informational  
Molecular Mechanics Conformational Search Calculations were performed using the MacroModel[322] 
Software package (version 9.9) accessed through Maestro (version 9.2)[323]. All MM calculations were 
performed using Grendel, the Unix computational resource of the School of Chemistry, University of 
Bristol. 
Conformational searching was performed using the Monte Carlo Multiple Minimum (MCMM)[120] 
conformational search method. The Merck Molecular Force Field (MMFFs)[236] was used with 500,000 
steps in the gas phase. Conformers within 21 kJ mol-1 of the global energy minima were retained. 
Structures were minimised using the Truncated Newton Conjugate Gradient (TNCG) method with 1000 
iterations and a convergence criterion of 0.05 Å. If poor convergence was observed, noted by a low 
number of times the low energy conformers were found, the number of iterations was increased to 5000.  
Following the conformational search, a redundant conformer elimination was performed using 
MacroModel. In this study, conformers are deemed redundant and eliminated using maximum atom 
deviations. This considers a conformer to be unique if the maximum atom deviation for any pair of 
corresponding atoms exceeds 0.5 Å. The atoms along the backbone and the first carbon atom of the side 
chains were selected for comparison (Figure 117). All conformers under 21 kJ mol-1 were retained.  
 
Figure 117. The atoms considered for comparison during the redundant conformer elimination. 
To generate the bubble plots, the dihedral angles along the backbone of each conformer were measured 
in MacroModel. The estimated relative potential energies of each conformer from MM was used to 
calculate the Boltzmann distribution of conformers according to Equation 13. A 3D plot was then 













Equation 13. The Boltzmann Distribution  
Where E is the estimated potential energy, relative to the global minimum, in kJ mol-1 of conformer i. 
R is the ideal gas constant (8.314 x 10 -3 kJ mol-1), T is the temperature of the system (298 K) and g is 
the degeneracy of conformer i (which is 1 for all conformers studied). 
9.1.2 Conformational Search Results of Initial Candidates 
A summary of the conformational search results of the structures investigated during the computational 
design stage of this report are shown in Table 21.  
















































































































































































































9.1.3 Conformational Search Results of Synthesised Structures  
A summary of the conformational search results of 119 
 
Table 22. The MM conformational search results of 119. 
Number of Conformers 
within 30 kJ mol-1 
Number of Conformers after 
Redundant Conformer 
Elimination 
% of Linear Structures. 
17380 1115 77% 
 
The lowest energy conformer of 119 is linear and has a population of 22%. 
 






Figure 119. The Bubble plot of 119. The size of the bubble is representative of the population of the conformer contributing 
to that dihedral angle. 
 
A summary of the conformational search results of 155 
 
Table 23. The MM conformational search results of 155 
Number of Conformers 
within 21 kJ mol-1 
Number of Conformers after 
Redundant Conformer 
Elimination 
% of Linear Structures. 





The lowest energy conformer of 155 is linear and has a population of 21%. 
 
Figure 120. The lowest energy conformer from MM for 155 
 
Figure 121. The Bubble plot of 155. The size of the bubble is representative of the population of the conformer contributing 







A summary of the conformational search results of 163 
 
Table 24. The MM conformational search results of 163 
Number of Conformers 
within 21 kJ mol-1 
Number of Conformers after 
Redundant Conformer 
Elimination 
% of Linear Structures. 
6277 188 75% 
 
The lowest energy conformer of 163 is linear and has a population of 37%. 
 





Figure 123. The Bubble plot of 163. The size of the bubble is representative of the population of the conformer contributing 
to that dihedral angle. 
 
A summary of the conformational search results of 171 
 
Table 25. The MM conformational search results of 171 
Number of Conformers 
within 21 kJ mol-1 
Number of Conformers after 
Redundant Conformer 
Elimination 
% of Linear Structures. 







The lowest energy conformer of 171 is linear and has a population of 13% 
 
Figure 124. The lowest energy conformer from MM for 171 
 
Figure 125. The Bubble plot of 171. The size of the bubble is representative of the population of the conformer contributing 










A summary of the conformational search results of 178 
 
Table 26. The MM conformational search results of 178 
Number of Conformers 
within 21 kJ mol-1 
Number of Conformers 
within 10 kJ mol-1 after 
Redundant Conformer 
Elimination* 
% of Linear Structures. 
86446 1581 <0.1% 
*only atoms of the backbone were selected. Side chains were ignored 
The lowest energy conformer of 178 is not linear and has a population of 5% 
 






Figure 127. The Bubble plot of 178. The size of the bubble is representative of the population of the conformer contributing 
to that dihedral angle. 
 
9.2 Molecular Docking using AutoDock Vina 
Molecular Docking was performed using AutoDock Vina, version 1.1.2.[243] All procedure for the 
docking experiment were followed as described in the user manual for AutoDock Vina with the 
exception of the exhaustiveness, which was increased to 24. The ligand and receptor were parameterised 
using Autodock Tools. Docked conformations were ranked automatically by AutoDock Vina using a 
force field scoring function. The parameters (centre point of binding and size of the search space) used 
in the calculation are:  
center_x = 30.804 
center_y = -18.102 
center_z = -3.946 
size_x = 30.0 
size_y = 30.0 








The binding of Nutlin-2 by AutoDock Vina 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of Nutlin-2, found 
from a MM conformational search, was used as the ligand. The best binding mode gave a predicted 
binding affinity of -41.4 kJ mol-1.  
Table 27. The top five binding poses of Nutlin-2 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -41.42 0.00 
2 -39.75 7.94 
3 -37.66 7.46 
4 -33.89 4.95 
5 -33.05 7.15 
 
 






The binding of 96 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 96, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -36.8 kJ mol-1. 
Table 28. The top five binding poses of 96 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -36.82 0.00 
2 -34.31 2.45 
3 -32.64 11.19 
4 -32.22 8.13 
5 -31.80 9.69 
 
Figure 129. The top ranked binding pose of 96 bound to Mdm2 found by AutoDock Vina. A surface representation of 96 





The binding of 103 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 103, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -34.73 kJ mol-1. 
Table 29. The top five binding poses of 103 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -34.73 0.00 
2 -32.64 3.98 
3 -32.22 2.49 
4 -31.38 4.50 
5 -30.96 3.30 
 
Figure 130. The top ranked binding pose of 103 bound to Mdm2 found by AutoDock Vina. A surface representation of 103 





The binding of 104 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 104, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -37.24 kJ mol-1. 
Table 30. The top five binding poses of 104 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -37.24 0.00 
2 -36.40 2.60 
3 -35.15 3.89 
4 -34.73 2.58 
5 -34.73 2.39 
 
Figure 131. The top ranked binding pose of 104 bound to Mdm2 found by AutoDock Vina. A surface representation of 104 





The binding of 105 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 105, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -38.9 kJ mol-1. 
Table 31. The top five binding poses of 105 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -38.91 0.00 
2 -37.24 2.38 
3 -35.98 2.23 
4 -35.56 2.59 
5 -33.89 4.33 
 
Figure 132. The top ranked binding pose of 105 bound to Mdm2 found by AutoDock Vina. A surface representation of 105 





The binding of 106 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 106, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -41.00 kJ mol-1. 
Table 32. The top five binding poses of 106 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -41.00 0.00 
2 -38.07 2.21 
3 -36.82 3.36 
4 -36.40 1.14 
5 -35.56 2.58 
 





The binding of 107 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 107, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -35.15 kJ mol-1. 
Table 33. The top five binding poses of 107 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -35.15 0.00 
2 -35.15 2.21 
3 -32.64 3.57 
4 -32.22 4.40 
5 -32.22 2.78 
 
Figure 134. The top ranked binding pose of 107 bound to Mdm2 found by AutoDock Vina. A surface representation of 107 





The binding of 108 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 108, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -37.7 kJ mol-1. 
Table 34. The top five binding poses of 108 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -37.66 0.00 
2 -36.82 1.76 
3 -36.40 1.91 
4 -36.40 4.88 
5 -35.98 2.43 
 
Figure 135. The top ranked binding pose of 108 bound to Mdm2 found by AutoDock Vina. A surface representation of 108 





The binding of 110 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 110, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -38.07 kJ mol-1. 
Table 35. The top five binding poses of 110 bound to Mdm2 found by AutoDock-Vina. 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -38.07 0.00 
2 -35.15 2.44 
3 -35.15 2.29 
4 -34.31 2.19 
5 -33.89 4.63 
 
Figure 136. The top ranked binding pose of 110 bound to Mdm2 found by AutoDock Vina. A surface representation of 110 





The binding of 111 by AutoDock Vina 
 
Mdm2 was taken from the crystal structure 1YCR and the lowest energy conformer of 111, found from 
a MM conformational search, was used as the ligand. The best binding mode gave a predicted binding 
affinity of -29.3 kJ mol-1. 
Table 36. The top five binding poses of 111 bound to Mdm2 found by AutoDock-Vina 
Mode Affinity (kJ mol-1) Distance from Best Mode (Å) 
1 -29.29 0.00 
2 -27.20 1.44 
3 -27.20 5.38 
4 -26.36 1.46 
5 -26.36 5.48 
 
Figure 137. The top ranked binding pose of 111 bound to Mdm2 found by AutoDock Vina. A surface representation of 111 





9.3 Synthetic Procedures  
9.3.1 General Synthetic Information 
All required fine chemicals were purchased from Acros Organics, Alfa Aesar, Fischer Scientific or 
Sigma-Aldrich and used as received unless otherwise specified. s-butyllithium (s-BuLi and n-
butyllithium (n-BuLi) were received from Acros Organics and the molarity was verified by titration 
with N-benzylbenzamide.[324] (–)-sparteine and (+)-sparteine were distilled over CaH2 and stored in a 
young’s tube under Argon/N2 at -5 °C to prevent absorption of atmospheric CO2. Anhydrous solvents 
were dried by passing through a modified Grubbs system of alumina columns, manufactured by 
Anhydrous Engineering, stored over 3Å molecular sieves (25% of total volume) and transferred under 
N2 via syringe. Ethyl 2,4,6-triisopropylbenzoate (51) was provided by Dr. Johan Pradeilles, a previous 
member of the Aggarwal group. 
All air- and water- sensitive reactions were carried out in flame dried glassware under a N2 atmosphere 
using standard Schlenk manifold techniques with magnetic stirring. Where reactions were monitored 
using TLC, aluminium backed plates pre-coated (0.25 mm) with Merck Silica Gel 60 F254 were used 
and compounds were visualised by exposure to UV light or stained using a 5% solution of 
phosphomolybdic acid (PMA) in EtOH followed by heating. Where compounds were either purified by 
flash column chromatography or passed through a plug of silica, Merck Silica Gel 60 (40-63 μm) was 
used. All mixed solvent eluents are reported as v/v solutions. 
1H- and 13C- NMR spectra were recorded on either a JEOL ECZ 300 MHZ, JEOL ECS 400 MHz, 
Varian 400 MHz, Varian VNMRS 500 MHz NMR spectrometers equipped with direct observe two 
channel probes, a Bruker AVANCE III HD 500 MHz NMR spectrometer with a 5 mm DCH 13C-1H/D 
Cryo Probe or a Bruker Avance III HDTM 700 MHz NMR Spectrometer with a 1.7 mm inverse triple 
resonance micro-Cryo Probe. Spectra were visualised and processed using MestreNova version 14.0. 
Chemical shifts (δ) are quoted in parts per millions (ppm) and are referenced to the residual proton 
signals of the solvent. 1H NMR coupling constants are reported in Hz. Data are reported as follows: 
chemical shift, multiplicity (s = singlet, br. s = broad singlet, d = doublet, t = triplet, q = quartet, quin = 
quintet, sext = sextet, sept = septet, m = multiplet, dd = doublet of doublets etc.), coupling constant, 
integration and assignment. Assignment of signals in 1H and 13C NMR spectra was performed using 
1H-1H COSY, 1H-1H-gDQFCOSY, DEPT, 1H-13C HSQC, 1H-13C pureshift-HSQC, 1H-13C HMBC, 1H-
13C H2BC experiments where appropriate. 11B NMR spectra were measured using Norell S-200-QTZ 
quartz NMR tubes at 96 or 128 MHz with complete proton decoupling. It should be noted that 13C 




GCMS was performed using an Agilent HP-5MS column (15 m × 0.250 mm), an Agilent 6890 GC, and 
Agilent 5973 MS system. Compounds were identified through extracted ion chromatogram and 
molecular ion analysis. Method 70-1X: Inlet temperature 250 °C; Flow rate: 1.0 mL/min; hold at 70 °C 
for 0 min; ramp 20 °C/min to 200 °C; ramp 45.0 °C/min to 300 °C; hold at 300 °C for 2 min. 
Chiral high pressure liquid chromatography (HPLC) separations were performed on an Agilent 1100 
Series HPLC unit equipped with UV-vis diode-array detector monitored at 210.8 nm, using Daicel 
Chiralpak IA, IB or IC columns (4.6 × 250 mm2, 5 μm) fitted with respective guards (4 × 10 mm2). 
High resolution mass spectra were recorded by the University of Bristol, School of Chemistry 
departmental mass spectrometry service using electron spray ionisation (ESI) or matrix assisted laser 
desorption (MALDI). HRMS ESI was performed on either a Bruker Daltonics Apex IV, 7-Tesla FT-
ICR or microTOF II. MALDI was performed in an Applied Biosystems 4700 Proteomics Analyser 
Instrument. Samples were submitted in either EtOAc or CHCl3. 
All Infrared spectra were recorded on the neat compounds using a PerkinElmer Spectrum One FT-IR 
spectrometer, irradiating between 4000 cm-1 and 600 cm-1. Only strong and selective absorbances 
above 1400 cm-1 are reported. Melting points were measured with a Stuart SMP30 melting point 
apparatus and are uncorrected. Optical rotations were obtained on a Bellingham + Stanley Ltd. ADP220 
polarimeter at 589 nm in a cell with a path length of 1dm. Specific rotations are given in (deg mL)/(g 
dm). Compound names are those generated by ChemBioDraw 13.0 (PerkinElmer), following the 
IUPAC nomenclature 
9.3.2 General Synthetic Procedures  
1. The Homologation of Boronic Esters using Stannanes (GP1) 
A solution of stannane 53 (1.35 equiv) in a Schlenk reaction vessel was dissolved in anhydrous Et2O 
(0.2 M) under an atmosphere of nitrogen. The reaction mixture was cooled to -78 °C and n-BuLi (1.5 – 
1.6 M in hexanes, 1.30 equiv) was added dropwise to the reaction mixture. The reaction mixture was 
stirred for 1 h at -78 °C after which the reaction mixture has become a translucent pale yellow solution 
with no white stannane precipitate remaining. The boronic ester (0.3 M in anhydrous Et2O, 1 equiv) 
was added dropwise at -78 °C. The reaction mixture was stirred at -78 °C until the pale yellow solution 
loses its colour on the addition of the boronic ester. The reaction mixture was then warmed to room 
temperature, and the 1,2-migration was monitored by 11B NMR. Once the 1,2-migration was complete 
a white precipitate was formed and filtered through a 1cm plug of silica, to give a pale yellow translucent 
solution. The silica was washed with Et2O and the solvent removed (in situ) under reduced pressure to 
give the crude boronic ester. The crude boronic ester was then either purified by flash column 




2. The Homologation of Boronic Esters using Primary Benzoates (GP2) 
A solution of benzoate 121 or 122 (1.35 equiv) and (+)-sparteine (1.30 equiv) in a Schlenk reaction 
vessel was dissolved in anhydrous Et2O (0.2 M) under an atmosphere of nitrogen. The reaction mixture 
was cooled to -78 °C and s-BuLi (1.3 - 1.4 M in hexanes, 1.30 equiv) was added dropwise to the reaction 
mixture. The reaction mixture was stirred for 1 h at -78 °C during which it became dark red in colour. 
The boronic ester (0.5 M in anhydrous Et2O, 1 equiv) was added dropwise at -78 °C. The reaction 
mixture was stirred at -78 °C until the dark red solution loses its colour and becomes yellow. The 
reaction mixture was then warmed to room temperature, and the 1,2-migration was monitored by 11B 
NMR. The reaction mixture was then quenched with 2M HCl and the aqueous layer was washed with 
Et2O three times. The organic layers were combined, dried using MgSO4, filtered and concentrated in 
vacuo. The crude boronic ester was then purified by flash column chromatography. 
9.3.3 Preparation of Compounds 
1-(Trimethylstannyl)ethyl 2,4,6-triisopropylbenzoate, (S)-53 
 
An oven dried 1 L, three neck flash, equipped with a 40 mm magnetic stirrer bar was cooled to rt under 
vacuum. The reaction flask was evacuated and refilled with N2 (3x). The flask was charged with ethyl 
2,4,6-triisopropylbenzoate (7.98 g, 28.9 mmol, 1.0 equiv) and (–)-sparteine (8.3 mL, 37.5 mmol, 
1.3 equiv) followed by the addition of anhydrous Et2O (135 mL) via cannula. The solution was cooled 
to -78 °C and allowed to equilibrate for 10 mins before the addition of sBuLi (1.3 mL in hexanes, 
28.8 mL, 37.5 mmol, 1.3 equiv) dropwise to the solution. The reaction mixture became dark brown 
after the addition of s-BuLi. The reaction mixture was stirred at -78 °C for 4 h before the addition of 
Me3SnCl (1.0 M in hexanes, 37.5 mL, 37.5 mmol, 1.3 equiv) to the reaction mixture. The reaction 
mixture was stirred at -78 °C for 20 mins, after which it had become a yellow solution. It was then 
warmed to rt and stirred for 1 h. The reaction mixture was diluted with 2 M HCl (60 mL) and stirred 
for a further 20 mins. The organic and aqueous layers were separated, and the organic layer was washed 
with 2 M HCl (4 x 60 mL). The combined aqueous layers were extracted with Et2O (3 x 60 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo to give the crude 




The opposite enantiomer (R)-53 was synthesised in identical yields and e.r. by substituting (–)-sparteine 
for (+)-sparteine. Stannanes used in this project were dried under high vacuum (1 mbar) with stirring 
overnight. 
Recrystallisation of (S)-53 
The crude stannane was dissolved in MeOH (3 mL/g) by bringing the solution to reflux. The solution 
was then allowed to cool to rt. Crystals appeared after 10 min to 5 h depending on the purity of the 
stannane. The white crystals were filtered and dried under reduced pressure. The recrystallisation was 
repeated until the e.r. was >99:1. After two recrystallisations (S)-53 was obtained (6.4 g, 52%, e.r. 
99.9:0.1) as a colourless solid.  
Sparteine Recovery[27]  
The combined aqueous layers were made basic with NaOH (20%). The aqueous phase was washed with 
Et2O (3 x 60 mL) and the combined organic layers were dried (K2CO3), filtered and concentrated in 
vacuo to give crude sparteine. Distillation over CaH2 of the crude material gave (–)-sparteine (6.7 mL, 
80%) as a colourless oil.  
Spectral data were in accordance with the published values[27]  
1H NMR (400 MHz, CDCl3) δ: 6.99 (s, 2H, H4), 5.04 (q, J = 7.4 Hz and quin, J = 7.7 Hz, 1H, H10), 
2.79 – 2.92 (m, 3H, H2 and H7), 1.59 (d, J = 7.6 Hz and dd, J = 56.5, 7.6 Hz and dd, J = 56.5, 7.6 Hz, 
3H, H11), 1.24 (d, J = 6.7 Hz, 18H, H1 and H8), 0.18 (s and d, J = 52.7 Hz and d, J = 52.7 Hz, 9H, H12)  
13C NMR (101 MHz, CDCl3) δ: 171.4 (C9), 150.0 (Ar), 144.9 (Ar), 130.9 (Ar), 120.9 (C4), 67.1 (C10), 
34.5 (C2), 31.4 (C8), 24.4 (C1 and C8), 24.2 (C1 or C8), 24.0 (C1 or C8), 19.3 (C11), -9.8 (d, J = 334 Hz 
(13C-119Sn) and d, J = 318 Hz (13C-117Sn), C12).  
Chiral HPLC: (Daicel Chiralpak-IB column (25 cm) with guard, hexane 0.7 mL/min, rt, 210.8 nm): tR 















2-(naphthalen-2-yl)ethyl 2,4,6-triisopropylbenzoate, 122 
 
To a stirred solution of PPh3 (1.67 g, 6.39 mmol, 1.1 equiv), 2-naphthalene alcohol (1.00 g, 5.81 mmol, 
1 equiv) and 2,4,6-triisopropylbenzoic acid (1.66 g, 6.68 mmol, 1.15 equiv) in anhydrous THF (8 mL) 
at 0 °C under an atmosphere of N2, was added DIAD (1.26  mL, 6.39 mmol, 1.1 equiv) dropwise. The 
reaction mixture was stirred at rt for 4 h, after which the volatiles were removed in vacuo. The remaining 
residue was dissolved in hexane, and the resulting suspension was filtered, and the filter cake washed 
with hexane. The filtrate was concentrated and the crude product was purified by flash column 
chromatography (1:10 Et2O:hexane) to obtain 2.06 g (88%) of 122 as a white solid. 
Rf:  0.42 (1:10 Et2O:hexane) 
FTIR (νmax/cm
-1, neat): 2961, 2930, 2867, 1716, 1606, 1460, 1248, 1082, 746 
1H NMR (400 MHz, CDCl3) δ: 7.85-7.76 (m, Naph, 3H), 7.72 (s, 1H, H10), 7.50-7.39 (m, 3H, Naph), 
6.97 (s, 2H, H18), 4.68 (t, J = 7.1 Hz, 2H, H12), 3.24 (t, J = 7.1 Hz, 2H, H11), 2.87 (sept, J = 6.7 Hz, 1H, 
H23), 2.74 (t, J = 6.7 Hz, 2H, H20), 2.13 (d, J = 6.7 Hz, 6H, H24, H25), 1.14 (d, J = 6.7 Hz, 12H, H21, H22) 
13C NMR (101 MHz, CDCl3) δ: 171.0 (C14), 150.2 (C19), 144.9 (C17), 135.2, 133.7, 132.5, 130.6 (C15), 
128.3, 127.7, 127.6, 127.4 (C10), 127.2, 126.2, 125.6, 120.9 (C18), 65.1 (C12), 35.3 (C11), 34.5 (C23), 31.6 
(C20), 24.2 (C21, C22), 24.1 (C25, C24). 
HRMS: (ESI) calcd. for C28H34O2Na (M+Na










Phenethyl 2,4,6-triisopropylbenzoate, 121 
 
To a stirred solution of PPh3 (2.89 g, 11 mmol, 1.1 equiv), 2-phenethyl alcohol (1.22 g, 10  mmol, 
1 equiv) and 2,4,6-triisopropylbenzoic acid (2.86 g, 11.5 mmol, 1.15 equiv) in anhydrous THF (15 mL) 
at rt under an atmosphere of N2, was added DIAD (2.17  mL, 11 mmol, 1.1 equiv) dropwise. The 
reaction mixture was stirred at 0 °C for 4 h, after which the volatiles were removed in vacuo. The 
remaining residue was dissolved in hexane, and the resulting suspension was filtered, and the filter cake 
washed with hexane. The filtrate was concentrated and the crude product was purified by flash column 
chromatography (1:10 Et2O:hexane) to obtain 3.52 g (93%) of 121 as a white solid.  
Spectral data were in accordance with the published values.[325]  
1H NMR (400 MHz, CDCl3) δ: 7.37-7.20 (m, 5H, C1,2,3,4,6), 7.00 (s, 2H, H14), 4.59 (t, J = 7.1 Hz, 2H, 
H8), 3.09 (t, J = 7.1 Hz, 2H, H7), 2.91 (sept, J = 6.8 Hz, 1H, H17), 2.80 (t, J = 6.8 Hz, 2H, H16), 1.27 (d, 
J = 6.8 Hz, 6H, H20, H21), 1.21 (d, J = 6.8 Hz, 12H, H18, H19). 
13C NMR (101 MHz, CDCl3) δ: 171.0 (C10), 150.2 (C15), 144.9 (C13), 137.8 (C5), 130.6 (C12), 128.9 
(C1,3), 128.6 (C4,6), 126.7 (C2), 120.9 (C14), 65.3 (C8), 35.1 (C7), 34.6 (C17), 31.6 (C16), 24.2 (C18, C19), 














Following a procedure previously reported by Back et. al.[263] 2-bromo-5-hydroxybenzaldehyde 131 
(5.00 g, 24.87 mmol) was dissolved in 83 mL of anhydrous DCM, and the solution was cooled to 0 °C. 
Diisopropylethylamine (6.49 mL, 37.31 mmol) was added, followed by methoxymethyl chloride 
(2.27 mL, 29.85 mmol). The solution was stirred at rt for 24 h and quenched by addition of water 
(100 mL). The solution was extracted with DCM (3 x 50 mL). The ether extracts were combined, 
washed with brine (100 mL), dried (MgSO4), and concentrated to afford a brown oil. The crude product 
was purified by flash column chromatography (2:1 hexane:Et2O) to afford 5.91 g (96%) of 2-bromo-5-
(methoxymethoxy)benzaldehyde 132 as a colourless oil. 
Spectral data were in accordance with the published values[263] 
1H NMR (400 MHz, CDCl3) δ: 10.29 (s, 1H, H13), 7.56 (d, J = 3.1 Hz, 1H, H4), 7.53 (d, J = 8.8 Hz, 
1H, H1), 7.14 (dd, J = 8.8, 3.1 Hz, 1H, H2), 5.19 (s, 2H, H9), 3.46 (s, 3H, H11) 
13C NMR (101 MHz, CDCl3) δ: 191.7 (C12), 157.0 (C3), 134.8 (C1), 134.3 (C5), 124.2 (C2), 118.9 (C6), 














Following a procedure previously reported by Spencer et. al.[259] n-BuLi (1.6 M in hexanes, 14.61 mL, 
23.38 mmol) was added to a solution of isobutyltriphenylphosphonium bromide (8.97 g, 22.4 mmol) in 
anhydrous THF (125 mL) at 0 °C dropwise. The reaction mixture became dark red in colour. The 
reaction mixture was maintained at 0 °C and 132 (5.00 g, 20.33 mmol) was added. The solution was 
warmed to rt over 1 h after which the solution had turned dark green. The reaction mixture was diluted 
with hexane (45 mL) and filtered through a silica plug. The solvent was removed in vacuo to afford the 
product as a pale yellow oil. The crude product was purified by flash column chromatography (3:1 
hexane:EtOAc) to afford 5.79 g (93%) of 1-bromo-4-(methoxymethoxy)-2-(3-methylbut-1-en-1-
yl)benzene 133 as a colourless oil (E:Z 1.09:1.0). 
Rf: 0.51 (3:1 hexane:EtOAc) 
FTIR (νmax/cm
-1, neat): 2958, 2930, 2867, 1647, 1462, 1151, 1001 
1H NMR (400 MHz, CDCl3) δ: 7.45 (d, J = 8.7 Hz, 1H, H1), 7.41 (d, J = 8.7 Hz, 1H, H1), 7.17 (d, J = 
3.0 Hz, 1H, H4), 6.99 (d, J = 3.0 Hz, 1H, H4), 6.82 (dd, J = 8.7, 3.0 Hz, 1H, H2), 6.78 (dd, J = 8.7, 3.0 
Hz, 1H, H2) 6.62 (dd, J = 15.9, 1.3 Hz, 1H, H12), 6.27 (d, J = 11.5 Hz, 1H, H12), 6.13 (dd J = 15.9, 6.9, 
1H, H13), 5.56 (dd J = 11.5, 10.5, 1H, H13), 5.16 (s, 2H, H9), 5.15 (s, 2H, H9), 3.48 (s, 3H, H11), 3.48 (s, 
3H, H11), 2.74-2.62 (m, 1H, H14), 2.51 (m, 1H, H14), 1.11 (d, J = 6.8 Hz, 6H, H16 and H15), 1.02 (d, J = 
6.8 Hz, 6H, H16 and H15)  
13C NMR (101 MHz, CDCl3) δ: 156.7 (C3), 156.3 (C3), 141.5 (C13), 141.4 (C13), 139.0 (C5), 138.7 (C5), 
133.5 (C1), 133.1 (C1), 126.1 (C12), 125.9 (C12), 118.6 (C4), 116.6 (C2), 116.4 (C2), 116.00 (C6), 115.6 
(C6), 114.5 (C4), 94.8 (C9), 94.7 (C9), 56.2 (C11), 56.1 (C11), 31.8 (C14), 27.5 (C14), 23.1 (C15, C16), 22.5 
(C15, C16) 








Following a procedure previously reported by Spencer et. al.[259] n-BuLi (1.6 M in hexanes, 13.13 mL, 
21.04 mmol) was added to a solution of 133 (5.00 g, 17.51 mmol) in 55 mL of anhydrous THF at - 78 °C. 
The mixture was stirred for 40 minutes after which the solution had turned dark green. 2-Isopropoxy-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.30 mL, 21.04 mmol) was added dropwise to the reaction 
mixture, maintaining the temperature at -78 °C. The reaction mixture turned blue on addition and after 
10 minutes the reaction was warmed to rt. Once the solution was at rt a yellow solution was obtained. 
The reaction was quenched with NH4Cl (50 mL) and extracted with diethyl ether (3 x 50 mL). The 
combined organic layers were dried (MgSO4) and concentrated to give a yellow oil. The crude product 
was purified by flash column chromatography (1:5 EtOAc:hexane) to obtain 5.81 g (95%) of 2-(4-
(methoxymethoxy)-2-(3-methylbut-1-en-1-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 134 as 
a colourless oil.  
Rf: 0.35 (1:5 EtOAc:hexane) 
FTIR (νmax/cm
-1, neat):  2959, 2931, 2868, 1596, 1343, 1144, 1007 
1H NMR (500 MHz, CDCl3) δ: 7.74 (d, J = 8.4 Hz, 1H, H1), 7.71 (d, J = 8.4 Hz, 1H, H1), 7.21 (d, J = 
2.5 Hz, 1H, H4), 7.19 (dd, J = 16.0, 1.6 Hz, 1H, H12), 6.97 (d, J = 2.5 Hz, 1H, H4), 6.89 (dd, J = 8.4, 2.5 
Hz, 1H, H2) 6.87 (dd, J = 8.4, 2.5 Hz, 1H, H2), 6.78 (d, J = 11.7 Hz, 1H, H12), 6.15 (dd J = 15.7, 6.3, 
1H, H13), 5.43 (dd J = 11.7, 10.3, 1H, H13), 5.21 (s, 2H, H9), 5.19 (s, 2H, H9), 3.47 (s, 3H, H11), 3.47 (s, 
3H, H11), 2.80-2.68 (m, 1H, H14), 2.49 (m, 1H, H14), 1.34 (s, 12H, C21-24), 1.31 (s, 12H, C21-24), 1.11 (d, 
J = 6.8 Hz, 6H, H16 and H15), 1.01 (d, J = 6.8 Hz, 6H, H16 and H15)  
13C NMR (126 MHz, CDCl3) δ: 159.4 (C3), 158.9 (C3), 146.4 (C5), 146.1 (C5), 139.2 (C13), 138.7 (C13), 
137.7 (C1), 137.4 (C1), 127.9 (C12), 127.5 (C4), 116.6 (C4), 113.7 (C2), 113.3 (C2), 111.8 (C12), 94.2 (C9), 
94.0 (C9), 83.3 (C19), 83.3 (C18), 56.0 (C11), 55.9 (C11), 31.3 (C14), 27.0 (C14), 24.9 (C21-24), 24.8 (C21-24) 
23.2 (C15, C16), 22.2 (C15, C16) 
HRMS: (ESI) calcd. for C19H29
11BO4Na (M+Na






To a solution of Pd/C (10 mol%, 0.005 equiv) in EtOH, was added 2-(4-(methoxymethoxy)-2-(3-
methylbut-1-en-1-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 134 (2.0 g, 6.02 mmol). The 
reaction was stirred at rt and a balloon of H2 was secured to a T-connector adaptor that was attached to 
the reaction vessel. The reaction vessel was evacuated and filled with N2 (3x) using the T-connector 
adaptor. This was then repeated, using H2 in place of N2. The reaction vessel was left open to H2 and 
stirred for 2 h at rt. The reaction mixture was passed through a pad of celite, taking care to not allow it 
to run dry. The crude NMR revealed complete conversion and the material was used directly in the next 
step without further purification. 2-(2-isopentyl-4-(methoxymethoxy)phenyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane, 123, was obtained in a 98% yield (1.97 g) as a colourless oil.  
Rf: 0.41 (1:4 Et2O:hexane) 
FTIR (νmax/cm
-1, neat): 2954, 2931, 2869, 1600, 1345, 1145, 1006 
1H NMR (400 MHz, CDCl3) δ: 7.73 (d, J = 8.9 Hz, 1H, H1), 6.86-6.82 (m, 2H, H2 and H4), 5.19 (s, 2H, 
H9), 3.47 (s, 3H, H11), 2.86 (m, 2H, H12), 1.65 (sept, J = 6.6 Hz, 1H, H14), 1.45 (m, 2H, H13), 1.33 (s, 
12H, C21-24), 0.95 (d, J = 6.6 Hz, 6H, H16 and H15)   
13C NMR (101 MHz, CDCl3) δ: 159.5 (C3), 153.0 (C5), 138.1 (C1), 116.9 (C4), 112.4 (C2), 94.1 (C9), 
83.2 (C18, C19), 56.1 (C11), 42.8 (C13), 34.2 (C12), 28.6 (C14), 24.9 (C21-24), 22.7 (C15, C16) 
HRMS: (ESI) calcd. for C19H31
11BO4Na (M+Na










Synthesised according to GP1. Stannane (S)-53 (356 mg, 0.81 mmol, 1.35 eq), n-BuLi (1.58 M in 
hexanes, 0.49 mL, 0.78 mmol, 1.30 eq) and boronic ester 123 (200 mg, 0.6 mmol, 1 eq). Lithiation time 
of 1 h, borylation time of 30 min, 1,2-migration time of 2 h. The crude boronic ester 145 was not isolated 
and was used as the crude material in the subsequent homologation. The conversion was monitored by 
GCMS.  
 









Synthesised according to GP1. Stannane (S)-53 (356 mg, 0.81 mmol, 1.35 eq), n-BuLi (1.58 M in 
hexanes, 0.49 mL, 0.78 mmol, 1.30 eq) and boronic ester 145 (217 mg, 0.6 mmol, 1 eq). Lithiation time 
of 1 h, borylation time of 30 min, 1,2-migration time of 2 h. The crude boronic ester was purified by 
flash column chromatography (1:10 Et2O:hexane) to give boronic ester 146 (195 mg, 83% over the two 
homologations, d.r. >99:1 by GCMS) as a colourless oil. 
Rf:  0.27 (1:10 Et2O:hexane) 
[α]20D: +16 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 2955, 2934, 2870, 1608, 1378, 1315, 1144, 1014 
1H NMR (500 MHz, CDCl3) δ: 7.12 (d, J = 8.5 Hz, 1H, H5), 6.86 (dd, J = 8.5, 2.8 Hz, 1H, H6), 6.79 (d, 
J = 2.8 Hz, 1H, H2), 5.15 (s, 2H, H14), 3.49 (s, 3H, H16), 2.95 (dsept, J = 10.6, 6.9 Hz, 1H, H13), 2.67 
(ddd, J = 13.7, 9.3, 7.4 Hz, 1H, H8’), 2.55 (ddd, J = 13.7, 9.3, 7.4 Hz, 1H, H8’’), 1.65 (sept, J = 6.7 Hz, 
1H, H10), 1.48-1.42 (m, 2H, H9), 1.28 (s, 12H, H24-27), 1.30-1.26 (m, 1H, H17), 1.19 (d, J = 6.9 Hz, 3H, 
H18), 0.97 (d, J = 6.7 Hz, 6H, H11,12), 0.76 (d, J = 7.4 Hz, 3H, H19) 
13C NMR (126 MHz, CDCl3) δ: 154.9 (C1), 142.3 (C3), 138.9 (C4), 126.8 (C5), 116.8 (C2), 113.5 (C6), 
94.7 (C14), 83.0 (C22, C23), 56.0 (C16), 40.9 (C9), 36.1 (C13), 31.0 (C8), 28.2 (C10), 25.0 (C24-27), 24.8 (C24-
27), 23.4 (C18), 22.7 (C11/12), 22.7 (C11/12), 14.6 (C19). 
HRMS: (ESI) calcd. for C23H39
11BO4Na (M+Na























Synthesised according to GP2. Benzoate 122 (288 mg, 0.74 mmol, 1.35 eq), s-BuLi (1.3 M in hexanes, 
0.57 mL, 0.72 mmol, 1.30 eq), (+)-sparteine (0.17 mL, 0.72 mmol, 1.30 eq) and boronic ester 145 
(215 mg, 0.55 mmol, 1 eq). Lithiation time of 1 h, borylation time of 2 h 30 min, 1,2-migration time of 
2 h. The crude boronic ester was purified by flash column chromatography (1:10 Et2O:hexane) to give 
boronic ester 147 (203 mg, 72%, d.r. >95:5 by NMR) as a colourless oil. 
Rf:  0.31 (1:10 Et2O:hexane) 
[α]20D: +24 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 2957, 2931, 2870, 1606, 1496, 1371, 1321, 1145, 1009 
1H NMR (500 MHz, CDCl3) δ: 7.87-7.77 (m, 4H, Naph), 7.54-7.40 (m, 3H, Naph), 7.23 (d, J = 8.5 Hz, 
1H, H5), 6.93 (dd, J = 8.5, 2.9 Hz, 1H, H6), 6.87 (d, J = 2.9 Hz, 1H, H2), 5.20 (s, 2H, H14), 3.53 (s, 3H, 
H16), 3.13 (dq, J = 10.6, 6.7 Hz, 1H, H13), 3.00 (dd, J = 13.9, 11.5 Hz, 1H, H21’), 2.94 (dd, J = 13.9, 3.9 
Hz, 1H, H21’’), 2.76 (ddd, J = 13.6, 9.9, 6.5 Hz, 1H, H8’), 2.61 (ddd, J = 13.6, 9.9, 6.5 Hz, 1H, H8’’), 2.08 
(dqd, J = 9.0, 6.8, 2.8 Hz, 1H, H17), 2.00 (ddd, J = 11.5, 3.9, 2.8 Hz, 1H, H18), 1.69 (sept, J = 6.6 Hz, 
1H, H10), 1.56-1.47 (m, 2H, H9), 1.38 (d, J = 6.7 Hz, 3H, H19), 1.17 (s, 12H, H26-29), 1.04 (d, J = 6.6 Hz, 
3H, H11/12), 1.02 (d, J = 6.6 Hz, 3H, H11/12), 0.86 (d, J = 6.8 Hz, 3H, H20) 
13C NMR (126 MHz, CDCl3) δ: 154.9 (C1), 142.0 (C3), 141.0 (C30), 139.2 (C4), 133.7 (C38), 132.0 (C33), 
128.2 (C31), 127.7, 127.6, 127.5, 127.3 (C5), 127.1 (C39), 125.8, 124.9, 117.0 (C2), 114.1 (C6), 94.7 (C14), 
83.2 (C24, C25), 56.0 (C16), 40.9 (C9), 40.6 (C17), 36.4 (C13), 31.5 (C8), 30.6 (C21), 28.5 (C18), 28.3 (C10), 
25.0 (C26-29), 24.6 (C26-29), 22.8 (C11/12), 22.7 (C11/12), 21.5 (C19), 16.5 (C20). 
HRMS: (ESI) calcd. for C35H49
11BO4Na (M+Na








Synthesised according to GP1. Stannane (R)-53 (221 mg, 0.5 mmol, 1.35 eq), n-BuLi (1.58 M in 
hexanes, 0.31 mL, 0.48 mmol, 1.30 eq) and boronic ester 147 (203 mg, 0.37 mmol, 1 eq). Lithiation 
time of 1 h, borylation time of 3 h, 1,2-migration time of 2 h. The crude boronic ester was purified by 
flash column chromatography (1:10 Et2O:hexane) to give boronic ester 148 (188 mg, 89%, d.r. >95:5 
by NMR) as a colourless oil. 
Rf:  0.17 (1:10 Et2O:hexane) 
[α]20D: +51 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 2956, 2870, 1606, 1497, 1463, 1370, 1313, 1144, 1013 
1H NMR (500 MHz, CDCl3) δ: 7.83-7.73 (m, 4H, C34, 36, 39, 41), 7.51 (dd, J = 8.4, 1.4 Hz, 1H, C33), 7.45 
(td, J = 7.9, 1.4 Hz, 1H, C38), 7.41 (td, J = 7.6, 1.4 Hz, 1H, C37), 7.06 (d, J = 8.6 Hz, 1H, H5), 6.84 (dd, 
J = 8.6, 2.3 Hz, 1H, H6), 6.74 (d, J = 2.3 Hz, 1H, H2), 5.14 (s, 2H, H14), 3.48 (s, 3H, H16), 2.88 (dd, J = 
14.3, 6.5 Hz, 1H, H22’), 2.76-2.66 (m, 2H, H22’’, H13), 2.56 (br. dddd J = 9.6, 6.8, 6.5, 1.9 Hz, 1H, H18), 
2.46 (ddd, J = 14.1, 9.6, 6.4 Hz, 1H, H8’), 2.36 (ddd, J = 14.1, 9.6, 6.4 Hz, 1H, H8’’), 1.96 (br. m, 1H, 
H17), 1.39 (sept, J = 6.8 Hz, 1H, H10), 1.25-1.18 (m, 3H, H19, H9), 1.18 (s, 6H, H28-31), 1.17 (s, 6H, H28-
31), 1.06 (br. d, J = 6.9 Hz, 6H, H20, H23), 0.84 (d, J = 6.8 Hz, 6H, H11, H12), 0.67 (d, J = 6.8 Hz, 3H, 
H21) 
13C NMR (126 MHz, CDCl3) δ: 154.6 (C1), 141.9 (C3), 140.3 (C32), 139.9 (C4), 133.8 (C40), 132.2 (C35), 
128.2, 127.8 (C33), 127.7, 127.6, 127.4, 127.1 (C5), 125.9 (C38), 125.1 (C37), 116.7 (C2), 113.8 (C6), 94.8 
(C14), 83.0 (C26, C27), 56.1 (C16), 41.7 (C17), 41.4 (C18), 40.5 (C9), 36.5 (C13), 36.1 (C22), 31.4 (C9), 27.8 
(C10), 25.0 (C28-31), 24.9 (C28-31), 22.8 (C11/12), 22.7 (C11/12), 21.6 (C20), 21.6 (C19), 13.6 (C23), 13.0 (C21). 








Synthesised according to GP1. Stannane (S)-53 (196 mg, 0.45 mmol, 1.35 eq), n-BuLi (1.58 M in 
hexanes, 0.27 mL, 0.43 mmol, 1.30 eq) and boronic ester 148 (188 mg, 0.33 mmol, 1 eq). Lithiation 
time of 1 h, borylation time of 3 h, 1,2-migration time of 2 h. The crude boronic ester was purified by 
flash column chromatography (1:10 Et2O:hexane) to give boronic ester 149 (170 mg, 86%, d.r. >95:5 
by NMR) as a colourless oil.  
Rf:  0.27 (1:10 Et2O:hexane) 
[α]20D: +35 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 2957, 2872, 1606, 1497, 1461, 1369, 1311, 1147, 1013 
1H NMR (500 MHz, CDCl3) δ: 7.83-7.76 (m, 3H, Naph), 7.69 (s, 1H, H43), 7.48-7.39 (m, 3H, Naph), 
7.12 (d, J = 8.0 Hz, 1H, H5), 6.85 (dd, J = 8.0, 2.3 Hz, 1H, H6), 6.75 (d, J = 2.3 Hz, 1H, H2), 5.15 (s, 
2H, H14), 3.49 (s, 3H, H16), 2.93 (dd, J = 14.3, 5.1 Hz, 1H, H23’), 2.81-2.72 (m, 2H, H23’’, H13), 2.54-
2.45 (br. m, 1H, H8’), 2.43-2.34 (br. m, 1H, H8’’), 2.31 (br. dddd, 7.8, 6.6, 5.1, 2.5 Hz, 1H, H18), 1.98 
(br. dqd, J =  9.5, 6.7, 2.5 Hz, 1H, H17), 1.87 (sept, J = 6.6 Hz, 1H, H19), 1.40 (sept, J = 6.5 Hz, 1H, H10), 
1.34 (m, 1H, H20), 1.24 (m, 2H, H9), 1.18 (s, 12H, H30-33), 1.15 (d, J = 6.8 Hz, 3H, H21), 0.97 (d, J = 7.1 
Hz, 3H, H24), 0.87 (d, J = 7.5 Hz, 3H, H25), 0.85 (d, J = 6.6 Hz, 6H, H11, H12), 0.68 (d, J = 6.7 Hz, 3H, 
H22) 
13C NMR (126 MHz, CDCl3) δ: 154.6 (C1), 141.8 (C3), 140.7 (C34), 139.6 (C4), 133.7 (C26), 131.9 (C27), 
127.9, 127.7, 127.6, 127.4, 127.1 (C5), 127.1 (C43), 125.7 (C40), 124.9 (C39), 116.6 (C2), 113.9 (C6), 94.6 
(C14), 82.7 (C28, C29), 55.9 (C16), 42.6 (C18), 40.4 (C9), 39.7 (C17), 36.7 (C13), 36.5 (C19), 35.0 (C23), 31.3 
(C8), 27.8 (C10), 24.8 (C30-33), 24.8 (C30-33), 22.6 (C11, C12), 21.8 (C21), 20.4 (C20), 15.3 (C24), 13.9 (C22), 
10.9 (C25). 
HRMS: (ESI) calcd. for C39H57
11BO4Na (M+Na







Synthesised according to GP1. Stannane (S)-53 (186 mg, 0.38 mmol, 1.35 eq), n-BuLi (1.58 M in 
hexanes, 0.23 mL, 0.36 mmol, 1.30 eq) and boronic ester 149 (170 mg, 0.28 mmol, 1 eq). Lithiation 
time of 1 h, borylation time of 3 h, 1,2-migration time of 2 h. The crude boronic ester was purified by 
flash column chromatography (1:10 Et2O:hexane) to give boronic ester 150 (133 mg, 76%, d.r. >95:5 
by NMR) as a colourless oil.  
Rf:  0.33 (1:10 Et2O:hexane) 
[α]20D: +38 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 2958, 2871, 1606, 1497, 1463, 1371, 1312, 1146, 1016 
1H NMR (500 MHz, CDCl3) δ: 7.83-7.75 (m, 3H, Naph), 7.70 (s, 1H, H45), 7.47-7.38 (m, 3H, Naph), 
7.08 (d, J = 8.4 Hz, 1H, H5), 6.85 (dd, J = 8.4, 2.4 Hz, 1H, H6), 6.75 (d, J = 2.4 Hz, 1H, H2), 5.14 (s, 
2H, H14), 3.49 (s, 3H, H16), 2.90 (dd, J = 15.0, 5.2 Hz, 1H, H24’), 2.81-2.72 (m, 2H, H24’’, H13), 2.52-
2.44 (br. m, 1H, H8’), 2.41-2.34 (br. m, 1H, H8’’), 2.32 (br. dddd, 8.0, 6.9, 5.2, 2.5 Hz, 1H, H18), 1.98 
(br. dqd, J =  9.5, 6.9, 2.5 Hz, 1H, H17), 1.79-1.69 (m, 2H, H19, H20), 1.39 (sept, J = 6.6 Hz, 1H, H10), 
1.31-1.19 (m, 3H, H9, H21), 1.13 (d, J = 6.6 Hz, 3H, H22), 1.10 (s, 6H, H32-35), 1.07 (s, 6H, H32-35), 0.92 
(d, J = 7.2 Hz, 3H, H26), 0.85 (d, J = 6.9 Hz, 3H, H25), 0.83 (d, J = 6.4 Hz, 6H, H11, H12), 0.74 (d, J = 
6.6 Hz, 3H, H27), 0.67 (d, J = 6.9 Hz, 3H, H23) 
13C NMR (126 MHz, CDCl3) δ: 154.8 (C1), 141.9 (C3), 141.0 (C36), 139.6 (C4), 133.8 (C44), 132.0 (C39), 
127.9, 127.8, 127.7, 127.6, 127.3, 127.2, 125.8 (C42), 125.0 (C51), 116.8 (C2), 114.0 (C6), 94.8 (C14), 
82.7 (C30, C31), 56.1 (C16), 41.8 (C18), 40.6 (C9), 40.4 (C17), 37.3 (C20), 36.7 (C19), 36.6 (C13), 35.4 (C24), 
31.4 (C8), 27.9 (C10), 24.8 (C32-35), 24.6 (C32-35, C21), 22.7 (C11/12), 22.7 (C11/12), 21.7 (C22), 14.8 (C27), 
14.4 (C26), 13.6 (C23), 12.0 (C25). 
HRMS: (ESI) calcd. for C41H61
11BO4Na (M+Na







Synthesised according to GP2. Benzoate 121 (73 mg, 0.21 mmol, 1.35 eq), s-BuLi (1.3 M in hexanes, 
0.15 mL, 0.2 mmol, 1.30 eq), (+)-sparteine (0.05 mL, 0.2 mmol, 1.30 eq) and boronic ester 150 (97 mg, 
0.15 mmol, 1 eq). Lithiation time of 1 h, borylation time of 3 h, 1,2-migration time of 2 h. The crude 
boronic ester was purified by flash column chromatography (1:10 Et2O:hexane) to give boronic ester 
120 (92 mg, 84%, d.r. >95:5 by NMR) as a colourless oil. 
Rf:  0.26 (1:10 Et2O:hexane) 
[α]20D: +24 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 2962, 2874, 1604, 1496, 1465, 1375, 1148, 1018 
1H NMR (500 MHz, CDCl3) δ: 7.81-7.71 (m, 4H, Ar), 7.47-7.37 (m, 3H, Ar), 7.13-7.02 (m, 4H, Ar), 
6.94 (d, J = 8.4 Hz, 2H, H5, Ar), 6.86 (dd, J = 8.4, 2.2 Hz, 1H, H6), 6.76 (d, J = 2.2 Hz, 1H, H2), 5.14 
(s, 2H, H14), 3.48 (s, 3H, H16), 3.01 (dd, J = 15.1, 3.6 Hz, 1H, H28’), 2.85 (dq, J = 10.8, 6.6 Hz, 1H, H13), 
2.67 (dd, J = 15.1, 6.8 Hz, 1H, H28’’), 2.57-2.46 (m, 2H, H8’, H30'), 2.46-2.37 (br. m, 1H, H8’’), 2.34 (br. 
dddd, 8.8, 6.8, 3.6, 2.0 Hz, 1H, H18), 2.25 (dd, J = 13.3, 3.1 Hz, 1H, H30’’), 2.03 (br. dqd, J =  10.8, 6.7, 
2.2 Hz, 1H, H17), 1.85-1.74 (m, 2H, H19, H20), 1.61 (br. dqd, J = 9.5, 6.7, 2.5 Hz, 1H, H23), 1.42 (sept, J 
= 7.0 Hz, 1H, H10), 1.38 (ddd, J = 12.0, 3.1, 2.5 Hz, 1H, H24), 1.33-1.24 (m, 2H, H9), 1.18 (d, J = 6.6 
Hz, 3H, H21), 1.10 (s, 6H, H35-38), 1.09 (s, 6H, H35-38), 0.96 (d, J = 6.7 Hz, 3H, H29), 0.83 (m, 9H, H11, 
H12, H22), 0.68 (d, J = 6.7 Hz, 3H, H27), 0.66 (d, J = 6.8 Hz, 3H, H26).  
13C NMR (126 MHz, CDCl3) δ: 154.8 (C1), 143.6 (C32), 141.9 (C3), 141.3 (C31), 139.5 (C4), 133.8 (C46), 
132.0 (C41), 129.1 (C48,52), 128.1, 127.9 (C49,51), 127.7, 127.7, 127.6, 127.2, 127.0, 126.1, 125.2, 125.1, 
116.9 (C2), 114.1 (C6), 94.8 (C14), 83.0 (C33, C34), 56.1 (C16), 42.5 (C18), 40.9 (C17), 40.7 (C9), 36.9, 36.8, 
36.2 (C13), 36.0 (C28), 31.5 (C8), 30.3 (C30), 28.6 (C24), 28.0 (C10), 24.9 (C35-38), 24.7 (C35-38), 22.7 (C11, 
C12), 21.8 (C21), 16.1 (C29), 12.9 (C27), 12.8 (C26), 12.1 (C22). 
HRMS: (MALDI) calcd. for C49H69
11BO4Na (M+Na







Boronic ester 120 (92 mg, 0.13 mmol) was taken up in MeOH and cooled to 0 °C. Concentrated HCl 
was added dropwise (5 drops) and the reaction mixture was stirred at 0 °C for 1 h then warmed to rt and 
stirred overnight. The reaction mixture was diluted with H2O (5 mL) and Et2O (5 mL). The phases were 
separated and the aqueous phase washes with Et2O (3 x 5 mL). The combined organic phases were dried 
(MgSO4) and concentrated under reduced pressure. The crude reaction mixture was taken up in THF 
(2 mL) and cooled to 0 °C. A premixed solution of NaOH (2M):H2O2 (30% aq) (2:1 3 mL) was added 
dropwise at 0 °C, warmed to room temperature and stirred for 4 h. The reaction mixture was diluted 
with H2O (5 mL) and Et2O (5 mL). The phases were separated and the aqueous phase washes with Et2O 
(3 x 5 mL). The combined organic phases were washed with H2O (5 mL), dried (MgSO4) and 
concentrated under reduced pressure. The crude material was purified by flash column chromatography 
(7:2:1 hexane:Et2O:EtOAc) to give 119 as a white solid (62 mg, 86% over two steps, d.r. >95:5 by 
NMR).  
m.p.: 161-163 °C (diethyl ether) 
Rf: 0.29 (7:2:1 hexane:Et2O:EtOAc) 
[α]20D: +31 (c 1.0, CHCl3)  
FTIR (νmax/cm
-1, neat): 3349, 2963, 2922, 1718, 1601, 1502, 1464, 1371, 1261, 1034, 807 
1H NMR (500 MHz, CDCl3) δ: 7.83-7.72 (m, 3H, Ar), 7.69 (s, 1H, H41), 7.46-7.38 (m, 3H, Ar), 7.25-
7.15 (m, 3H, Ar), 7.09 (d, J = 8.2 Hz, 1H, H5), 6.87 (m, 2H, Ar), 6.68 (dd, J = 8.2, 2.2 Hz, 1H, H6), 6.60 
(d, J = 2.2 Hz, 1H, H2), 4.86 (br.s, 1H, H25), 3.57 (ddd, J = 9.9, 4.6, 2.0 Hz, 1H, H24), 3.02 (dd, J = 14.9, 
3.1 Hz, 1H, H28’), 2.91 (br.dq, J = 9.5, 6.7 Hz, 1H, H13), 2.67 (dd, J = 14.9, 8.3 Hz, 1H, H28’’), 2.62-2.54 
(m, 1H, H8’), 2.48-2.40 (br.m, 2H, H8’’, H30’), 2.35 (br.dddd, J = 8.3, 8.1, 3.1, 1.7 Hz, 1H, H18), 2.24 (dd, 
J = 13.6, 9.9, 1H, H30’’), 2.03 (br.dqd, J = 9.5, 6.6, 1.7 Hz, 1H, H17), 1.88 (br.dq, J = 8.1, 2.4 Hz, 1H, 




J = 6.7 Hz, 1H, H10), 1.39-1.31 (m, 2H, H9), 1.27 (d, J = 6.7 Hz, 3H, H21), 0.93 (d, J = 6.7 Hz, 3H, H29), 
0.88 (d, J = 6.9 Hz, 3H, H22), 0.87 (d, J = 6.6 Hz, 6H, H11, H12), 0.70 (d, J = 6.7 Hz, 3H, H27), 0.70 (d, 
J = 6.7 Hz, 3H, H26) 
13C NMR (126 MHz, CDCl3) δ: 153.1  (C1), 142.1 (C3), 141.0 (C31), 139.4 (C32), 138.0 (C4), 133.7 (C40), 
132.0 (C35), 129.3 (C42,46), 128.6 (C43,45), 128.1, 127.8, 127.6, 127.5 (C5), 127.2, 126.4, 126.2, 125.3, 
115.8 (C2), 113.4 (C6), 74.0 (C24), 42.6 (C18, C23), 40.7 (C9), 40.3 (C17), 38.3 (C30), 36.5 (C13), 36.3 (C20), 
36.0 (C19), 35.8 (C28), 31.3 (C8), 28.0 (C10), 22.7 (C11/12), 22.7 (C11/12), 21.7 (C21), 13.4 (C27), 13.1 (C26), 
12.1 (C22), 12.0 (C29) 
HRMS: (MALDI) calcd. for C41H54O2Na (M+Na
+): 601.4016; Found 601.4026 
 






















A solution of the boronic ester 120 (95 mg, 0.13 mmol) and bromochloromethane (0.026 mL, 
0.39 mmol) in Et2O (0.65 mL) was cooled to -78 °C. n-BuLi (1.6 M in hexanes, 0.21 mL, 0.33 mmol) 
was added slowly (1 drop every 10 seconds) to the reaction mixture, maintaining a temperature of -
78 °C. The reaction mixture was stirred at -78 °C for 1 h and then warmed to rt for 1 h. The reaction 
mixture was filtered through a plug of wetted (Et2O) silica of ~1 cm depth to give a colourless solution. 
The silica was washed with Et2O (3 mL) and the solvent was removed in vacuo to give crude boronic 
ester. The crude boronic ester was taken up in MeOH and cooled to 0 °C. Concentrated HCl was added 
(5 drops) and the reaction mixture was stirred at 0 °Cf for 1 h and then warmed to rt overnight. The 
reaction mixture was diluted with H2O (5 mL) and Et2O (5 mL). The phases were separated and the 
aqueous phase washes with Et2O (3 x 5 mL). The combined organic phases were dried (MgSO4) and 
concentrated under reduced pressure. The crude reaction mixture was taken up in THF (2 mL) and 
cooled to 0 °C. A premixed solution of NaOH (2M):H2O2 (30% aq) (2:1 3 mL) was added dropwise at 
0 °C, warmed to room temperature and stirred for 4 h. The reaction mixture was diluted with H2O (5 mL) 
and Et2O (5 mL). The phases were separated and the aqueous phase washes with Et2O (3 x 5 mL). The 
combined organic phases were washed with H2O (5 mL), dried (MgSO4) and concentrated under 
reduced pressure. The crude material was purified by flash column chromatography (7:2:1 
hexane:Et2O:EtOAc) to give 155 as a white solid (59 mg, 77% over three steps, d.r. >95:5 by NMR).  
m.p.: 169-174 °C (diethyl ether) 
Rf: 0.25 (7:2:1 hexane:Et2O:EtOAc) 
[α]20D: +20 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 3360, 2959, 2934, 1605, 1502, 1470, 1385, 1240, 1027, 818  
1H NMR (500 MHz, CDCl3) δ: 7.80-7.74 (m, 2H, Ar), 7.73-7.67 (m, 2H, Ar), 7.44-7.35 (m, 3H, Ar), 




2.9 Hz, 1H, H6), 6.58 (d, J = 2.9 Hz, 1H, H2), 4.62 (br.s, 1H, H34), 3.46 (dd, J = 11.1, 4.3 Hz, 1H, H25’), 
3.37 (dd, J = 11.1, 8.9 Hz, 1H, H25’’), 3.02 (dd, J = 15.1, 3.9 Hz, 1H, H18’), 2.86 (br. dq, J = 9.9, 6.6 Hz, 
1H, H8), 2.63 (dd, J = 15.1, 7.2 Hz, 1H, H18’’), 2.56-2.48 (m, 1H, H7’), 2.44-2.37 (br.m, 1H, H7’’), 2.37 
(dd, J = 14.1, 2.6 Hz, 1H, H26’), 2.36-2.30 (m, 1H, H15), 2.05-1.97 (m, 1H, H13), 2.00 (dd, J = 14.1, 11.2 
Hz, 1H, H26’’), 1.84 (br. dqd, J = 8.7, 6.9, 2.0 Hz, 1H, H17), 1.82-1.75 (m, 1H, H23), 1.73-1.65 (m, 2H, 
H19,21), 1.44 (sept, J = 6.9 Hz, 1H, H10), 1.32-1.26 (m, 2H, H9), 1.22 (d, J = 6.6 Hz, 3H, H14), 0.86 (d, J 
=  6.9 Hz, 3H, H20), 0.83 (d, J = 6.5, 9H, H11,12,24), 0.68-0.64 (m, 6H, H16,22) 
13C NMR (126 MHz, CDCl3) δ: 153.0 (C1), 142.1 (C3), 141.6 (C27), 141.1 (C35), 138.1, 133.7, 132.0, 
129.0 (C28,32), 128.4 (C29,31), 128.1, 127.7, 127.7, 127.5, 127.0, 126.1, 125.8 (C30), 125.2, 115.8 (C2), 
113.3 (C6), 64.5 (C25), 44.1 (C15), 42.3 (C15), 40.7 (C13), 40.7 (C9), 36.9 (C17), 36.2 (C8), 36.1 (C18), 36.0 
(C19,21), 32.5 (C26), 31.3 (C7), 28.0 (C10), 22.7 (C11/12), 22.7 (C11/12), 21.7 (C14), 13.0 (C16), 12.9 (C22), 
12.3 (C24), 12.0 (C20). 
HRMS: (ESI) calcd. for C42H56O2Na (M+Na
+): 615.4173; Found 615.4156 
 






















The bisalcohol 155 (19.0 mg, 0.033 mmol, 1.0 eq) was solubilised in DCM (1 mL) and cooled to 0 °C. 
Pyridine (0.045 mL, 0.66 mmol, 20.0 eq) was added dropwise followed by the dropwise addition of 
phosgene (15 wt.% in toluene) (0.49 mL, 0.66 mmol, 20.0 eq). The reaction was warmed to room 
temperature and stirred for 12 h. The reaction was monitored by TLC (1:10 MeOH:DCM) and if not 
complete, stirred at 40 °C for 12 h. Upon completion of the reaction, the solvent was removed in. vacuo 
and the crude reaction mixture was resuspended in DCM (1 mL). The reaction mixture was cooled to 
0 °C and pyridine was added dropwise (0.023 mL, 0.33 mmol, 10.0 eq). A solution of 
methoxypolyethylene glycol amine (750 average Mw) in DCM (247 mg, 0.33 mmol, 10 eq) was added 
dropwise to the reaction mixture. The reaction was warmed to rt and stirred for 12 h. The reaction was 
monitored by TLC and if not complete, stirred at 40 °C for 12 h. The crude reaction mixture was filtered 
through a plug of silica (1cm depth, wetted with DCM, eluted with 10% MeOH in DCM). The crude 
reaction mixture was then purified by reversed phase HPLC (1:10 AcCN:H2O) to yield the 
bisPEGylated product 157 (3.7 mg, 11%) as a colourless oil.  
Rf: 0.09 (1:10 MeOH:DCM) 
[α]20D: +0.42 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 3318, 2964, 1731, 1679, 1611, 1465, 1306, 1135, 814 
1H NMR (500 MHz, MeOD) δ: 7.85-7.68 (m, 4H, Ar), 7.46 (dd, J = 8.4, 0.9 Hz, 1H, Ar), 7.41-7.35 (m, 
2H, Ar), 7.13-7.01 (m, 4H, Ar), 6.78 (dd, J = 7.7, 1.4 Hz, 2H, Ar), 6.64 (dd, J = 8.4, 2.3 Hz, 1H, H6), 
6.54 (d, J = 2.3 Hz, 1H, H2), 3.94 (dd, J = 11.2, 8.3 Hz, 1H, H25’), 3.88 (dd, J = 11.2, 5.2 Hz, 1H, H25’’), 
3.79 (m, 2H, CH2-PEG), 3.73-3.60 (m, 140H, PEG), 3.59-3.49 (m, 8H, PEG), 3.37 (s, 6H, CH3-PEG), 
3.08 (dd, J = 15.1, 3.0 Hz, 1H, H18’), 2.92 (br. dq, J = 10.1, 6.5 Hz, 1H, H8), 2.65 (dd, J = 15.1, 7.6 Hz, 
1H, H18’’), 2.61-2.53 (m, 1H, H7’), 2.43-2.33 (m, 3H, H7’’, H15, H26’), 2.12-2.02 (m, 2H, H26’’, H13), 1.99-




J = 9.7, 6.8, 2.8 Hz, 1H, H21), 1.43 (sept, J = 6.5 Hz, 1H, H10), 1.36-1.22 (m, 5H, H9, H14), 0.94-0.85 
(br.d, 6H, H20, H24), 0.84 (br.d, J = 6.5 Hz, 6H, H11, H12), 0.69 (d, J = 6.9 Hz, 3H, H16), 0.65 (d, J = 6.6 
Hz, 3H, H22) 
 13C NMR (126 MHz, MeOD) δ: 171.5, 164.1, 155.7, 142.6, 142.3, 142.3, 137.6, 135.1, 133.4, 129.9, 
129.2, 129.1, 128.7, 128.5, 128.4, 128.1, 127.1, 126.8, 126.2, 116.8 (C2), 114.4 (C6), 73.7 (PEG), 73.0 
(PEG), 71.6 (PEG), 71.5 (PEG), 71.5 (PEG), 71.4 (PEG), 71.3 (PEG), 67.5 (C25), 62.2, 59.9 (CH3-PEG), 
59.1, 54.2, 43.5 (C15), 42.1 (C9), 41.8 (C13), 38.0 (C17), 37.9 (C19), 37.3 (C18), 37.2 (C8), 33.3 (C26), 32.5 
(C7), 29.0 (C10), 23.0 (C11/12), 22.9 (C11/12), 21.9 (C14), 13.2 (C22), 13.2 (C16), 12.9 (C20 or C24), 12.1 (C20 
or C24) 
MALDI MS: 
Table 37. The Mw distribution table obtained from MALDI for PEG derivative 157 
n Calculated Mw 
[M + Na]+ 
%Intensity Calculated Observed 
25 1895.2 1918.2 1918.2 14 
26 1939.2 1962.2 1962.3 21 
27 1983.2 2006.2 2006.3 36 
28 2027.3 2050.3 2050.3 47 
29 2071.3 2094.3 2094.3 63 
30 2115.3 2138.3 2138.4 77 
31 2159.3 2182.3 2182.4 86 
32 2203.4 2226.4 2226.4 92 
33 2247.4 2270.4 2270.4 100 
34 2291.4 2314.4 2314.5 90 
35 2335.4 2358.4 2358.5 88 
36 2379.5 2402.5 2402.5 81 
37 2423.5 2446.5 2446.5 61 
38 2467.5 2490.5 2490.6 53 
39 2511.5 2534.5 2534.6 40 
40 2555.6 2578.6 2578.6 34 
41 2599.6 2622.6 2622.6 31 
42 2643.6 2666.6 2667.7 26 
43 2687.7 2710.7 2710.7 25 
44 2731.7 2754.7 2754.7 22 
45 2775.7 2798.5 2798.7 19 
46 2819.7 2842.7 2842.7 18 
47 2863.8 2886.8 2886.8 16 
48 2907.8 2930.8 2930.8 14 
49 2951.8 2974.8 2974.9 13 





Figure 145. The MALDI MS spectrum of 157 
 
 






















Compound 163 was synthesised by Dr. Madhavachary Rudrakshula using a lithiation–borylation 
sequence resembling 155.  
Rf:  0.22 (3:7 EtOAc:hexane) 
[α]20D: +0.23 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 3440, 3158, 2968, 2935, 1605, 1515, 1497, 1382, 1255, 1061 
1H NMR (500 MHz, CDCl3) δ: 7.32-7.26 (m, 2H, Ar), 7.23-7.17 (m, 5H, Ar), 7.13-7.08 (m, 2H, Ar), 
7.03 (d, J = 8.4 Hz, 1H, H5), 6.66 (dd, J = 8.4, 2.7 Hz, 1H, H6), 6.60 (d, J = 2.7 Hz, 1H, H2), 4.59 (s, 
1H,), 3.61 (dd, J = 11.0, 4.6 Hz, 1H, H31’), 3.57-3.49 (m, 1H, H31’’), 2.91-2.80 (m, 1H, H14), 2.73 (dd, J 
= 13.5, 2.9 Hz, 1H, H29’), 2.71-2.60 (m, 3H), 2.55-2.45 (m, 1H, H7’), 2.23 (dd, J = 13.5, 11.2 Hz, 1H, 
H29’’), 2.19-2.11 (m, 1H, H28), 1.94-1.86 (m, 1H, H15), 1.86-1.79 (m, 1H, H26), 1.79-1.69 (m, 4H, 
H19’,24,16,22), 1.63 (sept, J = 6.6 Hz, 1H, H9), 1.48-1.36 (m, 3H, H8,19’’), 1.17 (d, J = 6.7 Hz, 3H, H17), 
1.07-1.00 (brs, 1H, H32), 0.97 (d, J = 6.5 Hz, 3H, H25), 0.94 (d, J = 6.6 Hz, 3H, H11), 0.93 (d, J = 6.6 Hz, 
3H, H10), 0.89 (d, J = 6.8 Hz, 3H, H27), 0.80 (d, J = 5.8 Hz, 3H, H23), 0.50 (d, J = 6.8 Hz, 3H, H18) 
13C NMR (126 MHz, CDCl3) δ: 152.9 (C1), 141.9 (C3), 141.5 (C21), 141.4 (C30), 137.9 (C4), 131.5, 
129.5, 128.9, 128.6, 128.5, 127.3 (C5), 126.1, 115.7 (C2), 113.3 (C6), 64.5 (C31), 44.0 (C28), 40.8 (C8), 
40.5 (C15), 40.2 (C16), 36.6 (C20), 36.3 (C22), 36.0 (C14), 35.8 (C24), 35.6 (C26), 32.4 (C29), 31.6 (C19), 
31.4 (C7), 28.3 (C9), 22.7 (C11), 22.6 (C10), 21.5 (C17), 12.6 (C25), 12.3 (C27), 12.2 (C18), 11.8 (C23) 
HRMS: (MALDI) calcd. for C39H55ClO2Na (M+Na





Figure 148. The 1H NMR spectra of 163 
 








Compound 164 was synthesised by Dr. Madhavachary Rudrakshula using the same method as 
described for 157.  
Rf:  0.12 (1:9 MeOH:DCM) 
FTIR (νmax/cm
-1, neat): 3353, 2927, 2868, 1743, 1719, 1495, 1459, 1350, 1247, 1103, 1039 
1H NMR (500 MHz, MeOD) δ 7.28 (t, J = 7.5 Hz, 2H, Ar), 7.26-7.15 (m, 8H, Ar), 6.94 (dd, J = 8.5, 
2.6 Hz, 1H, H6), 6.88 (d, J = 2.5 Hz, 1H, H2), 4.04-3.91 (m, 2H, H31), 3.81-3.75 (m, 1H), 3.75-3.57 (m, 
126H, PEG), 3.57-3.53 (m, 4H, CH2-PEG), 3.53-3.47 (m, 2H, CH2-PEG), 3.38 (t, J = 5.5 Hz, 2H, CH2-
PEG), 3.37 (s, 6H, CH3-PEG), 3.26 (t, J = 5.5 Hz, 2H), 3.01-2.91 (m, 1H, H14), 2.81-2.67 (m, 4H, 
H20,7’,29’’), 2.63-2.54 (m, 1H, H7’’), 2.42-2.32 (m, 2H, H29’’,28), 2.04-1.95 (m, 1H, H15), 1.87-1.73 (m, 5H), 
1.66-1.56 (m, 1H, H9), 1.52-1.42 (m, 3H), 1.19 (d, J = 6.8 Hz, 3H, H17), 1.01-0.91 (m, 12H), 0.84 (d, J 
= 6.1 Hz, 3H, H23), 0.55 (d, J = 6.9 Hz, 3H, H18) 
13C NMR (101 MHz, MeOD) δ: 157.7, 156.0, 148.7, 142.3, 141.5, 141.4, 140.9, 131.3, 129.5, 128.6, 
128.2, 128.2, 126.7, 125.7, 121.8 (C2), 119.3 (C6), 71.6, 70.2, 70.2, 70.0, 69.9, 69.9, 69.6, 69.4, 65.7 
(C31), 57.7, 40.8, 40.7, 40.6, 40.3, 40.0, 36.2, 36.1, 36.0, 35.9, 35.5, 31.8 (C29), 31.2 (C7), 31.0 (C19), 









Table 38. The Mw distribution table obtained from MALDI for PEG derivative 164 
n Calculated Mw 
[M + Na]+ 
%Intensity Calculated Observed 
27 1981.2 2004.2 2004.4 30 
28 2025.2 2048.2 2048.5 46 
29 2069.2 2092.2 2092.5 52 
30 2113.3 2136.3 2136.5 73 
31 2157.3 2180.3 2180.6 86 
32 2201.3 2224.3 2224.6 96 
33 2245.3 2268.3 2268.6 100 
34 2289.4 2312.4 2312.7 86 
35 2333.4 2356.4 2356.7 89 
36 2377.4 2400.4 2400.7 78 
37 2421.4 2444.4 2444.7 50 
38 2465.5 2488.5 2488.8 58 
39 2509.5 2532.5 2532.8 46 
40 2553.5 2576.5 2576.8 34 
41 2597.5 2620.5 2620.8 30 
43 2685.6 2708.6 2708.9 19 
 
 





Figure 151. The 1H NMR spectra of 164 
 






Compound 171 was synthesised by Dr. Madhavachary Rudrakshula using a lithiation–borylation 
sequence resembling 155.  
Rf:  0.22 (3:7 EtOAc:hexane) 
[α]20D: +35.0 (c 1.0, CHCl3) 
FTIR (νmax/cm
-1, neat): 3438, 3119, 2957, 2920, 1594, 1514, 1381, 1254, 1225, 1059, 830 
1H NMR (500 MHz, MeOD) δ: 6.98 (d, J = 8.5 Hz, 2H, H2,4), 6.71 (d, J = 8.5 Hz, 2H, H1,5), 3.50-3.39 
(m, 2H, H24), 3.37 (s, 1H), 2.45 (dq, J = 10.3, 6.9 Hz, 1H, H9), 1.97 (hd, J = 7.0, 2.2 Hz, 1H, H19), 1.85-
1.79 (m, 1H, H10), 1.79-1.73 (m, 1H), 1.68-1.61 (m, 2H), 1.61-1.54 (m, 1H, H13), 1.18 (d, J = 6.9 Hz, 
3H, H11), 0.82 (d, J = 5.8 Hz, 3H), 0.80 (d, J = 6.6 Hz, 3H), 0.79 (d, J = 6.6 Hz, 3H, H15), 0.77 (d, J = 
7.0 Hz, 3H, H23), 0.73 (d, J = 6.3 Hz, 3H), 0.50 (d, J = 6.8 Hz, 3H) 
13C NMR (126 MHz, MeOD) δ: 154.9 (C6), 139.0 (C3), 127.9 (C2,4), 114.6 (C1,5), 66.3 (C24), 43.2 (C9), 
39.8 (C10), 35.8 (C19), 35.2, 35.2, 35.1, 35.1, 19.6 (C11), 10.8 (C12), 10.2, 10.1, 10.1, 9.9, 8.8 (C23) 
HRMS: (MALDI) calcd. for C21H36O2Na (M+Na













Figure 153. The 1H NMR spectra of 171 
 





hexamethylnonyl poly-(2-(2-methoxyethoxy)ethyl)carbamate, 172 
 
Compound 172 was synthesised by Dr. Madhavachary Rudrakshula using the same method as 
described for 157.  
Rf:  0.20 (1:9 MeOH:DCM) 
FTIR (νmax/cm-1, neat): 3360, 2924, 2870, 1743, 1605, 1460, 1350, 1250, 1105 
1H NMR (500 MHz, MeOD) δ: 7.20 (d, J = 8.7 Hz, 2H, H2,4), 7.04 (d, J = 8.7 Hz, 2H, H1,5), 3.95 (d, J 
= 7.3 Hz, 2H, H24), 3.84-3.76 (m, 2H, CH2-PEG), 3.74-3.58 (m, 128H, PEG), 3.58-3.53 (m, 6H, CH2-
PEG), 3.53-3.46 (m, 2H, CH2-PEG), 3.39 (t, J = 5.4 Hz, 2H, CH2-PEG), 3.38 (s, 6H, CH3-PEG), 3.30 
(t, J = 5.6 Hz, 2H, H26), 2.67-2.48 (m, 1H, H9), 2.27-2.06 (m, 1H, H18), 1.95-1.75 (m, 2H, H10,13), 1.71-
1.49 (m, 3H), 1.22 (d, J = 6.9 Hz, 3H, H11), 0.90-0.72 (m, 15H), 0.52 (d, J = 6.8 Hz, 3H, H12) 
13C NMR (101 MHz, MeOD) δ: 157.8 (C25), 156.0 (C28), 149.3 (C6), 145.1 (C3), 127.9 (C2,4), 121.2 
(C1,5), 71.6, 70.3, 70.2, 70.2, 70.2, 70.1, 70.0, 69.9, 69.9, 69.6, 69.4, 68. (C24), 57.7, 43.5 (C9), 40.6, 40., 














Table 39. The Mw distribution table obtained from MALDI for PEG derivative 172 
n Calculated Mw 
[M + Na]+ 
%Intensity Calculated Observed 
23 1535.0 1557.9 1558.2 20 
24 1579.0 1602.0 1602.2 30 
25 1623.0 1646.0 1646.3 46 
26 1667.0 1690.0 1690.3 53 
27 1711.1 1734.1 1734.3 63 
28 1755.1 1778.1 1778.4 56 
29 1799.1 1822.1 1822.4 66 
30 1843.1 1866.1 1866.4 80 
31 1887.1 1910.2 1910.4 86 
32 1931.2 1954.2 1954.5 100 
33 1975.2 1998.2 1998.5 93 
34 2019.2 2042.2 2042.5 70 
35 2063.3 2086.3 2086.6 53 
36 2107.3 2130.3 2130.6 36 
37 2195.4 2218.3 2218.6 30 
39 2239.4 2262.4 2262.7 23 
 
 






Figure 156. The 1H NMR spectra of 172 
 






Compound 178 was synthesised by Dr. Madhavachary Rudrakshula using a lithiation–borylation 
sequence resembling 155 
Rf:  0.4 (4:6 EtOAc:Hexane) 
[α]20D: −0.41 (c 1.0, MeOH) 
IR (νmax/cm
-1, neat): 3438, 3119, 2967, 2920, 1594, 1514, 1460, 1382, 1254, 1226, 1060, 830 
1H NMR (500 MHz, MeOD) δ: 7.81 (dd, J = 7.7, 1.2 Hz, 1H, Ar), 7.79-7.75 (m, 2H, Ar), 7.58 (s, 1H, 
Ar), 7.48-7.39 (m, 2H, Ar), 7.29 (dd, J = 8.3, 1.8 Hz, 1H, Ar), 7.25-7.19 (m, 2H, Ar), 7.17-7.11 (m, 3H, 
Ar), 6.84 (d, J = 8.1 Hz, 1H, H5), 6.53 (d, J = 2.5 Hz, 1H, H2), 6.50 (dd, J = 8.1, 2.5 Hz, 1H, H6), 3.45-
3.42 (m, 2H, H25), 2.79 (dd, J = 13.6, 6.8 Hz, 1H, H17’), 2.72 (dd, J = 13.6, 3.0 Hz, 1H, H17’’), 2.68 (dd, 
J = 9.3, 2.8 Hz, 1H, H23’), 2.61-2.54 (m, 1H, H14’), 2.53-2.48 (m, 1H, H23’’), 2.49-2.43 (m, 1H, H14’’), 
2.39 (td, J = 7.4, 3.1 Hz, 2H, H7), 1.87-1.79 (m, 1H, H16), 1.79-1.70 (m, 1H, H22), 1.56-1.18 (br m, 12H), 
0.86 (d, J = 6.7 Hz, 3H), 0.84 (d, J = 6.7 Hz, 3H) 
13C NMR (126 MHz, MeOD) δ: 154.8 (C1), 141.5, 140.9, 138.9, 133.7, 132.2, 131.1, 129.9 (C5), 128.8, 
127.8, 127.4, 127.3, 127.2, 127.0, 126.9, 125.4, 125.4, 124.7, 115.3 (C2), 112.3 (C6), 63.7 (C25), 42.4 
(C22), 40.5, 40.5, 39.2 (C16), 37.1 (C23), 35.3, 33.4, 30.4, 30.3, 29.0 (C14), 27.9 (C9), 23.5, 21.6 
HRMS: (MALDI) calcd. for C37H46O2Na (M+Na










Figure 158. The 1H NMR spectra of 178 
 






Compound 179 was synthesised by Dr. Madhavachary Rudrakshula using the same method as 
described for 157.  
Rf: 0.25 (1:9 MeOH:DCM) 
FTIR (νmax/cm
-1, neat): 3431, 2921, 1610, 1514, 1462, 1382, 1225, 1060 
1H NMR (500 MHz, Methanol-d4) δ: 8.56 (s, 2H, Ar), 7.83 (d, J = 7.8 Hz, 1H, Ar), 7.79 (d, J = 8.1 Hz, 
2H, Ar), 7.61 (s, 1H, Ar), 7.48-7.41 (m, 2H, Ar), 7.31 (d, J = 8.4 Hz, 1H, Ar), 7.25 (t, J = 7.5 Hz, 2H, 
Ar), 7.20-7.12 (m, 3H, Ar), 7.04 (d, J = 8.0 Hz, 1H, H5), 6.85-6.78 (m, 2H, H1,6), 3.97-3.89 (m, 2H, H25), 
3.72-3.57 (m, 110H, PEG), 3.57-3.51 (m, 6H, CH2-PEG), 3.37 (s, 6H, CH3-PEG), 2.86-2.81 (m, 1H, 
H17), 2.77-2.54 (m, 5H), 2.50-2.43 (m, 2H, H7), 2.08-2.02 (m, 1H), 1.97-1.90 (m, 1H, H22), 1.89-1.83 
(m, 1H, H16), 1.57-1.43 (m, 4H), 0.87 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.7 Hz, 3H) 
13C NMR (126 MHz, Methanol-d4) δ: 
13C NMR (126 MHz, MeOD) δ 165.4, 149.2, 141.6, 140.2, 138.6, 
137.2, 133.7, 132.2, 129.7, 128.8, 128.0, 127.5, 127.3, 127.0, 125.6, 124.9, 121.7, 118.7, 71.6, 70.1, 













Table 40. The Mw distribution table obtained from MALDI for PEG derivative 179 
n Calculated Mw 
[M + Na]+ 
%Intensity Calculated Observed 
27 1781.1 1804.1 1804.4 11 
28 1825.1 1848.1 1848.4 26 
29 1869.1 1892.1 1892.4 34 
30 1913.1 1936.1 1936.4 46 
31 1957.2 1980.2 1980.5 76 
32 2001.2 2024.2 2024.5 80 
33 2045.2 2068.2 2068.5 100 
34 2089.2 2112.2 2112.6 97 
35 2133.3 2156.3 2156.6 96 
36 2177.3 2200.3 2200.6 84 
37 2221.3 2244.3 2244.6 61 
38 2265.4 2288.3 2288.7 42 
39 2309.4 2332.4 2332.7 30 
40 2353.4 2376.4 2376.7 13 
41 2397.4 2420.4 2420.8 7 
 
 






Figure 161. The 1H NMR spectra of 179 
 




9.4 The Calculation of Gibbs Free Energies, Boltzmann Populations and 
Boltzmann Averaged NMR Parameters using Density Functional Theory  
All raw computational data is available in \\ads.bris.ac.uk\folders\Science\Chemistry\Chemistry 
filestore (chm-fs)\MyShared_nmr\shareall\Computational Data_Thesis. 
9.4.1 General Computational Information  
DFT Calculations, including geometry optimisations, frequency calculations and NMR calculations, 
were performed using the Gaussian 09 Software Package.[326] DFT calculations were performed using 
BlueCrystal Phase 3, a supercomputing facility available within the advanced computing research 
center at the University of Bristol (http://www.bris.ac.uk/acrc). 
Following the conformational search, the top 99.9% of conformers, corresponding to 241 conformers 
for 119, were subjected to a DFT geometry optimisation-frequency calculation using mPW1PW91/6-
31g(d) basis set (basis set 1-BS1). The integral equation formalism polarisable continuum model was 
used for solvation (IEFPCM, chloroform). Conformers that either did not converge or converged to an 
imaginary frequency were eliminated from the conformational pool.  
The optimised geometries were subjected to a frequency single point calculation using mPW1PW91/6-
311g(d,p) (basis set 2-BS2) to obtain a more accurate description of conformer energies. The 
calculations were performed using the same solvation method in chloroform. The Gibbs free energies 
(in kJ mol-1) of each conformer were estimated according to Equation 14:  
Gi
BS2 =  Ei
BS2  + (Gi
BS1 −  Ei
BS1) 
Equation 14. The estimation of the Gibbs energy of conformer i. 
Where Gi
BS2  is the estimated Gibbs energy of conformer i using 6-311g(d,p), Ei
BS2  is the potential 
energy of conformer i calculated using 6-311g(d,p), Gi
BS1 is the calculated Gibbs energy of conformer 
i using 6-31g(d) and Ei
BS1 is the potential energy of conformer i calculated using 6-31g(d).  
The estimated Gibbs energies of each conformer were subsequently used in the Boltzmann analysis of 
conformer population according to Equation 15:  















Where Pi is the Boltzmann population of conformer i, ΔGi
BS2 is the relative estimated Gibbs energy in 
kJ mol-1 of conformer i, R is the ideal gas constant (8.314 x 10-3 kJ mol-1), T is the temperature of the 
system (298 K) and g is the degeneracy of conformer i (which is 1 for all conformers in this study).  
The Boltzmann distribution was used to select the top 99% of conformers to subject to the DFT NMR 
calculations to calculate scalar coupling constants and magnetic shielding tensors. The NMR properties 
were computed using the GIAO (gauge-independent atomic orbitals) method using mPW1PW91/6-
311g(d,p). The IEFPCM solvation model was used with the solvent chloroform chosen. The additional 
keyword ‘mixed’ was included to allow for mixing between the core orbitals and the valence orbitals.  
9.4.2 The Calculation of Boltzmann Averaged Chemical Shifts 
The Boltzmann averaged magnetic shielding tensors were calculated according to Equation 16. 





Equation 16. The calculation of the Boltzmann averaged magnetic shielding tensors. 
Where σx is the magnetic shielding tensor of nucleus x for conformer i, pi is the Boltzmann population 
of conformer i and ∑ p is the combined population of conformers involved.  
The chemical shifts were calculated according to Equation 17. 
δcalc
x =  
σTMS −  σx




Equation 17. The calculation of chemical shift from magnetic shielding tensor 
Where δcalc
x  is the calculated chemical shift of nucleus x, σx is the magnetic shielding tensor of nucleus 
x, σTMS is the magnetic shielding tensor of the relevant nuclei of TMS calculated in the same solvent 
and at the same level of theory. For proton this corresponds to 31.92258 and for carbon this corresponds 
to 189.3625.  
The calculated chemical shifts were linearly scaled to remove any systematic errors according to 
Equation 18 
δscaled = (δcalculated − intercept)/slope 




Where the intercept and the slope were obtained by plotting the calculated chemical shifts (δcalculated) 
against the experimental chemical shifts. 
9.4.3 The Calculation of Boltzmann Averaged Scalar Coupling Constants  
The calculated scalar coupling constants for each conformer, both HH and HC, were Boltzmann 
averaged against their calculated Boltzmann populations according to Equation 19. 
nJHX,calc =  
∑ (JHX,i x pi)i
∑ p
 
Equation 19. The calculation of the Boltzmann averaged scalar coupling constants 
Where nJHX,calc is the Boltzmann averaged scalar coupling constant in Hz, JHX,i is the scalar coupling 
constant of conformer i, pi is the population of conformer i and ∑ p is the combined population of 
conformers involved. 
9.4.4 The Calculation of Boltzmann Averaged Interproton Distances  
 The interproton distances were obtained from the optimised geometries after the geometry optimisation 
and frequency calculation, performed using mPW1PW91/6-31g(d) basis set. The interproton distances 
of each conformer were Boltzmann averaged against their calculated Boltzmann populations according 
to Equation 20. 








Equation 20. The calculation of Boltzmann averaged interproton distances 
Where rHa−Hb,calc is the Boltzmann averaged interproton distance between Ha and Hb, rHa−Hb,i is the 
calculated interproton distance between Ha and Hb for conformer i and pi is the population of 









9.4.5 The DFT Calculated Gibbs free energies and Boltzmann Populations for 
Conformers of Structure 119 
The method described above was used to calculate the Gibbs energies of the conformers of 119 and 
their corresponding Boltzmann populations. The relative potential and Gibbs energies calculated using 
both basis set 1 and basis set 2, for all conformers under 10 kJ mol-1 are provided in Table 41. The 
relative Gibbs energies estimated for basis set 2 were used to calculate the conformer Boltzmann 
populations.  



























2 0.33 2.38 0.00 1.66 0.00 23.99 
3 1.57 5.06 0.85 3.73 0.24 21.74 
1 0.00 3.18 2.93 1.86 2.34 9.34 
4 3.95 3.12 3.62 1.62 2.84 7.62 
12 7.08 7.17 5.03 5.84 4.43 4.02 
189 18.73 2.64 4.36 2.33 4.77 3.50 
14 7.27 7.80 5.47 6.38 4.78 3.49 
30 10.39 7.72 5.62 6.39 5.01 3.17 
9 5.66 5.32 6.42 4.07 5.90 2.21 
18 8.24 5.88 7.10 4.46 6.40 1.81 
41 11.82 12.77 7.25 11.19 6.40 1.81 
67 13.90 3.91 6.45 3.36 6.63 1.65 
8 4.93 6.28 7.32 4.95 6.71 1.60 
19 8.76 0.94 5.93 1.38 7.09 1.37 
11 7.02 0.00 6.86 0.00 7.59 1.12 
147 17.38 6.13 7.56 5.93 8.09 0.92 
110 16.24 6.85 8.08 6.33 8.28 0.85 
86 14.93 7.33 8.71 7.16 9.26 0.57 
188 18.72 7.37 9.30 7.25 9.91 0.44 
131 16.87 12.88 9.98 12.32 10.15 0.40 
*mPW1PW91/6-31g(d) 
**mPW1PW91/6-311g(d,p) 
The Boltzmann populations calculated by DFT can be used to plot a 3D-bubble plot of dihedral number, 
dihedral angle and population (Figure 163). The size of each bubble represents the population of the 
conformer contributing to that dihedral angle. The total population of conformers adopting a linear 





Figure 163. The bubble plot of 119 using populations calculated from DFT calculations. 
The superposition of the three lowest energy conformers, which have a combined population of 55%, 
show very similar backbones with changes only in the side chains (Figure 164). 
 




9.5 The Acquisition of NMR Parameters in Conformational Analysis 
9.5.1 The Measurement of nJHH Scalar Coupling Constants  
nJHH scalar coupling constants were measured either directly from multiplets in the 1D 
1H spectrum or 
from simulations of the 1H NMR spectrum using Spin Simulation in MestreNova. Prior to Spin 
Simulation, a PSYCHE pureshift 1H spectrum was obtained to provide exact chemical shifts. The 
measured chemical shifts, estimated J-couplings and line widths of the peaks were entered into the Spin 
Simulation software and the spectrum was simulated (Table 42, Table 43). The simulated spectrum 
(Figure 165) was superimposed with the experimental spectrum (Figure 166) and the J-couplings were 
changed in steps of 0.1 Hz until the best fit between the experimental and simulated spectrum was 
observed.  
Table 42. The parameters used in the partial simulation of the spectrum of 119 
 
Atom Chemical Shift N Spin Line Width 
1 2.9048 1 ½ 3.8 
2 2.0221 1 ½ 4.5 
3 2.3428 1 ½ 4.5 
4 1.8814 1 ½ 3.0 
5 1.6855 1 ½ 2.8 
6 1.6309 1 ½ 3.0 
7 3.5727 1 ½ 2.5 
8 1.2666 3 ½ 2.0 
9 0.6955 3 ½ 2.0 
10’ 3.0223 1 ½ 3.0 
10’ 2.6628 1 ½ 3.5 
11 0.8801 3 ½ 2.0 
12 0.6967 3 ½ 2.5 
13 0.9281 3 ½ 2.5 
14’ 2.4323 1 ½ 3.0 




Table 43. The coupling constants used in the simulation of the spectrum of 119 
 1 2 3 4 5 6 7 8 9 10’ 10’’ 11 12 13 14’ 14’’ 
1                 
2 10.3                
3  2.0               
4   8.2              
5    2.9             
6     9.2            
7      4.6           
8 6.7                
9  6.6               
10’   3.1              
10’’   8.4       15.1       
11    6.9             
12     6.8            
13      6.8           
14’       2.2          
14’’       9.8        13.4  
 





Figure 166. The overlay of the simulated spectrum (blue) and the experimental spectrum (red). Some of the backbone peaks 
are highlighted by coloured boxes and a zoom in of these peaks is shown in the subsequent figures. 
 
 





Figure 168. The simulated (blue) and experimental (red) peak of H1. 
 
Figure 169. The simulated (blue) and experimental (red) peaks of H2, H4, H5 and H6. 
 
9.5.2 The Measurement of nJCH Scalar Coupling Constants 
nJCH coupling constants were measured using Accordion In-Phase and Anti Phase (IPAP) HSQMBC 
NMR Spectra. The In-Phase and Anti Phase spectra were acquired interleaved. The acquisition 
parameters include: 8 scans, 2048 f1 increments and 16384 f2 data points, f1 spectral width of 180 ppm 
(22624 Hz), f2 spectral width of 11 ppm (5507 Hz). The spectrum was acquired in CDCl3 with 9 mg in 
0.7 mL. The sum (Figure 170) and difference (Figure 171) were created by adding and subtracting the 
IP and AP spectra. The offset between the sum and the difference multiplets allows the extraction of 
the values of nJCH (Figure 172). The data was measured using a Bruker AVANCE III HD 500 MHz 





Figure 170. The sum of the IP and AP spectra of the IPAP_HSQMBC of 119. 
 





Figure 172. A horizontal 1D trace at 40.3 ppm of both the sum (a) and difference (b) spectra. c) shows the overlay of both 










9.5.3 The Measurement of Quantitative Interproton Distances  
The interproton distances were measured using the CSSF-NOESY experiment (256 scans, 2 s relaxation 
delay, 500 ms mixing time, 30 ppm (15015 Hz) spectral width, 65536 f1 data points). The data was 
measured using a Bruker AVANCE III HD 500 MHz NMR spectrometer with a 5 mm DCH 13C-1H/D 
Cryo Probe.  
NOE intensities can be used to derive interproton distances because the distance between two atoms is 
proportional to the NOE intensity between the same atoms. Thus using a known distance as a reference, 
typically a methylene pair, it is possible to calculate the interproton distance between two atoms using 
Equation 21.  






Equation 21. The calculation of interproton distances from NOE intensities. 
Where rNOE is the interproton distance between the atoms of interest, rref is the interproton distance 
between two reference atoms, ηNOE is the NOE intensity between two atoms of interest and ηref is the 
NOE intensity between two reference atoms. In order to compare all NOE intensities across different 
1D-NOESY spectra, differing rates of external relaxation for each proton needs to be corrected for. This 
can be achieved by applying the PANIC method described by Macura.[106]  By setting the irradiated 
peak to 1000 in all selective 1D-NOSY experiments, differing rates of external relaxation are corrected 
for.  
For 119, the reference distance was that between H10’’ and H10’ (1.74 Å). The reference distance is 
incrementally changed to reduce the overall MAD for the dataset. This means that there may be a 
small %deviation between the experimental reference distance and its calculated value, however the 
overall MAD will be reduced. Thus, using this reference distance and NOE intensity, all measured NOE 





Figure 173. Deriving the H10''-H4 interproton distance. 
 
9.6 The Conformational Analysis of 119 using the hybrid NMR 
Spectroscopy and Computational Approach 
The Boltzmann averaged NMR parameters, calculated as described in the previous section, were then 
compared to the experimentally measured NMR parameters. The quality of the fit between the two sets 
of data was assessed using the mean absolute deviation (MAD) and Standard Deviation (SD).  
The MAD was calculated using either Equation 22 when calculating the %deviation between 
experimental and calculated interproton distances or Equation 23 when calculating the deviation 




) 𝑥 100 
Equation 22. The calculation of %deviation for interproton distances 
Deviation = (𝛿/𝐽𝑐𝑎𝑙𝑐 −  𝛿/𝐽𝑒𝑥𝑝) 






9.6.1 The Comparison of Experimental and Calculated nJHH Coupling Constants  
 
Table 44. A comparison of the experimentally derived nJHH scalar coupling constants to those calculated by DFT 







1 2 10.3 10.7 0.4 
1 8 6.7 7.2 0.5 
2 3 2.0 2.6 0.6 
2 9 6.6 7.4 0.8 
3 4 8.2 9.3 1.1 
3 10’ 3.1 1.7 -1.4 
3 10’’ 8.4 9.7 1.3 
4 5 2.9 3.2 0.3 
4 11 6.9 7.4 0.5 
5 6 9.2 9.4 0.2 
5 12 6.8 7.2 0.4 
6 7 4.6 4.9 0.3 
6 13 6.8 7.2 0.4 
7 14’ 9.8 9.1 -0.7 
7 14’’ 2.2 2.1 -0.1 
10’ 10’’ 15.1 17.6 2.5 
14’ 14’’ 13.4 12.7 -0.7 
Mean Absolute Deviation (Hz)  








9.6.2 The Comparison of Experimental and Calculated nJCH Coupling Constants  
 
Table 45. A comparison of the experimentally derived nJCH scalar coupling constants to those calculated by DFT 






 Deviation (Hz) 
1 9 2.5 1.7 -0.7 
1 8 4.5 4.3 -0.2 
2 8 3.3 3.3 0.0 
2 1 5.4 5.3 -0.1 
3 11 3.2 2.4 -0.8 
3 9 6.1 6.2 0.1 
3 4 4.8 5.0 0.2 
3 2 4.9 4.7 -0.2 
3 26 4.3 4.8 0.4 
4 12 5.6 5.5 -0.1 
4 2 2.7 2.2 -0.5 
4 11 4.7 4.3 -0.4 
4 5 5.5 4.7 -0.8 
5 7 2.2 2.4 0.2 
5 12 4.5 4.3 -0.2 
6 12 2.6 2.6 0.1 
6 14 5.0 5.2 0.2 
6 13 3.7 3.8 0.1 
6 5 5.4 4.7 -0.7 
7 5 2.0 1.3 -0.7 
7 13 4.4 4.5 0.1 
7 6 2.5 2.2 -0.3 
10’ 4 5.7 6.6 0.9 
10’ 2 3.7 4.6 1.0 
10’ 3 4.4 4.7 0.3 
10’ 26 6.7 8.0 1.3 
10’’ 4 4.5 5.4 0.8 
10’’ 3 4.6 4.5 -0.1 
10’’ 26 5.8 5.4 -0.4 
13 5 4.1 4.2 0.1 
13 6 3.9 3.8 0.0 
13 7 4.3 4.3 0.0 
14’ 6 2.2 2.2 0.1 




14’’ 6 1.3 0.8 -0.5 
14’’ 7 1.9 1.8 -0.1 
15 19 4.7 4.9 0.2 
15 20 2.7 2.6 0.0 
16 1 3.5 3.7 0.2 
16 20 10.4 10.3 -0.1 
19 21 4.7 5.3 0.7 
19 1 1.4 0.6 -0.8 
19 15 5.0 5.3 0.3 
19 20 3.1 3.9 0.8 
21’ 23 2.6 2.3 -0.3 
21’ 22 4.9 5.0 0.1 
21’ 19 5.8 6.1 0.3 
Mean Absolute Deviation (Hz) 


















9.6.3 The Comparison of Experimental and Calculated Interproton Distances 
 
Table 46. A comparison between the experimentally derived interproton distances from 1D-NOE spectroscopy to those 




















7 14’ 17.18 2.60 2.49 -4.42 
 14’’ 6.77 3.04 3.04 -0.02 
 4 14.04 2.69 3.11 15.66 
 13 2.37 3.62 3.59 -0.63 
 12 12.67 2.74 2.77 1.40 
10’ 1 60.52 2.11 2.08 -1.48 
 10’’ 182.70 1.75 1.74 -0.64 
 3 19.99 2.54 2.67 5.28 
1 10’ 34.86 2.31 2.08 -10.13 
 20’ 40.61 2.25 2.19 -2.84 
 20’’ 21.76 2.50 2.45 -2.20 
 3 11.73 2.77 2.91 5.03 
 2 5.66 3.13 3.02 -3.56 
10’’ 10’ (rref) 191.53 1.74 1.74 0.15 
 4 31.63 2.35 2.41 2.53 
3 10’ 15.69 2.64 2.67 1.11 
 1 13.11 2.72 2.91 7.00 
 2 25.06 2.44 2.48 1.54 
 4 13.14 2.72 2.83 4.08 
 8 18.88 2.56 2.51 -1.97 
 11 4.27 3.28 3.27 -0.19 
2 16 48.81 2.19 2.27 4.10 
 3 22.77 2.48 2.48 -0.07 
 8 6.96 3.02 2.93 -3.18 
 11 15.60 2.64 2.68 1.46 
4 7 14.60 2.67 3.11 16.42 
 10’’ 20.57 2.52 2.41 -4.56 
 3 11.13 2.80 2.83 1.24 
 13 15.17 2.66 2.75 3.49 
 Mean Absolute Deviation (%) 3.67 





9.6.4 The Comparison of Experimental and Calculated Chemical Shifts  
 
Table 47. A comparison of the experimental δH to those calculated by DFT calculations for 119. 
Proton 
Experimental 





Scaled δH (ppm)  
Deviation 
(ppm) 
1 2.91 28.80 3.13 3.00 0.09 
2 2.03 29.79 2.14 2.05 0.02 
3 2.35 29.34 2.59 2.48 0.13 
4 1.88 29.84 2.08 2.00 0.12 
5 1.70 30.23 1.69 1.62 -0.08 
6 1.64 30.21 1.71 1.64 0.00 
7 3.57 28.67 3.25 3.12 -0.45 
8 1.27 30.39 1.54 1.47 0.20 
9 0.70 31.23 0.69 0.66 -0.04 
10’ 3.02 28.54 3.38 3.24 0.22 
10’’ 2.67 29.28 2.65 2.54 -0.13 
11 0.88 31.03 0.90 0.86 -0.02 
12 0.70 31.44 0.49 0.47 -0.23 
13 0.93 30.89 1.04 1.00 0.07 
14’ 2.24 29.66 2.26 2.17 -0.07 
14’’ 2.45 29.70 2.23 2.14 -0.31 
15 6.68 25.08 6.85 6.57 -0.11 
16 7.09 24.43 7.50 7.19 0.10 
19 6.60 24.95 6.98 6.70 -0.10 
21’ 2.59 29.03 2.90 2.78 0.19 
21’’ 2.45 29.36 2.56 2.46 0.01 
22’ 1.34 30.43 1.49 1.43 0.09 
22’’ 1.34 30.50 1.43 1.37 0.03 
23 1.50 30.30 1.63 1.56 0.06 
24/25 0.87 31.00 0.93 0.89 0.02 
Mean Absolute Deviation (ppm) 0.11 








Table 48. A comparison of the experimental δc to those calculated by DFT calculations for 119. 
Carbon Experimental 





Scaled δC (ppm)  
Deviation 
(ppm) 
1 36.5 149.09 40.3 37.0 0.5 
2 40.3 144.69 44.7 41.3 1.0 
3 42.6 143.36 46.0 42.5 -0.1 
4 36.0 148.10 41.3 38.0 2.0 
5 36.3 149.64 39.7 36.5 0.2 
6 42.6 144.86 44.5 41.1 -1.5 
7 74.0 113.05 76.3 71.7 -2.3 
8 21.7 164.82 24.5 21.9 0.2 
9 13.4 175.48 13.9 11.6 -1.8 
10 35.8 148.60 40.8 37.5 1.7 
11 12.1 175.66 13.7 11.4 -0.7 
12 13.1 175.38 14.0 11.7 -1.4 
13 12.0 175.53 13.8 11.6 -0.4 
14 38.3 147.95 41.4 38.1 -0.2 
15 113.4 73.01 116.4 110.2 -3.2 
16 127.5 55.28 134.1 127.3 -0.2 
17 138.0 45.53 143.9 136.7 -1.3 
18 142.1 39.14 150.2 142.8 0.7 
19 115.8 69.17 120.2 113.9 -1.9 
20 153.1 28.42 161.0 153.2 0.1 
21 31.3 152.29 37.1 33.9 2.6 
22 40.7 144.64 44.7 41.3 0.6 
23 28.0 155.76 33.6 30.6 2.6 
24/25 22.7/22.7 164.47/165.67 24.9/23.7 22.2/21.1 -0.5/-1.6 
26 141.0 39.55 149.8 142.5 1.5 
27 139.4 42.42 147.0 139.7 0.3 
Mean Absolute Deviation (ppm) 1.14 


















9.7 The Binding of the Designed Inhibitors to Mdm2 using 1H-15N HSQC 
Spectroscopy 
9.7.1 The Expression and Purification of 15N-Mdm2 




A fragment of the N-terminal domain of human Mdm2 (residues 27-127) was cloned into the pET-20 
(Novagen) vector and expressed in the E.Coli BL21(DE3) strain. 200 μL of sterile media was added to 
the BL21(DE3) cells and incubated for one hour at 37 °C. E.Coli BL21(DE3) cells were grown on an 
LB agar plate overnight at 37 °C. Three cell colonies were harvested and added to 50 mL of LB media. 
50 μL of a 50 mg/mL solution of ampicillin was added for plasma selection. Cell colonies were 
incubated at 37 °C overnight. 2 mL of the seed broth was used to inoculate flasks containing 200 mL 
of LB media and 400 μL of ampicillin. Flasks were incubated at 37 °C until an OD600 of 1.0-1.4 was 
reached. Cell cultures were cooled to 16 °C and induced with 200 μM of IPTG. Protein expression was 
maintained overnight at 16 °C. Cells were harvested by centrifugation at 6000 rpm at 4 °C. The cell 
pellet was resuspended in 20 mL of column buffer (50 mM Tris base, 0.5 M NaCl, pH 8.0) followed by 
flash freezing in liquid nitrogen. The cell suspension was stored at -4 °C until ready for purification. 
Prior to purification, the cells were lysed at -10 °C by sonication for a total time of 10 minutes consisting 
of cycles of 5 seconds sonication followed by 20 seconds rest. Cells were clarified by centrifuged at 
15000 rpm and the cell lysate was purified using a HisTrap HP 5 mL Ni column. Protein was eluted via 
a linear gradient from 5 to 100% elution buffer (50 mM Tris buffer at pH 8.0 with 0.3 M NaCl and 
0.8 M imidazole) and collected in 1 mL fractions. The pure fractions were analysed by SDS PAGE 





Figure 175. The SDS-PAGE results following the first purification using a HisTrap HP 5 mL Ni column.  
TEV protease was used to attempt to cleave the His6-tag however, all conditions used were unsuccessful. 
The combined fractions after the first HisTrap HP 5 mL Ni column were subjected to a second 
purification using a HiLoad 26/60 Superdex 75 prep grade column, equilibrated with 20 mM Tris, 250 
mM NaCl, 1 mM TCEP at pH 7.5. SDS-PAGE was used to confirm the fractions containing pure Mdm2 





Figure 176. The SDS-PAGE results following the second purification using a HiLoad 26/60 Superdex 75 prep grade column. 
Samples were desalted for MALDI mass spectrometry using a C4 ZipTip
TM (Millipore). The ZipTip 
was activated with 3 10 μL washes of 50% acetonitrile in water and equilibrated with five 10 μL washes 
of 0.1% TFA in water. A 10 μL sample was then loaded onto the ZipTip with 15 washes. The protein 
was desalted with ten 10 μL washes with 5% MeOH, 0.1% TFA in water and discarded to waste. Finally, 
the sample was eluted with 10 μL of 70% acetonitrile, 0.1% TFA in water. MALDI mass spectrometry 
confirm that Mdm2 had been successfully expressed, and a Mw of 15233.0 Da was observed, 
corresponding to the expected average Mw of the His6-tagged Mdm2 (sequence shown below). Obs: 

















































































































































































































































































































































Following the successful expression of unlabelled Mdm2, 5N-labelled Mdm2 was expressed. Three 
colonies of BL21-(DE3) cells were harvested and added to 50 mL of LB media. 50 μL of a 50 mg/mL 
solution of ampicillin was added for plasma selection. Cell colonies were incubated at 37 °C overnight. 
2 mL of the seed broth was used to inoculate flasks containing 200 mL of LB media and 400 μL of 
ampicillin. Flasks were incubated at 37 °C until an OD600 of 1.0-1.4 was reached. Cells were harvested 
by centrifugation at 6000 rpm and washed twice with sterile M9 media. The cells were resuspended in 
M9 and inoculated with 450 μL of ampicillin. 15NH4Cl (1 g/L), glucose (3 g/L), MgSO4 (200 μg/mL) 
and a trace metal mix (150 μL) were added followed by incubation at 37 °C for 1 hour. The cultures 
were induced with IPTG (200 μM) at 16 °C overnight. Cells were harvested by centrifugation at 6000 
rpm and purified as described for the unlabelled Mdm2. MALDI mass spectroscopy confirmed that full 



























































































































































































































































NMR spectroscopy was performed to confirm the purity of Mdm2 and that it had folded well. A 2D- 
1H-15N TROSY of Mdm2 was acquired at a concentration of 130 μM on a 700 MHz spectrometer fitted 
with a 1.7 mm inverse triple resonance micro-Cryo Probe at 20 °C. The DPFGSE sequence was used 
for water suppression. The protein was solubilised in a 10 mM NaHPO4 solution with 150 mM NaCl at 
pH 7.4. 10% D2O was added to the sample to provide a lock signal. The total sample volume was 50 µl 
using 1.7 mm NMR tubes. The acquisition parameters include: 512 scans, 256 f1 increments and 512 
f2 data points, f1 spectral width of 25 ppm (1774 Hz), f2 spectral width of 12 ppm (8403 Hz). Spectra 
were processed and analysed in MestreNova v14.0. Spectra were zero filled to 4096 data points and 
manually phase corrected using the largest peak as the pivot point. The acquired TROSY was partially 
assigned using previously reported assignments of Mdm2 in the literature (Figure 92, Table 49).[300,306]  
Table 49. A comprehensive list of the resolved peaks with their assignments 
F1 (ppm) F2 (ppm) Assignment 
8.20 118.35 14Thr 
7.51 116.50 26Thr 
8.45 128.15 27Leu 
9.66 116.10 28Val 
9.25 121.99 29Arg 
8.71 118.64 33Leu 
7.30 118.35 34Leu 
8.56 120.22 (35Leu/56Tyr) 
7.35 121.33 37Leu 
8.18 120.52 38Leu 
8.66 118.33 39Lys 
7.83 116.57 40Ser 
7.23 112.63 41Val 
7.46 106.35 42Gly 
7.31 124.78 43Ala 
8.70 118.06 44Gln 
7.67 116.26 45Lys 
6.97 111.17 47Thr 
8.59 120.72 48Tyr 
8.89 110.11 49Thr 
8.25 121.14 50Met 
7.82 119.93 52Glu 
8.30 118.93 54Leu 
8.17 122.73 55Phe 
8.63 121.30 57Leu 
8.26 106.37 58Gly 
7.82 121.83 59Gln 
8.76 124.15 60Tyr 
8.58 119.18 61Ile 
7.92 116.17 62Met 
8.63 116.04 63Thr 




7.61 115.17 66Leu 
6.75 113.96 67Tyr 
8.49 123.74 68Asp 
8.54 124.00 69Glu 
8.21 116.67 70Lys 
8.29 120.92 71Gln 
8.29 119.39 72Gln 
7.96 113.50 73His 
7.58 122.30 74Ile 
8.27 125.89 75Val 
8.24 125.73 76Tyr 
8.38 117.27 77Cys 
7.62 118.11 80Asp 
9.81 118.83 82Leu 
7.77 106.86 83Gly 
7.49 123.04 84Asp 
8.00 119.38 85Leu 
8.36 116.99 86Phe 
8.24 108.39 87Gly 
7.05 108.50 88Val 
7.21 111.25 90Ser 
8.27 114.43 91Phe 
8.71 112.86 92Ser 
9.37 122.42 93Val 
7.97 117.28 94Lys 
7.34 120.37 95Glu 
7.69 120.48 96His 
7.73 121.32 98Lys 
7.74 119.05 99Ile 
8.39 121.11 100Tyr 
8.12 112.73 101Thr 
7.59 120.05 102Met 
8.73 120.22 104Tyr 
8.67 127.85 (108Val/109Val) 
8.29 127.29 110Val 
8.25 123.42 111Asn 
8.37 122.07 117Asp 
8.31 115.93 118Ser 
7.45 119.18 None 
7.49 118.78 None 
7.71 118.35 None 
7.77 118.46 None 
7.80 118.18 None 
7.88 117.90 None 
7.97 124.49 None 
7.99 114.62 None 
8.03 115.45 None 
8.04 118.96 None 




8.09 118.63 None 
8.12 118.45 None 
8.14 121.59 None 
8.32 116.80 None 
8.39 121.42 None 























9.7.2 The binding of 157 by TROSY spectroscopy 
A 2D-1H-15N TROSY of Mdm2 was acquired at a concentration of 50 μM on a 700 MHz spectrometer 
fitted with a 1.7 mm inverse triple resonance micro-Cryo Probe at 20 °C. The DPFGSE sequence was 
used for water suppression. The protein was solubilised in a 20 mM Tris buffer with 250 mM NaCl at 
pH 7.5. 10% D2O was added to the sample to provide a lock signal. 10% Acetone-d6 was added for 
ligand solubility. The total concentration of ligand 157 was 70 µM. The total sample volume was 50 µl 
using 1.7 mm NMR tubes. The acquisition parameters include: 512 scans, 256 f1 increments and 512 
f2 data points, f1 spectral width of 25 ppm (1774 Hz), f2 spectral width of 12 ppm (8403 Hz). A 2D-
1H-15N TROSY of Mdm2 (50 μM) with ligand 157 (70 μM) in the same buffer conditions was acquired 
with the same acquisition parameters. Spectra were processed and analysed in MestreNova v14.0. 
Spectra were zero filled to 4096 data points and manually phase corrected using the largest peak as the 
pivot point. The overlaid spectra of apo-Mdm2 and Mdm2+ligand 157 can be seen in Figure 179 
Chemical shift perturbations (CSP’s) were calculated as a Euclidean distance using Equation 24 with 
a value of α=0.14. The value of α was calculated from the ratio of the chemical shift range (in ppm) of 
1H to that of 15N (3.08/22.1 = 0.139). The calculated CSPs, or Euclidean Distances, are shown in Table 
50. 






Equation 24. The calculation of Euclidean distance 
 
 












Table 50. The Euclidean Distances for the CSP's observed upon binding of ligand 157 to Mdm2. The first section 
corresponds to CSPs >2σ, the second section corresponds to CSPs >σ while the last section corresponds to CSPs <σ. 
Residue ΔδH (ppm) ΔδN (ppm) Euclidean Distance (α = 0.14) (ppm) 
T101 0.052 0.450 0.176 
F86 0.007 0.470 0.176 
K98 0.002 0.420 0.157 
K94 0.009 0.350 0.131 
V110 0.018 0.270 0.103 
T26 0.002 0.250 0.094 
T47 0.007 0.240 0.090 
V93 0.037 0.210 0.087 
S92 0.062 0.160 0.086 
Y100 0.003 0.220 0.082 
E52 0.023 0.210 0.082 
V53 0.033 0.200 0.082 
F55 0.025 0.180 0.072 
V28 0.021 0.180 0.071 
M102 0.042 0.140 0.067 
L85 0.038 0.140 0.065 
V108 0.023 0.160 0.064 
H73 0.011 0.160 0.061 
E95 0.052 0.080 0.060 
L57 0.024 0.140 0.058 
D68 0.011 0.140 0.054 
C77 0.010 0.140 0.053 
L54 0.022 0.120 0.050 
L34 0.015 0.120 0.047 
T63 0.015 0.120 0.047 
K51 0.022 0.111 0.047 
Y104 0.012 0.120 0.046 
S40 0.007 0.120 0.045 
L66 0.004 0.120 0.045 
Y56 0.017 0.110 0.045 
G58 0.021 0.100 0.043 
I99 0.037 0.051 0.042 
G87 0.002 0.110 0.041 
F91 0.029 0.078 0.041 
R65 0.008 0.100 0.038 
E69 0.004 0.090 0.034 
D111 0.015 0.080 0.033 
Q44 0.012 0.080 0.032 
L33 0.023 0.060 0.032 
D84 0.011 0.080 0.032 
I74 0.014 0.070 0.030 
Y60 0.025 0.040 0.029 
S118 0.023 0.040 0.027 
L37 0.015 0.050 0.024 
M62 0.018 0.040 0.023 
M50 0.021 0.010 0.021 
I61 0.017 0.020 0.019 




9.7.3 The Estimation of Kd using 1H-15N SOFAST HMQC for 157  
A 2D 1H-15N SOFAST HMQC of Mdm2 at a concentration of 70 μM with five concentrations of ligand 
157 ranging from 17.5 to 280 μM was acquired on a 700 MHz spectrometer fitted with a 1.7 mm inverse 
triple resonance micro-Cryo Probe 20 °C using the sofasthmqc sequence. The DPFGSE sequence was 
used for water suppression. The protein was solubilised in a 20 mM Tris buffer with 250 mM NaCl at 
pH 7.5. 10% D2O was added to the sample to provide a lock signal. 10% Acetone-d6 was added for 
ligand solubility. A 10 mM stock solution of ligand 157 in acetone-d6 was prepared and the required 
volume was added to the protein sample to give final ligand concentrations of 17.5 μM, 35 μM, 70 μM, 
140 μM and 280 μM. The total sample volume was 50 µL using 1.7 mm NMR tubes. The acquisition 
parameters include: 64 scans, 128 f1 increments and 757 f2 data points, f1 spectral width of 25 ppm 
(1774 Hz), f2 spectral width of 12 ppm (8418 Hz). Spectra were processed and analysed in MestreNova 
v14.0. Spectra were zero filled to 4096 data points and manually phase corrected using the largest peak 
as the pivot point. Figure 180 shows an overlay of the spectrum obtained from all five titration points 
and apo-Mdm2.  
The 1H-15N SOFAST HMQC spectra were analysed using Mbinding from MestreNova. The Euclidean 
distances are calculated using Equation 24 and the value of α used was 0.14. The experimental CSP’s 
were used to calculate binding curves. The CSP’s measured at different protein concentrations can be 
used in a nonlinear least-square fitting to calculate Kd using Equation 25. The final Kd was calculated 
as the average of the individual values of Kd obtained for 20 different peaks. A summary of the Kd 
obtained for each peak is provided in Table 51. Example binding data obtained using Mbinding for 
three different peaks is also shown below.  
𝛥𝛿𝑜𝑏𝑠 =  𝛥𝛿𝑚𝑎𝑥






Equation 25. Using CSP’s to estimate Kd. 
Where 𝛥𝛿𝑜𝑏𝑠 is the change in the observed shift from the shift of the native protein, 𝛥𝛿𝑚𝑎𝑥  is the 
maximum chemical shift change on saturation of the protein with ligand, [P]t is the total protein 








Figure 180. The titration of ligand 157 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 17.5 μM ligand), 
orange (70 μM Mdm2 + 35 μM ligand), green (70 μM Mdm2 + 70 μM ligand), pink (70 μM Mdm2 + 140 μM ligand), dark 




Table 51. The calculated value of Kd and maximum CSP for 20 different residues interacting with 157. The average Kd and 
σ Kd are also shown. 
Residue  K
d
 (μM) CSP Max (ppm) 
C77 16.91 0.09 
E95 15.98 0.03 
F86 13.21 0.06 
G42 20.28 0.02 
G83 24.96 0.03 
K94 12.27 0.06 
K98 12.90 0.05 
L107 15.17 0.04 
L37 23.39 0.07 
L82 21.47 0.04 
M62 20.88 0.03 
R29 17.07 0.05 
S40 18.17 0.03 
S92 11.62 0.06 
T101 10.49 0.07 
T47 12.08 0.05 
Y104 15.34 0.04 
E69 20.96 0.03 
unassigned1 (U1) 24.23 0.05 








Experimental Binding Data for T101 
Table 52. A table showing the chemical shifts of the T101 residue at increasing concentrations of 157. The measured and 
calculated CSP’s are also shown.  
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 113.18 8.20 0.000 0.000 
0.25 113.24 8.21 0.015 0.015 
0.5 113.30 8.22 0.031 0.027 
1 113.37 8.23 0.045 0.046 
2 113.40 8.25 0.058 0.060 





Figure 181. The peaks of the T101 residue at increasing concentrations of 157 (left) and the binding curve plotted using 
Mbinding. The blue are the experimental CSP’s and the red are the calculated CSP’s. 
Experimental Binding Data for F86 
Table 53. A table showing the chemical shifts of the F86 residue at increasing concentrations of 157. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 117.01 8.52 0.000 0.000 
0.25 117.08 8.51 0.014 0.012 
0.5 117.20 8.52 0.030 0.022 
1 117.20 8.51 0.030 0.037 
2 117.34 8.51 0.053 0.049 
4 117.34 8.52 0.052 0.054 
 
Figure 182. The peaks of the F86 residue at increasing concentrations of 157 (left) and the binding curve plotted using 




Experimental Binding Data for M62 
Table 54. A table showing the chemical shifts of the M62 residue at increasing concentrations of 157. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 116.17 7.97 0.000 0.000 
0.25 116.18 7.98 0.006 0.006 
0.5 116.18 7.99 0.012 0.011 
1 116.21 7.99 0.018 0.018 
2 116.27 7.99 0.025 0.025 
4 116.23 8.00 0.029 0.029 
 
Figure 183. The peaks of the M62 residue at increasing concentrations of 157 (left) and the binding curve plotted using 











9.7.4 The Estimation of Kd using 1H-15N SOFAST HMQC for 164 
A series of 2D 1H-15N SOFAST HMQC spectra of Mdm2 (70 μM) with five different concentrations of 
ligand 164, ranging from 17.5 to 280 μM, were acquired using the same conditions and procedures as 
described for ligand 157 previously. Figure 184 shows an overlay of the spectrum obtained from all 
five titration points and apo-Mdm2. The 1H-15N SOFAST HMQC spectra were analysed using 
Mbinding from MestreNova and an average value of Kd was obtained across 20 peaks (Table 55). 
Example binding data obtained using Mbinding for three different peaks is also shown below. 
 
Table 55. The calculated value of Kd and maximum CSP for 20 different residues interacting with 164. The average Kd and 
σ Kd are also shown. 
Residue  K
d
 (μM) CSP Max (ppm) 
C77 11.84 0.09 
E69 3.29 0.05 
F86 5.43 0.13 
F91 7.34 0.06 
G83 6.86 0.05 
K64 9.70 0.06 
K94 6.85 0.11 
L107 8.04 0.08 
L37 12.41 0.05 
L82 11.07 0.04 
M62 14.47 0.08 
S40 10.62 0.07 
S92 3.72 0.13 
T47 7.38 0.10 
T49 9.96 0.06 
U1 7.17 0.07 
U2 11.70 0.07 
Y104 8.55 0.07 
Y48 6.71 0.04 












Figure 184. The titration of ligand 164 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 17.5 μM ligand), 
orange (70 μM Mdm2 + 35 μM ligand), green (70 μM Mdm2 + 70 μM ligand), pink (70 μM Mdm2 + 140 μM ligand), dark 
blue (70 μM Mdm2 + 280 μM ligand). The 20 peaks that were considered in the calculation of Kd are highlighted. 
Experimental Binding Data for Y104  
Table 56. A table showing the chemical shifts of the Y104 residue at increasing concentrations of 164. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 120.32 8.70 0.000 0.000 
0.25 120.43 8.72 0.025 0.015 
0.5 120.47 8.72 0.030 0.027 
1 120.54 8.73 0.043 0.046 
2 120.64 8.73 0.058 0.059 





Figure 185. The peaks of the Y104 residue at increasing concentrations of 164 (left) and the binding curve plotted using 
Mbinding. The blue are the experimental CSP’s and the red are the calculated CSP’s. 
Experimental Binding Data for K94 
Table 57. A table showing the chemical shifts of the K94 residue at increasing concentrations of 164. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 117.34 7.95 0.000 0.000 
0.25 117.63 7.96 0.044 0.025 
0.5 117.77 7.96 0.065 0.047 
1 117.79 7.97 0.069 0.080 
2 117.98 7.97 0.098 0.101 
4 118.01 7.98 0.105 0.106 
 
Figure 186. The peaks of the K94 residue at increasing concentrations of 164 (left) and the binding curve plotted using 




Experimental Binding Data for M62 
Table 58. A table showing the chemical shifts of the M62 residue at increasing concentrations of 164. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 116.03 7.92 0.000 0.000 
0.25 116.06 7.94 0.023 0.015 
0.5 116.10 7.95 0.031 0.027 
1 116.16 7.95 0.043 0.046 
2 116.22 7.97 0.061 0.063 
4 116.22 7.98 0.072 0.071 
 
Figure 187. The peaks of the M62 residue at increasing concentrations of 164 (left) and the binding curve plotted using 











9.7.5 The Qualitative Binding of 172 to Mdm2 using 1H-15N SOFAST HMQC  
A series of 2D 1H-15N SOFAST HMQC spectra of Mdm2 (70 μM) with five different concentrations of 
ligand 172, ranging from 35 to 350 μM, were acquired using the same conditions and procedures as 
described for ligand 157 previously. Figure 188 shows an overlay of the spectrum obtained from all 
five titration points and apo-Mdm2. The 1H-15N SOFAST HMQC spectra were analysed using 
Mbinding from MestreNova. Example binding data obtained using Mbinding for two different peaks is 
also shown below. 
 
 
Figure 188. The titration of ligand 172 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 35 μM ligand), 
orange (70 μM Mdm2 + 70 μM ligand), green (70 μM Mdm2 + 140 μM ligand), pink (70 μM Mdm2 + 280 μM ligand), dark 






Example Binding Curve for T101 
Table 59. A table showing the chemical shifts of the T101 residue at increasing concentrations of 172. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 113.09 8.191 0.000 0.000 
0.25 113.17 8.20 0.017 0.011 
0.5 113.18 8.21 0.022 0.020 
1 113.20 8.21 0.025 0.032 
2 113.36 8.22 0.052 0.048 
4 113.34 8.23 0.052 0.053 
 
Figure 189. The peaks of the T101 residue at increasing concentrations of 172 (left) and the binding curve plotted using 
Mbinding. The blue are the experimental CSP’s and the red are the calculated CSP’s. 
Example Binding Curve for M62 
Table 60. A table showing the chemical shifts of the M62 residue at increasing concentrations of 172. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 116.13 7.98 0.000 0.000 
0.25 116.15 7.98 0.004 0.004 
0.5 116.18 7.98 0.010 0.008 
1 116.14 7.99 0.012 0.013 
2 116.22 7.99 0.019 0.020 





Figure 190. The peaks of the M62 residue at increasing concentrations of 172 (left) and the binding curve plotted using 















9.7.6 The Qualitative Binding of 179 to Mdm2 using 1H-15N SOFAST HMQC  
A series of 2D 1H-15N SOFAST HMQC spectra of Mdm2 (70 μM) with six different concentrations of 
ligand 179, ranging from 35 to 350 μM, were acquired using the same conditions and procedures as 
described for ligand 157 previously. Figure 191 shows an overlay of the spectrum obtained from all six 
titration points and apo-Mdm2. The 1H-15N SOFAST HMQC spectra were analysed using Mbinding 




Figure 191. The titration of ligand 179 against Mdm2. Purple (70 μM Mdm2), light blue (70 μM Mdm2 + 35 μM ligand), 
orange (70 μM Mdm2 + 70 μM ligand), green (70 μM Mdm2 + 105 μM ligand), yellow (70 μM Mdm2 + 140 μM ligand) 
pink (70 μM Mdm2 + 280 μM ligand), dark blue (70 μM Mdm2 + 350 μM). The 5 peaks that were considered in the 




Example Binding Curve for F86 
Table 61. A table showing the chemical shifts of the F86 residue at increasing concentrations of 179. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 116.97 8.52 0.000 0.000 
0.5 117.01 8.51 0.011 0.012 
1 117.05 8.50 0.019 0.022 
1.5 117.15 8.50 0.032 0.030 
2 117.21 8.51 0.038 0.036 
4 117.29 8.50 0.049 0.053 
5 117.35 8.50 0.060 0.058 
 
Figure 192. The peaks of the F86 residue at increasing concentrations of 179 (left) and the binding curve plotted using 
Mbinding. The blue are the experimental CSP’s and the red are the calculated CSP’s. 
Example Binding Curve for C77 
Table 62. A table showing the chemical shifts of the F86 residue at increasing concentrations of 179. The measured and 
calculated CSP is also shown. 
Lt/Pt F1 (ppm) F2 (ppm) CSP (ppm) Calculated CSP (ppm) 
0 116.16 8.45 0.000 0.000 
0.5 116.26 8.44 0.016 0.024 
1 116.40 8.44 0.036 0.043 
1.5 116.55 8.44 0.059 0.058 
2 116.69 8.45 0.079 0.071 
4 116.88 8.44 0.108 0.102 





Figure 193. The peaks of the F86 residue at increasing concentrations of 179 (left) and the binding curve plotted using 





[1] R. W. Hoffmann, Angew. Chem. Int. Ed. 2000, 39, 2054–2070. 
[2] E. Breitmaier, Structure Elucidation by NMR in Organic Chemistry, John Wiley & Sons, 2002. 
[3] P. H. Willoughby, M. J. Jansma, T. R. Hoye, Nat. Protoc. 2014, 9, 643–660. 
[4] A. C. Anderson, Chem. Biol. 2003, 10, 787–797. 
[5] R. L. M. Van Montfort, P. Workman, Essays Biochem. 2017, 61, 431–437. 
[6] E. Chiarparin, M. J. Packer, D. M. Wilson, Future Med. Chem. 2019, 11, 79–82. 
[7] V. Lounnas, T. Ritschel, J. Kelder, R. McGuire, R. P. Bywater, N. Foloppe, Comput. Struct. Biotechnol. 
J. 2013, 5, 1–14. 
[8] Y. Zheng, C. M. Tice, S. B. Singh, Bioorganic Med. Chem. Lett. 2017, 27, 2825–2837. 
[9] E. Perola, P. S. Charifson, J. Med. Chem. 2004, 47, 2499–2510. 
[10] A. E. Tron, M. A. Belmonte, A. Adam, B. M. Aquila, L. H. Boise, E. Chiarparin, J. Cidado, K. J. Embrey, 
E. Gangl, F. D. Gibbons, et al., Nat. Commun. 2018, 9, 1–14. 
[11] M. Reggelin, H. Hoffmann, M. Köck, D. F. Mierke, J. Am. Chem. Soc. 1992, 114, 3272–3277. 
[12] Z. Fang, Y. Song, P. Zhan, Q. Zhang, X. Liu, Future Med. Chem. 2014, 6, 885–901. 
[13] N. Foloppe, I. J. Chen, Bioorganic Med. Chem. 2016, 24, 2159–2189. 
[14] N. Foloppe, I.-J. Chen, Future Med. Chem. 2019, 11, 97–118. 
[15] E. Perola, P. S. Charifson, J. Med. Chem 2004, 47, 2499–2510. 
[16] S. Michielssens, B. L. De Groot, H. Grubmüller, Biophys. J. 2015, 108, 2585–2590. 
[17] A. M. Aronov, T. Qing, G. Martinez-Botella, G. W. Bemis, J. Cao, G. Chen, N. P. Ewing, P. J. Ford, U. 
A. Germann, J. Green, et al., J. Med. Chem. 2009, 52, 6362–6368. 
[18] Y. Wang, A. Kirschner, A. K. Fabian, R. Gopalakrishnan, C. Kress, B. Hoogeland, U. Koch, C. Kozany, 
A. Bracher, F. Hausch, J. Med. Chem. 2013, 56, 3922–3935. 
[19] A. Y. S. Balazs, R. J. Carbajo, N. L. Davies, Y. Dong, A. W. Hird, J. W. Johannes, M. L. Lamb, W. 
McCoull, P. Raubo, G. R. Robb, et al., J. Med. Chem. 2019, 62, 9418–9437. 
[20] F. Weinhold, Nature 2001, 411, 539–541. 
[21] V. Dragojlovic, ChemTexts 2015, 1, 1–30. 
[22] M. A. Murcko, H. Castejon, K. B. Wiberg, J. Phys. Chem. 1996, 100, 16162–16168. 
[23] G. D. Smith, R. L. Jaffe, J. Phys. Chem. 1996, 100, 18718–18724. 
[24] S. Tsuzuki, L. Schafer, H. Goto, E. D. Jemmis, H. Hosoya, K. Siam, K. Tanabe, E. Osawa, J. Am. Chem. 
Soc. 1991, 4665–4671. 
[25] A. W. Burgess, L. L. Shipman, H. A. Scheraga, Proc. Natl. Acad. Sci. U. S. A. 1975, 72, 854–858. 
[26] R. W. Hoffmann, M. Stahl, U. Schopfer, G. Frenking, Chem. Eur. J. 1998, 4, 559–566. 
[27] M. Burns, S. Essafi, J. R. Bame, S. P. Bull, M. P. Webster, S. Balieu, J. W. Dale, C. P. Butts, J. N. Harvey, 
V. K. Aggarwal, Nature 2014, 513, 183–188. 
[28] H. Goto, E. Osawa, M. Yamato, Tetrahedron 1993, 49, 387–396. 
[29] J. M. L. Martin, J. Phys. Chem. A 2009, 113, 11974–11983. 
[30] P. W. Smith, W. C. Still, J. Am. Chem. Soc. 1988, 110, 7917–7919. 
[31] J. Mallinson, I. Collins, Future Med. Chem. 2012, 4, 1409–1438. 
[32] C. A. Lipinski, Adv. Drug Deliv. Rev. 2016, 101, 34–41. 




[34] S. K. Malhotra, F. Johnson, J. Am. Chem. Soc. 1965, 87, 5493–5495. 
[35] F. Johnson, Chem. Rev. 1968, 68, 375–413. 
[36] J. L. Broeker, R. W. Hoffmann, K. N. Houk, J. Am. Chem. Soc. 1991, 113, 5006–5017. 
[37] R. W. Hoffmann, Chem. Rev. 1989, 89, 1841–1860. 
[38] R. W. Hoffmann, Angew. Chem. Int. Ed. 1992, 31, 1124–1134. 
[39] R. Göttlich, B. Colin Kahrs, J. Krüger, R. W. Hoffmann, Chem. Commun. 1997, 3, 247–252. 
[40] S. Tsuzuki, L. Schäfer, H. Gotō, E. D. Jemmis, H. Hosoya, K. Siam, K. Tanabe, E. Ōsawa, J. Am. Chem. 
Soc. 1991, 113, 4665–4671. 
[41] R. H. Boyd, S. M. Breitling, Macromolecules 1972, 5, 279–286. 
[42] D. Leonori, V. K. Aggarwal, Acc. Chem. Res. 2014, 47, 3174–3183. 
[43] J. W. Johannes, S. Bates, C. Beigie, M. A. Belmonte, J. Breen, S. Cao, P. A. Centrella, M. A. Clark, J. W. 
Cuozzo, C. E. Dumelin, et al., ACS Med. Chem. Lett. 2017, 8, 239–244. 
[44] L. W. Thomas, C. Lam, S. W. Edwards, FEBS Lett. 2010, 584, 2981–2989. 
[45] R. E. Taylor, Y. Chen, G. M. Galvin, P. K. Pabba, Org. Biomol. Chem. 2004, 2, 127–132. 
[46] W. McCoull, R. D. Abrams, E. Anderson, K. Blades, P. Barton, M. Box, J. Burgess, K. Byth, Q. Cao, C. 
Chuaqui, et al., J. Med. Chem. 2017, 60, 4386–4402. 
[47] E. M. Driggers, S. P. Hale, J. Lee, N. K. Terrett, Nat. Rev. Drug Discov. 2008, 7, 608–624. 
[48] E. Marsault, M. L. Peterson, J. Med. Chem. 2011, 54, 1961–2004. 
[49] D. J. Craik, D. P. Fairlie, S. Liras, D. Price, Chem. Biol. Drug Des. 2013, 81, 136–147. 
[50] J. L. Lau, M. K. Dunn, Bioorganic Med. Chem. 2018, 26, 2700–2707. 
[51] A. M. Ali, J. Atmaj, N. Van Oosterwijk, M. R. Groves, A. Dömling, Comput. Struct. Biotechnol. J. 2019, 
17, 263–281. 
[52] L. D. Walensky, G. H. Bird, J. Med. Chem 2014, 57, 6275−6288. 
[53] A. Bhat, L. R. Roberts, J. J. Dwyer, Eur. J. Med. Chem. 2015, 94, 471–479. 
[54] G. L. Verdine, G. J. Hilinski, Stapled Peptides for Intracellular Drug Targets, Elsevier Inc., 2012. 
[55] R. Rezaei Araghi, J. A. Ryan, A. Letai, A. E. Keating, ACS Chem. Biol. 2016, 11, 1238–1244. 
[56] M. Llinàs-Brunet, M. Bailey, G. Fazal, S. Goulet, T. Halmos, S. Laplante, R. Maurice, M. Poirier, M. A. 
Poupart, D. Thibeault, et al., Bioorganic Med. Chem. Lett. 1998, 8, 1713–1718. 
[57] S. R. LaPlante, H. Nar, C. T. Lemke, A. Jakalian, N. Aubry, S. H. Kawai, J. Med. Chem. 2014, 57, 1777–
1789. 
[58] K. H. A. Lau, Biomater. Sci. 2014, 2, 627–633. 
[59] R. J. Simon, R. S. Kania, R. N. Zuckermann, V. D. Huebner, D. A. Jewell, S. Banville, S. Ng, L. Wang, 
S. Rosenberg, C. K. Marlowe, et al., Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 9367–9371. 
[60] G. W. Collie, K. Pulka-Ziach, C. M. Lombardo, J. Fremaux, F. Rosu, M. Decossas, L. Mauran, O. Lambert, 
V. Gabelica, C. D. Mackereth, et al., Nat. Chem. 2015, 7, 871–878. 
[61] P. S. Farmer, E. J. Ariëns, Trends Pharmacol. Sci. 1982, 3, 362–365. 
[62] B. C. Gorske, E. M. Mumford, C. G. Gerrity, I. Ko, J. Am. Chem. Soc. 2017, 139, 8070–8073. 
[63] O. Roy, C. Caumes, Y. Esvan, C. Didierjean, S. Faure, C. Taillefumier, Org. Lett. 2013, 15, 2246–2249. 
[64] T. Kodadek, P. J. McEnaney, Chem. Commun. 2016, 52, 6038–6059. 
[65] J. Morimoto, Y. Fukuda, D. Kuroda, T. Watanabe, F. Yoshida, M. Asada, T. Nakamura, A. Senoo, S. 
Nagatoishi, K. Tsumoto, et al., J. Am. Chem. Soc. 2019, 141, 14612–14623. 
[66] A. J. Levine, M. Oren, Nat. Rev. Cancer 2009, 9, 749–58. 




[68] C. Sandford, V. K. Aggarwal, Chem. Commun. 2017, 53, 5481–5494. 
[69] D. S. Matteson, J. Organomet. Chem. 1999, 581, 51–65. 
[70] V. K. Aggarwal, G. Y. Fang, X. Ginesta, D. M. Howells, M. Zaja, Pure Appl. Chem. 2006, 78, 215–229. 
[71] D. S. Matteson, D. Majumdar, J. Am. Chem. Soc. 1980, 102, 7588–7590. 
[72] D. Majumdar, D. S. Matteson, J. Am. Chem. Soc. 1980, 102, 7590–7591. 
[73] S. P. Thomas, R. M. French, V. Jheengut, V. K. Aggarwal, Chem. Rec. 2009, 9, 24–39. 
[74] S. Essafi, S. Tomasi, V. K. Aggarwal, J. N. Harvey, J. Org. Chem. 2014, 79, 12148–12158. 
[75] J. L. Stymiest, G. Dutheuil, A. Mahmood, V. K. Aggarwal, Angew. Chem. Int. Ed. 2007, 46, 7491–7494. 
[76] E. Beckmann, D. Hoppe, Synthesis (Stuttg). 2005, 2, 217–222. 
[77] E. Beckmann, V. Desai, D. Hoppe, Synlett 2004, 10, 2275–2280. 
[78] R. C. Mykura, S. Veth, A. Varela, L. Dewis, J. J. Farndon, E. L. Myers, V. K. Aggarwal, J. Am. Chem. 
Soc. 2018, 140, 14677–14686. 
[79] G. Besong, K. Jarowicki, P. J. Kocienski, E. Sliwinski, F. T. Boyle, Org. Biomol. Chem. 2006, 4, 2193–
2207. 
[80] P. Beak, M. Baillargeon, L. G. Carter, J. Org. Chem. 1978, 43, 4255–4256. 
[81] P. Beak, L. G. Carter, J. Org. Chem. 1981, 46, 2363–2373. 
[82] R. Larouche-Gauthier, C. J. Fletcher, I. Couto, V. K. Aggarwal, Chem. Commun. 2011, 47, 12592–4. 
[83] M. P. Webster, PhD Thesis. University of Bristol. Multiple Homologations of Boronic Esters and 
Applications in Synthesis, 2010. 
[84] M. Elyashberg, TrAC - Trends Anal. Chem. 2015, 69, 88–97. 
[85] U. Sternberg, R. Witter, A. S. Ulrich, Annu. Reports NMR Spectrosc. 2004, 52, 53–104. 
[86] G. Bifulco, P. Dambruoso, L. Gomez-Paloma, R. Riccio, Chem. Rev. 2007, 107, 3744–3779. 
[87] M. Karplus, J. Chem. Phys. 1959, 30, 11–15. 
[88] M. Karplus, J. Am. Chem. Soc. 1963, 85, 2870–2871. 
[89] C. A. G. Haasnoot, F. A. A. M. de Leeuw, C. Altona, Tetrahedron 1980, 36, 2783–2792. 
[90] C. A. G. Haasnoot, F. A. A. M. De Leeuw, H. P. M. De Leeuw, C. Altona, Biopolymers 1981, 20, 1211–
1245. 
[91] C. Altona, J. H. Ippel, A. J. A. W. Hoekzema, C. Erkelens, M. Groesbeek, L. A. Donders, Magn. Reson. 
Chem. 1989, 27, 564–576. 
[92] G. J. Karabatsos, C. E. Orzech, N. Hsi, J. Am. Chem. Soc. 1966, 88, 1817–1818. 
[93] M. J. Minch, Concepts Magn. Reson. Part A 1994, 6, 41–56. 
[94] M. Foroozandeh, R. W. Adams, P. Kiraly, M. Nilsson, G. A. Morris, Chem. Commun. 2015, 51, 15410–
15413. 
[95] P. Kiraly, M. Foroozandeh, M. Nilsson, G. A. Morris, Chem. Phys. Lett. 2017, 683, 398–403. 
[96] N. Matsumori, D. Kaneno, M. Murata, H. Nakamura, K. Tachibana, J. Org. Chem. 1999, 64, 866–876. 
[97] J. L. Marshall, D. E. Müller, S. A. Conn, R. Seiwell, Acc. Chem. Res. 1974, 7, 333–339. 
[98] T. Parella, J. F. Espinosa, Prog. Nucl. Magn. Reson. Spectrosc. 2013, 73, 17–55. 
[99] C. L. Dickson, C. D. Blundell, C. P. Butts, A. Felton, A. Jeffreys, Z. Takacs, Analyst 2017, 142, 621–633. 
[100] J. Saurí, T. Parella, Magn. Reson. Chem. 2013, 51, 509–516. 
[101] S. Gil, J. F. Espinosa, T. Parella, J. Magn. Reson. 2010, 207, 312–321. 
[102] C. P. Butts, C. R. Jones, J. N. Harvey, Chem. Commun. 2011, 47, 1193–1195. 




[104] C. P. Butts, C. R. Jones, E. C. Towers, J. L. Flynn, L. Appleby, N. J. Barron, Org. Biomol. Chem. 2011, 
9, 177–184. 
[105] G. Bodenhausen, R. R. Ernst, J. Am. Chem. Soc 1982, 104, 1304–1309. 
[106] S. Macura, B. T. Farmer, L. R. Brown, J. Magn. Reson. 1986, 70, 493–499. 
[107] H. Hu, K. Krishnamurthy, J. Magn. Reson. 2006, 182, 173–177. 
[108] M. G. Chini, C. R. Jones, A. Zampella, M. V. D’Auria, B. Renga, S. Fiorucci, C. P. Butts, G. Bifulco, J. 
Org. Chem. 2012, 77, 1489–1496. 
[109] S. Di Micco, A. Zampella, M. V. D’Auria, C. Festa, S. De Marino, R. Riccio, C. P. Butts, G. Bifulco, 
Beilstein J. Org. Chem. 2013, 9, 2940–2949. 
[110] G. Barone, L. Gomez-Paloma, D. Duca, A. Silvestri, R. Riccio, G. Bifulco, Chem. Eur. J. 2002, 8, 3233–
3239. 
[111] I. Chen, N. Foloppe, Drug Dev. Res. 2011, 94, 85–94. 
[112] T. Kamachi, K. Yoshizawa, J. Chem. Inf. Model 2016, 56, 347–353. 
[113] J. Schlitter, J. Mol. Graph. 1994, 12, 84–89. 
[114] D. K. Agrafiotis, A. C. Gibbs, F. Zhu, S. Izrailev, E. Martin, J. Chem. Inf. Model 2007, 47, 1067–1086. 
[115] R. G. Woolley, chem phys lett 1977, 45, 393–398. 
[116] M. Molecular, F. Field, T. A. Halgren, J. Comput. Chem. 1996, 17, 490–519. 
[117] V. T. Terms, G. R. March, N. L. Allinger, J. Am. Chem. Soc. 1977, 99, 8127–8134. 
[118] L. Norman, H. Young, J. Am. Chem. Soc. 1989, 111, 8551–8566. 
[119] G. A. Kaminski, R. A. Friesner, J. Tirado-rives, W. L. Jorgensen, J. Phys. Chem. B 2001, 2, 6474–6487. 
[120] G. Chang, W. C. Guida, W. C. Still, J. Am. Chem. Soc. 1989, 111, 4379–4386. 
[121] D. Bagayoko, AIP Adv. 2014, 4, 1–12. 
[122] A. D. Becke, J. Chem. Phys. 2014, 140, 0–18. 
[123] A. D. Becke, J. Chem. Phys. 1993, 98, 5648–5652. 
[124] P. J. Stephens, F. J. Devlin, C. F. Chabalowski, M. J. Frisch, J. Phys. Chem. 1994, 98, 11623–11627. 
[125] C. Adamo, V. Barone, J. Chem. Phys 1998, 108, 664–675. 
[126] K. Burke, J. Chem. Phys. 2012, 136, 1–9. 
[127] C. J. Cramer, Essentials of Computational Chemistry, 2004. 
[128] R. Ditchfield, W. J. Hehre, J. A. Pople, J. Chem. Phys. 1971, 54, 724–728. 
[129] J. A. Montgomery, M. J. Frisch, J. W. Ochterski, G. A. Petersson, J. Chem. Phys. 1999, 110, 2822–2827. 
[130] M. J. Frisch, J. A. Pople, J. S. Binkley, J. Chem. Phys. 1984, 80, 3265–3269. 
[131] A. Bagno, Chem. - A Eur. J. 2001, 7, 1652–1661. 
[132] A. Bagno, F. Rastrelli, G. Saielli, Chem. - A Eur. J. 2006, 12, 5514–5525. 
[133] N. Grimblat, A. M. Sarotti, Chem. - A Eur. J. 2016, 22, 12246–12261. 
[134] S. K. Wolff, T. Ziegler, J. Chem. Phys. 1998, 109, 895–905. 
[135] S. G. Smith, J. M. Goodman, J. Am. Chem. Soc. 2010, 132, 12946–12959. 
[136] S. Di Micco, M. G. Chini, R. Riccio, G. Bifulco, European J. Org. Chem. 2010, 8, 1411–1434. 
[137] G. Barone, D. Duca, A. Silvestri, L. Gomez-Paloma, R. Riccio, G. Bifulco, Chem. - A Eur. J. 2002, 8, 
3240–3245. 
[138] P. Cimino, L. Gomez-Paloma, D. Duca, R. Riccio, G. Bifulco, Magn. Reson. Chem. 2004, 42, 26–33. 
[139] T. A. Palazzo, T. T. Truong, S. M. T. Wong, E. T. Mack, M. W. Lodewyk, J. G. Harrison, R. A. Gamage, 




[140] S. Zaretsky, J. L. Hickey, M. A. St, C. C. G. Scully, A. L. Roughton, D. J. Tantillo, M. W. Lodewyk, A. 
K. Yudin, Tetrahedron 2014, 70, 7655–7663. 
[141] Q. N. N. Nguyen, J. Schwochert, D. J. Tantillo, R. S. Lokey, Phys. Chem. Chem. Phys. 2018, 20, 14003–
14012. 
[142] K. Ermanis, K. E. B. Parkes, J. M. Goodman, T. Agback, Org. Biomol. Chem. 2019, 17, 5886–5890. 
[143] J. De Las Rivas, C. Fontanillo, M. Furumichi, M. Tanabe, M. Hirakawa, PLoS Comput. Biol. 2010, 6, 1–
8. 
[144] I. M. A. Nooren, J. M. Thornton, Eur. Mol. Biol. Organ. 2003, 22, 3486–3492. 
[145] V. Azzarito, K. Long, N. S. Murphy, A. J. Wilson, Nat. Chem. 2013, 5, 161–173. 
[146] H. Yin, A. D. Hamilton, Angew. Chem. Int. Ed. 2005, 44, 4130–4163. 
[147] C. V. Dang, E. P. Reddy, K. M. Shokat, L. Soucek, Nat. Rev. Cancer 2017, 17, 502–508. 
[148] X. Ran, J. E. Gestwicki, Curr. Opin. Chem. Biol. 2018, 44, 75–86. 
[149] L. Mabonga, A. P. Kappo, Biophys. Rev. 2019, 11, 559–581. 
[150] M. Bakail, F. Ochsenbein, Comptes Rendus Chim. 2016, 19, 19–27. 
[151] A. Groß, C. Hashimoto, H. Sticht, J. Eichler, Front. Bioeng. Biotechnol. 2016, 3, 1–16. 
[152] S. Lien, H. B. Lowman, Trends Biotechnol. 2003, 21, 556–562. 
[153] K. Fosgerau, T. Hoffmann, Drug Discov. Today 2015, 20, 122–128. 
[154] T. Clackson, J. A. Wells, Science. 1995, 267, 383–386. 
[155] J. Kenneth Morrow, S. Zhang, Curr. Drug Metab. 2012, 18, 1255–1265. 
[156] E. Cukuroglu, H. B. Engin, A. Gursoy, O. Keskin, Prog. Biophys. Mol. Biol. 2014, 116, 165–173. 
[157] M. Guharoy, P. Chakrabarti, BMC Bioinformatics 2010, 11, 1–17. 
[158] M. R. Arkin, Y. Tang, J. A. Wells, Chem. Biol. 2014, 21, 1102–1114. 
[159] A. Mullard, Nat. Rev. Drug Discov. 2012, 11, 173–175. 
[160] A. J. Wilson, Chem. Soc. Rev. 2009, 38, 3289–3300. 
[161] D. P. Lane, S. Benchimol, Genes Dev. 1990, 4, 1–8. 
[162] D. P. Lane, Nature 1992, 358, 15–16. 
[163] J. Bargonetti, C. Prives, J. Mol. Cell Biol. 2019, 11, 605–609. 
[164] B. Vogelstein, D. Lane, A. J. Levine, Nature 2000, 408, 307–310. 
[165] N. Baptiste, P. Friedlander, X. Chen, C. Prives, Oncogene 2002, 21, 9–21. 
[166] J. Zhu, W. Zhou, J. Jiang, X. Chen, J. Biol. Chem. 1998, 273, 13030–13036. 
[167] S. E. Kern, K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, B. Vogelstein, Science. 1991, 
252, 1708–1711. 
[168] K. G. McLure, P. W. K. Lee, EMBO J. 1998, 17, 3342–3350. 
[169] P. Chène, Oncogene 2001, 20, 2611–2617. 
[170] W. Gu, R. G. Roeder, Cell 1997, 90, 595–606. 
[171] A. M. Goh, C. R. Coffill, D. P. Lane, J. Pathol. 2011, 223, 116–126. 
[172] S. W. Chi, S. H. Lee, D. H. Kim, M. J. Ahn, J. S. Kim, J. Y. Woo, T. Torizawa, M. Kainosho, K. H. Han, 
J. Biol. Chem. 2005, 280, 38795–38802. 
[173] O. Schon, A. Friedler, M. Bycroft, S. M. V Freund, A. R. Fersht, J. Mol. Biol. 2002, 323, 491–501. 
[174] H. Lee, K. H. Mok, R. Muhandiram, K. H. Park, J. E. Suk, D. H. Kim, J. Chang, Y. C. Sung, K. Y. Choi, 
K. H. Han, J. Biol. Chem. 2000, 275, 29426–29432. 




[176] J. Momand, H.-H. Wu, G. Dasgupta, Gene 2000, 242, 15–29. 
[177] Y. Haupt, R. Maya, A. Kazaz, M. Oren, Nature 1997, 387, 296–9. 
[178] M. H. G. Kubbutat, S. N. Jones, K. H. Vousden, Nature 1997, 387, 299–303. 
[179] U. M. Moll, O. Petrenko, Mol. Cancer Res. 2003, 1, 1001–1008. 
[180] S. Y. Shieh, J. Ahn, K. Tamai, Y. Taya, C. Prives, Genes Dev. 2000, 14, 289–300. 
[181] Y. Liu, O. Tavana, W. Gu, J. Mol. Cell Biol. 2019, 11, 564–577. 
[182] S. L. Harris, A. J. Levine, Oncogene 2005, 24, 2899–2908. 
[183] P. A. J. Muller, K. H. Vousden, Nat. Cell Biol. 2013, 15, 2–8. 
[184] M. Hollstein, D. Sidransky, B. Vogelstein, C. C. Harris, Science. 1991, 253, 49–54. 
[185] A. Sigal, V. Rotter, Cancer Res. 2000, 60, 6788–6793. 
[186] N. Rivlin, R. Brosh, M. Oren, V. Rotter, Genes and Cancer 2011, 2, 466–474. 
[187] Ö. Demir, P. U. Ieong, R. E. Amaro, Oncogene 2017, 36, 1451–1460. 
[188] A. Perdrix, A. Najem, S. Saussez, A. Awada, F. Journe, G. Ghanem, M. Krayem, Cancers (Basel). 2017, 
9, 1–17. 
[189] V. J. N. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. 
Wiman, G. Selivanova, Nat. Med. 2002, 8, 282–288. 
[190] J. M. R. Lambert, P. Gorzov, D. B. Veprintsev, M. Söderqvist, D. Segerbäck, J. Bergman, A. R. Fersht, 
P. Hainaut, K. G. Wiman, V. J. N. Bykov, Cancer Cell 2009, 15, 376–388. 
[191] C. D. Wassman, R. Baronio, Ö. Demir, B. D. Wallentine, C.-K. Chen, L. V Hall, F. Salehi, D.-W. Lin, B. 
P. Chung, G. W. Hatfield, et al., Nat. Commun. 2013, 4, 1407. 
[192] S. N. Jones, A. R. Hancock, H. Vogel, L. A. Donehower, A. Bradley, Proc. Natl. Acad. Sci. U. S. A. 1998, 
95, 15608–15612. 
[193] P. M. Fischer, D. P. Lane, Trends Pharmacol. Sci. 2004, 25, 343–346. 
[194] P. H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, N. P. Pavletich, a. 1996, 274, 
948–953. 
[195] L. T. Vassilev, B. T. Vu, B. Craves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. 
Lukacs, C. Klein, et al., Science. 2004, 303, 844–848. 
[196] Y. Zhao, A. Aguilar, D. Bernard, S. Wang, J. Med. Chem. 2015, 58, 1038–1052. 
[197] B. Vu, P. Wovkulich, G. Pizzolato, A. Lovey, Q. Ding, N. Jiang, J. J. Liu, C. Zhao, K. Glenn, Y. Wen, et 
al., Med. Chem. Lett. 2013, 4, 466–469. 
[198] A. Michael, K. R. Kelly, K. Yee, S. Assouline, R. Strair, L. Popplewell, D. Bowen, G. Martinelli, M. W. 
Drummond, P. Vyas, et al., Clin Cancer Res 2016, 22, 868–876. 
[199] S. Shangary, D. Qin, D. McEachern, M. Liu, R. S. Miller, S. Qiu, Z. Nikolovska-Coleska, K. Ding, G. 
Wang, J. Chen, et al., Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 3933–8. 
[200] Q. Ding, Z. Zhang, J.-J. Liu, N. Jiang, J. Zhang, T. M. Ross, X.-J. Chu, D. Bartkovitz, F. Podlaski, C. 
Janson, et al., J. Med. Chem. 2013, 56, 5979–5983. 
[201] S. Wang, Y. Zhao, A. Aguilar, D. Bernard, C. Y. Yang, Cold Spring Harb. Perspect. Med. 2017, 7, 1–11. 
[202] J. Lu, D. McEachern, S. Li, M. J. Ellis, S. Wang, Mol. Cancer Ther. 2016, 15, 2887–2893. 
[203] H. Yin, G. I. Lee, S. P. Hyung, G. A. Payne, J. M. Rodriguez, S. M. Sebti, A. D. Hamilton, Angew. Chemie 
- Int. Ed. 2005, 44, 2704–2707. 
[204] M. K. P. Jayatunga, S. Thompson, A. D. Hamilton, Bioorganic Med. Chem. Lett. 2014, 24, 717–724. 
[205] B. N. Bullock, A. L. Jochim, P. S. Arora, J. Am. Chem. Soc. 2011, 133, 14220–14223. 
[206] A. L. Jochim, P. S. Arora, ACS Chem. Biol. 2010, 5, 919–923. 




[208] M. Raj, B. N. Bullock, P. S. Arora, Bioorganic Med. Chem. 2013, 21, 4051–4057. 
[209] B. P. Orner, J. T. Ernst, A. D. Hamilton, J. Am. Chem. Soc. 2001, 123, 5382–5383. 
[210] J. T. Ernst, O. Kutzki, A. K. Debnath, S. Jiang, H. Lu, A. D. Hamilton, Angew. Chem. Int. Ed. 2002, 41, 
278–281. 
[211] H. Yin, G. I. Lee, K. A. Sedey, O. Kutzki, H. S. Park, B. P. Orner, J. T. Ernst, H. G. Wang, S. M. Sebti, 
A. D. Hamilton, J. Am. Chem. Soc. 2005, 127, 10191–10196. 
[212] C. G. Cummings, A. D. Hamilton, Curr. Opin. Chem. Biol. 2010, 14, 341–346. 
[213] O. Kutzki, H. S. Park, J. T. Ernst, B. P. Orner, H. Yin, A. D. Hamilton, J. Am. Chem. Soc. 2002, 124, 
11838–11839. 
[214] J. M. Davis, A. Truong, A. D. Hamilton, Org. Lett. 2005, 7, 5405–5408. 
[215] H. Yin, G. Lee, K. A. Sedey, J. M. Rodriguez, H. Wang, S. M. Sebti, A. D. Hamilton, Y. U. V, P. O. Box, 
J. Am. Chem. Soc. 2005, 127, 5463–5468. 
[216] D. Vodak, J. Wachter, M. O. Keeffe, O. M. Yaghi, P. J. Hagraman, J. Zubieta, A. Chem, M. O. Keeffe, 
O. M. Yaghi, J. A. C. Soc, et al., Angew. Chem. Int. Ed. 2003, 42, 535–539. 
[217] I. C. Kim, A. D. Hamilton, Org. Lett. 2006, 8, 1751–1754. 
[218] C. G. Cummings, N. T. Ross, W. P. Katt, A. D. Hamilton, Org. Lett. 2009, 11, 25–28. 
[219] J. M. Rodriguez, L. Nevola, N. T. Ross, G. Lee, A. D. Hamilton, Chem. Bio. Chem 2009, 10, 829–833. 
[220] J. M. Rodriguez, A. D. Hamilton, Tetrahedron Lett. 2006, 47, 7443–7446. 
[221] J. M. Rodriguez, A. D. Hamilton, Angew. Chem. Int. Ed. 2007, 46, 8614–8617. 
[222] J. M. Davis, L. K. Tsou, A. D. Hamilton, Chem. Soc. Rev. 2007, 36, 326–334. 
[223] S. Fletcher, A. D. Hamilton, J. R. Soc. Interface 2006, 3, 215–233. 
[224] Y. Lee, H. Im, S. Das, M. Oh, J. H. Lee, S. Ham, H. S. Lim, Chem. Commun. 2019, 55, 13311–13314. 
[225] M. Oh, J. H. Lee, W. Wang, H. S. Lee, W. S. Lee, C. Burlak, W. Im, Q. Q. Hoang, H. S. Lim, Proc. Natl. 
Acad. Sci. U. S. A. 2014, 111, 11007–11012. 
[226] H. Oguri, A. Oomura, S. Tanabe, M. Hirama, Tetrahedron Lett. 2005, 46, 2179–2183. 
[227] S. Thompson, R. Vallinayagam, M. J. Adler, R. T. W. Scott, A. D. Hamilton, Tetrahedron 2012, 68, 
4501–4505. 
[228] S. Thompson, A. D. Hamilton, Org. Biomol. Chem. 2012, 10, 5780–5782. 
[229] K. Jung, K. Vanommeslaeghe, M. E. Lanning, J. L. Yap, C. Gordon, P. T. Wilder, D. M. Jr, S. Fletcher, 
Org. Lett. 2013, 15, 3234–3237. 
[230] D. S. Kemp, Z. Q. Li, Tetrahedron Lett. 1995, 36, 4175–4178. 
[231] R. Larouche-Gauthier, C. J. Fletcher, I. Couto, V. K. Aggarwal, Chem. Commun. 2011, 47, 12592–12594. 
[232] F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. 
Hendrickson, W. C. Still, J. Comput. Chem. 1990, 11, 440–467. 
[233] A. K. Ghose, E. P. Jaeger, P. J. Kowalczyk, M. L. Peterson, A. M. Treasurywala, J. Comput. Chem. 1993, 
14, 1050–1065. 
[234] T. Schlick, M. Overton, J. Comput. Chem. 1987, 8, 1025–1039. 
[235] J. W. Ponder, F. M. Richards, J. Comput. Chem. 1987, 8, 1016–1024. 
[236] T. a Halgren, J. Comput. Chem. 1996, 17, 490–519. 
[237] R. W. Hoffmann, Angew. Chem. Int. Ed. 1992, 31, 1124–1134. 
[238] L. G. Ferreira, R. N. Dos Santos, G. Oliva, A. D. Andricopulo, Molecules 2015, 20, 13384–13421. 
[239] D. B. Kitchen, H. Decornez, J. R. Furr, J. Bajorath, Nat. Rev. Drug Discov. 2004, 3, 935–949. 




[241] E. Yuriev, J. Holien, P. A. Ramsland, J. Mol. Recognit. 2015, 28, 581–604. 
[242] S. Forli, R. Huey, M. E. Pique, M. F. Sanner, D. S. Goodsell, A. J. Olson, Nat. Protoc. 2016, 11, 905–
919. 
[243] O. Trott, A. J. Olson, J. Comput. Chem. 2010, 31, 455–461. 
[244] S. F. Sousa, P. A. F. M. Ramos, PROTEINS Struct. Funct. Bioinforma. 2006, 65, 15–26. 
[245] M. M. Jaghoori, B. Bleijlevens, S. D. Olabarriaga, J. Comput. Aided. Mol. Des. 2016, 30, 237–249. 
[246] M. W. Chang, C. Ayeni, S. Breuer, B. E. Torbett, PLoS One 2010, 5, 1–9. 
[247] A. Castro-Alvarez, A. M. Costa, J. Vilarrasa, Molecules 2017, 22, 2–14. 
[248] Z. Wang, H. Sun, X. Yao, D. Li, L. Xu, Y. Li, S. Tian, T. Hou, Phys. Chem. Chem. Phys. 2016, 18, 12964–
12975. 
[249] S. Uhrinova, D. Uhrin, H. Powers, K. Watt, D. Zheleva, P. Fischer, C. McInnes, P. N. Barlow, J. Mol. 
Biol. 2005, 350, 587–598. 
[250] L. M. Espinoza-Fonseca, J. G. Trujillo-Ferrara, Biopolymers 2006, 83, 365–373. 
[251] O. Schon, A. Friedler, S. Freund, A. R. Fersht, J. Mol. Biol. 2004, 336, 197–202. 
[252] S. Yadahalli, J. Li, D. P. Lane, S. Gosavi, C. S. Verma, Sci. Rep. 2017, 7, 1–12. 
[253] J. J. Sutherland, R. K. Nandigam, J. A. Erickson, M. Vieth, J. Chem. Inf. Model. 2007, 47, 2293–2302. 
[254] S. Shityakov, C. Förste, Adv. Appl. Bioinforma. Chem. 2014, 7, 1–14. 
[255] C. Garcia-Echeverria, P. Chene, M. J. J. Blommers, P. Furet, J. Med. Chem. 2000, 43, 3205–3208. 
[256] K. Sakurai, C. Schubert, D. Kahne, J. Am. Chem. Soc. 2006, 128, 11000–11001. 
[257] A. M. Beekman, M. M. D. Cominetti, S. J. Walpole, S. Prabhu, M. A. O’Connell, J. Angulo, M. Searcey, 
Chem. Sci. 2019, 10, 4502–4508. 
[258] T. Bootwicha, J. M. Feilner, E. L. Myers, V. K. Aggarwal, Nat. Chem. 2017, 9, 896–902. 
[259] Y. Gan, T. A. Spencer, J. Org. Chem. 2006, 71, 5870–5875. 
[260] D. J. Pasto, R. T. Taylor, in Org. React., 2004. 
[261] C. Gaviglio, F. Doctorovich, J. Org. Chem. 2008, 73, 5379–5384. 
[262] Z. Lim, P. J. Duggan, S. S. Wan, G. Lessene, A. G. Meyer, K. L. Tuck, Tetrahedron 2016, 72, 1151–1160. 
[263] N. M. R. McNeil, D. J. Press, D. M. Mayder, P. Garnica, L. M. Doyle, T. G. Back, J. Org. Chem. 2016, 
81, 7884–7897. 
[264] Y. Wang, A. Noble, E. L. Myers, V. K. Aggarwal, Angew. Chem. Int. Ed. 2016, 55, 4270–4274. 
[265] H. Yin, G. I. Lee, S. P. Hyung, G. A. Payne, J. M. Rodriguez, S. M. Sebti, A. D. Hamilton, Angew. Chem. 
Int. Ed. 2005, 44, 2704–2707. 
[266] B. B. Snider, R. A. H. F. Hui, Y. S. Kulkarni, J. Am. Chem. Soc. 1985, 107, 2194–2196. 
[267] P. E. Gormisky, M. C. White, J. Am. Chem. Soc. 2011, 133, 12584–12589. 
[268] K. M. Sadhu, D. S. Matteson, Organometallics 1985, 4, 1687–1689. 
[269] G. Molineux, Cancer Treat. Rev. 2002, 28, 13–16. 
[270] J. M. Harris, R. B. Chess, Nat. Rev. Drug Discov. 2003, 2, 214–221. 
[271] M. Swierczewska, K. C. Lee, S. Lee, M. Swierczewska, K. C. Lee, S. Lee, Expert Opin. Emerg. Drugs 
2015, 20, 531–536. 
[272] A. K. Mailyan, K. Young, J. L. Chen, B. T. Reid, A. Zakarian, Org. Lett. 2016, 18, 5532–5535. 
[273] J. Palà-Pujadas, F. Albericio, J. B. Blanco-Canosa, Angew. Chem. Int. Ed. 2018, 57, 16120–16125. 
[274] G. Bifulco, P. Dambruoso, L. Gomez-Paloma, R. Riccio, Chem. Rev. 2007, 107, 3744–3779. 




and Assembly-Line Synthesis for Studying Molecular Conformations., 2019. 
[276] W. Deng, J. R. Cheeseman, M. J. Frisch, J. Chem. Theory Comput. 2006, 2, 1028–1037. 
[277] G. Palermo, R. Riccio, G. Bifulco, J. Org. Chem. 2010, 75, 1982–1991. 
[278] C. P. Butts, C. R. Jones, J. N. Harvey, C. P. Butts, C. R. Jones, E. C. Towers, J. L. Flynn, L. Appleby, N. 
Barron, A. Bagno, et al., Chem. Commun. 2011, 47, 1193–1195. 
[279] P. T. Robinson, T. N. Pham, D. Uhrín, J. Magn. Reson. 2004, 170, 97–103. 
[280] G. Batta, K. E. Kover, Tetrahedron 1991, 47, 3535–3544. 
[281] J. Wu, P. Lorenzo, S. Zhong, M. Ali, C. P. Butts, E. L. Myers, V. K. Aggarwal, Nature 2017, 547, 436–
440. 
[282] S. Maity, R. K. Gundampati, T. K. S. Kumar, Nat. Prod. Commun. 2019, 14, 1–17. 
[283] L. Fielding, Prog. Nucl. Magn. Reson. Spectrosc. 2007, 51, 219–242. 
[284] S. B. Shuker, P. J. Hajduk, R. P. Meadows, S. W. Fesik, Science. 1996, 274, 1531–1534. 
[285] J. Vaynberg, J. Qin, Trends Biotechnol. 2006, 24, 22–27. 
[286] A. Bax, M. Ikura, L. E. Kay, D. A. Torchia, R. Tschudin, J. Magn. Reson. 1990, 86, 304–318. 
[287] L. Fielding, Curr. Top. Med. Chem. 2003, 3, 39–53. 
[288] E. R. P. Zuiderweg, Biochemistry 2002, 41, 1–7. 
[289] A. Medek, P. J. Hajduk, J. Mack, S. W. Fesik, J. Am. Chem. Soc. 2000, 122, 1241–1242. 
[290] W. Becker, K. C. Bhattiprolu, N. Gubensäk, K. Zangger, ChemPhysChem 2018, 19, 895–906. 
[291] M. P. Williamson, Prog. Nucl. Magn. Reson. Spectrosc. 2013, 73, 1–16. 
[292] J. Cavanagh, A. G. Palmer, W. J. Fairbrother, M. Rance, N. J. Skelton, M. Rance, Protein NMR 
Spectroscopy: Principles and Practice, Elsevier Science & Technology, 2006. 
[293] B. Meyer, T. Peters, Angew. Chem. Int. Ed. 2003, 42, 864–890. 
[294] J. J. Ziarek, F. C. Peterson, B. L. Lytle, B. F. Volkman, Methods Enzymol. 2011, 493, 241–275. 
[295] A. Furukawa, T. Konuma, S. Yanaka, K. Sugase, Prog. Nucl. Magn. Reson. Spectrosc. 2016, 96, 47–57. 
[296] C. H. Hardman, R. William Broadhurst, A. R. C. Raine, K. D. Grasser, J. O. Thomas, E. D. Laue, 
Biochemistry 1995, 34, 16596–16607. 
[297] B. E. Coggins, X. Li, A. L. McClerren, O. Hindsgaul, C. R. H. Raetz, P. Zhou, Nat. Struct. Biol. 2003, 10, 
645–651. 
[298] R. Stoll, C. Renner, S. Hansen, S. Palme, C. Klein, A. Belling, W. Zeslawski, M. Kamionka, T. Rehm, P. 
Mühlhahn, et al., Biochemistry 2001, 40, 336–344. 
[299] C. Riedinger, M. E. Noble, D. J. Wright, F. Mulks, I. R. Hardcastle, J. A. Endicott, J. M. Mcdonnell, 
Chem. Biol. Drug Des. 2011, 77, 301–308. 
[300] R. Stoll, C. Renner, P. Muhlhahn, S. Hansen, R. Schumacher, F. Hesse, B. Kaluza, R. A. Engh, W. Voelter, 
T. A. Holak, J. Biomol. Nmr 2000, 17, 91–92. 
[301] C. G. Neochoritis, M. K. Miraki, E. M. M. Abdelraheem, E. Surmiak, T. Zarganes-Tzitzikas, B. Łabuzek, 
T. A. Holak, A. Dömling, Beilstein J. Org. Chem. 2019, 15, 513–520. 
[302] M. Bista, S. Wolf, K. Khoury, K. Kowalska, Y. Huang, E. Wrona, M. Arciniega, G. M. Popowicz, T. A. 
Holak, A. Dömling, Structure 2013, 21, 2143–2151. 
[303] D. Muszak, B. Łabuzek, M. Z. Brela, A. Twarda-Clapa, M. Czub, B. Musielak, E. Surmiak, T. A. Holak, 
J. Mol. Struct. 2019, 1189, 161–174. 
[304] B. Graves, T. Thompson, M. Xia, C. Janson, C. Lukacs, D. Deo, P. Di Lello, D. Fry, C. Garvie, K. Sen 
Huang, et al., Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 11788–11793. 
[305] E. Surmiak, C. G. Neochoritis, B. Musielak, A. Twarda-Clapa, K. Kurpiewska, G. Dubin, C. Camacho, 




[306] C. Riedinger, J. A. Endicott, S. J. Kemp, L. A. Smyth, A. Watson, E. Valeur, B. T. Golding, R. J. Griffin, 
I. R. Hardcastle, M. E. Noble, et al., J. Am. Chem. Soc. 2008, 130, 16038–16044. 
[307] N. Estrada-Ortiz, C. G. Neochoritis, A. Twarda-Clapa, B. Musielak, T. A. Holak, A. Dömling, ACS Med. 
Chem. Lett. 2017, 8, 1025–1030. 
[308] M. Krajewski, P. Ozdowy, L. D’Silva, U. Rothweiler, T. A. Holak, Nat. Med. 2005, 11, 1135–1136. 
[309] R. A. Tromans, T. S. Carter, L. Chabanne, M. P. Crump, H. Li, J. V. Matlock, M. G. Orchard, A. P. Davis, 
Nat. Chem. 2019, 11, 52–56. 
[310] P. Ríos, T. J. Mooibroek, T. S. Carter, C. Williams, M. R. Wilson, M. P. Crump, A. P. Davis, Chem. Sci. 
2017, 8, 4056–4061. 
[311] C. C. Lee, J. A. MacKay, J. M. J. Fréchet, F. C. Szoka, Nat. Biotechnol. 2005, 23, 1517–1526. 
[312] E. R. Gillies, J. M. J. Fréchet, Drug Discov. Today 2005, 10, 35–43. 
[313] S. Choudhary, L. Gupta, S. Rani, K. Dave, U. Gupta, Front. Pharmacol. 2017, 8, 1–23. 
[314] J. P. Renaud, C. W. Chung, U. H. Danielson, U. Egner, M. Hennig, R. E. Hubbard, H. Nar, Nat. Rev. 
Drug Discov. 2016, 15, 679–698. 
[315] O. Cala, F. Guillière, I. Krimm, Anal. Bioanal. Chem. 2014, 406, 943–956. 
[316] A. M. Rossi, C. W. Taylor, Nat. Protoc. 2011, 6, 365–387. 
[317] M. A. Williams, Protein-Ligand Interactions: Methods and Applications, Springer International 
Publishing, 2013. 
[318] P. C. Weber, F. R. Salemme, Curr. Opin. Struct. Biol. 2003, 13, 115–121. 
[319] M. C. Jecklin, S. Schauer, C. E. Dumelin, R. Zenobi, J. Mol. Recognit. 2009, 22, 319–329. 
[320] E. Ko, J. Liu, L. M. Perez, G. Lu, A. Schaefer, K. Burgess, J. Am. Chem. Soc. 2011, 133, 462–477. 
[321] J. M. Fletcher, K. A. Horner, G. J. Bartlett, G. G. Rhys, A. J. Wilson, D. N. Woolfson, Chem. Sci. 2018, 
9, 7656–7665. 
[322] F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. 
Hendrickson, W. C. Still, J. Comput. Chem. 1990, 11, 440–467. 
[323] N. Maestro, Version 9.2, Schrödinger, LLC, New York, 2011. 
[324] N. A. Nikolic, P. Beak, Org. Synth. 1997, 74, 23. 
[325] D. C. Kapeller, F. Hammerschmidt, J. Org. Chem. 2009, 74, 2380–2388. 
[326] G. E. S. M. J. Frisch, G. W. Trucks, H. B. Schlegel, V. B. M. A. Robb, J. R. Cheeseman, G. Scalmani, M. 
C. B. Mennucci, G. A. Petersson, H. Nakatsuji, G. Z. X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, 
R. F. J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, O. K. J. Hasegawa, M. Ishida, T. Nakajima, Y. 
Honda, J. E. P. H. Nakai, T. Vreven, J. A. Montgomery Jr., E. B. F. Ogliaro, M. Bearpark, J. J. Heyd, J. 
N. K. N. Kudin, V. N. Staroverov, R. Kobayashi, S. S. I. K. Raghavachari, A. Rendell, J. C. Burant, et al., 
Gaussian 09, Revis. D.01, Gaussian, Inc., Wallingford CT 2013. 
 
 
311 
 
 
